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Abstract 
Introduction: Amyotrophic Lateral Sclerosis (ALS) is a devastating, chronic 
progressive neurodegenerative disorder, characterized by the loss of the upper 
motor neurons in the motor cortex and the lower motor neurons of the brainstem 
and spinal cord. This leads to muscle weakness, atrophy and paralysis. Death 
usually occurs 3-5 years from onset. In familial ALS, mutations in TARDBP, 
encoding the RNA binding protein TDP-43, cause 5% of cases. TDP-43 is mainly 
localized in the nucleus and has multiple functions, of which the best 
characterised is regulation of splicing/alternative splicing of hnRNA. In ALS TDP-
43 mislocates to the cytoplasm causing the characteristic protein aggregations. 
The current work investigates the possible effects of both TARDBP missense 
mutations and a truncation mutation on RNA processing. This was approached 
by examining the changes in gene expression in both the cytoplasm and nucleus 
in fibroblasts derived from familial ALS-TARDBP patients. Hypothesis: The 
cytoplasmic and nuclear transcriptomic profile from mutant TARDBP fibroblasts 
will generate different transcriptomic profiles than control fibroblasts and will 
establish transcripts and pathways dysregulated in the presence of mutations in 
TARDBP. The objectives were 1) to optimize the separation of nuclear and 
cytoplasmic RNA from patient and control fibroblasts, 2) to compare the 
expression profiles of the cytoplasmic and nuclear compartments from control 
and mutant fibroblasts and 3) to determine the effect of both mutation types on 
gene expression in fALS. Methodology: Fibroblast cell culture from fALS-
TARDBP missense mutation, truncation mutation and controls was performed. In 
addition, cell fractionation and RNA extraction were performed by two methods, 
osmotic pressure and Trizol and commercially available kit. Gene expression 
profiling was achieved using the Human Exon Array 1.0 ST, Human 
Transcriptome Array 2.0 (HTA) and RNA Sequencing. Findings: The presence 
of a TARDBP mutation causes change in gene expression in fALS. Cytoplasmic 
fALS-TARDBP missense mutations were significantly enriched with dysregulated 
RNA processing genes using both the Human Exon Arrays 1.0 ST and the HTAs 
while cytoplasmic fALS-TARDBP truncated mutation were enriched with 
dysregulated angiogenesis using the HTA and dysregulated vesicle mediated 
transport genes using RNA sequencing. The nuclear fALS-TARDBP missense 
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mutations demonstrated dysregulated RNA splicing using both the Human Exon 
Arrays 1.0 ST and the HTA while nuclear fALS-TARDBP truncated mutation was 
mainly enriched with G-protein coupled receptors using the HTAs. Therefore, 
fALS-TARDBP subtype mutations revealed distinct affected biological processes. 
Conclusion: The different types of TARDBP mutations assayed here have 
different effects on gene expression and subsequently on cellular pathways 
involved in TARDBP-related ALS. 
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Chapter 1: Introduction  
 
 
1.1 Amyotrophic Lateral Sclerosis 
 
Jean Marie Charcot was the first to report the characteristics of Amyotrophic 
Lateral Sclerosis (ALS) in the early 18th century. ALS is known as Charcot 
disease in many countries as an appreciation of his work. It is also known as Lou 
Gehrig’s disease after the death of a famous New Yorker baseball player Lou 
Gehrig who suffered from ALS in 1939 (Kumar et al., 2011). ALS is a devastating 
chronic progressive neurodegenerative disorder characterized by the loss of the 
upper motor neurons in the motor cortex and the lower motor neurons of the 
brainstem and spinal cord. The average disease onset is 55 – 60 years. However, 
there is a juvenile form of ALS where patients are diagnosed in their twenties or 
earlier. Patients generally present with voluntary muscle weakness beginning in 
the limbs or bulbar musculature with progressive atrophy and paralysis. The 
fatality of the disease usually results from respiratory failure (Chen et al., 2013). 
 
The average survival rate is approximately 2-5 years from the appearance of 
symptoms. The prevalence of ALS is nearly 2:100,000 with a higher incidence in 
men than in women (Ferraiuolo et al., 2011). ALS is multifactorial and in the 
majority of cases the actual cause is unknown. Moreover, ALS is categorized into 
two major types: familial ALS (fALS); which accounts for 5-10% of the cases; and 
sporadic ALS (sALS); which accounts for 90-95% of the cases. Both types 
present similarly, which may suggest common pathological causes. It was 
estimated that around 3-10% of ALS patients develop frontotemporal dementia 
(FTD) which is a condition characterized by the degeneration of the anterior part 
of the brain and also involves memory loss  (Cooper-Knock et al., 2015c). 
 
1.1.1 Clinical features 
 
Most ALS cases present with limb onset ALS which accounts for ~80% of the 
cases. Limb onset ALS is further subdivided into lower limb onset ALS and upper 
limb onset ALS according to the location of motorneuron cell loss. Lower limb 
onset ALS patients usually complain about tripping or stumbling when walking. 
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However, the upper limb onset ALS patients usually complain from finger stiffness 
and weakness of the hand muscles.  In ~20% of cases, ALS patients present with 
bulbar complications and are referred to as bulbar onset ALS. The bulbar onset 
ALS patients mainly suffer from slurred speech, dysphagia and excessive 
salivation (Kiernan et al., 2011). Also, rare cases of respiratory onset ALS have 
been reported accounting for <3% of cases (Shoesmith et al., 2007). 
 
1.1.2 Diagnosis 
 
ALS diagnosis is mainly dependent on the patient’s symptoms across time. As 
motor neuron diseases (MND) have overlapping symptoms a definitive diagnosis 
may require a period of time to observe disease progression. Diagnosis is mainly 
accomplished by physical examination, investigative family history and 
electrodiagnostic testing, excluding other disorders. Electromyography and nerve 
conduction studies are both mostly used to assess and to evaluate muscle and 
nerve function.  fALS patients may be offered genetic testing to confirm the 
diagnosis. Therefore, recent research has been focusing on the identification of 
biomarkers that help in the early detection of ALS and monitor the disease 
progression (Turner et al., 2009).      
  
1.1.3 Treatment and management  
 
To date there is no cure for ALS. However, there are a limited number of 
treatments available in the market which manage the disease progress. In most 
ALS cases, rapid deterioration as a result of disease is observed. Riluzole is the 
treatment given to all ALS patients in an attempt to slow the disease progression. 
It requires careful monitoring as it may induce liver damage and may suppress 
immunity by reducing leucocytes (Miller et al., 2007). Dramatic changes in ALS 
patient life style occur within the short course of the disease. Percutaneous 
endoscopic gastrostomy is offered to ALS patients to minimize the amount of 
body mass loss during disease progression and is especially given to those with 
bulbar disease onset who experience dysphagia (Spataro et al., 2011). Also, non-
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invasive ventilation is offered to overcome respiratory insufficiency. In some 
countries, when disease worsens ALS patients undergo invasive ventilation due 
to respiratory failure (Swash, 2013). 
 
 
1.1.4 Pathogenesis  
  
To date, the exact defective molecular pathways in ALS are not fully understood, 
however, several studies have revealed evidence of pathogenic mechanisms 
involved in the disease. These include: genetic factors, dysregulated RNA 
processing, oxidative stress, mitochondrial dysfunction, glutamate excitotoxicity, 
defective axonal transport, protein aggregation, neuroinflammation, dysregulated 
endosomal  trafficking and endoplasmic reticulum stress (Ferraiuolo et al., 2011) 
(Figure 1.1). An expanded elucidation of the role of the genetic risk factors and 
the dysregulated RNA processing proteins in ALS will be discussed.  
 
 
 
 
 
 
   Figure 1.1: Pathogenic mechanisms involved in amyotrophic lateral sclerosis 
 
 
23 
 
 
1.1.4.1 The role of genetic risk factors in ALS 
 
Genetic studies of fALS are growing rapidly in the field. To date there are 22 
identified genes associated with disease (Table 1.1). The most common mutated 
genes related to ALS are: copper zinc (Cu-Zn) superoxide dismutase1 (SOD1) 
which is responsible of 12-20% of fALS and 1-2% of sALS (Banci et al., 2008, 
Marangi and Traynor, 2015), the trans active response DNA binding protein 
(TARDBP) which accounts for 4% of fALS and nearly 1% of sALS (Kirby et al., 
2010, Millecamps et al., 2010, Ticozzi et al., 2011), fused in sarcoma (FUS) which 
was shown to be responsible for ~5% of fALS and ~1% of sALS (Rademakers et 
al., 2010, Ticozzi et al., 2011) and the newly discovered gene chromosome 9 
open reading frame 72 (C9ORF72) which is responsible for 43% of fALS and 7% 
in sALS (Cooper-Knock et al., 2015c). A further discussion of these genes occurs 
below. 
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Table1.1: ALS types. AD= Autosomal dominant, AR= Autosomal recessive, 
Inher.= inheritance 
ALS types Locus Gene 
symbol 
Gene name  Inher Onset Reference 
ALS1 21q22.1
1 
SOD1 Cu/Zn superoxide 
dismutase 
AD Adult (Rosen, 1993) 
ALS2 2q33.1 ALS2 Alsin AR Juvenile (Yang et al., 2001) 
ALS3 18q21 Unknown Unknown AD Adult (Hand et al., 2002) 
ALS4 9q34.13 SETX Senataxin AD Juvenile (Chen et al., 2004) 
ALS5 15q21.1 SPG11 Spatacsin AR Juvenile (Orlacchio et al., 
2010) 
ALS6 16p11.2 FUS Fused in sarcoma AD/ 
AR 
Adult (Kwiatkowski et al., 
2009),(Vance et al., 
2009) 
ALS7 20p13 Unknown Unknown AD Adult (Sapp et al., 2003) 
ALS8 20q13.2
3 
VAPB VAMP-associated 
protein B 
AD Adult (Nishimura et al., 
2004) 
ALS9 
 
14q11.2 ANG Angiogenion AD Adult (Greenway et al., 
2006) 
ALS10 1p36.22 TARDBP TAR DNA-binding 
protein 
AD Adult (Sreedharan et al., 
2008) 
ALS11 6q21 FIG4 Polyphosphoinositid
e phosphatase 
AD Adult (Chow et al., 2009) 
ALS12 10p13 OPTN Optineurin AD/AR Adult (Maruyama et al., 
2010) 
ALS13 
 
12q24.1
2 
ATAXN2 Ataxin-2 AD Adult (Figueroa et al., 
2009), (Van Damme 
et al., 2011) 
ALS14 9p13.3 VCP Valosin-containing 
protein 
AD Adult (Johnson et al., 
2010) 
ALS15 Xp11.21 UBQLN2 Ubiquilin 2 X-
linked 
Adult (Deng et al., 2011) 
ALS16 9p13.3 SIGMAR1 σ Non opioid 
receptor 1 
AD Adult/ 
Juvenile 
(Luty et al., 2010) 
(Al-Saif et al., 2011) 
ALS17 3p11.2 CHMP2B Charged 
Multivesicular Body 
Protein 2B 
AD Adult (Parkinson et al., 
2006) 
ALS18 17p13.2 PFN1 Proflin1 AD Adult (Wu et al., 2012) 
ALS19 2q34 ERBB4 Erythroblastic 
Leukemia Viral 
Oncogene 
AD Adult (Takahashi et al., 
2013) 
ALS20 12q13.1
3 
hnRNPA1 Heterogeneous 
nuclear 
ribonucleoprotein A1 
AD Adult (Kim et al., 2013) 
ALS21 5q31.2 MATR3 Matrin 3 AD Adult (Johnson et al., 
2014) 
ALS22 2q35 TUBA4A Tubulin alpha-4A AD Adult (Smith et al., 2014) 
FTD-
ALS1 
9q21 C9ORF72 Unknown AD Adult (Hosler et al., 2000), 
(Renton et al., 2011), 
(DeJesus-
Hernandez et al., 
2011) 
FTD-
ALS2 
5q35.3 CHCHD10 Coiled-coil-helix-
coiled-coil-helix 
domain-containing 
protein 10 
AD Adult (Bannwarth et al., 
2014) 
FTD-
ALS3 
12q14.2 SQSTM1 Sequestosome1 AD Adult (Fecto et al., 2011) 
FTD-
ALS4 
12q14.2 TBK1 TANK-binding 
kinase1 
AD Adult (Freischmidt et al., 
2015) 
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1.1.4.1.1 Cu-Zn superoxide dismutase1 (SOD1) 
 
A mutation in the SOD1 gene was the first described genetic cause of ALS. In 
1993, Rosen and his colleagues discovered mutations in the SOD1 gene on 
chromosome 21q22.11 to be associated with the disease (Rosen, 1993). The 
pattern of inheritance of SOD1 mutation(s) is primarily autosomal dominant. 
SOD1 mutations are mainly missense however insertions and deletions have 
also been reported (Lill et al., 2011). The mutations are not restricted to the 
familial ALS; they were also reported in apparent sALS (Mackenzie et al., 2007). 
 
The SOD1 gene encodes for the enzyme Cu-Zn superoxide dismutase 1; a 153 
amino acids long protein which is localized in the cytoplasm and the mitochondria. 
Normally it converts harmful superoxide radicals into oxygen and hydrogen 
peroxide (Yamanaka and Cleveland, 2005). Mutated SOD1 protein results in a 
toxic gain of function though the nature of this is unclear. It was shown that over 
expression of SOD1 mutation, mutant SOD1G93A and SOD1A4V, in transgenic mice 
causes the mice to develop an ALS-like phenotype (Gurney et al., 1994). 
Overexpression of wild type SOD1 gene in mouse has also shown a 
neuropathological outcome resembling ALS (Jaarsma et al., 2000). A complete 
depletion of the SOD1 gene in mouse model did not show any ALS-like 
phenotype (Bruijn et al., 1998). Therefore, it hypothesized that dysfunctional 
SOD1 enzyme causes ALS through a toxic gain of function, rather than a loss of 
function (Ince et al., 2011). 
 
1.1.4.1.2 Trans-active response DNA-binding protein (TARDBP)  
 
The TARDBP encoded TDP-43 was first recognized by Neumann et al. as a 
major protein signature for ALS and FTD. Using immunohistochemical methods, 
TDP-43 was found to be present in the ubiquitinated cytoplasmic inclusions in 
ALS (Neumann et al., 2006). TARDBP is located on chromosome 1p36.22 and 
TARDBP mutations are inherited in an autosomal dominant pattern (Sreedharan 
et al., 2008). 53 TARDBP mutations have been identified so far with the majority 
being missense mutations located in the glycine rich domain of the encoded 
protein and only one truncation mutation has been identified 
26 
 
(http://alsod.iop.kcl.ac.uk/Overview/gene.aspx?gene_id=TARDBP) (Figure 1.2, 
adapted from (Lagier-Tourenne et al., 2010)). There are several protein isoforms 
encoded by the TARDBP gene which are mainly localized in the nucleus. TDP-
43 is recognized to be the most significant isoform that plays a major role in ALS. 
Structurally, TDP-43 consists of 414 amino acids with a molecular weight of 43 
kDa. It has three major domains; two RNA recognition motifs (RRM1 and RRM2) 
and a glycine rich domain. These structures facilitate nuclear localization and 
protein-protein interaction (Van Deerlin et al., 2008, Kuo et al., 2009a). TDP-43 
binds directly to RNA preferably at the UG-rich sequences and also binds to 
double strand DNA at the TG-rich sequences. Therefor it is involved in 
transcription and RNA processing (Kuo et al., 2009c, Kirby et al., 2010) (see 
section 1.1.4.2.1 for more details).  
 
 
 
 
 
Figure 1.2: Illustrates the location of 38 of the 53 mutations identified to date in TDP-43.  
RRM1= RNA recognition motifs1, RRM2= RNA recognition motifs2, GLY-rich= Glycine rich, NLS= 
nuclear localization signal, NES= nuclear export signal, variants labelled in red were studied in 
the current work. Figure adapted from (Lagier-Tourenne et al., 2010), 
http://alsod.iop.kcl.ac.uk/Overview/gene.aspx?gene_id=TARDBP. 
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1.1.4.1.3 Fused in sarcoma/ translocated in liposarcoma (FUS/TLS)  
 
The FUS gene was identified as playing a role in ALS by Kwiatkowski and 
colleagues in a Cape Verde family. The FUS gene is linked to chromosome 
16p11.2 and the related defect is inherited both in autosomal dominant and 
autosomal recessive patterns. 25% of FUS mutations are located in exon 5-6 and 
75% in exon 13-14 (Kwiatkowski et al., 2009, Vance et al., 2009, Hewitt et al., 
2010). Mutations mostly occur in the glycine rich domain or at the nuclear signal 
domain, as a result the protein molecule loses its nuclear compartmentalization 
and there is an increase in cellular toxicity (Ince et al., 2011). FUS belongs to the 
heterogeneous ribonucleoprotein (hnRNP) family. It was shown that FUS binds 
directly to RNA and also to single strand DNA. Therefore it is involved in 
transcription and  splicing (Wang et al., 2015).  
 
1.1.4.1.4 Chromosome 9 open reading frame 72 (C9ORF72) 
 
The large expansion hexanucleotide GGGGCC repeats of C9ORF72 was 
recently discovered to be the most common cause of ALS and FTD. The mutation 
is located in intron 1 of the C9ORF72 gene which is located at chromosome 9q21 
(DeJesus-Hernandez et al., 2011, Renton et al., 2011). It was reported that the 
frequency of C9ORF72 in ALS patients is ~43% in fALS and 7% in sALS (Cooper-
Knock et al., 2012a). In addition, up to ~50% of ALS-C9ORF72 had a history of 
FTD. Furthermore, it has been shown that both ALS-C9ORF72 positive and ALS-
C9ORF72 negative patients share similar clinical presentation however the ALS-
C9ORF72 positive patients demonstrated a shorter survival rate (mean<32 
months) (Cooper-Knock et al., 2012a). Also, a study has shown that in ALS-
C9ORF72, neurons and glial cells from post mortem tissue showed TDP-43 
positive inclusions (Stewart et al., 2012). 
 
1.1.4.2 The role of RNA processing in ALS 
 
RNA processing is a group of different molecular events that take place in the 
nucleus (Figure 1.3). These events include: 5’capping (7-methylguanosine), 
splicing and 3’ polyadenylation (Garneau et al., 2007). Transcription is the first 
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step in which a DNA template is copied, both exons and introns, with the thymine 
replaced by uracil. 5’capping-7-methylguanosine is added simultaneously during 
transcription processes. Splicing occurs co-transcriptionally, this is a modification 
step in which intronic regions (noncoding) are removed and the exonic regions 
(coding) are joined. Also 3’ polyadenylation takes place. (Garneau et al., 2007).       
 
Mutations in RNA processing genes have been identified in ALS. Mutations in the 
TARDBP gene which encodes for the RNA binding protein TDP-43 were 
identified in both fALS and sALS (Neumann et al., 2006, Van Deerlin et al., 2008). 
Furthermore, changes in FUS were then discovered and it was found to be an 
hnRNP that is involved in several aspects of RNA processing. Mutations in FUS 
were associated with ALS (Kwiatkowski et al., 2009). The newly identified 
mutation in the C9ORF72 gene, which is responsible for the majority of the 
genetic related cases of ALS, has also been demonstrated to disrupt RNA 
processing (Cooper-Knock et al., 2015a) 
 
Additional RNA processing proteins that are involved in the pathogenesis of ALS 
have been described. Some variants of the angiogenin gene (ANG) were 
suggested as a risk factor for fALS and sALS in individuals of Scottish or Irish 
ancestry (Greenway et al., 2006). ANG is considered a member of the pancreatic 
RNase A superfamily. It is also capable of stimulating rRNA transcription under 
hypoxic conditions, thereby promoting neovascularisation (Gao and Xu, 2008). 
Furthermore, mutations in senataxin (SETX) were associated with a juvenile form 
of ALS (Chen et al., 2004). SETX has a DNA/RNA helicase activity which is 
involved in RNA processing by unwinding the DNA or RNA molecule (Zhao et al., 
2009). Mutations in some variants of the elongator protein 3 (ELP3) were 
suggested be a risk factor for ALS. ELP3 is a component of the RNA polymerase 
II which is involved in RNA processing (Simpson et al., 2009a). In addition, 
abnormal copy number of the survival motor neuron 1 (SMN1) gene is  a risk 
factor for sALS (Corcia et al., 2002). SMN1 is also involved in transcription and 
RNA splicing (Eggert et al., 2006). 
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As TDP-43, FUS and C9ORF72 are three most commonly dysregulated RNA 
processing proteins associated with ALS, further discussion of their pathogenic 
mechanisms in relation to RNA processing will follow. 
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Figure 1.3: Schematic diagram representing the transcription, co-transcriptional processing 
event, mRNA transport, translation and degradation. 
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1.1.4.2.1 TAR DNA binding protein 34 (TDP-43) 
 
TDP-43 is a heterogeneous ribonucleoprotein (hnRNP) with a 43kDa molecular 
weight. As explained previously (section 1.1.4.1.2), TDP-43 consists of 414 
amino acids. It has N terminus homodimerization domain with an ubiquitin-like 
fold, RNA recognition motifs (RRM1 and RRM2) and a glycine rich domain (Kuo 
et al., 2009a). TDP-43 was first recognized as a transcription repressor which 
binds to TAR DNA in Human immunodeficiency virus-1(HIV-1) (Ou et al., 1995). 
In addition, Abhyankar et al. demonstrated that TDP-43 is capable of binding to 
the SP-10 promoter region in mouse which is essential for spermatogenesis 
(Abhyankar et al., 2007).  
 
The majority of TDP-43 functions were observed in regulation of other RNA 
processing mechanisms. TDP-43 has been shown to regulate alternative splicing 
of the genes for several proteins such as: apolipoprotein A-II and cystic fibrosis 
trans-membrane regulator (CFTR). In the case of CFTR, TDP-43 binds to a UG 
rich area of a CFTR intronic region, specifically the intron 8 – exon 9 junction. 
This action promotes exon 9 skipping of CFTR mRNA (Buratti et al., 2001). 
Depletion of TDP-43 leads to ineffective exon 9 skipping (D'Ambrogio et al., 
2009). TDP-43 also regulates alternative splicing of the apolipoprotein A-II gene 
by binding to the intron 2 – exon 3 region (Mercado et al., 2005).  
 
In sALS mutant forms of TDP-43 has been strongly implicated in dysregulated 
RNA splicing and affected spliceosome components (Highley et al., 2014). 
Furthermore, genes involved in RNA splicing were also shown to be dysregulated 
in sALS cases with TARDBP mutations (Raman et al., 2015). A recently identified 
function of TDP-43 was its ability to suppress cryptic exonic splicing.  Cryptic 
exons are non-conserved sequences expression of which might result in faulty 
mRNA transcripts that deteriorate and therefore be cleared by the nonsense-
mediated decay machinery. De Conti et al. has recently shown that the loss of 
TDP-43 function directly affects the splicing profile of six genes which were:  BIM, 
SKAR/POLDIP3, STAG2, MADD, FNIP1 and BRD8 (De Conti et al., 2015). 
Studies have also shown that TDP-43 binds to multiple mRNA transcripts and is 
hence thought to regulate their splicing (Polymenidou et al., 2011, Sephton et al., 
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2011, Xiao et al., 2011). Ayala et al., have recently shown the role of TDP-43 in 
autoregulation. It was demonstrated the ability of TDP-43 to bind to the 3’ end 
untranslated region (3’UTR) of TARDBP mRNA leading to instability and decay 
(Ayala et al., 2011). Moreover, Tollervey et al., showed that TDP-43 binds to 
transcripts at the UG-rich sequences of long pre-mRNAs (Tollervey et al., 2011).  
 
TDP-43 has also been demonstrated to play a role in microRNA processing. It 
was shown that TDP-43 is capable of binding to the RNA ΙΙΙ endonuclease Drosha 
in the nucleus during microRNA synthesis. It was also shown to participate in  
microRNA cleavage in the cytoplasm by interacting with the protein argonaute 2 
during microRNA maturation (Freibaum et al., 2010). Finally, TDP-43 may be 
involved in mRNA transport to the cytoplasm (Wang et al., 2008).   
 
1.1.4.2.2 Fused in sarcoma/ translocated in liposarcoma (FUS/TLS) 
 
The FUS protein consists of 526 amino acids and is characterized by; an N-
terminal domain rich in tyrosine, serine, glycine and glutamine, a C-terminal 
domain which contain a nuclear localization signal (NLS), an RNA recognition 
motif (RRM) and a zinc finger motif (Kwiatkowski et al., 2009, Vance et al., 2009). 
Similarly to TDP-43, FUS belongs to the heterogeneous ribonucleoprotein 
(hnRNP) family and is mainly involved in RNA processing such as: transcription, 
transport, and splicing (Lagier-Tourenne et al., 2010). FUS is an ubiquitinated 
protein which is normally located in the nucleus, however in ALS it is mutated and 
was shown to form characteristic cytoplasmic inclusion bodies (Kwiatkowski et 
al., 2009, Vance et al., 2009).    
 
1.1.4.2.3 Chromosome 9 open reading frame 72 (C9ORF72) 
 
C9ORF72 was shown to encode for three mRNA isoforms which encode for two 
protein isoforms of 481 amino acids ~50kDa and 222 amino acids ~25 kDa 
(DeJesus-Hernandez et al., 2011). The normal function of C9ORF72 is still not 
fully understood. However, a recent study by Webster et al., showed that normal 
C9ORF72 mediates the initiation of the autophagy pathway by forming 
complexes with two other proteins, Rab1a and ULK1, to facilitate the 
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autophagosome formation (Webster et al., 2016). Furthermore, it was also 
suggested that C9ORF72 is a nucleocytoplasmic shuttling protein (Xiao et al., 
2015). Other studies showed the possible pathological role of the C9ORF72 in 
the disease pathogenesis. Researchers have suggested two main pathologic 
mechanisms of the C9ORF72, either loss of function or toxic gain of function. 
These proposed mechanisms were based on current observations, first was the 
low expression levels of the C9ORF72 variant 1 in patients compared to controls 
which may support loss of function (Fratta et al., 2012). In contrast, the toxic gain 
of function was proposed based on two suggestions, GGGGCC hexanucleotide 
repeats were suggested to undergo a non-ATG translation which results in the 
formation of pathogenic toxic dipeptide proteins (Cleary and Ranum, 2013). In 
addition, the formation of nuclear RNA foci which sequestered RNA and RNA 
binding proteins which might be toxic to the cell and their presence may indicate 
a defective RNA processing mechanism however this is still under study 
(Mizielinska and Isaacs, 2014). A study by Cooper-Knock et al., showed that RNA 
splicing was defective which may lead to neuron injury. In ALS-C9ORF72 cases, 
defective RNA splicing correlated positively with the disease progression 
(Cooper-Knock et al., 2015a). This supports the hypothesis that the C9ORF72 
hexanucleotide expansion disrupts RNA processing. Whether the normal protein 
is involved in RNA processing remain to be established. 
 
1.1.5 Gene expression profiling in ALS using human tissues and cells  
 
An adequate amount of RNA is required for gene expression profiling studies and 
for qRT-PCR validations. Current studies showed that different tissue sources 
from ALS patients can be used to extract RNA material and study gene 
expression changes that occur in the disease process. The three main tissue 
types previously used to study ALS are: motor neurons extracted from post-
mortem tissue, venous whole blood and fibroblasts. Each of the advantages and 
limitation of these tissue sources will be discussed below.  
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1.1.5.1 Use of human CNS tissue 
 
There is no doubt that motor neurons from the central nervous system (CNS) are 
the best source to study ALS as they demonstrate the actual changes that occur 
in the disease. However major limitations have been identified. Motor neurons 
are not accessible during the course of the disease and only available from post-
mortem tissue where most of the motor neurons are lost. This may result in an 
examination of a sub-population of motor neurons that have survived the worst 
of the disease process and hence are not fully representative. RNA extracted 
from post-mortem tissue is often markedly degraded. This may be due to delay 
in processing the CNS tissue, the pre-mortem state of the sample and also as an 
effect of any chemical preservation (Sidova et al., 2015). As stated another 
essential point is that studying gene expression changes from post-mortem tissue 
will only reflect the end stage of the disease giving limited therapeutic approaches 
(Cooper-Knock et al., 2012d). With these kind of limitations a shift towards 
utilizing peripheral tissue derived from ALS patients has been applied.     
 
1.1.5.2 Use of human peripheral tissue  
 
1.1.5.2.1 Venous whole blood  
 
Venous whole blood has been shown to overcome some of the limitations of post-
mortem tissues. Fresh blood samples are easy to collect from ALS patients at 
any stage of the disease. Also, adequate quantities of RNA can be obtained from 
blood collected via a simple venipuncture procedure. Studies on ALS using 
peripheral blood were shown to be a great source that may mimic some changes 
in the motor neurons (Bayatti et al., 2014, Bury et al., 2016). The limitation of 
using of whole blood is the mixed cell population and the increased amount of 
globin RNA which may mask some changes in gene expression (Wright et al., 
2008), though this can be limited by using commercially available globin RNA 
removal kits. However, this remains a favourable source of material for diagnostic 
biomarker identification.    
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1.1.5.2.2 Fibroblasts 
 
Fibroblasts are easy to collect from patients via skin biopsies and also are easy 
to grow in the laboratory. They have shown to be a good model to study gene 
expression profiling in neurodegenerative disorders. Fibroblasts from Parkinson’s 
disease patients with a mutated parkin gene showed mitochondrial abnormalities 
which mimic the changes in the neurons (Mortiboys et al., 2008). Fibroblasts from 
siblings to familial Alzheimer’s disease patients with mutations in one of the 
genes, amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 
(PSEN2), were utilized to detect diagnostic biomarkers before the onset of 
cognitive decline (Nagasaka et al., 2005). Furthermore, fibroblasts from ALS 
patients were used to study gene expression changes during the disease (Raman 
et al., 2015). Fibroblasts have been used to investigate the role of oxidative 
stress, mitochondrial dysfunction and dysregulated RNA processing in ALS (Allen 
et al., 2014, Highley et al., 2014, Raman et al., 2015). In these studies, fibroblasts 
have been shown to be a good source of cells that can be used in the laboratory 
and showed changes that mimics those observed in the disease process. 
 
1.1.6 Gene expression profiling 
 
The discovery of microarray technology has helped considerably in 
understanding the gene activity in biological samples (Heller, 2002). In research, 
GeneChip® microarrays have been used for a wide range of purposes, such as: 
identification of biomarkers and discovery of novel genes. Whilst several 
GeneChip® arrays have been designed throughout the years they share common 
method of design and production. GeneChip® platforms consist of short 
sequences of probes attached to a plastic wafer via both chemical reactions and 
photolithography (http://www.affymetrix.com).  
 
The three main human microarray GeneChips® designed by Affymetrix® used to 
study global gene expression were, the In Vitro Transcription (IVT) Array, Human 
Exon 1.0 ST Array and Human Transcriptome Arrays 2.0. More recently next 
generation sequencing (RNA sequencing) has been developed to study global 
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gene expression profiling. A further description of these microarrays and the next 
generation sequencing is shown below. 
 
1.1.6.1 In Vitro Transcription (IVT) Array GeneChip® 
 
The IVT Array GeneChip® were first made commercially available in April 2001, 
to enable global gene expression profiling.  The arrays were designed targeting 
the 3’ end region of mRNA. It consists of 1.3 million features with a total of ~ 
54,000 probe sets. Each transcript is represented with 11 perfect match probes 
and 11 mismatched probes at the 13th position of the 25 base pair long probe. 
The probe sequences were designed against the available known sequences in 
the data bases NCBI, dbEST, GenBank® and RefSeq database 
(http://www.affymetrix.com). 
 
Gene expression profiling using the IVT arrays has been used extensively. 
However, these arrays had limitations. They were dependent on the detection of 
polyadenylated mRNA which may result in the loss of several transcripts that lack 
a poly A tail. A challenging issue was also the detection of mRNA transcripts 
which undergo alternative polyadenylation. The 3’ IVT arrays probe sets were 
designed based on available known 3’ end sequences. Therefore, they were 
unable to detect alternatively polyadenylated transcripts (D'Mello et al., 2006). 
With these limitations in mind Affymetrix® designed the Human Exon 1.0 ST Array 
GeneChip® with better features (see 1.1.6.2).  
 
1.1.6.2 Human Exon 1.0 ST Array GeneChip® 
 
The Human Exon 1.0 ST Array GeneChip® has shown several advantages over 
the conventional 3’ IVT array GeneChip®. They provide the maximum information 
needed to understand total gene expression as their target is to detect transcripts 
along the entire length of mRNA rather than the 3’ end region. This unique feature 
also suggested that novel spliced transcripts could be discovered. Each exon is 
presented on the GeneChip® by four perfect match probes scattered throughout 
the chip. The array consists of 1.4 million probe sets and over a million exon 
clusters. The feature size is 5µm X 5µm and each probe is 25 base pair long. 
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These exons were identified against known sequences from databases, 
Genbank, Ensembl and dbEST (in July, 2003) (www.Affymetrix.com).   
 
1.1.6.3 Human Transcriptome Arrays 2.0 GeneChip®  
 
 In 2011, Affymetrix® designed the Human Transcriptome Arrays 2.0 (HTA) which 
showed improved features compared to the Human Exon 1.0 ST Array 
GeneChip®. This was achieved by increasing the probe density from 4 probes 
per exon to 10 probes per exon and including 4 probes for each predicted exon-
exon splice junction. Furthermore, these probe sequences have been compared 
to an available mRNA database. ~94% of mRNA sequences in the data mapped 
to the probes designed on the arrays. 85% of the mapped mRNA sequences from 
the database were exons and 7% were exon-exon junctions (Xu et al., 2011). The 
HTA contain > 6.0 million feature oligonucleotides and they utilize low RNA 
concentrations of total RNA (50ng – 500ng) for input. These highly efficient arrays 
were designed to identify instances of alternative splicing, coding SNP and 
noncoding transcripts. Furthermore, they are designed to be analysed with their 
own software known as Transcriptome Analysis Console (TAC). The software 
has a unique feature which is the assembling of multiple data sources in one 
compact software package. Thus, all transcript isoforms of a known gene can be 
analysed in a single analysis tool (Xu et al., 2011).  
 
1.1.6.4 Next generation sequencing (NGS) (RNA sequencing) 
 
The first widely used DNA sequencing method was developed by Frederick 
Sanger who described the chain-termination method that led to the initial 
identification of the human genome sequence (Sanger et al., 1977). In the past 
decade there has been a rapid development of new sequencing technologies. 
Now, NGS is widely available in the market and serves numerous areas such as: 
clinical diagnostics, genetic disease studies and molecular biology studies 
(Morozova and Marra, 2008). The most commonly used type of DNA sequencing 
nowadays is the sequencing by synthesis which was first introduced by 
Balasubramanian and Klenerman in 1989 and commercialised under the banner 
Solexa (http://www.illumina.com/technology/next-generation-sequencing/solexa-
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technology.html).  In 2004, the Solexa technology was purchased and enhanced 
by introducing the DNA cluster amplification method which increased the 
accuracy of base calling which was then known as Illumina sequencing. 
(http://www.illumina.com/technology/next-generation-sequencing/solexa-
technology.html) 
 
The principle of this method is that mRNA is converted into double stranded 
cDNA molecule which is then fragmented and tagged by an index sequence and 
a flow cell adaptor sequence. Each fragmented single stranded molecule is 
clustered via an isothermal amplification method. This is performed within a flow 
cell glass slide that is composed of different lanes. Each lane is internally coated 
with short sequence oligonucleotides complementary to the adaptor region on the 
fragmented single stranded cDNA. Once the reaction starts the fragmented 
double stranded molecules are made single stranded and bound to the short 
sequence oligonucleotides complementary to the adapter region. These 
processes initiate the DNA polymerase to synthesise the reverse stand. The 
original stand is denatured and cleaved. The reverse strand is then cloned by a 
bridge amplification method forming millions of clusters. This process is followed 
by the sequencing step, also known as sequencing by synthesis, reversible 
fluorescent terminator nucleotides are incorporated into the newly synthesised 
DNA sequence. The four chemically modified nucleotides (2,3 dideoxynucleotide) 
are added to the DNA molecule by DNA polymerase allowing one of the four 
nucleotides to bind to the DNA sequence in each synthesis cycle as a result of 
complementary hybridisation. This is followed by a washing step to remove all 
the remaining nucleotides. The nucleotides are then excited by a light source and 
a snapshot image of the incorporated terminated nucleotides is taken by a 
camera.  The synthesis cycle is repeated until the cDNA fragment is sequenced. 
These images are then combined and interpreted as a cDNA sequence 
(http://www.illumina.com/technology/next-generation-sequencing/sequencing-
technology.html) (Figure 1.4).  
 
This method has major advantages. It is the only one that can perform a single 
read as well as paired-end reads which increases the efficiency and resolution of 
the genome sequence. Paired-end read generation overcomes many issues that 
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are faced in sequencing, for example: the alignment of DNA sequence that 
contains repetitive sequences. It can, to some degree, identify rearrangements 
such as deletions, insertions and inversions in addition to novel spliced isoforms 
(Figure 1.5), depending on the size of the expansion, insertion, deletion or 
inversion. 
(http://www.illumina.com/technology/next-generation-sequencing/sequencing-
technology.html) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
 
 
Figure 1.4: Illumina Sequencing workflow. (1) the DNA is fragmented and ligated to the adaptors 
(2)The fragmented single stranded DNA is attached to the surface of the flow cell in the channels 
(3) unlabelled nucleotides are added along with enzymes to initiate the bridge amplification (4) A 
double strand bridge is synthesis on the flow cell (5) the original stand is denatured and cleaved 
leaving the reverse strand (6) bridge amplification continues to form millions of clusters (7) the 
sequencing cycle starts by the addition of the four labelled reverse terminator nucleotides along 
with DNA polymerase and primers (8) the laser excite the fluorescent labelled incorporated 
nucleotide and an image is captured to detect the first base (9&10) is a repeated process of the 
synthesis cycle steps 7&8 (11) all the images are combined to identify the DNA sequence (12) 
data alignment to the reference sequence. (Image from Illumina sequencing webpage: 
http://www.illumina.com/documents/products/techspotlights/techspotlight_sequencing.pdf ) 
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Figure 1.5: Paired-end Sequencing and alignment detecting sequence repeats. 
(Adapted from: http://www.illumina.com/technology/next-generation-sequencing/paired-end-
sequencing_assay.html) 
  
 
 
 
1.1.7 Studying alternative splicing 
 
Alternative splicing is defined as the mechanism that allows the production of 
different transcript isoforms from a single gene. It is one of the most complex 
functions that the human genome undergoes. Over 92% of the human genome 
is alternatively spliced which indicates its importance in many cellular 
mechanisms and pathways (Blencowe et al., 2009). A defective alternative 
splicing process has been implicated in several neurodegenerative disorders. 
Mutations in RNA processing genes lead to disorders other than ALS, for 
example: Alzheimer’s disease (AD) (Amyloid-β), Parkinson’s disease (PD) (α-
synuclein), FTD (TDP-43) and spinal muscular atrophy (SMA) (SMN1) (Tang, 
2016).  Each of these neurological disorders has distinct complex defective 
cellular mechanisms and pathways. Thus, studying the role of RNA processing 
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genes is potentially important to underline how these diseases develop as well to 
establish therapy.  
   
 
1.1.8 The rationale behind the project ‘cytoplasmic and nuclear gene 
expression profiling’ 
 
This study was developed based on two major observations. The first was that 
TDP-43 is an RNA binding protein that is normally located in the nucleus and has 
a role in RNA processing and particularly in splicing. In ALS TDP-43 is mutated 
and mislocalized resulting in the characteristic cytoplasmic inclusion bodies 
(Neumann et al., 2006). Studies have shown that TDP-43 binds to multiple mRNA 
transcripts, thereby thought to regulate their splicing (Polymenidou et al., 2011, 
Sephton et al., 2011, Xiao et al., 2011). However the actual effect of how mutant 
TDP-43 dysregulates the splicing machinery in ALS has not been studied before. 
Thus, the current work aimed to uncover possible dysregulated mRNA spliced 
transcripts in fALS-TARDBP.  
 
The second observation which initiated this current work was an interesting study 
conducted by Trask et al., in 2009, which studied gene expression profiling on 
separate cellular components i.e. cytoplasmic RNA and nuclear RNA extracted 
from the same cell line. They showed strong supporting evidence that mRNA 
extracted from the whole cell does not accurately represent cytoplasmic mRNA 
and that polyadenylated nuclear mRNA should not be neglected as their 
contribution is significant (Trask et al., 2009).  
 
Therefore, it was interesting to explore the possible effects of mutant TDP-43 on 
mRNA splicing on both cellular compartments in fALS-TARDBP mutations as this 
was not been studied before. As TDP-43 is an ubiquitinated protein which is 
expressed in fibroblasts of ALS patients (Sabatelli et al., 2015), the present study 
aimed to utilize fibroblasts derived from fALS patients to understand the cellular 
defective mechanisms and pathways related to TDP-43 mutation using the 
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following technologies: the Human Exon 1.0 ST Arrays, the Human 
Transcriptome Arrays and RNA sequencing. 
 
1.1.9 Hypothesis 
 
Cytoplasmic and nuclear transcriptomic profile from mutant TARDBP will 
generate different transcriptomic profiles than control fibroblasts. 
 
This will establish the dysregulated pathways in the presence of mutations in 
TARDBP.  
 
 
1.1.10 Objectives  
 
1. To produce a good quality and quantity of separated cytoplasmic and 
nuclear RNA from mutant TARDBP fibroblasts and control fibroblasts. 
 
2. To compare the expression profiles of the cytoplasmic and nuclear 
compartments of the cell from control and mutant TARDBP fibroblasts.  
 
3. To determine the effect of the TARDBP mutation in the cytoplasmic and 
nuclear RNA expression profile.  
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Chapter 2: Materials and methods  
 
Table 2.1: Reagents and suppliers 
 
Reagents  Supplier  
 
Agencourt AMPure XP beads Beckman Coulter 
Ammonium acetate Sigma  
Chloroform Fisher Scientific 
Cytoplasmic and nuclear RNA purification kit Norgen biotek 
DMSO Sigma  
DNase treatment New England Biolabs 
Dithiothreitol Sigma  
Ethanol Fisher scientific 
Ethidium bromide Fluka 
Essential Media (MEM) with Earle’s Salts and L-Glutamine Lonza 
Fetal bovine serum (FBS) Biosera 
GeneChip® arrays and reagents  Affymetrix 
Glycoblue Ambion 
HEPES Sigma  
Hyper ladder lV Bioline 
Hyper ladder V Bioline 
Isopropanol Fisher Scientific 
KCl Fisher 
MgCl2 Sigma  
MycoAlert ® Mycoplasma Detection Kit  Lonza 
Na pyruvate  Sigma  
Non-essential amino acids Lonza 
Penicillin / streptomycin solution Lonza 
pH meter  ORION 
Protease Inhibitor Cocktail  Sigma  
Quantitect Reverse Transcriptase kit  Qiagen 
RNAse inhibitor Bioline 
RNase-free water Ambion 
Stratagene Brilliant II SYBR® Green PCR Master Mix Agilent Technologies 
Trizol Ambion 
Trypan blue Sigma 
Trypsin  Lonza  
Uridine Alfa Aesar 
Vitamins  Lonza 
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Table 2.2: Equipment and suppliers 
 
Equipment   Supplier  
 
BioAnalyser 2100 Agilent 
Centrifuge  Sigma  
Filtered pipette tips Fisher Scientific 
G25 needles BD microlance TM  
Hoods  Envair 
Incubator  SANYO 
M3000P qPCR Agilent Technologies 
Nanochips  Agilent Technologies 
Nanodrop 1000 Spectrophotometer Labtech International, UK 
Next generation sequencing (Hi scan SQ system) Illumina 
PCR plates and sealing caps  BIOplastics 
Serological pipette  Fisherbrand 
TBE gel (4-20%) Invitrogen 
Thermo Cycler  MJ Research 
T75 flasks Thermo scientific  
Water bath Grant 
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2.1 Fibroblast cell culture 
All samples were collected according to the ethical approval granted by NRES 
Committee for Yorkshire and Humber (REC ref 12/YH/0330; Protocol number 
STH16573).Frozen control and TARDBP patient fibroblasts were closely 
matched for age and sex (Table 2.3). 
 
Control and TARDBP patient fibroblasts were defrosted from liquid nitrogen at 
room temperature and were cultured using the minimum essential media (MEM) 
with Earle’s Salts and L-Glutamine supplemented with the following: 10%fetal 
bovine serum (FBS), 1%Sodium pyruvate, 1%non-essential amino acids, 
1%vitamins, 0.25mg/ml uridine and 1%penicillin streptomycin solution. To each 
cultured fibroblasts 10ml of pre-warmed media was added to the cells in a T75 
flask and allowed to grow at 37°C, 5%CO2 in a humid incubator. Cells were 
examined regularly under a light microscope and estimated confluency was 
recorded. 
 
 
Table 2.3: Control and patient fibroblasts characteristics. Fibcon= Fibroblast 
control, Fibpat=Fibroblast patient  
 
Condition   Fibroblast 
ID  
Gender  Mutation  Age at time of skin 
biopsy   
Controls  Fibcon 2303 Male None  62 
Fibcon 155 Male 40 
Fibcon 170 Male 63 
Fibcon 159 Female 62 
Fibcon 8 Female 41 
Fibcon 11 Male 58 
Missense 
mutation  
Fibpat 48 Female p.A321V 40 
Fibpat 51 Male p.M337V 62 
Fibpat 55 Male p.G287S 56 
Truncated 
mutation  
Fibpat 192 Male p.Y374X 41 
Fibpat 193 Male p.Y374X 53 
Fibpat 194 Male p.Y374X 68 
 
 
 
 
 
 
 
47 
 
2.1.1 Splitting fibroblasts 
 
Fibroblasts were passaged regularly when they reached ~90% confluency. Cells 
were washed with 5ml of 1x phosphate buffered saline (PBS), harvested with 1ml 
of trypsin (0.5μg/l-EDTA 0.2μg/L) and neutralized with MEM at a ratio of 1:3. Then 
cells were equally distributed into a number of flasks with 10ml of pre-warmed 
MEM, incubated at 37°C, 5% CO2.  
2.1.2 Mycoplasma testing 
 
In SITraN all cell samples were tested by a member of the technical team staff. 
The kit used was MycoAlert ® Mycoplasma Detection Kit by Lonza. 
 
2.2 Cell fractionation and RNA extraction 
2.2.1 Cell fractionation and RNA extraction using Norgen kit for 
Cytoplasmic and Nuclear RNA Purification 
When fibroblasts reached ~90% confluency they were harvested for cell 
fractionation and RNA extraction (Figure 2.1). The procedure was performed 
using Norgen kit for cytoplasmic and nuclear RNA purification, (product number 
2100).  
 
 
Figure 2.1: A flow chart illustrating cell fractionation and RNA extraction. Adapted from: 
https://norgenbiotek.com/sites/default/files/resources/Cytoplasmic-Nuclear-RNA-Kit-Insert-
PI21000-19-M14.pdf 
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2.2.2 Cell fractionation by osmotic pressure 
 
Fibroblast cell membranes were lysed using freshly prepared lysis buffer (1ml of 
hypotonic lysis buffer (10mM HEPES pH 7.9, 1.5mM MgCl2 ,10mM KCl, 0.5mM 
DTT), 1x  of protease inhibitors complete (PIC), 2µl of (40 u=U/µl) RNAse 
inhibitor. To the contents of three combined confluent T75 flasks 200µl of lysis 
buffer was added. Cells were slowly re-suspended then passed through a G25 
needle 10 times every 10min. The lysate was examined under light microscope 
to evaluate the lysed cells and to monitor the nucleus integrity. Trypan blue was 
used to stain the nuclei by mixing 1:10 ratio of lysate to trypan blue. 10µl of the 
stained lysate was applied on a plain slide and covered with coverslip then 
examined under a light microscope. After 20min, the cytoplasm was separated 
from nuclei by centrifugation at 13,000rpm for 3min at 4°C. At that point the 
supernatant was the cytosol and the pellet was the nuclei. The supernatant was 
transferred to a fresh tube and placed on ice. 100µl of lysis buffer was then added 
to the nuclei to lyse the nuclear membrane. It was carefully mixed and passed 
through a G25 needle several times. The nuclear lysate was examined under 
light microscope to evaluate nuclei lysis. After complete nuclear lysis, RNA 
extraction was performed on both the cytoplasmic and the nuclear fractions. 
 
2.2.2.1 RNA extraction by Trizol method 
 
A ratio of 3:1 of Trizol was mixed with the lysate and incubated for 10min at room 
temperature. Afterwards, 1:5 ratio of chloroform was added and mixed for 20sec 
then incubated for 5min at room temperature followed by centrifugation at 
11,000rpm for 10min at room temperature. The aqueous phase was transferred 
to a new tube. Then RNA was washed with equal volume of absolute isopropanol.  
The precipitated using the glycoblue precipitation method (see below section 2.3) 
 
2.3 Glycoblue precipitation method 
  
1µl of 15mg/ml glycoblue reagent was applied to the RNA samples. Next, a ratio 
of 1:15 of 7.5M ammonium acetate was added.  Then, an equal amount of 
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absolute isopropanol was added to the total volume, mixed and incubated at -
20°C overnight. After incubation, RNA samples were spun down at 12000g for 20 
min at 4°C. The supernatant was removed and the blue pellet was resuspended 
in 100µl of 75% ethanol. Samples were spun down at 12000g for 20 min at 4°C. 
The ethanol was discarded and the tubes were left to air dry. The concentrated 
RNA was then resuspended in the 50µl of nuclease free water.   
 
2.4 Nanodrop 1000 spectrophotometer 
 
The principle of the Nanodrop 1000 spectrophotometer was to measure the 
quantity of RNA by measuring the absorbance of UV light at a wavelength 260nm 
and 280nm. The measurement at 260nm indicates the amount of RNA in the 
sample and the amount of protein was estimated at 280nm. In addition, the purity 
was measured by the calculating the ratio of both absorbance which ranges 
between1.8 - 2.0. 
 
2.5 Agilent Bioanalyser 2100 
 
The Agilent Bioanalyser analyzer was used to analyse the RNA quality. The 
technique is based on using chips designed with a set of microchannels that 
separates nucleic acid species based on size by electrophoresis. The procedure 
was performed using the manufacture instructions. 
(http://www.genomics.bham.ac.uk/Nano_Kit.pdf). 
 
2.6 DNase treatment 
 
DNase treatment was performed on the nuclear samples. 1µg of RNA was mixed 
with 1x DNase І reaction buffer. 2 units of DNase І was added and the mixture 
was incubated at 37°C for 10min. Finally, to stop the reaction 1µl 0.5M EDTA was 
added. The mixture was then incubated at 75°C for 10min. 
 
50 
 
2.7 GeneChip® Arrays 
 
Two GeneChip® array types were used in the current work, therefore, two 
manuals were followed to prepare the samples for hybridization. The Human 
Exon Arrays 1.0 ST (The Ambion® WT Expression Kit For Affymetrix® GeneChip® Whole 
Transcript (WT) Expression Arrays and GeneChip® Whole Transcript (WT) Sense Target 
Labeling Assay Manual part number 701880) and for the Human Transcriptome Arrays 
(GeneChip® WT PLUS Reagent Kit Manual Target Preparation for GeneChip® Whole Transcript 
(WT) Expression Arrays part number 703174). Most of the steps were similar therefore 
were described together. However some steps were different thus were 
described separately.    
 
2.7.1 Sample preparation for both Human Exon Arrays 1.0 ST (HEA) and 
Human Transcriptome Arrays (HTA) RNA samples 
 
The ultimate RNA concentration prior RNA labelling was ~200ng diluted in 3µl of 
RNase free water. Thus, the amount of RNA required in the experiment was 
calculated then precipitated using the glycoblue method and resuspended in 3µl 
of RNase free water (Table 2.4 & 2.5). 
The poly-A RNA spike in controls, synthesis of first strand cDNA, synthesis of 
second strand cDNA, synthesis of cRNA by In Vitro Transcription (IVT), purifying  
cRNA, synthesis of  2nd cycle cDNA, Hydrolysis using RNase H and purifying 2nd 
cycle cDNA steps were performed as shown below. 
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Table 2.4: RNA precipitation by glycoblue method for the HEA. ng/µl 
=nanograms/ microliter, µl =microliter, GB= glycoblue, conc=concentration, 
pat=patients, con=control  
 
 
Cell 
fraction  
Mutation 
type 
Fibroblasts ID  RNA 
conc. 
(ng/µl) 
200ng of 
RNA  
GB (µl) Ammonium 
acetate  
100% 
Isopropanol 
 
Cytoplasm - Con 8 60.5 5 1 0.3 7 
Con 11 27 10 1 0.6 12 
Con 170 70 5 1 0.3 7 
Missense 
mutation 
Pat 48 16 15 1 1 17 
Pat 51 20 12 1 0.8 14 
Pat 55 82 5 1 0.3 7 
Nuclear  - Con 8 13 20 1 1.3 23 
Con 11 21 20 1 1.3 23 
Con 170 25 20 1 1.3 23 
Missense 
mutation 
Pat 48 11 20 1 1.3 23 
Pat 51 15 20 1 1.3 23 
Pat 55 12 20 1 1.3 23 
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Table 2.5: RNA precipitation by glycoblue method for HTA. ng/µl =nanograms/ microliter, µl =microliter, GB= glycoblue. 
 
Cell fraction  Mutation type Fibroblasts 
ID  
 
RNA conc. 
(ng/µl) 
Amount required 
200ng  
GB (µl) Ammonium 
acetate 
 
100% 
Isopropanol  
 
Cytoplasm  - Con 155 284 1 - - - 
Con 2303 198 1 - - - 
Con 170 148 1.5 - - - 
Con 159 216 1 - - - 
Missense 
mutation 
Pat 48 81 2.5 - - - 
Pat 55 68 3 - - - 
Pat 51 100 2 - - - 
Truncated 
mutation 
Pat 192 81 2.5 - - - 
Pat 193 128 2.5 - - - 
Pat 194 50 4 1 0.5 5.5 
Nuclear  - Con 155 128 2 - - - 
Con 2303 192 1.5 - - - 
Con 170 136 1.5 - - - 
Con 159 218 1 - - - 
Missense 
mutation 
Pat 48 27 8 1 0.5 9.5 
Pat 55 72 3 - - - 
Pat 51 147 1.5 - - - 
Truncated 
mutation 
Pat 192 36 6 1 0.5 7.5 
Pat 193 144 1.5 - - - 
Pat 194 16 13 - 0.8 13.8 
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2.7.2 Poly-A RNA controls preparation for both HEA and HTA RNA 
samples 
 
To each RNA sample a series of exogenous positive controls were added to the 
reaction in order to monitor the labelling process. These controls were artificially 
polyadenylated RNA designed against B. subtilis genes which are absent in 
human cells. The genes were: lys, phe, thr, and dap. The dap gene was expected 
to show the highest intensity followed by thr, phe and lys. The poly-A RNA 
controls were spiked in at a certain concentration prior to the first strand synthesis 
reaction step (Table 2.6). 
Stepwise, first 2µl of poly-A control stock was mixed with 38μL of poly-A control 
dilution buffer to achieve (1:20) dilution. Secondly, 2μL of the first dilution was 
added to 98μL of poly-A control dilution buffer to prepare the second dilution 
(1:50). Afterwards, 2μL of the second dilution was mixed with 98μL of poly-A 
control dilution buffer to make the third dilution (1:50). Finally, the fourth dilution 
was prepared by diluting the third dilution (1:4) using poly-A control dilution buffer 
according to the number to samples in the experiment. 2μL of this fourth dilution 
was added to the prepared 200ng of total RNA samples (Table 2.7). 
 
Table 2.6: Final concentrations of the spiked in poly-A RNA controls for both HEA 
and HTA  
Poly-A RNA Spike Final concentration 
lys 1:100,000 
phe 1:50,000 
thr 1:25,000 
dap 1:6,667 
 
Table 2.7: Total RNA/Poly-A RNA control mixture for both HEA and HTA  
 
Component  Volume for one reaction (µl) 
Total RNA sample (200ng)  3 
Diluted 4th Poly-A RNA Controls  2 
Total volume 5 
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2.7.3 Synthesis of first strand cDNA, second strand cDNA and cRNA by In 
Vitro Transcription (IVT) for both HEA and HTA 
 
To synthesize the first strand cDNA a reverse transcription reaction was 
performed (Tables 2.8 and 2.9). The RNA samples were primed with a mixed 
random and oligo dT primer each supplemented with T7 promoter sequence. This 
reaction produced ss cDNA. The ss cDNA was then converted to double stranded 
cDNA and the T7 polymerase promoter was completed (Tables 2.10, 2.11 & 
2.12). Afterwards, using T7 RNA polymerase enzyme, an antisense cRNA was 
synthesized and amplified from the second strand cDNA template (Tables 2.13, 
2.14). 
 
 
Table 2.8: First strand master mix components for both HEA and HTA 
 
First strand master mix component  Volume for one reaction (µl) 
First strand buffer mix 4 
First strand enzyme mix 1 
Total volume added to each sample  5 
 
 
Table 2.9: First strand amplification protocol using thermocycler for both HEA 
and HTA 
 Temperature ( °C) Time  
 Annealing  25 1 hour  
Reverse transcription  42 1 hour 
Hold 4 2 min 
 Single cycle  
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Table 2.10: Second strand cDNA master mix components of the HEA 
 
Second-Strand Master Mix component Volume for one reaction (μL) 
Nuclease-free Water 32.5 
Second-Strand Buffer Mix 12.5 
Second-Strand Enzyme Mix 5 
Total Volume 50 
 
Table 2.11: Second strand cDNA master mix components for the HTA 
 
Second strand master mix component Volume for one reaction (μL) 
Second strand buffer 18 
Second strand enzyme 2 
Total volume 20 
 
 
Table 2.12: Second strand amplification protocol using thermocycler for both 
HEA and HTA 
 Temperature (°C) Time  
Second strand synthesis 16 1 hour  
Enzyme denaturation  65 10 min 
Hold 4 2 min 
Single cycle  
 
Table 2.13: IVT Master Mix components for both HEA and HTA 
 
IVT master mix component Volume for one reaction (μL) 
IVT buffer mix 24 
IVT enzyme mix 6 
Total volume 30 
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Table 2.14: IVT amplification protocol using thermocycler for both HEA and HTA 
 
 Temperature ( °C) Time  
Incubation 40 16 hour  
Hold 4 Indefinitely 
 
 
2.7.4 cRNA purification for both HEA and HTA 
In this step all interfering substances are removed leaving a clean stable cRNA. 
These substances include: salts, enzymes, unincorporated nucleotides and 
inorganic phosphates. The purification step is based on using nucleic acid binding 
beads. cRNA binds to the magnetic beads which allows the removal of all the 
unbound interfering material. The procedure was performed using the 
manufacturer’s instructions.  
 
2.7.5 Synthesize 2nd cycle cDNA 
 
2.7.5.1 Synthesize 2nd cycle cDNA for HEA 
 
A sense strand cDNA was synthesized by using random primers and the purified 
cRNA. In this step 10μg of cRNA was required diluted in a total volume of 22ul of 
nuclease free water (Table 2.15). 2µl of random primers were added to the 10µg 
cRNA, mixed thoroughly and incubated in the thermal cycler (Table 2.16). 
Afterwards, the 2nd-cycle master mix was prepared as shown in (Table 2.17) and 
16μL of the master mix was added to each sample, mixed and incubated in the 
thermal cycler (Table 2.20). 
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Table 2.15: 2nd cycle cDNA synthesis (10μg /22µl) of cRNA for the HEA. ng/ µl= 
nanograms/microliter, µl=microliter, con=control, pat=patient    
 
Cellular 
fraction 
Mutation 
type 
Sample ID cRNA (ng/µl) cRNA 
(µl) 
Nuclease 
free water 
(µl) 
Cytoplasm - Con 8 1688.73 6ul 16ul 
Con 11 481.41 20ul 2ul 
Con170 1093.68 9ul 13ul 
Missense 
mutation 
Pat 48 718.27 14ul 8ul 
Pat 51 2406.26 4ul 18ul 
Pat 55 1412.87 7ul 15ul 
Nuclear - Con 8 1494.49 7ul 15ul 
Con 11 2658.18 4ul 18ul 
Con 170 3010.44 3ul 19ul 
Truncated 
mutation  
Pat 48 1312.43 8ul 14ul 
Pat 51 2223.56 5ul 17ul 
Pat 55 616.55 16ul 6ul 
 
Table 2.16: Thermocycler protocol for 2nd cycle cDNA synthesis using random 
primers for the HEA 
 
 Temperature ( °C) Time  
Denature 70 5 min  
Annealing  25 5 min 
Hold 4 2 min 
 Single cycle 
 
Table 2.17: 2nd cycle master mix components for the HEA 
 
2nd cycle master mix component Volume for one reaction (μL) 
2nd cycle buffer mix 8 
2nd cycle enzyme mix 8 
Total volume 16 
 
 
 
2.7.5.2 Synthesize 2nd cycle ss cDNA for HTA  
 
In this step, 15μg cRNA in a total volume of 24μL was required (Table 2.18).To 
each 15µg sample 4µl of 2nd cycle primers was added, mixed thoroughly by 
vortexing and incubated for 5 min at 70°C, 5min at 25°C, then 2min at 4°C. 
Immediately after the incubation, 2nd cycle sense strand cDNA master mix was 
prepared and 12µl of the master mix was added to each sample (Table 2.19). 
Samples were incubated in the thermal cycler (Table 2.20). 
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Table 2.18: 2nd-cycle ss cDNA (15μg /24µl cRNA) for the HTA. ng/ µl= 
nanograms/microliter, µl=microliter, con=control, pat=patient    
 
Cellular fraction  Mutation type  Sample ID cRNA (µl) Nuclease-free 
water (µl) 
Cytoplasmic  - Con 2303 12.3 11.7 
Con 155 7 17 
Con 170 13.6 10.4 
Con159 20.3 3.7 
Missense 
mutation  
Pat 51 16.9 7.1 
Pat 48 13 11 
Pat 55 4.5 19.5 
Truncated 
mutation 
Pat 192 8 16 
Pat 193 10 14 
Pat 194 8 16 
Nuclear - Con 2303 12.5 11.5 
Con 155 4.5 19.5 
Con 170 7.3 16.7 
Con 159 10 14 
Missense 
mutation  
Pat 48 8.7 15.3 
Pat 55  10 14 
Pat 51 23 1 
Truncated 
mutation 
Pat 192 6.5 17.5 
Pat 193 5 19 
Pat 194 8 16 
 
Table 2.19: 2nd cycle sense strand cDNA master mix for HTA  
 
Master mix component Volume for one reaction (μL) 
2nd cycle sense strand cDNA buffer 8 
2nd cycle sense strand cDNA enzyme 4 
Total volume 12  
 
Table 2.20: 2nd cycle cDNA thermocycler protocol for both HEA and HTA 
 
 Temperature ( °C) Time  
Annealing 25 10min  
extension  42 90min 
stop reaction 70 10min 
Hold 4 2min 
Single step 
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2.7.6 Hydrolyze cRNA using RNase H 
cRNA template was degraded using RNase H enzyme leaving ss cDNA. 
 
2.7.6.1 Hydrolyze cRNA using RNase H for HEA 
2µl of RNase H was added to the sense strand cDNA samples. The samples 
were mixed thoroughly and incubated using the thermocycler (Table 2.21). 
 
2.7.6.2 Hydrolyze cRNA using RNase H for the HTA 
4µl of the RNase H was added to sense strand cDNA samples. The samples 
were mixed thoroughly and incubated using the thermocycler (Table 2.21). After 
incubation, 11μL of the nuclease-free water was added to each sample to achieve 
a final volume of 55ul.     
 
Table 2.21 The thermocycler protocol for the hydrolysis of cRNA using RNase H 
for both HEA and HTA 
 Temperature ( °C) Time  
Incubation  37 45min  
Enzyme denaturation 95 5min 
Hold 4 2min 
Single cycle 
 
2.7.7 Purify 2nd cycle cDNA for both the HEA and HTA 
 
This step is similar to the previous purification procedure. All interfering 
substances were removed. These include: salts, enzymes and unincorporated 
dNTPs. The purification step was based on using nucleic acid binding beads 
which allows the removal of all the unbound interfering material leaving purified 
sense strand cDNA. The procedure was performed using the manufacturers’ 
instructions (refer to section 2.7)  
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2.7.8 Fragmentation for both HEA and HTA 
 
The ss cDNA was fragmented by uracil-DNA glycosylase (UDG) and 
apurinic/apyrimidinic endonuclease 1 (APE 1) at the unnatural dUTP residues 
which resulted in DNA breakage. Sense strand cDNA samples were prepared to 
achieve 5.5µg in a total volume of 31.2µl (Tables 2.22 and 2.23). Fragmentation 
master mix was prepared (Table 2.24) and 16.8μL of mixture was added to each 
sample, mixed and incubated in the thermocycler (Table 2.25). The quality of the 
samples was examined using the Agilent Bioanalyser. 
 
 
Table 2.22: HEA sample preparation for fragmentation 
 
 
 
 
 
 
 
 
 
 
 
 
Cellular 
component 
Mutation type Sample ID ss-cDNA =5.5µg 
 
RNase free 
water 
 
Cytoplasmic  - Con 8 15 16.2 
Con 11 22 9.2 
Con 170 20 11.2 
Missense 
mutation  
Pat 48 18 13.2 
Pat 51 18 13.2 
Pat 55 21 10.2 
Nuclear - Con 8 18 13.2 
Con 11  17 14.2 
Con 170 18 13.2 
Missense 
mutation 
Pat 48 20 11.2 
Pat 51 20 11.2 
Pat 55 21 10.2 
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Table 2.23: HTA sample preparation for fragmentation. ss cDNA = sense strand 
complementary DNA , Con=control, Pat=patient, µl= microliter, µg= micrograms   
 
Cellular 
fraction 
Mutation type 
 
Sample ID 5.5µg ss cDNA Nuclease free 
water 31.2µl 
Cytoplasmic  - Con 2303 10.8 20.4 
Con 155 8 23.2 
Con 170 11.4 19.8 
Con 159 12.6 18.6 
Missense 
mutation 
Pat 48 12.7 18.5 
Pat 51 11.5 19.7 
Pat 55 7.5 23.7 
Truncated 
mutation 
Pat 192 9 22.2 
Pat 193 9 22.2 
Pat 194 10 21.2 
Nuclear  - Con 2303 11.3 19.9 
Con 155 7 24.2 
Con 170 9.5 21.7 
Con 159 10.4 20.8 
Missense 
mutation 
Pat 48 10 21.2 
Pat 51 13.5 17.7 
Pat 55 8.5 22.7 
Truncated 
mutation 
Pat 192 8.5 22.7 
Pat 193 7 24.2 
Pat 194 11.5 19.7 
 
Table 2.24: Fragmentation master mix for both HEA and HTA 
 
Component Volume for one reaction (µl) 
RNase-free Water 10  
10X cDNA Fragmentation Buffer 4.8  
UDG, 10 U/μL 1  
APE 1, 1,000 U/μL 1  
Total Volume 16.8  
 
Table 2.25: Thermocycler protocol for fragmentation step for both HEA and HTA  
 
 Temperature ( °C) Time  
Incubation 37 60min  
Stop reaction 93 2min 
Hold 4 2min 
Single cycle 
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2.7.9 Labelling for both HEA and HTA 
 
The fragmented ss cDNA were labelled with biotin by adding 60µl of labelling 
reaction master mix to each sample (Table 2.26). The samples were incubated 
using the thermocycler (Tables 2.27) 
 
Table 2.26: The labelling reaction master mix for both HEA and HTA 
Component Volume for one reaction (µl) 
Fragmented sense strand DNA  45 
5X TdT Buffer 12 
TdT 2 
DNA Labeling Reagent, 5mM 1 
Total Volume 60  
 
Table 2.27: The thermocycler protocol for labelling for both HEA and HTA 
 
 Temperature (°C) Time  
Incubation 37 60min  
Enzyme 
denaturation 
70 10min 
Keep 4 2min 
Single cycle 
 
 
2.7.10 Gel-Shift Assay for both HEA and HTA 
 
The gel shift assay is a procedure that assesses the efficiency of the labelling 
step. This will prevent poor hybridization of fragmented ss cDNA to the targeted 
probe on the array. First, 2mg/mL of NeutrAvidin solution was prepared in of in 
1XPBS. Meanwhile, 4-20% gradient TBE gel was placed into the gel holder and 
loaded with 1XTBE buffer. Random samples were selected to be tested as 
positive and negative controls. 1μL of the fragmented ss cDNA was heated at 
70°C for 2min. For the positive samples, 5μL of 2mg/mL NeutrAvidin was added 
to each sample. Samples were mixed and incubated for 5min at room 
temperature. Negative samples were treated with 1μL of 1XPBS instead of 
NeutrAvidin. 5µl of loading dye was added to all samples and 10µl of the samples 
were loaded to the wells and 5µl of Hyper ladder lV or Hyper ladder V was added 
to the first well. The samples were then run at 150 volts for 1h. After the run was 
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completed the gel was stained with 1X ethidium bromide for 10min. Finally, the 
gel was visualized under UV light.   
 
2.7.11 Hybridization  
 
BioB, BioC, BioD and Cre are pre-labeled hybridization controls that monitor the 
hybridization, washing and staining process of the each array. These controls are 
a mixture of fragmented and biotinylated cRNA extracted from Escherichia.coli 
except for Cre which is extracted from P1 bacteriophage. They were designed to 
bind to the arrays in different intensities.  It is expected that the Cre generates 
the highest signal intensity followed by BioD, BioC, BioB. 
 
Hybridization Cocktail was prepared in a 1.5mL RNase-free microfuge tube as 
shown below (Table 2.28 and 2.29). The 20X Eukaryotic Hybridization Controls 
was heated at 65°C for 5min to ensure a complete dissolution before use. The 
complete Hybridization Cocktail was heated at 99°C for 5min then cool to 45°C 
for 5min. The GeneChip® Arrays were labelled and allowed to equilibrate to 21°C 
prior use. 200µl of the mixture was injected to each array then were placed in 
45°C hybridization oven, rotating at 60rpm, and incubated for 16h. 
  
Table 2.28: Hybridization cocktail for HEA 
 
Component Volume in each sample (µl) 
 
Fragmented and labeled DNA 
target 
59  
Control oligonucleotide B2 (3 nM) 3.7 
20X Eukaryotic hybridization 
controls (bioB, bioC, bioD, cre) 
1 
2X Hybridization mix 110 
DMSO 15.4 
Nuclease-free water 20.9  
Total volume  220 
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Table 2.29: Hybridization cocktail for the HTA 
 
Component Volume in each sample (µl) 
Control oligonucleotide B2 (3 nM) 3.7  
20X Eukaryotic Hybridization 
Controls (bioB, bioC, bioD, cre) 
11  
2X Hybridization mix 110  
DMSO 15.4  
Nuclease-free Water 19.9  
Total Volume  160  
 
 
2.7.12 Wash, Stain and Scan for both HEA and HTA 
 
The Genechips® were serially washed to remove any unspecific materials 
followed by staining with Streptavidin Phycoerythrin (SAPE). Afterwards, the 
Genechips® were scanned (Table 2.30). The scanner emits laser that detects the 
bound labelled sense strand fragmented cDNA which corresponds to the level of 
expression. 
 
 
Table 2.30: Fluidics protocols for the GeneChip® ST Arrays 
 
 Fluidics Station 
Post Hyb Wash #1 10 cycles of 2 mixes/cycle with Wash Buffer A at 30°C 
Post Hyb Wash #2 6 cycles of 15 mixes/cycle with Wash Buffer B at 50°C 
Stain Stain the probe array for 5 minutes in SAPE solution at 
35°C 
Post stain wash 10 cycles of 4 mixes/cycle with Wash Buffer A at 30°C 
2nd Stain Stain the probe array for 5 minutes in antibody solution at 
35°C 
3rd Stain Stain the probe array for 5 minutes in SAPE solution at 
35°C 
Final wash 15 cycles of 4 mixes/cycle with Wash Buffer A at 35°C. 
Holding buffer Fill the probe array with Array Holding Buffer. 
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2.7.13 Quality control for both HEA and HTA 
 
The raw data was generated as CEL files using the Affymetrix GeneChip 
Command Console (AGCC) software. Quality control checks of the arrays was 
performed through Affymetrix Expression Console v1.0 software. This was used 
to check the hybridization quality control of the arrays as it produces informative 
quality control charts and graphs.  
 
2.8 Gene expression analysis 
 
2.8.1 Gene expression analysis using Partek® Genomics Suite TM software 
 
Partek® Genomics Suite TM 6.6 software was used to explore the differentially 
expressed genes of the Human Exon Array 1.0 ST. An ANOVA test was 
performed and the genes with a significant P-value ≤ 0.05 and FC > +1.2 were 
identified. The analysis was performed as the following: cytoplasmic missense 
mutation MT vs. cytoplasmic controls CON and nuclear missense mutation MT 
vs. nuclear controls CON. This allows the identification of differentially expressed 
genes in the cellular compartments. DAVID v6.7 was used to identify the 
biological processes dysregulated in fALS-TARDBP fibroblasts. Biological 
pathways containing differentially expressed genes that had an enrichment score 
(ES) > 1.3 were highlighted as significant which is equivalent to p-value of 0.05. 
 
2.8.2 Gene expression profiling using Qlucore Omics Explorer software 
 
Qlucore Omics Explorer software was used to explore the differentially expressed 
genes of the HTA. CEL files were uploaded into the Qlucore Omics Explorer 
software and samples were normalized according to their cellular fraction type 
prior to the analysis. The p-value was set to < 0.05 and fold change to > + 1.2. 
Two comparison studies were carried out on each type of mutation. For the 
missense mutation; cytoplasmic missense mutation MT vs. cytoplasmic controls 
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CON and nuclear missense mutation MT vs. nuclear controls CON. For the 
truncated mutation, cytoplasmic missense mutation TT vs. cytoplasmic controls 
CON and nuclear missense mutation TT vs. nuclear controls CON. Similarly to 
the Human Exon Arrays 1.0 ST, DAVID v6.7 was used to identify the 
dysregulated biological processes in fALS-TARDBP fibroblasts in both mutation 
types. Biological pathways with enrichment score > 1.3 were highlighted as 
significant which is equivalent to p-value of 0.05 (Huang da et al., 2009). 
 
2.9 Quantitative reverse transcription polymerase chain reaction (qRT-
PCR)  
2.9.1 cDNA synthesis 
1µg of RNA was converted into cDNA using the (QuantiTect® reverse 
transcription kit). First, a genomic DNA elimination reaction was prepared for 
each sample as shown in (Table 2.31). Samples were incubated at 42°C for 2min 
then were placed immediately on ice. Next, the reverse transcription reaction was 
prepared as shown (Table 2.32). Samples were incubated at 42°C for 15 min. 
The reaction was completed by an enzyme inactivation step, 95°C for 3 min. 
cDNA samples were stored at -20°C.   
 
Table 2.31: Genomic DNA elimination reaction component 
  
Component  Volume (µl) 
gDNA wipeout buffer  2 
Template RNA (1µg) variable 
RNase free water  variable 
Total reaction volume  14 
 
Table 2.32: Reverse transcription reaction component  
 
Component  Volume (µl) 
Reverse transcription master mix  1 
Quantiscript RT buffer  4 
RT primer mix  1 
The template RNA after genomic DNA 
elimination   
14 
Total volume  20 
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2.9.2 SYBR green qRT-PCR method 
 
SYBR green is a dye has the ability to bind to double stranded DNA and is widely 
used in experimental studies. In the current work primers were optimized prior to 
use. 
The optimal forward and reverse primers were determined by testing a 
combination of primer concentrations, 150nmol, 300nmol and 600nmol. This was 
achieved by testing the multiple primer concentrations against a universal total 
cDNA. 1µg of universal total RNA was converted to cDNA using (QuantiTect® 
reverse transcription kit) and the staring concentration for the optimization utilized 
12.5ng/µl of cDNA as a starting concentration. The test was performed in 
triplicates using the Brilliant ׀׀ SYBR green master mix from with a total volume 
20µl for each reaction (Table 2.33). The samples were run on the MX3000P Real-
Time PCR machine (Table 2.34). For primer sequences see (Table 2.35). 
 
The optimal primers where those with the lowest cycle thresholds (Ct) value 
showing a single amplified product in the dissociation curve. The efficiency of the 
optimal primers to detect variable cDNA concentrations tested by generating a 
standard curve of two fold serial dilution of the universal cDNA, 12.5ng/µl- 
0.0ng/µl against the optimized primers. The statistical analysis was carried out 
using Graph Pad Prism Software.  
 
Table 2.33: Primer optimization using SYBR green method  
Forward primer 
concentration 
Reverse  primer 
concentration 
SYBR 
green x2 
master 
mix (µl) 
Universal 
cDNA 
(12.5ng/µl) 
RNase 
free water 
(µl) 
150nmol (0.6µl) 150nmol (0.6µl) 10 1 7.8 
150nmol (0.6µl) 300nmol (1.2µl) 10 1 7.2 
300nmol (1.2µl) 150nmol (0.6µl) 10 1 7.2 
300nmol (1.2µl) 300nmol (1.2µl) 10 1 6.6 
300nmol (1.2µl) 600nmol (2.4µl) 10 1 5.4 
600nmol (2.4µl) 600nmol (2.4µl) 10 1 4.2 
NTC 300nmol 
(1.2µl) 
300nmol (1.2µl) 10 - 7.6 
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Table 2.34: qRT-PCR thermocycler program using SYBR green method  
  
 Temperature (°C) Time (min) 
Initial denaturation  95 10min 
Denaturation 95 30sec 
Annealing and extension 60 1min 
Number of cycles 40 
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Table 2.35: Primer sequences generated by prime blast (SYBR green method) 
 
 
Gene 
symbol  
Gene name  Sequence 5’ -> 
3’ 
Forward 
CG% Tm  
ºC 
Sequence 5’ -
> 3’ 
Reverse   
CG
% 
Conc. 
(pmol/µl) 
Tm  
ºC 
Primer 
location  
ACTB Actin beta TCCCCCAACT
TGAGATGTAT
GAAG 
46  58 AACTGGTCT
CAAGTCAG
TGTACAGG 
 
48 100 58 Exon 6-6 
TARDBP TAR DNA 
binding 
protein 
ACAACCGAA
CAGGACCTG
AA 
50 57.3 ACGAACAA
AGCCAAAC
CCCT 
50 100 57.3 Exon 3-4 
SRSF10 FUS 
interacting 
protein 
(serine/argi
nine-rich) 1 
TCTGTTCGTC
AGGAACGTG
G 
55 59.4 AAATCCTCT
TGGACGGC
GAG 
55 100 59.4 Exon 1-2 
NRNP200 Small 
nuclear 
ribonucleop
rotein 
200kDa 
(U5) 
GGATGTAAC
CGCCCGTAG
TC 
60 61.4 CAAACAAG
GGACAGCA
CCTCT 
55 100 59.4 Exon 1-2 
SF3A1 Splicing 
factor 3a, 
subunit 1, 
120kDa 
CAAGACTGC
CAGCTTTGTG
G 
55 59.4 GACCTTGT
GGCGGTAG
TAGG 
60 100 59.4 Exon 2-3 
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2.9.3 Prime time qRT-PCR method 
 
The prime time qRT-PCR application guide fourth edition (IDT) was followed in 
this reaction.   
  
This method was developed to increase primer specificity by utilizing a third 
oligonucleotide labelled probe that binds to the targeted sequence of interest 
along with the forward and the reverse primers but which is tagged with a 
fluorescent label and a quencher. The principle of the reaction is that after primers 
and probes anneal to the targeted DNA sequence, the Taq polymerase enzyme 
extends the forward and reverse primer sequences. Thus, as Taq polymerase 
encounters the bound labelled probe, it cleaves the labelled molecule on the 
probe by 5’->3’ nuclease activity which releases the quencher and causes an 
excitation that is detected by the instrument. This method has better measures 
than the classical SYBR green methods as it has higher sensitivity, primers were 
optimized by the manufacturer (IDT) and are heat stable.  
 
Samples were run in triplicates. Table 2.36 and 2.37 shows the qRT-PCR 
component for a single reaction and the thermocycler program followed 
respectively. For primer specification see (Table 2.38). 
 
Table 2.36: Prime time qRT-PCR reaction component using prime time qRT-PCR 
method 
Component  Amount for 1 reaction (µl) 
20X prime time assay 0.5 
2X master mix 5 
50ng cDNA 1 
RNase free water 3.3 
Total volume  10 
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Table 2.37: qRT-PCR thermocycler program using prime time qRT-PCR method 
  
 Temperature (°C) Time (min) 
Initial denaturation  95 10min 
Denaturation 95 30sec 
Annealing and extension 60 1min 
Number of cycles 40 
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Table 2.38: Primer sequences using prime time qRT-PCR method 
 
Gene 
symbol  
Gene name  Sequence 5’ -> 
3’ 
Forward 
GC% Sequence 5’ -> 
3’ 
Reverse   
GC% Conc. 
(nM) 
Probe 
5’ -> 3’ 
Primer 
location 
Probe 
location  
GAPDH Glyceraldehyd
e-3-phosphate 
dehydrogenas
e 
TGTAGTTGA
GGTCAATGA
AGGG 
45.5 ACATCGCTC
AGACACCAT
G 
52.6 500 56-
FAM/AAGGTCGGA/
ZEN/GTCAACGGAT
TTGGTC/31ABkFQ 
Exon 2-3 Exon 3 
ADARB1  Adenosine 
deaminase, 
RNA-specific, 
B1 (RED1 
homolog rat) 
TGGGATCAG
AGCAAGACA
TAAAG 
47.6 GCGGTTTTC
CTTCACATTC
AG 
45.5 500 56-
FAM/TCCGCCAGT/
ZEN/CAAGAAACCC
TCAAA/31ABkFQ 
Exon 2-4 Exon 3 
METTL1 Methyltransfer
ase like 1 
AGCCACGAT
GACCCAAAG 
55.6 CTTGTGCTTT
GTCCGCTTG 
52.6 500 
 
56-
FAM/TCTTCCTCT/Z
EN/TCCCCGACCCA
CAT /31ABkFQ 
Exon 2-3 Exon 3  
SEMA5A Sema domain, 
seven 
thrombospondi
n repeats (type 
1 and type 1-
like), 
transmembran
e domain (TM) 
and short 
cytoplasmic 
domain, 
(semaphorin) 
5A 
CAGATCCTG
CACAGCCAG 
61.1 TCTTCATTAC
CACATCCCA
GC 
47.6 500 56-
FAM/CAGTTCTAC/Z
EN/CGCACACACG
CAGC/31ABkFQ 
Exon 12-14 Exon 13 
ENAH Enabled 
homolog 
(Drosophila) 
ACTCACAAC
TACCTGCTC
AAG 
45.5 CTCTCCAAC
CTTTCTCTTT
CCA 
50 500 56-
FAM/TCTTTCTCG/Z
EN/CTCCAGCCTTT
CCC/31ABkFQ 
Exon 4-6 Exon 5 
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2.10 RNA Sequencing 
 
The mRNA isolation, fragmentation and priming, first strand cDNA synthesis, 
second strand cDNA synthesis, end prep of cDNA library, adaptor ligation and 
PCR library enrichment were performed using NEBNext® Ultra™ Directional 
RNA library prep kit for  Illumina, part number NEB #E7420S/L. 
 
2.10.1 The mRNA Isolation, fragmentation and priming 
 
The sample concentrations were calculated to achieve 500ng of RNA in a total 
volume of 50μl of nuclease-free water. First, 20μl of the NEBNext Oligo d(T)25 
beads were aliquoted in a clean-up plate  and washed by adding 100μl of RNA 
binding buffer (2X) to the beads and mixed by pipetting the entire volume up and 
down 6 times. The plate was then placed on the magnetic rack for 2min at room 
temperature. After incubation, all the supernatant was removed and discarded 
without disturbing the beads. The plate was then removed from the magnetic rack 
and a second washing step was performed. 50μl of RNA binding buffer (2X) and 
50μl of total RNA sample was added to the beads. The whole mixture was 
carefully resuspended. The plate was then placed on the thermal cycler and 
incubated at 65°C for 5min then kept at 4°C to denature the RNA and facilitate 
binding of the polyadenylated  mRNA to the beads. After incubation, the plate 
was removed from the thermocycler. The beads were resuspended by slow 
mixing followed by 5min incubation at room temperature this allowed mRNA to 
bind to the beads. The beads were mixed for a second time and incubated for 
5min at room temperature. After incubation the plate was placed on the magnetic 
rack for 2min at room temperature in order to separate the polyadenylated  mRNA 
that was bound to the beads from the solution. Carefully, the supernatant was 
aspirated and discarded. Then the plate was removed from the magnetic rack 
and the beads were washed. The unbound RNA was washed-out by adding 200μl 
of wash buffer to each sample. This was then mixed thoroughly by pipetting the 
entire volume up and down 6 times. The plate was placed on the magnetic rack 
for 2min. The supernatant was carefully removed and discarded without 
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disturbing the beads. The plate was then removed from the magnetic rack and 
the washing step was repeated for a total of two washes. Afterwards, 50μl of Tris 
buffer was added to each well and gently mixed by pipetted up and down 6 time. 
The plate was then placed on the thermal cycler, incubated at 80°C for 2min, then 
hold at 25°C in order to elute the polyadenylated mRNA from the beads. After 
incubation was completed 50μl of RNA binding buffer (2X) was added to each 
sample allowing the mRNA to rebind to the beads. The entire volume was mixed 
thoroughly and incubated at room temperature for 5min. After incubation the 
mixture was resuspended by pipetting up and down 6 times and left at room 
temperature for 5min in order for mRNA to bind to the beads. Next, the plate was 
placed on the magnetic rack for 2min at room temperature. The supernatant was 
aspirated and discarded without disturbing the beads. The plate was then 
removed from the magnetic rack and the beads were washed. 200μl of wash 
buffer was added to each sample and was mixed thoroughly by pipette the entire 
volume up and down 6 times. The plate was then placed on the magnetic rack at 
room temperature for 2min. The entire supernatant was removed and discarded. 
The mRNA was eluted from the beads by adding 15.5μl of the first strand 
synthesis reaction buffer and random primer mix (2X) (Table 2.39), the samples 
were then incubated at 94°C for 15min and immediately placed on the magnetic 
rack. 13.5μl of the supernatant was transferred to a clean nuclease-free PCR 
tube which contains the purified mRNA. The purified mRNA were paced on ice to 
be taken forward for the next step first strand cDNA synthesis. 
 
The first strand cDNA synthesis reaction was prepared as shown in (Table 2.40) 
and incubated in the thermocycler (Table 2.41). Then, the second strand cDNA 
synthesis reaction was immediately prepared as described in (Table 2.42) and 
was incubated in the thermocycler for 1 hour at 16°C, with heated lid set at ≤ 
40°C. 
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Table 2.39: First strand synthesis reaction buffer and random primer mix (2X)  
 
Component Amounts per reaction 
(µl) 
NEBNext first strand synthesis reaction buffer (5X) 8  
NEBNext random primers 2 
Nuclease-free water 10  
Total volume 20  
 
 
Table 2.40: First strand cDNA synthesis 
 
Component Amounts per reaction 
(μl) 
Murin RNase inhibitor  0.5  
Actinomycin D ( 0.1 μg/μl) 5  
ProtoScript Reverse transcriptase  1  
Total volume 20  
  
Table 2.41: Thermocycler incubation, heated lid set 105°C 
 
Temperature  Time  
25°C 10 min 
42°C 15 min  
70°C 15 min  
4°C   Hold 
 
Table 2.42: Second strand cDNA synthesis 
 
Component  Amount per reaction (μl) 
Second Strand Synthesis Reaction Buffer (10X)  8 
Second Strand Synthesis Enzyme Mix  4 
RNase free water 48 
Total volume 80 
 
 
2.10.2 Purify the double stranded cDNA using 1.8X Agencourt AMPure XP 
Beads 
 
144μl of (1.8x) resuspended AMPure XP Beads was added to each second 
strand synthesis reaction. The mixture was thoroughly mixed by pipetting up and 
down 10 times followed by 5min incubation at room temperature. Next the plate 
was placed on the magnetic rack to separate the beads from the supernatant. 
After 5min the clear supernatant was removed and discarded. A washing step 
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was performed by adding 200μl of freshly prepared 80% ethanol to each sample 
while the plate on magnetic rack. The samples were incubated for 30sec then the 
ethanol was aspirated and discarded. This washing step was repeated for a total 
of two washes. Afterwards, the beads were incubated for 5min to air dry while on 
magnetic rack. The plate was then removed in order to elute the ds cDNA target 
from the beads. 60μl of 10mM Tris-HCl was added to each sample, mixed well 
and incubated at room temperature for 2min. The plate was placed on the 
magnetic rack and left until the solution was clear. 55.5μl of the supernatant was 
removed and transferred to a clean nuclease free PCR tube. The ds cDNA 
samples were then taken forward to perform the end preparation and adaptor 
ligation. 
 
2.10.3 End preparation and adaptor ligation 
 
The end preparation was prepared as shown in (Table 2.43) and was incubated 
in the thermocycler (Table 2.44). In addition, 15μM NEBNext Adaptor for Illumina 
was diluted 10 fold to achieve a concentration of 1.5μM using 10mM Tris-HCl. 
The adaptor ligation components were directly added to each sample and were 
not pre-mixed (Table 2.45), as this would prevent adaptor-dimer formation. The 
samples were mixed by pipetting and incubated at 20°C for 15min in thermocycler 
with the heated lid turned off. 
 
Table 2.43: End preparation of cDNA Library 
 
Component  Amount per reaction (μl) 
Purified ds cDNA 55.5 
NEBNext End Repair Reaction Buffer (10X) 6.5  
NEBNext End Prep Enzyme Mix 3  
Total 65  
 
Table 2.44: The thermocycler incubation  
 
Temperature  Time  
20°C 30 min 
65 °C 30 min 
4°C Hold  
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Table 2.45: Adaptor ligation 
 
Components  Amounts per reaction 
(μl) 
End Prep Reaction 65  
Blunt/TA Ligase Master Mix 15 
Diluted NEBNext Adaptor 1  
Nuclease-free Water 2.5  
Total 83.5  
 
 
2.10.4 Purify the Ligation Reaction Using AMPure XP Beads 
 
16.5μl of nuclease-free water was added to each ligation reaction to bring the 
final volume to 100μl prior to adding AMPure XP Beads. 100μl of (1.0X) 
resuspended AMPure XP Beads was added to each sample, mixed well by 
pipetting the entire volume up and down 10 times followed by 5min incubation at 
room temperature. After incubation the plate was placed on the magnetic rack to 
separate the beads from the supernatant. Once the supernatant was clear (~ 
5min), it was discarded. A washing step was performed by adding 200µl of freshly 
prepared 80% ethanol to each sample on the magnetic rack, incubated for 30sec 
at room temperature then was carefully removed and discarded. This step was 
repeated for a total of two washes. The beads were left to air dry for 5min while 
the plate on the magnetic rack. Next, the DNA target was eluted from the beads 
with 52µl of 10mM Tris-HCl. The beads were mixed thoroughly and incubated for 
2min at room temperature. Then, the plate was placed on the magnetic rack until 
the solution was clear (~2min). 50µl of the supernatant was transferred to a clean 
well-plate and the beads were discarded. 50µl of (1.0X) resuspended AMPure 
XP Beads were added to each sample and mixed well by pipetting up and down 
10 times, incubated for 5min at room temperature. After incubation, the plate was 
placed on the magnetic rack and incubated for about 5min, until the supernatant 
was clear then was discarded.    
 
A washing step was then performed by adding 200µl of freshly prepared 80% 
ethanol to each sample on the magnetic rack, incubated for 30sec at room 
temperature then was carefully removed and discarded. This step was repeated 
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for a total of two washes. The beads were left to air dry for 5min while the plate 
on the magnetic rack. Next, the DNA target was eluted from the beads with 19µl 
of 10mM Tris-HCl, mixed well and incubated for 2min. Then, the plate was placed 
on the magnetic rack until the solution was clear (~2min). 17μl of the supernatant 
was transferred to a clean PCR tube and proceed to PCR enrichment.   
 
2.10.5 PCR library enrichment 
 
To each 17µl a PCR library enrichment was performed as shown in (Table 2.46). 
The samples were mixed and a PCR reaction was performed (Table 2.47).  
  
Table 2.46: PCR library enrichment component 
 
Components Amounts per reaction (µl)  
NEBNext USER enzyme 3  
NEBNext Q5 Hot Start HiFi PCR 
Master 
25  
Index (X) primer 1  
Universal PCR primer 1  
Sterile H2O 3  
Total  50  
   (X) Index number  
 
 
Table 2.47: PCR cycling conditions 
 
Cycle step Temperature Time Cycles 
USER Digestion  37 °C 15 min 1 
Initial denaturation  98 °C 30 sec 1 
Denaturation  98 °C 10 sec 12 
Annealing/Extension 65 °C 75 sec 
Final Extension 65 °C 5 min 1 
Hold 4°C ∞  
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2.10.6 Purify the PCR reaction using Agencourt AMPure XP Beads 
 
The samples were transferred from the PCR tubes to a PCR plate. 45μl (0.9X) of 
resuspended Agencourt AMPure XP Beads were added to each 50μl PCR 
reaction, mixed well and incubated for 5min at room temperature. After incubation 
the plate was placed on the magnetic rack. After 5min carefully the supernatant 
was aspirated and discarded without disturbing the beads. A washing step was 
performed by adding 200µl of freshly prepared 80% ethanol to each sample while 
on the magnetic rack, incubated for 30sec at room temperature then was carefully 
removed and discarded. This step was repeated for a total of two washes. The 
beads were left to air dry for 5min with the plate on the magnetic rack. Next, the 
plate was removed and the DNA target was eluted from the beads with 23μl 
0.1XTE. The beads were mixed thoroughly and incubated for 2min at room 
temperature. The plate was then placed on the magnetic rack until the solution 
was clear (~ 2min). Next, 20μl of the supernatant was transferred to a clean PCR 
tube and stored at –20°C. 
 
The quality of the fragmented ds cDNA libraries were assessed using Bioanlayser 
High Sensitivity DNA Chip, product number G2938-90321. The libraries were 
quantified using the Qubit Fluorometer.  2ul from each DNA library was measured 
and the concentration of each library was obtained, this was then converted into 
nmol/µl. The total nM for each sample was calculated and diluted to achieve 2nM. 
10 libraries were pooled together in a lane i.e. lane 6 and 7. The libraries were 
loaded into the Illumina HiScan SQ and the standard protocol was followed for 
2x93bp paired end sequencing. The bioinformatics analysis was performed in 
collaboration with Dr Wenbin Wei/ Professor Winston Hide group.  
The Illumina sequencer generated the bcl files which then were converted to fastq 
files by bcl2fastq program. The fastq files were then aligned to the GRCh37 
human genome using bcbio’s star aligner. The reads were counted using the 
feature Counts. Furthermore, the differentially expressed genes were identified 
using the edgeR program with the criteria of a fold change > +1.5 and p-value 
<0.05 (Figure 2.2).  
 (http://bcbionextgen.readthedocs.io/en/latest/contents/introduction.html) 
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Figure 2.2: Schematic diagram showing the analysis of the RNA sequencing data.  
2.11 Fluorescence in situ hybridization 
 
Fluorescence in situ hybridization (FISH) is a powerful technique that reveals the 
location of nucleic acid inside the cell using a designed complementary labelled 
probe. In the current work three probes were designed by the manufacturer 
against potential nuclear mRNAs (Table 2.48). 
 
Table 2.48: Labelled probe sets 
Condition  Gene  Filter set 
Control 155 RNU6-1 Cy5 (650) 
Patient 48 (missense mutation)  MMP1 FITC (488) 
Patient 192 (truncated mutation)  LUC7L3 Cy3 (550) 
      
 
2.11.1 Fibroblast culture in 24 round well plate and 4% formaldehyde cell 
fixation 
A representative fibroblast from each condition was cultured in a 24 round well 
plate, control 155, patient 48 missense mutation and patient 192 truncated 
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mutation. A pre-immersed cover slips in 70% ethanol were placed in each well 
prior to culture using sterile forceps. Then each fibroblast condition was placed in 
a well. Cells were allowed to grow in MEM and were monitored until they reached 
~90% confluency.  
 
In a fume hood, 10mL of fresh 4% formaldehyde solution was prepared by diluting 
1.08mL of a 37% stock formaldehyde with 8.92mL of 1XPBS and was briefly 
mixed. The culture medium was carefully aspirated off, avoiding contact with 
cover slips and cells. Then, gently the cover slips were rinsed twice, each time 
with 2mL/well of 1XPBS. The final 1XPBS wash was aspirated off and 400μL/well 
of freshly prepared 4% formaldehyde was added, making sure that the cover slips 
are immersed completely. Incubated at RT for 30min. Next, the formaldehyde 
solution was aspirated off and gently rinsed three times each with 2mL/well of 
1XPBS. Finally, fixed cells were used immediately in the in situ assay. 
2.11.2 QuantiGene® ViewRNA FISH cell assay 
 
The following were prepared prior to experiment: the dry incubator (GeneChip® 
Hybridization oven 640 by Affymetrix) was set at 40 ± 1°C prior, 420mL of 1XPBS 
was prepared by adding 42mL of 10X PBS to 378mL of H20 and mixed well and 
the protease QS was placed on ice. Also, wash buffer was prepared by adding 
the following components in order to avoid formation of precipitates: 624.96mL 
H20, 1.89mL wash comp 1 and 3.15mL wash comp 2. The probe set diluent QF, 
amplifier diluent QF and label probe diluent QF were pre-warm to 40°C in a water 
bath for 30min.  The probe sets: pre-amplifier mix, amplifier mix, label probe mix 
and 100X DAPI were thawed at RT then placed on ice. The label probe mix was 
protected from light. 
2.11.3 Permeabilize cells with detergent solution 
 
The 1XPBS was aspirated and replaced with 400μL/well of detergent solution 
QC. The plate was covered with lid and incubated for 5 min at RT. After incubation 
the detergent solution QC was aspirated and cells were rinsed twice with 
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2mL/well of 1XPBS. The cells were allowed to sit in the final 1XPBS wash while 
preparing the working protease solution for the next step. 
2.11.4 Digestion with working protease solution 
 
The working protease solution was prepared by diluting the protease QS 1:4,000 
in 1X PBS (Table 2.49). The mixture was mixed briefly then 1XPBS was replaced 
with 400μL/well of working protease solution. The plate was covered with lid and 
incubated for 10 min at RT. After incubation the working protease solution was 
aspirated off and cells were rinsed three times with 2mL/well of 1XPBS. Samples 
were allowed to sit in the final 1XPBS wash while preparing the working probe 
set solution for the next step. 
Table 2.49: Working protease solution for 1 well  
Component  Amount (μL) 
Protease QS 0.1  
1XPBS 399.9 
Total volume 400.0  
 
2.11.5 Hybridization with probe sets 
 
The working probe set solution was prepared by diluting each Probe Set 1:100 in 
pre-warmed probe set diluent QF (Table 2.50). The mixture was mixed briefly, 
the 1XPBS was aspirated off and replaced with 400μL/well of the appropriate 
working probe set solution. For the “no probe” negative control, 400μL/well of pre-
warmed probe set diluent QF was used. The wells were covered with lid and 
incubate at 40 ± 1°C for 3h. 
Table 2.50: Working probe set solution for 1 well 
Component  Amount (µl) 
Probe set  4  
Probe set diluent QF (pre-warmed at 40 °C) 396  
Total volume 400 
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2.11.6 Cells wash  
 
The plate was removed from the incubator and the working probe set solution 
was aspirated off. The cells were washed three times each with 2mL/well of wash 
buffer. Then cells were allowed to soak in wash buffer for 2min in each wash. 
Samples were left in the final washing buffer while preparing the pre-amplifier mix 
solution. 
  
2.11.7 Hybridize with pre-amplifier 
 
The working pre-amplifier mix solution was prepared by diluting pre-amplifier mix 
1:25 in pre-warmed amplifier diluent QF (Table 2.51). The mixture was mixed 
briefly, the wash buffer was aspirated and replaced with 400μL/well of working 
pre-amplifier mix solution. The plate was covered with a lid and incubate at 40 ± 
1°C for 30min. 
 
Table 2.51: Working pre-amplifier mix solution for 1 well  
Component  Amount (μL) 
Amplifier Diluent QF (pre-warmed at 40 °C) 384  
Pre-amplifier Mix 16 
Total volume 400 
 
 
2.11.8 Cells wash  
 
The plate was removed from the incubator and the working pre-amplifier mix 
solution was aspirated off. The cells were washed three times each with 2mL/well 
of wash buffer. Cells were allowed to soak in wash buffer for 2min in each wash. 
Samples were then left in the final washing buffer while preparing the amplifier 
mix solution. 
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2.11.9 Hybridize with amplifier 
The working amplifier mix solution was prepared by diluting amplifier mix 1:25 in 
pre-warmed amplifier diluent QF (Table 2.52). 
 
Table 2.52: Working amplifier mix solution for 1 well  
Component  Amount (μL) 
Amplifier diluent QF (pre-warmed at 40 °C) 384  
Amplifier mix 16 
Total volume 400 
 
 
2.11.10 Cells wash  
 
The plate was removed from the incubator and the working amplifier mix solution 
was aspirated off. The cells were washed three times each with 2mL/well of wash 
Buffer. Cells were allowed to soak in wash buffer for 2min in each wash. Samples 
were then left in the final washing buffer while preparing the working label probe 
mix solution. 
 
2.11.11 Hybridize with labelled probe 
 
The working label probe mix solution was prepared by diluting label probe mix 
1:25 in pre-warmed label probe diluent QF (Table 2.53). The mixture was mixed 
briefly and was protected from light. The wash buffer was aspirated and replaced 
with 400μL/well of working label probe. The plate was covered with a lid and 
incubated at 40 ± 1 °C for 30min. 
 
Table 2.53: Working label probe mix solution for 1 well  
Component  Amount (μL) 
Label probe diluent QF (pre-warmed at 40 °C) 384 
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Label probe mix 16 
Total volume 400 
 
2.11.12 Cells wash  
 
The plate was removed from the incubator and the working label probe mix 
solution was aspirated off. The cells were washed three times each with 2mL/well 
of wash buffer. At the first two washes cells were allowed to sock in wash buffer 
for 2min and the final wash was incubated for 10min. Samples were then left in 
the final washing buffer while preparing the working DAPI solution. 
2.11.12 DAPI staining 
 
The working DAPI solution was prepared by diluting the 100X DAPI 1:100 in 
1XPBS (Table 2.54). The mixture was mixed briefly and was protected from light. 
The wash buffer was aspirated and replaced working DAPI solution. Cells were 
incubated at RT for 1min. Afterwards, DAPI working solution was aspirated off 
and cells were washed once with 2mL/well of 1X PBS. Then 400μL/well of fresh 
1XPBS was added. 
 
Table 2.54: Working DAPI solution for 1 well  
Component  Amount (μL) 
1XPBS 396  
100XDAPI 4  
Total volume 400 
 
2.11.13 Mounting on glass slide 
 
A small drop of VECTASHIELD anti-fade mounting medium was placed on a 
microscope slide avoiding air bubbles. Using a fine tipped forceps the cover slip 
was removed from the 24 round well plate and the edge of the cover slip was 
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gently dabbed on a dry laboratory wipe to remove excess 1XPBS. The cover slips 
were mounded facing down on the spot of mounting media avoiding air bubbles. 
Slides were left to cure overnight at RT. After that slides were stored at 2-8°C 
protected from light from light. The fluorescent signals were stable for up to one 
week. 
 
2.11.14 Image samples using confocal microscope 
 
Leica SP5 confocal microscope using 63x 1.20 lens along with the appropriate 
filter settings (Table 2.55) were applied to examine the cells.   
 
Table 2.55: Leica SP5 confocal microscope filter settings 
RNA Probe  Probe set  Filter set  
Human RNU6  Type 6 Cy5 (650) 
Human MMP1 Type 4 FITC (488) 
Human LUC7L3 Type 1 Cy3 (550) 
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Chapter 3: Human Exon 1.0 ST Array GeneChip®  
3.1 Human Exon 1.0 ST Array GeneChip® 
 
Affymetrix GeneChip® Human Exon 1.0 ST Arrays were designed with better 
features over conventional 3’ IVT microarrays as discussed in section 1.1.6.1 and 
1.1.6.2. They provide the maximum information needed to understand gene 
expression as their aim is to detect transcripts along the entire length of an mRNA 
rather than the 3’ end region only. Each transcript isoform of a particular gene 
consists of exons which can be identified by measuring the signal intensities of 
each exon which is presented on the GeneChip® by four probes. Measuring the 
combination of these signals allows the identification of known or novel 
alternatively spliced transcripts when compared to the current data bases 
(http://www.affymetrix.com). 
In this chapter, RNA extracted from fibroblasts of fALS-TARDBP missense 
mutation and controls was hybridized to the Human Exon 1.0 ST Arrays and the 
resulting gene expression profiles were analysed in order to identify dysregulated 
pathways occurring in the presence of mutant TARDBP. 
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3.2 Fibroblast culture 
 
Primary fibroblasts from three fALS-TARDBP cases carrying missense mutation 
and three aged and gender matched controls (Table 2.3 in chapter 2: materials 
and methods) were grown and the doubling rate was monitored carefully. Cells 
were evaluated under the light microscope. The goal was to achieve evenly 
distributed monolayer fibroblasts throughout the flasks avoiding clump formation 
or contamination. Cells were allowed to grow to no more than 90% confluency to 
avoid contact inhibition (Abercrombie, 1970).   
 
3.3 Cytoplasmic and nuclear RNA concentrations using the Nanodrop 
spectrophotometer 
 
Cell fractionation and RNA extraction was carried out using the Cytoplasmic and 
Nuclear RNA purification kit (Norgen Biotek). The Nanodrop spectrophotometer 
was used to measure the quantity of RNA in the samples. RNA yields from each 
cellular compartment are shown in Table 3.1. All samples presented good 
quantity of RNA except cytoplasmic control 11 which showed the lowest RNA 
concentration (yield= 7.47ng/µl). All RNA samples were eluted in 50µl of RNase 
free water, thus the total RNA yield of cytoplasmic control 11 was 373.5ng which 
was sufficient for the Human Exon 1.0 ST Array experiment which requires a total 
of 200ng. However, a further accurate measurement of the quantity and quality 
was necessary using the Agilent Bioanalyser for all samples prior to the Human 
Exon 1.0 ST Array RNA preparation. 
 
The nuclear samples were DNase treated in order to eliminate any genomic DNA 
that might interfere with the Human Exon 1.0 ST Array experiment or in qRT-PCR 
validation. Table 3.2 illustrates the RNA yields post-DNase treatment. Nuclear 
samples demonstrated good quantity of RNA. The lowest RNA concentration 
post-DNase treatment was patient 51(28.86ng/µl). The total yields of patient 51 
=1443ng which was sufficient.  
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Table 3.1: Controls and patients RNA yields using the Nanodrop 
spectrophotometer. ng/µl=nanograms/microliter, Con= Control, Pat= Patient, 
ID= identification 
 
Cellular 
fraction   
Mutation 
type 
Sample 
ID 
RNA yields (ng/µl) Total yields (ng/µl) 
Cytoplasmic 
 
- Con 8  68.47 3423.5 
Con 11 7.47 373.5 
Con 170 50.61 2530.5 
Missense 
mutation 
Pat 48 10.24 512 
Pat 51 20.41 1020.5 
Pat 55 71.25 3562.5 
Nuclear 
Pre-DNase 
treatment 
- Con 8  79.42 3971 
Con 11 32.99 1649.5 
Con 170 88.25 4412.5 
Missense 
mutation 
Pat 48 84.47 4223.5 
Pat 51 13.57 678.5 
Pat 55 59.42 2971 
 
 
 
 
 
Table 3.2:  Nuclear RNA yields post-DNase treatment using the Nanodrop 
spectrophotometer. Cytoplasmic RNA samples were not DNase treated. 
ng/µl= nanograms/microliter, Con= Control, Pat= Patient, ID= identification     
 
Cellular 
fraction  
Mutation 
type 
Sample ID RNA yields (ng/µl) Total RNA yields (ng/µl) 
 
Nuclear 
Post-
DNase 
treatment 
- Con 8 48.03 2401.5 
Con 11 36.2 1810 
Con 170 66.14 3307 
Missense 
mutation 
Pat 48 38.3 1915 
Pat 51 28.86 1443 
Pat 55 45.64 2282 
 
 
 
 
 
 
 
 
90 
 
3.4 RNA quality using Agilent Bioanalyser 2100 
 
An accurate measurement of the RNA concentrations and integrity was 
performed by the Agilent Bioanalyser 2100. The device separates 1µl of RNA 
sample into its different major species creating informative electropherograms 
that can be visibly interpreted. A good RNA integrity can be defined as achieving 
the following two characteristics: first, detecting two distinct peaks of rRNA both 
18s and 28s. Second, the level of rRNA28s is required to be approximately twice 
the level of rRNA18s. This implies that mRNA transcripts are full length (Figure 
3.1). Figure 3.1B is the cytoplasmic control 8 RNA demonstrating sharp distinct 
peaks of rRNA18s and rRNA28s at sizes ~2000 (nt) and ~4000 (nt) respectively 
and the rRNA28s was about double the level of rRNA18s. Similarly, pre-DNase 
treated nuclear RNA of control 8 showed the same characteristics of the 
cytoplasmic RNA however a peak between rRNA18s and rRNA28s was present 
which is suggested to be genomic DNA and degraded rRNA highlighted in a red 
box (see figure 3.1C). Post-DNase treated nuclear RNA of control 8 is shown in 
(Figure 3.1D) the graph indicates that genomic DNA was reduced effectively. 
However, it is clearly observed that RNA integrity was affected. This was also 
confirmed by the RIN values which were shown to be decreased following DNase 
treatment (Table 3.3). RNA sample selection for the Human Exon 1.0 ST Array 
experiment was based on two criteria:  RIN cut-off value >5 and a minimum of 
~200ng RNA yields. The cytoplasmic RNA samples yields ranged ~4000ng to 
800ng and the post-DNase nuclear RNA samples ranged ~200ng to 500ng 
(Table 3.3). All RINs were >5, therefore, all samples were taken forward.  
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Figure 3.1: Representative electropherograms generated by the Agilent Bioanalyser 2100 of 
sample (Control 8). (A) Standard ladder graph that represents the RNA markers which act as a 
reference for the other RNA samples. (B) Cytoplasmic RNA sample (Control 8), (C) Nuclear RNA 
sample (Control 8) and (D) Post-DNase treated nuclear RNA sample (Control 8). The Y axis 
represents the UV light absorption in fluorescence unit (FU) and the X axis represents the size in 
nucleotides (nt).  
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Table 3.3: Cytoplasmic and post-DNase treated nuclear RNA yields using Agilent 
Bioanalyser. ng=nanograms, RIN= RNA integrity number, ng/µl= nanograms/ 
microliter, Con= Control, Pat= Patient, ID= identification   
 
Cellular 
fraction   
Mutation 
type 
Sample ID RNA yields 
(ng/µl) 
RIN  Total RNA 
yields (ng) 
Cytoplasmic  - Con 8 40 10 2000 
Con11 27 5 1350 
Con 170 70 8.7 3500 
Missense 
mutation 
Pat 48 16 8.5 800 
Pat 51 20 9.8 1000 
Pat 55 82 10 4100 
Nuclear 
Post-DNase 
treatment  
- Con 8 13 6.8 260 
Con11 21 5.4 420 
Con 170 25 6.9 500 
Missense 
mutation 
Pat 48 11 5.3 220 
Pat 51 15 5 300 
Pat 55 12 5 240 
 
 
 
 
3.5 Human Exon 1.0 ST Arrays GeneChip® 
 
Human Exon 1.0 ST Arrays GeneChip® Affymetrix were used to measure gene 
expression. Samples were prepared and quality checked at various stages to 
ensure sufficient amount of transcripts of good quality were prepared. This was 
achieved using both the Nanodrop spectrophotometer and the Agilent 
Bioanalyser (see materials and methods section 2.4 and 2.5). RNA samples were 
linearly amplified to obtain 10µg of cRNA that is required for the preparation of ss 
cDNA. RNA samples were successfully amplified and the cRNA yields were 
greater than the required concentration (10µg) ranging from 19.2µg to 120.4µg 
(Table 3.4). ss cDNA preparation was performed and the threshold was to obtain 
5.5µg of ss cDNA in order to proceed with the fragmentation and labelling step. 
The ss cDNA was properly synthesized and high yields were achieved. Table 3.5 
list the ss cDNA concentrations ranging from 7.44µg to 11.19µg.     
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Table 3.4: cRNA yields. µg= micrograms, ng/µl=nanograms/microliter, Con= 
control, Pat= Patient, ID= identification  
 
Cellular 
fraction  
Mutation 
type 
Sample ID  cRNA yields 
(ng/µl) 
Total yield 
(µg) 
Cytoplasmic  - Con 8 1688.73 67.5 
Con11 481.41 19.2 
Con 170 1093.68 43.7 
Missense 
mutation 
Pat 48 718.27 28.7 
Pat 51 2406.26 96.2 
Pat 55 1412.87 56.5 
Nuclear 
Post-DNase 
treatment  
- Con 8 1494.49 69.7 
Con11 2658.18 106.3 
Con 170 3010.44 120.4 
Missense 
mutation 
Pat 48 1312.43 52.4 
Pat 51 2223.56 88.9 
Pat 55 616.55 24.6 
 
 
 
Table 3.5: ss cDNA yields. µg= micrograms, ng/µl= nanograms/microliter, Con= 
Control, Pat= Patient, ID= identification 
 
Cellular 
fraction  
Mutation 
type  
Sample ID cRNA yields (ng/µl) Total yield (µg) 
Cytoplasmic  - Con 8 373.61 11.19 
Con11 248.11 7.44 
Con 170 277.76  8.31 
Missense 
mutation  
Pat 48 303.06 9.09 
Pat 51 308.72 9.24 
Pat 55 266.68 7.98 
Nuclear 
Post-DNase 
treatment 
- Con 8 301.74 9.03 
Con11 328.37 9.84 
Con 170 300.07 9 
Missense 
mutation 
Pat 48 270.85 8.1 
Pat 51 282.50 8.46 
Pat 55 262.75 7.86 
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3.5.1 Fragmentation 
 
After preparing ss cDNA samples to the desired concentrations, they were 
fragmented and labelled in order to facilitate their binding to the probes on the 
array and for this to be detected. The recommended length is ~ 25 nt. Controls 
and patients fragmented ss cDNA were within the acceptable length. Figure 3.2 
illustrates a representative fragmented ss cDNA (Control 8). 
 
 
 
 
Figure 3.2: Representative electropherogram of fragmented single stranded DNA samples 
(Control8). The Y axis represents the UV light absorption (FU) and the X axis represents size in 
(nt). The peak point of fragments can be assessed to be approximately 24-25 nucleotides in length 
when compared to the ladder.  
 
3.5.2 Gel shift assay 
 
The gel shift assay is a procedure that assesses the efficiency of the labelling 
step (see materials and methods section 2.7.10). Briefly, randomly selected 
samples were incubated with neutravidin to facilitate its attachment to biotin 
labelled fragmented ss cDNA. Samples were then separated on a 4-20% gradient 
TBE gel by electrophoresis. The gel was stained with ethidium bromide in order 
to visualize the bands under UV light. All 9 of the 12 samples, were treated with 
neutravidin and considered the positive samples. 3 samples were treated with 
PBS instead of neutravidin. Positive samples showed bands at the expected 
position (400bp) and the negative samples did not show bands (Figure 3.3). This 
indicated that the labelled samples contained biotin which had hybridized to the 
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neutravidin and caused an altered movement of the molecules in the gel. 
Therefore, all the labelled samples were considered to have passed quality 
control and could be put on the arrays. 
 
 
 
 
                                           
                                                                                                    
 
Figure 3.3: Gel shift assay presenting 4-20% TBE gel electrophoresis stained with ethidium 
bromide and visualized under UV light. The positive samples showed bands at the expected 
positions (400 bp). The negative samples did not show any bands.  
Well no 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Sample 
ID 
Hyper 
ladder 
IV 
Con 
N8 
Con 
C8 
Pat 
N48  
Pat 
C48 
Con 
N11 
Con 
C11 
Pat 
N51 
Pat 
C51 
Con 
N170 
Con 
C170 
Pat 
N55 
Pat 
C55 
Empty 
well 
Hyper 
ladder 
IV 
 Positive samples  Negative samples  
*Con= Control, Pat= Patient, N= Nuclear, C= Cytoplasmic 
 
 
 
 
 
 
 
 
 
96 
 
3.5.3 Human Exon 1.0 ST Arrays quality control 
 
The Human Exon 1.0 ST Arrays raw data was generated as CEL files using the 
Affymetrix GeneChip® Command Console (AGCC) software. Quality control 
checks of the arrays was performed through Affymetrix Expression Console v1.0 
software. 
 
The spiked in poly-A RNA controls are exogenous positive controls that are 
included in sample preparation (See section 2.7.2 for full description). Poly-A 
spiked in controls were prepared at different levels of concentrations. The dap 
gene was expected to demonstrate the highest intensity followed by thr, phe and 
lys. Figure 3.4 demonstrates the poly-A spiked in controls in a linear graph. As 
seen in figure 3.4A all cytoplasmic samples showed good quality of amplification 
except control 11 showed a slight flip in the concentration of (lys) with (phe). That 
might be due to low concentration of cytoplasmic control 11 RNA yields and the 
input RIN was near the lower limit (see table 3.1 & 3.3). Also there might be a 
technical reason i.e. inadequate spiked in poly-A control dilution preparation. 
Hybridization intensities of the poly-A spiked in controls of the post-DNase treated 
nuclear samples are shown in Figure 3.4B. Uneven hybridization intensities were 
demonstrated which might be due to the effect of DNase treatment on the RNA 
integrity. 
 
In addition hybridization spiked in controls intensities were measured (Figure 
3.5). BioB, BioC, BioD and Cre are prelabeled hybridization controls that monitor 
the hybridization, washing and staining process of the arrays (see section 2.7.11 
for full description). It is expected that the Cre would have the highest signal 
intensity followed by BioD, BioC and BioB. All cytoplasmic and post-DNase 
treated samples showed good and even distribution of the hybridization signal 
intensity (Figure 3.5 A&B). The probe set intensities were measured and a box 
plot graph was generated to demonstrate the overall deviation of probe set 
signals for each array. The box represents the upper quartile, lower quartiles and 
median. The whiskers represent the highest and the lowest average signal 
intensities of the probes (Figure 3.6). The median value across samples was 
97 
 
detected at ~ 0.1 (red line across the boxes Figure 3.6 A&B) which is within 
expected range (0.1-0.2).   
 
 
    
 
 
Figure 3.4: Poly-A spiked in controls linear graph from the Human Exon 1.0 ST Array. 
(A)The cytoplasmic hybridization intensities of the poly-A spiked in controls. All cytoplasmic 
samples showed good quality of amplification except control 11 showed a slight flip in the 
concentration of (lys) with (phe). (B) The poly-A spiked in hybridization intensities of the post-
DNase treated nuclear samples. Uneven hybridization intensities which might be due to DNase 
treatment. 
 
 
    
Figure 3.5:  BioB, BioC, BioD and Cre hybridization spiked in controls linear graph from the 
Human Exon 1.0 ST Array. (A) The cytoplasmic samples, (B) The post-DNase treated nuclear 
samples.  
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Figure 3.6: Box plot graph of normalized relative log expression signals from the Human Exon 
1.0 ST Array. Each box plot represents the mean and standard deviation of an array. The red 
middle line across the boxes is the median gene expression of all samples. The whiskers 
represent the highest and the lowest average signal intensities of the probes. (A) Cytoplasmic 
samples relative expression signals. (B) The post-DNase treated nuclear samples relative 
expression signals.   
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3.6 Gene expression profiling using Partek® Genomics Suite TM 6.6 
software 
CEL files from controls and patients were uploaded into Partek® Genomics Suite 
TM 6.6 software. The differentially expressed genes were analysed using an 
ANOVA test. Genes with a significant p-value ≤ 0.05 and fold change > +1.2 were 
identified. These parameters were set to identify the maximum number of 
differentially expressed genes. 
To investigate the hypothesis that, cytoplasmic and nuclear transcriptomic profile 
from mutant TARDBP fibroblasts will generate different transcriptomic profiles 
than control fibroblasts and will establish transcripts and pathways dysregulated 
in the presence of mutations in TARDBP, the analysis was performed as follows: 
cytoplasmic missense mutation MT vs. cytoplasmic controls CON and nuclear 
missense mutation MT vs. nuclear controls CON. This facilitates the identification 
of differentially expressed genes in the cellular compartments which then allows 
the identification of dysregulated biological processes in fALS related TARDBP 
missense mutation cases. Cytoplasmic MT vs. cytoplasmic CON showed 702 
differentially expressed genes. 426 were up-regulated and 276 were down-
regulated (Figure 3.7A). The nuclear MT vs. nuclear CON demonstrated 685 
differentially expressed genes. 345 were up-regulated and were 340 down-
regulated (Figure 3.7B). 
 
 
 
Figure 3.7: Differentially expressed genes in cytoplasmic and nuclear fALS-TARDBP compared 
to controls   
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3.6.1 Cytoplasmic MT vs. cytoplasmic CON gene expression profiling 
using the Human Exon 1.0 ST Arrays  
 
The transcript IDs of the differentially expressed genes from cytoplasmic MT vs. 
cytoplasmic CON analysis were uploaded into DAVID v6.7 in order to identify the 
biological processes dysregulated in fALS-TARDBP fibroblasts. Biological 
pathways containing differentially expressed genes that had an enrichment score 
(ES) > 1.3 were highlighted as significant which is equivalent to p-value of 0.05 
(Huang da et al., 2009). The highest enrichment score hit was found in 
methylation, whereas the largest number of genes were clustered in RNA 
processing, neuron differentiation and cytoskeleton organization (Table 3.6).  
 
3.6.1.1 Differential gene expression of cytoplasmic MT vs. CON  
 
Table 3.6 shows that methylation, neuron differentiation, RNA processing, and 
cytoskeleton organization were the top four highest enriched biological processes 
in fALS cytoplasmic missense mutation. Thus, they were selected for further 
investigation. 
 
Table 3.6: Functionally enriched biological processes generated by DAVID of 
the cytoplasmic MT vs. CON differentially expressed genes. GO=Gene 
ontology, ES=Enrichment score, no.=number 
 
ES P-
value  
Gene no.  Biological process  GO 
2 3.9E-3 8 Methylation BP_FAT 
1.81 1.8E-1 16 Neuron differentiation BP_FAT 
1.73 2.7E-3 27 RNA processing BP_FAT 
1.48 1.8E-1 16 Cytoskeleton organization BP_FAT 
1.37 2.8E-2 6 Telencephalon development BP_FAT 
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3.6.1.1.1 Methylation 
 
Methylation is known to be an epigenetic modification process that can affect 
gene expression by silencing or activating genes (Grewal and Rice, 2004). Table 
3.7 lists the methylation related genes dysregulated in the fALS-TARDBP 
cytoplasmic missense mutation. A number of genes involved in the methylation 
process were found to be down-regulated in the mutant TARDBP fibroblasts. 
 
A reduction was found in the expression of the DNA (cytosine-5)-
methyltransferase 1 (DNMT1) (FC=-1.5). DNMT1 is a modifying enzyme that 
binds to the CpG dinucleotide sequences at the promotor region to facilitate the 
addition of methyl group to the cytosine leading to gene silencing. In addition, it 
is responsible for the maintenance of DNA methylation following cell 
differentiation (Bonfils et al., 2000). Furthermore the GATA zinc finger domain 
containing 2A (GATAD2A) gene which belongs to the methyl-CpG-binding 
protein-1 complex and encodes for two proteins (p66-α and p66-β proteins) was 
decreased (FC=-1.2). These proteins are involved in the modulation of gene 
repression by the deacetylation of methylated nucleosomes (Brackertz et al., 
2002). The helicase, lymphoid-specific (HELLS) gene was reduced (FC=-2). It 
encodes for the chromatin-remodelling ATPase enzyme that is involved in DNA 
strand separation that allows DNA methylation to take place (Lungu et al., 2015). 
Moreover, the coactivator-associated arginine methyltransferase 1 (CARM1) 
gene expression was down-regulated (FC=-1.2). This gene belongs to the protein 
arginine methyltransferase family and is involved in the methylation of the 
guanidine nitrogen molecules of arginine residues in a protein. It is also involved 
in the repression of the cAMP-dependent pathway and the activation of nuclear 
hormones by triggering different signalling cascades (Xu et al., 2001). 
 
Furthermore, the euchromatic histone-lysine N-methyltransferase 1 (EHMT1) 
was decreased (FC=-1.2). It is a part of the DNA repressor complex PR domain-
containing protein 16 (PRDM) which is involved in the brown adipocyte 
differentiation (Ohno et al., 2013). In addition, it was suggested to plays a role in 
silencing the Myc gene (Dominguez-Sola et al., 2007). Myc is a transcription 
factor that functions both as an activator and suppressor. It is involved in cell 
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proliferation, cell growth and apoptosis. It is activated through different signalling 
pathways including the MAP kinases (Dominguez-Sola et al., 2007). EHMT1 was 
also suggested to participate in cell cycle G1 phase (Ogawa et al., 2002). The 
RAB6C member RAS oncogene family (RAB6C), a member of the RAS 
oncogene family showed a reduction in gene expression (FC=-1.2) (Rajalingam 
et al., 2007).  
 
In contrast only a single gene was up-regulated, the BTG family, member 2 
(BTG2) (FC=1.3). BTG2 is an anti-proliferative protein which is involved in the 
regulation of cell cycle at the G1/S phase and is triggered by the p53 tumour 
suppresser protein during DNA damage (Rouault et al., 1996, Duriez et al., 2002). 
 
 
Table 3.7: Genes involved in methylation in cytoplasmic missense mutation 
Gene 
symbol 
Gene names P-value  Fold 
change 
BTG2 BTG family, member 2 0.02 1.35 
CARM1 
 
Coactivator-associated 
arginine methyltransferase 1 
0.05 
 
-1.28 
 
DNMT1 DNA (cytosine-5-)-
methyltransferase 1 
0.04 -1.50 
EHMT1 
 
Euchromatic histone-lysine N-
methyltransferase 1 
0.04 
 
-1.29 
 
GATAD2A GATA zinc finger domain 
containing 2A 
0.05 -1.28 
HELLS Helicase, lymphoid-specific 0.03 -2.02 
RAB6C RAB6C, member RAS 
oncogene family 
0.04 -1.24 
SUZ12 Suppressor of zeste 12 
homolog (Drosophila) 
0.006 -1.32 
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3.6.1.1.2 Neuron differentiation 
 
As the model used in the current study were fibroblasts, it was surprising to find 
a group of genes assigned under the term neuron differentiation by DAVID and 
many of these genes were up-regulated (see Table 3.8). A further description of 
each gene is addressed below. 
 
The BTG family member 2 (BTG2), as well as being involved in methylation was 
found to be increased (FC=1.3). It encodes for an anti-proliferative protein which 
is involved in the regulation of the cell cycle and is induced by the DNA damage 
and p53 tumour suppresser protein (Rouault et al., 1996, Duriez et al., 2002).  An 
increased expression was observed in dopamine receptor D1 gene (DRD1).  
(FC=1.2). DRD1 is a G-protein coupled receptor that is activated by the 
neurotransmitter dopamine which itself stimulates the enzyme adenylyl cyclase 
(Monsma et al., 1990). Adenylyl cyclase converts ATP into cyclic AMP (cAMP) 
which then stimulates the phosphorylation of the protein kinase A (PKA) 
(Sassone-Corsi, 1998). PKA is involved in several pathways however, one of the 
final stages of this signalling pathway is the phosphorylation of the cAMP 
response element-binding protein by PKA which is then diffused into the nuclear 
membrane and binds to the promoter region of a particular gene causing a down-
regulation or up-regulation of gene expression (Dearry et al., 1990, Sassone-
Corsi, 1998).  
 
Moreover, an elevated gene expression was found in the inhibitor of DNA binding 
3, dominant negative helix-loop-helix protein (ID3) and inhibitor of DNA binding 
4, dominant negative helix-loop-helix protein (ID4) (FC=1.8 & FC=1.5 
respectively). These encode proteins belonging to the inhibitor of DNA binding 
(ID) family of helix-loop-helix (HLH) proteins. They interact with helix-loop-helix 
transcription factors and prevent their binding to the DNA. It has been shown that 
ID3 is involved in neural cell differentiation, whereas ID4 was found to be highly 
expressed in undifferentiated cells and growing cells (Lyden et al., 1999, Shan et 
al., 2003). 
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The laminin beta 1(LAMB1) was increased (FC=1.8). LAMB1 belongs to the 
laminin protein structure which is part of the basal lamina located in the 
extracellular matrix and found in nearly all tissue organs. LAMB1 expression was 
suggested to be associated with pial basement membrane of the brain 
(Radmanesh et al., 2013).  
 
The Myosin, heavy chain 10, non-muscle (MYH10) is an important protein for cell 
division during cytokinesis and was shown to be up-regulated (FC=1.6) (Takeda 
et al., 2003). Moreover, the protein kinase, cGMP-dependent, type I (PRKG1) 
expression was elevated (FC=1.2). PRKG1 is essential for platelet function, cell 
division and smooth muscle relaxation (Li et al., 2003, Burgoyne et al., 2007). 
Furthermore, the protein tyrosine phosphatase, receptor type, M (PTPRM) which 
is involved in many cellular signalling cascades that result in cell differentiation, 
mitosis and cell growth was increased (FC=1.2) (Hendriks et al., 2013). The 
Septin 2 (SEPT2) gene was also increased (FC=1.3). It belongs to the septin 
family which are divided into four major groups: septin2, septin3, septin6 and 
septin7. They are important in activating the cellular signalling pathways in 
response to DNA damage (Kremer et al., 2007, Mostowy and Cossart, 2012). 
 
On the other hand, the following genes were decreased. The LIM homeobox 2 
(LHX2) was down-regulated (FC=-1.3). This gene encodes for a transcription 
factor that regulates stem cell differentiation to neuroepithelium (Mangale et al., 
2008). Furthermore, the notch homolog 1, translocation-associated (drosophila) 
(NOTCH1) was reduced (FC=-1.3). NOTCH1 is part of the notch family which are 
single-pass transmembrane receptors that interact with extracellular molecules 
that activate inner signalling pathways which control cell fate decision. The 
activation of NOTCH1 has been shown to facilitate progenitor cell differentiation 
to astroglia (Tanigaki et al., 2001). A down-regulation of the empty spiracles 
homeobox 2 (EMX2) gene was observed (FC=-1.2). This gene is known as empty 
spiracles gene in drosophila however, in human this gene encodes for a 
homeobox-containing transcription factor which is expressed during the 
development of the cortical cells (Bishop et al., 2000). Finally, the plexin A3 
(PLXNA3) was also reduced (FC=-1.2). It is a transmembrane protein which is 
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involved in the development of the neuronal and epithelial cells (Maestrini et al., 
1996).  
 
Interestingly, although the model used in the present work is fibroblasts, observed 
changes in gene expression related to the CNS in respect to cell differentiation, 
adhesion and DNA damage response were dysregulated. This strongly suggests 
that ALS-derived fibroblasts would be a good model to study neurodegenerative 
disorders.   
 
 
Table 3.8: Genes involved in neuron differentiation in cytoplasmic missense 
mutation 
 
Gene 
symbol 
Gene names P-value  Fold 
change 
BTG2 BTG family, member 2 0.02 1.35 
DRD1 Dopamine receptor D1 0.02 1.25 
EMX2 Empty spiracles homeobox 2 0.04 -1.23 
ETV4 Ets variant 4 0.01 -1.26 
HOXA2 Homeobox A2 0.04 -1.64 
ID3 
 
Inhibitor of DNA binding 3, dominant 
negative helix-loop-helix protein 
0.03 
 
1.88 
 
ID4 
 
Inhibitor of DNA binding 4, dominant 
negative helix-loop-helix protein 
0.02 
 
1.57 
 
LAMB1 laminin, beta 1 0.05 1.82 
LHX2 LIM homeobox 2 0.01 -1.36 
MYH10 Myosin, heavy chain 10, non-muscle 0.05 1.60 
NOTCH1 
 
Notch homolog 1, translocation-
associated (Drosophila) 
0.02 -1.32 
PLXNA3 Plexin A3 0.04 -1.25 
PRKG1 Protein kinase, cGMP-dependent, type 
I 
0.03 1.28 
PTPRM 
 
Protein tyrosine phosphatase, receptor 
type, M 
0.03 1.20 
 
RXRA Retinoid X receptor, alpha 0.01 -1.31 
SEPT2 Septin 2 0.002 1.38 
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3.6.1.1.3 RNA processing 
 
RNA processing describes mechanisms by which nascent mRNA is converted to 
a mature mRNA molecule. In eukaryotic cells this process takes place both during 
and after mRNA transcription in the nucleus and can be stepwise listed as the 
following: 5’capping (7-Methylguanosine), 3’ polyadenylation, splicing/alternative 
splicing, editing and mRNA export. RNA processing has been shown to be altered 
in ALS and several genes involved in RNA processing were found to be mutated 
in some forms of fALS (Polymenidou et al., 2012, Raman et al., 2015). Table 3.9 
lists the genes dysregulated in the fALS-TARDBP cytoplasmic missense 
mutation. Genes were also grouped according to functional similarity as shown 
below (also see figure 3.8).  
 
3.6.1.1.3.1 RNA splicing/ alternative splicing 
 
RNA splicing is a process by which the intronic regions of the nascent mRNA are 
removed and exonic regions are joined together. Alternative splicing is the 
mechanism that allows the production of different transcript isoforms from a single 
gene (Blencowe et al., 2009). Genes involved in RNA splicing/ alternative splicing 
were dysregulated.   
The DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 (DDX58) was increased 
(FC=1.2). DDX58 belongs to the DEAD box helicase family and has an RNA-
dependent ATPase activity which is essential for RNA metabolism (Yoneyama et 
al., 2004). Furthermore, the RNA binding protein squamous cell carcinoma 
antigen recognized by T cells 3 (SART-3) showed an increase in gene expression 
(FC=1.4). It is involved in mRNA splicing by its association with the snRNPs 
U6/U4 at the recycling step of the spliceosome cycle (Harada et al., 2001, Long 
et al., 2014). In addition, the zinc finger CCHC-type and RNA binding motif 1 
(ZCRB1) a part of the of the U11/U12 di-snRNP spliceosome that act in pre-
mRNA splicing was increased (FC=1.3) (Wang et al., 2007). The heterogeneous 
nuclear ribonucleoprotein M which is  a splicing regulatory factor that participates 
in RNA alternative splicing was increased (FC=1.8) (Hovhannisyan and Carstens, 
2007). The RNA binding motif protein 39 (RBM39) was up-regulated (FC=1.3). 
RBM39 belongs to the U2AF65 family of proteins which form one of the core 
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spliceosomal nuclear proteins and has a role in the alternative splicing of steroid 
hormone receptor genes (Jung et al., 2002).  
 
In contrast, three splicing factors were decreased, splicing factor 3a, subunit 1, 
120kDa (SF3A1), splicing factor 3a, subunit 3, 60kDa (SF3A3) and splicing factor, 
arginine/serine-rich 15 (SFRS15) (FC=-1.28,-1.22 & -1.26 respectively). 
Moreover, U5 snRNP-specific protein, 200 kDa which is a member of the 
spliceosome assembly molecule and also belongs to the DEAD box helicase 
family showed a decrease in gene expression (FC=-1.3) (Liu and Cheng, 2015). 
Finally, the pre-mRNA processing factor 8 homolog (S. cerevisiae) (PRPF8) was 
decreased (FC=-1.4). PRPF8 is part of the U2 and U12 dependent spliceosomes 
complex that mediate mRNA splicing  (Luo et al., 1999).  
 
Whilst some genes suggests an increase in splicing this is associated with 
decrease in splicing factors. A further investigation is required to assess the 
overall effect of the missense mutation on splicing. 
   
3.6.1.1.3.2 3’ polyadenylation 
 
Polyadenylation is the process of adding several adenine bases to the mRNA 
molecule prior to mRNA export to the cytoplasm where translation takes place 
(Tian and Manley, 2016). Two genes involved in 3’ end processing and 
polyadenylation were down-regulated.  
 
The U7 small nuclear RNA associated molecule (known as LSM10) which is a 
member of the ribonucleoproteins that are involved in 3’ end processing of non-
polyadenylated histone mRNA was reduced (FC=-1.3). Although, histone 
mRNAs lack a poly-A tail they have a unique stem and loop structure and a 
histone downstream element (HDE) sequence (Marzluff et al., 2008). During 
3’end processing U7 snRNA binds to the HDE sequence resulting in the 
recruitment of cleavage and polyadenylation specific factor 73 which is 
associated with a zinc finger that catalyses the cleavage reaction (Marzluff et al., 
2008). Moreover, the cleavage and polyadenylation specific factor 1, 160kDa 
protein (CPSF1) gene expression was reduced (FC= -1.2). This protein is part of 
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a large complex protein known as cleavage and polyadenylation specific factors 
which are involved in the cleavage of the 3’ end of nascent mRNA and the 
addition of poly-A tail by recognizing the (AAUAAA) sequence (Murthy and 
Manley, 1995). Thus, there may be a reduction in polyadenylation. 
 
3.6.1.1.3.3 RNA editing 
 
RNA editing is a post-transcriptional modification step that involves a chemical 
alteration of the transcript bases (Schoenberg and Maquat, 2012). The adenosine 
deaminase, RNA-specific, B1 (ADARB1) encodes for a vital enzyme that 
participates in pre-mRNA editing was increased (FC=1.9). It is one of the 
adenosine deaminases acting on RNA (ADAR), a group of enzymes responsible 
for RNA editing (Bass, 2002). ADARB1 edits the Q/R site of GluR2 pre-mRNA 
converting adenosine to inosine causing an alteration of the translated codon 
from arginine to glycine. This has a major effect on Ca++ ion permeability through 
the glutamate receptor (Eckmann et al., 2001). An increased level of ADARB1 
may lead to more editing which may result in disrupted intracellular Ca++ 
homeostasis.  
 
3.6.1.1.3.4 Pseudouridylation 
 
Pseudouridylation is defined as the isomerization of the nucleoside uridine by 
altering the chemical bond attachment of the nucleotide uracil to the ribose sugar 
ring from nitrogen-carbon to carbon- carbon via the pseudouridine synthases. 
This modification was observed to increase tRNA stability, promote the RNA 
recognition in the translation process and be involved in the biogenesis of 
spliceosome (Ge and Yu, 2013). Two enzymes from the pseudouridine synthase 
family were increased in fALS-TARDBP, the pseudouridylate synthase 10 
(PUS10) which acts on tRNA and rRNA, and the pseudouridylate synthase 3 
(PUS3) that catalyse the pseudouridylation of tRNA (FC=1.3 & FC=1.2 
respectively) (Chen and Patton, 2000, Hamma and Ferre-D'Amare, 2006, 
McCleverty et al., 2007). 
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3.6.1.3.3.5 Other RNA processing genes 
 
The eukaryotic translation initiation factor 2C (EIF2C), also known AGO2, which 
has a major impact on microRNA synthesis, was reduced (FC=-1.3) 
(Turchinovich and Burwinkel, 2012). In addition, the exosome component 10 
(EXOSC10) which is a part of the exosome complex that functions in RNA 
processing of several RNA species as well as mediating RNA fidelity via the 
nonsense mediated decay pathways was decreased (FC=-1.2) (Garneau et al., 
2007).  
 
An increase in the enzyme tRNA nucleotidyl transferase, CCA-adding, 1(TRNT1) 
was observed (FC=1.2). It is responsible for the addition of the CCA nucleotides 
to the tRNA 3’ end which is a key step for its maturation to a functional 
aminoacylated tRNA that can participate in polypeptide synthesis in the 
translation machinery (Lizano et al., 2007). In addition, ribonuclease P/MRP 
21kDa subunit (RPP21) which is involved in the tRNA maturation process was 
reduced (FC= -1.3) (Jarrous et al., 2001).   
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Table 3.9: Genes involved in RNA processing in cytoplasmic missense mutation 
 
Fold 
change 
P-value  Gene names Gene 
symbol 
1.97 
 
0.03 
 
Adenosine deaminase, RNA-specific, B1 
(RED1 homolog rat) 
ADARB1 
1.36 0.04 Chloride channel, nucleotide-sensitive, 1A CLNS1A 
-1.20 0.02 Cleavage and polyadenylation specific factor 
1, 160kDa 
CPSF1 
1.29 0.02 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 DDX58 
-1.21 0.03 DiGeorge syndrome critical region gene 14 DGCR14 
- 1.38 0.03 Eukaryotic translation initiation factor 2C, 2 EIF2C2 
-1.29 0.003 Exosome component 10 EXOSC10 
1.35 0.003 Ferredoxin-fold anticodon binding domain 
containing 1 
FDXACB1 
-1.25 0.03 Gem (nuclear organelle) associated protein 
7 
GEMIN7 
1.84 0.01 Heterogeneous nuclear ribonucleoprotein M HNRNPM 
- 1.37 0.04 LSM10, U7 small nuclear RNA associated LSM10 
1.28 
 
0.03 
 
Mago-nashi homolog, proliferation-
associated (Drosophila) 
MAGOH 
 
1.27 0.014 Protein phosphatase 4, regulatory subunit 2 PPP4R2 
 
- 1.48 0.05 PRP8 pre-mRNA processing factor 8 
homolog (S. cerevisiae) 
PRPF8 
1.21 0.01 Pseudouridylate synthase 3 PUS3 
1.36 0.02 Pseudouridylate synthase 10 PUS10 
1.25 0.01 RNA binding motif protein 6 RBM6 
1.30 0.04 RNA binding motif protein 39 RBM39 
-1.37 0.03 Ribonuclease P/MRP 21kDa subunit RPP21 
1.44 0.001 Squamous cell carcinoma antigen 
recognized by T cells 3 
SART-3 
-1.28 0.05 Splicing factor 3a, subunit 1, 120kDa (*)SF3A1 
-1.22 0.04 Splicing factor 3a, subunit 3, 60kDa SF3A3 
-1.34 0.032 Small nuclear ribonucleoprotein 200kDa (U5) (*)SNRNP200 
-1.26 0.02 Splicing factor, arginine/serine-rich 15 SFRS15 
- 1.29 0.003 Serine-arginine repressor protein (35 kDa) SRSF12 
1.24 0.057 tRNA nucleotidyl transferase, CCA-adding, 1 TRNT1 
1.37 0.002 Zinc finger CCHC-type and RNA binding 
motif 1 
ZCRB1 
*selected genes for qRT-PCR validation 
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Figure 3.8: A representative diagram showing the dysregulated RNA processing genes in fALS-
TARDBP cytoplasmic missense mutation   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 
 
3.6.1.1.4 Cytoskeleton organization 
 
The cytoskeleton is one of the most important structures of the cell as it maintains 
the cell shape, organelle location within the cell and cell movement. The 
dysregulation of the cytoskeleton has been shown to be associated with 
neurodegenerative disorders such as: AD, PD and ALS (McMurray, 2000). A 
group of genes from this structure were found to be dysregulated in fALS and are 
discussed below (Table 3.10).  
   
The ATPase, Ca++ transporting, type 2C, member 1 (ATP2C1) expression was 
increased (FC=1.3). It encodes for a magnesium-dependent enzyme that is 
involved in transporting Ca++ ions to cells (Ton et al., 2002). Furthermore, 
caldesmon1 (CALD1) was increased (FC= 1.58). CALD1 is an actin binding 
protein which regulates smooth muscle and non-muscle contraction (Hayashi et 
al., 1992). The actin depolymerizing factor destrin (DSTN) showed an up-
regulation (FC=1.5). It is a part of the microfilament protein component which is 
involved in the turnover rate of actin filaments (Hawkins et al., 1993). An increase 
in the dynein, light chain, LC8-type 1(DYNLL1) was observed (FC=1.38). 
DYNLL1 acts as a regulator for protein dimerization. It is involved in DNA damage 
response, transcription, nitric oxide signalling, and cell migration (Jurado et al., 
2012). The tropomyosin 1 (alpha) (TPM1) is an actin-binding protein which is 
involved in smooth muscle, striated muscle and cytoskeletal contractile system 
was up-regulated (FC=1.4) (Denz et al., 2004). Two genes previously described 
in the neuronal differentiation biological process appeared in the cytoskeleton 
organization group and showed an increased gene expression, the myosin, 
heavy chain 10, non-muscle (MYH10) (FC=1.6) and the protein kinase, cGMP-
dependent, type I (PRKG1) (FC= 1.28). Both genes were involved in cytokinesis 
(Li et al., 2003, Takeda et al., 2003, Burgoyne et al., 2007).  
 
On the other hand, a group of genes were down-regulated. The CDC28 protein 
kinase regulatory subunit 2 (CKS2) has shown a reduction in gene expression 
(FC=-2.1). CKS2 has shown to be involved in the cell cycle process (Richardson 
et al., 1990). Furthermore, the FYVE, RhoGEF, PH domain containing 1 (FGD1) 
was also decreased (FC=-1.4). FGD1 has been shown to interact with actin-
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binding protein-1 (mAbp1) which regulates the polymerization of the Arp2/3 
cytoskeleton complex (Hou et al., 2003). The angiomotin (AMOT) gene was 
down-regulated (FC=-1.4). This gene was suggested to have a role in cell 
migration and motility (Troyanovsky et al., 2001). Moreover, the inverted formin, 
FH2 and WH2 domain containing (INF2) was reduced (FC=-1.2). INF2 interacts 
with actin in the cell to facilitate the polymerization and de-polymerization of actin 
filaments (Chhabra and Higgs, 2006). Talin 2 (TLN2) gene expression was 
decreased. TLN2 is highly expressed in the synapse region of brain tissue, heart 
and skeletal muscle. In addition, it is involved in facilitating the binding of integrin 
to actin filaments (Senetar et al., 2007, Debrand et al., 2009). 
 
A group of genes involved in cytoskeleton organization were shown to be 
disrupted within the fibroblasts. This observation may demonstrate a similar effect 
of the mutation on impaired axonal transport shown in ALS.   
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Table 3.10: Genes involved in cytoskeleton organization in cytoplasmic missense 
mutation 
 
Gene 
symbol 
Gene names P-value  Fold 
change 
ABL1 C-abl oncogene 1, receptor tyrosine 
kinase 
0.04 -1.29 
AMOT Angiomotin 0.01 -1.48 
ATP2C1 ATPase, Ca++ transporting, type 2C, 
member 1 
0.05 1.30 
CALD1 Caldesmon 1 0.03 1.58 
CKS2 CDC28 protein kinase regulatory 
subunit 2 
0.03 -2.14 
DSTN Destrin (actin depolymerizing factor) 0.03 1.50 
DYNLL1 Dynein, light chain, LC8-type 1 0.05 1.38 
FGD1 FYVE, RhoGEF, PH domain containing 
1 
0.05 -1.41 
FHDC1 FH2 domain containing 1 0.05 1.29 
INF2 
 
Inverted formin, FH2 and WH2 domain 
containing 
0.02 
 
-1.26 
MYH10 Myosin, heavy chain 10, non-muscle 0.05 1.60 
OFD1 Oral-facial-digital syndrome 1 0.04 1.38 
PRKG1 Protein kinase, cGMP-dependent, type 
I 
0.03 1.28 
TLN2 Talin 2 0.01 -1.28 
TMSB15A Thymosin beta 15a 0.01 -1.50 
TPM1 Tropomyosin 1 (alpha) 0.05 1.45 
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3.6.2 Nuclear MT vs. nuclear CON gene expression profiling using the 
Human Exon 1.0 ST Arrays 
 
As in the cytoplasmic fALS-TARDBP study, the nuclear MT vs. nuclear CON 
transcript IDs were uploaded into DAVID v6.7 to identify the significant biological 
processes dysregulated in fALS fibroblasts. The criteria of selection was based 
on the enrichment score (ES> 1.3) as this is equivalent to a p-value of 0.05 
(Huang da et al., 2009).  
 
3.6.2.1 Differential gene expression of nuclear MT vs. CON  
 
Table 3.11 illustrates that nuclear division, cellular response to stress and mRNA 
processing were the top three highest enriched biological processes with the 
highest gene number. Thus, they were selected for further discussion. 
 
Table 3.11: Functionally enriched biological processes generated by DAVID of 
the nuclear MT vs. CON differentially expressed genes. GO=Gene ontology, 
ES=Enrichment score, no.=number 
ES P-value  Gene no.  Biological process  GO 
6.8 3.1E-7 22 Nuclear division BP_FAT 
4.3 1.9E-3 28 Cellular response to 
stress 
BP_FAT 
1.53 4.3E-2 15 mRNA processing BP_FAT 
1.48 2.9E-2 5 Spindle organization BP_FAT 
1.42 1.2E-3 9 Chromosome 
segregation 
BP_FAT 
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3.6.2.1.1 Nuclear division 
 
Nuclear division is the process through which a single eukaryotic cell is divided 
into daughter cells during the process of mitosis or meiosis. In the nuclear fALS-
TARDBP missense mutation, it was shown that genes involved in nuclear division 
were down-regulated (Table 3.12). 
 
The DSN1, MIND kinetochore complex component, homolog (S. cerevisiae) 
(DSN1) gene was down-regulated (FC=-1.5). It is a part of the multiprotein 
complex kinetochore,  which is known for its role in chromatin alignment and 
separation during mitosis (Liu et al., 2005). Furthermore, HAUS augmin-like 
complex, subunit 6 (HAUS6) was reduced (FC=-1.3). It is a component of the 
human augmin complex, this is a microtubule-binding complex that is involved in 
microtubule spindle assembly and stabilization of the kinetochore during mitosis 
(Lawo et al., 2009). In addition, the chromosome 13 open reading frame 34 
(C13orf34), also known as Aurora kinase A activator, was down-regulated (FC=-
1.3). It has a role in spindle assembly and centrosome development during 
mitosis (Seki et al., 2008). The PDZ binding kinase (PBK) gene was down-
regulated (FC=-1.9). PBK is associated with mitotic spindles and was shown to 
be expressed during cytokinesis at the interphase stage (Matsumoto et al., 2004).  
Moreover, the kinetochore associated complex subunit 3 (SKA3) which is a 
component of the kinetochore-associated protein complex was reduced (FC=-
1.6). SKA3 functions in regulating the attachment of the microtubules to the 
kinetochore during cell division (Gaitanos et al., 2009). Also the ZW10 interactor 
(ZWINT) was down-regulated (FC=-1.5). ZWINT is associated with the 
kinetochore complex (Obuse et al., 2004).  
 
The budding uninhibited by benzimidazoles 1 homolog beta (yeast) (BUB1B) 
gene was decreased (FC=-2). It encodes for a protein that is involved in the 
spindle assembly checkpoint. It ensures a correct chromosome segregation prior 
to anaphase in mitosis (Lampson and Kapoor, 2005). Two further genes also 
involved in chromosomal segregation were down-regulated, the non-SMC 
condensin II complex, subunit D3 (NCAPD3) and nucleolar and spindle 
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associated protein 1 (NUSAP1) (FC=- 1.3 and FC=-1.9 respectively) (Ono et al., 
2003, Raemaekers et al., 2003b). Moreover, citron (rho-interacting, 
serine/threonine kinase 21) (CIT) expression was reduced (FC=-1.7). CIT was 
reported to be localized in the central spindle and is involved in maintaining 
effective cytokinesis (Di Cunto et al., 2000, Kato, 2007). 
 
The kinesin family member 20B (KIF20B) gene was down-regulated (FC=-1.4). 
Kinesins are mobile proteins that move along the microtubule in the cell. They 
mediate anterograde axonal transport of the cellular organelles such as: 
mitochondria, macromolecules and vesicles (De Vos et al., 2008). Defects in the 
Kinesin gene have been shown to be associated with ALS (Bosco et al., 2010). 
In addition, TAR DNA binding protein (TARDBP) was found to be down-regulated 
(FC=-1.5) which is involved in RNA processing (Xia et al., 2016) (see section 
1.1.4.1.2 and 1.1.4.2.1 for more details). Finally, the YEATS domain containing 4 
(YEATS4) gene was reduced (FC=-1.3). It has been suggested to be associated 
with RNA transcription (Zimmermann et al., 2002). 
 
This marked reduction of nuclear division genes may explain the slow growth rate 
of patient’s fibroblasts in the laboratory.  
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Table 3.12: Genes involved in nuclear division in nuclear missense mutation 
 
Gene 
symbol  
Gene name  P-value  Fold change  
ANAPC10 Anaphase promoting complex 
subunit 10 
0.01 -1.35 
BUB1B 
 
Budding uninhibited by 
benzimidazoles 1 homolog beta 
(yeast) 
0.04 
 
-2.10 
 
C13orf34 Chromosome 13 open reading 
frame 34 
0.03 -1.32 
CIT 
 
Citron(rho-interacting, 
serine/threonine kinase 21) 
0.04 
 
-1.73 
 
DSN1 
 
DSN1, MIND kinetochore complex 
component, homolog (S. 
cerevisiae) 
0.02 
 
-1.55 
 
HAUS6 HAUS augmin-like complex, 
subunit 6 
0.04 -1.33 
HELLS Helicase, lymphoid-specific 0.02 -1.85 
KIF20B Kinesin family member 20B 0.03 -1.49 
NCAPD3 Non-SMC condensin II complex, 
subunit D3 
0.04 -1.39 
NEK4 NIMA (never in mitosis gene a)-
related kinase 4 
0.01 -1.25 
NUP43 Nucleoporin 43kDa 0.02 -1.29 
NUSAP1 Nucleolar and spindle associated 
protein 1 
0.03 -1.93 
OIP5 Opa interacting protein 5 0.01 -1.30 
PBK PDZ binding kinase 0.03 -1.98 
PTTG1 Pituitary tumor-transforming 1  0.02 -1.57 
SKA3 kinetochore associated complex 
subunit 3 
0.03 -1.66 
SMC2 Structural maintenance of 
chromosomes 2 
0.0003 -1.61 
TARDBP TAR DNA binding protein 0.04 -1.55 
TUBB5 Tubulin, beta; similar to tubulin, 
beta 5  
0.006 -1.27 
YEATS4 YEATS domain containing 4 0.02 -1.34 
ZWILCH 
 
Zwilch, kinetochore associated, 
homolog (Drosophila) 
0.01 
 
-1.37 
ZWINT10 ZW10 interactor 0.03 -1.55 
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3.6.2.1.2 Cellular response to stress 
 
Cellular response to stress can be defined as any exogenous or endogenous 
stress insult that can alter the normal cell function and activate intracellular 
pathways to prevent sudden cell death. There are several known cellular 
responses, for example: the response to oxidative stress, DNA damage 
response, unfolded protein response and heat shock response. Several genes 
involved in the DNA damage response were dysregulated in the nuclear fALS 
fibroblasts (see table 3.13). A further explanation is addressed below. 
 
The RAD9A-related pathway involves several genes which can promote either 
cell survival or death depending on the level of cellular DNA damage that 
occurred (Ta and Gioeli, 2014). One of these gene is ATPase family, AAA domain 
containing 5 (ATAD5) which is activated during DNA damage to initiate DNA 
repair was shown to be reduced (FC= -1.5) (Sikdar et al., 2009). The down-
regulation of ATAD5 was suggested to provoke the RAD9A to associate with the 
oncogene B-cell lymphoma 2 (BCL2) which promotes cell apoptosis, was also 
decreased (FC=-1.2). The binding of RAD9A/ BCL2 accelerates apoptosis (Ishii 
et al., 2005). Also, the checkpoint kinase 1 (CHK1) was shown to be reduced 
(FC=-1.3) (Feijoo et al., 2001).  
 
Furthermore, the RAD51 homolog C (S. cerevisiae) was reduced (FC=-1.2). It is 
involved in DNA repair by homologous recombination when double stranded DNA 
breaks occur (Park et al., 2008). In addition, the breast cancer 2, early onset gene 
(BRCA2) whose protein participates in transporting the RAD51 protein to the DNA 
repair site was down-regulated (FC=-1.3) (Pellegrini et al., 2002, Park et al., 
2008). Two gene involved in the BRCA associated complex were reduced, the 
chromosome 19 open reading frame 62 which is involved in DNA repair 
(C19orf62) (FC=-1.2) and the mortality factor 4 like 1 (MORF4L1) (FC=-1.2). Both 
of these genes interact with BRCA2 and RAD51 in response to DNA damage 
(Feng et al., 2009, Hayakawa et al., 2010). Furthermore, the chromosome 9 open 
reading frame 80 (C9orf80) which has shown to be involved in DNA damage 
repair was reduced (FC=-1.4) (Huang et al., 2009).  
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The minichromosome maintenance complex component 7 (MCM7) gene which 
is essential during the cell cycle and mainly at the time of DNA replication was 
shown to be also reduced (FC=-1.4) (Spanjaard et al., 1997). Moreover, the 
ERO1-like (S. cerevisiae) (ERO1L) was down-regulated (FC=-1.4). The encoded 
protein is localized in the endoplasmic reticulum (ER) and belongs to the 
oxidation reduction reaction (Redox) family that are involved in oxidative protein 
folding and the formation of disulfide bonds between two cysteine residues. It has 
been suggested that it may have a role in ER stress induced apoptosis (Li et al., 
2009). Two DNA polymerase enzymes were down-regulated, the polymerase 
(DNA directed), epsilon 2 (p59 subunit) (FC=-1.7) and polymerase (DNA-
directed), delta 3, accessory subunit (FC=-1.5) which are both involved in the 
elongation of primed DNA strand (Syvaoja et al., 1990). In addition, three genes 
that encode for the replication factor C complex that are essential for DNA 
elongation, synthesis and repair were down-regulated,  the replication factor C 
(activator 1) 2 40kDa (RFC2) (FC=-1.2), the replication factor C (activator 1) 3 
38kDa (RFC3) (FC=-1.6), and replication factor C (activator 1) 5  36.5kDa (RFC5) 
(FC=-1.3) (Tsurimoto and Stillman, 1990, Wang et al., 2000). The thymidylate 
synthetase (TYMS) was reduced (FC=-1.5). TYMS functions in converting the 
deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate 
(dTMP). Reduction in the thymidylate synthetase activity results in incomplete 
DNA synthesis leading to DNA damage (Kaneda et al., 1990). The thyroid 
hormone receptor interactor 13 (TRIP13) which is considered a hormone-
dependent transcription factor that interacts with thyroid hormone receptors to 
regulate their expression was reduced (FC=-1.7) (Lee et al., 1995). 
 
In contrast, the glutathione peroxidase 3 (plasma) (GPX3) was shown to be up-
regulated (FC=1.3). GPX3 is an important enzyme which protects the cell from 
oxidative damage by the elimination of hydrogen peroxide molecules (Chambers 
et al., 1986). Furthermore, the thyroid peroxidase was also increased (FC=1.2). 
Thyroid peroxidase functions in the iodination of tyrosine residues in thyroglobulin 
to form the thyroid hormones which are: triiodothyronine (T3) and thyroxine (T4) 
(Park and Chatterjee, 2005).  
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Overall, it has been shown that nuclear fALS-TARDBP fibroblasts showed a 
significant reduction in gene expression in response to stress. 
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Table 3.13: Genes involved in cellular response to stress in nuclear missense 
mutation 
 
Gene 
symbol  
Gene name  P-value  Fold 
change  
ATAD5 ATPase family, AAA domain containing 
5 
0.04 -1.56 
BCL2 B-cell CLL/lymphoma 2 0.005 -1.25 
BRCA2 Breast cancer 2, early onset 0.02 -1.34 
BTG2 BTG family, member 2 0.04 1.50 
CDKN2D 
 
Cyclin-dependent kinase inhibitor 2D 
(p19, inhibits CDK4) 
0.003 1.23 
CHAF1B Chromatin assembly factor 1 0.03 -1.29 
CHEK1 CHK1 checkpoint homolog (S. pombe) 0.006 -1.37 
C19orf62 Chromosome 19 open reading frame 62 0.004 -1.24 
C9orf80 Chromosome 9 open reading frame 80 0.04 -1.40 
DHX9 DEAH (Asp-Glu-Ala-His) box 
polypeptide 9 
0.01 -1.32 
DTL Denticleless homolog (Drosophila) 0.03 -1.91 
ERO1L ERO1-like (S. cerevisiae) 0.02 -1.48 
GPX3 Glutathione peroxidase 3 (plasma) 0.02 1.31 
MAP3K13 
 
Mitogen-activated protein kinase kinase 
kinase 13 
0.04 1.32 
MCM7 Minichromosome maintenance complex 
component 7 
0.02 
 
-1.48 
 
MORF4L1 Mortality factor 4; mortality factor 4 like 
1 
0.03 -1.20 
NONO Non-POU domain containing, octamer-
binding 
0.03 -1.35 
POLD3 
 
Polymerase (DNA-directed), delta 3, 
accessory subunit 
0.04 
 
-1.52 
 
POLE2 
 
Polymerase (DNA directed), epsilon 2 
(p59 subunit) 
0.04 
 
-1.74 
 
PTTG1 Pituitary tumor-transforming 1 0.02 -1.57 
RAD51C RAD51 homolog C (S. cerevisiae) 0.02 -1.21 
RFC2 Replication factor C (activator 1) 2, 
40kDa 
0.02 -1.25 
RFC3 Replication factor C (activator 1) 3, 
38kDa 
0.02 -1.69 
RFC5 Replication factor C (activator 1) 5, 
36.5kDa 
0.02 -1.31 
TDP1 Tyrosyl-DNA phosphodiesterase 1 0.007 -1.20 
TPO Thyroid peroxidase 0.03 1.27 
TRIP13 Thyroid hormone receptor interactor 13 0.04 -1.7 
TYMS Thymidylate synthetase 0.04 -1.52 
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3.6.2.1.3 mRNA processing 
 
It was shown that the majority of the genes in the nuclear mRNA processing list 
were down-regulated and were mainly involved in splicing/alternative splicing. In 
addition, a single gene from each of the following processes were found to be 
down-regulated: RNA silencing, transcription, translation, hormone response and 
RNA decay. Table 3.14 demonstrates the gene list and a further exploration of 
these genes is described below.  
  
3.6.2.1.3.1 Splicing / alternative splicing 
 
The FUS interacting protein (serine/arginine-rich) 1 (SRSF10), one of the serine-
arginine (SR) family, is involved in RNA processing and in particular alternative 
RNA splicing was down-regulated (FC=-1.3) (Cowper et al., 2001, Shin et al., 
2004). In addition the TAR DNA binding protein (TARDBP) is an RNA/DNA-
binding protein that is involved in RNA processing including; transcription, 
splicing and mRNA transport was also reduced (FC=-1.5) (Xia et al., 2016) (see 
section 1.1.4.1.2 and 1.1.4.2.1 for more details).  Moreover, the heterogeneous 
nuclear ribonucleoprotein K (HNRNPK) was down-regulated (FC=-1.3). 
HNRNPK is involved in mRNA splicing along with other cellular functions such 
as: transcription activation and repression, translation and DNA damage 
response (Fukuda et al., 2009). The splicing regulatory factor heterogeneous 
nuclear ribonucleoprotein M (HNRNPM) was down-regulated (FC=-1.5) and is 
also involved in RNA alternative splicing (Hovhannisyan and Carstens, 2007).  
 
The KH domain containing, RNA binding, signal transduction associated 1 
(KHDRBS1), also known as Sam68, was reduced (FC=-1.2). It is involved in the 
alternative splicing of the CD44 gene though binding to the splice-regulatory 
elements of exon v5 (Matter et al., 2002). It also alternatively splices mRNAs 
involved in normal neuronal differentiation (Chawla et al., 2009). Furthermore, 
Sam68 induces exon 7 skipping of the SMN2 gene. Mutation in the Sam68 gene 
leads to the production of non-functional SMN2 protein which is known to be a 
feature of spinal muscular atrophy (SMA) (Pedrotti et al., 2010). The Non-POU 
domain containing octamer-binding (NONO) gene was reduced (FC=-1.3). The 
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NONO is involved in pre-mRNA processing including: transcription activation and 
repression, splicing and transport (Mircsof et al., 2015). 
 
Three genes which are part of the spliceosomal complex involved in nascent RNA 
splicing were down-regulated, small nuclear ribonucleoprotein polypeptides B 
and B1(SNRPB) (FC=-1.3), PRP4 pre-mRNA processing factor 4 homolog 
(yeast) (PRPF4) (FC=-1.2) and PRP8 pre-mRNA processing factor 8 homolog 
(PRPF8) (FC=-1.2) (Luo et al., 1999, Gonzalez-Santos et al., 2002, Chari et al., 
2008). 
 
A marked reduction in RNA splicing genes was observed in the nuclear fALS 
missense mutation which strongly suggest an alteration in splicing regulation 
caused by the TARDBP mutation (Figure 3.9).   
     
 
3.6.2.1.3.2 RNA silencing /transcription/ translation/ hormone response/ 
RNA decay 
 
The DEAH (Asp-Glu-Ala-His) box polypeptide 9 (DHX9) was reduced (FC=-1.3). 
It belongs to the RNA helicase family which are generally considered 
transcriptional regulators involved in RNA metabolism. DHX9 is also known as 
RNA Helicase A and has been shown to be associated with the RNA silencing 
pathway i.e. the RISC complex (Robb and Rana, 2007). Furthermore, the 
polymerase (RNA) II (DNA directed) polypeptide B (POLR2B) was also reduced 
(FC=-1.3). The cytoplasmic polyadenylation element binding protein 1(CPEB1) 
gene expression was also down-regulated (FC=-1.4). The protein encoded by 
this gene binds to the 3’end of the mRNA to initiate the translation machinery 
(Welk et al., 2001). Moreover, the heterogeneous nuclear ribonucleoprotein C 
(C1/C2) (HNRNPC) was reduced (FC=-1.3). It is an RNA binding protein involved 
in RNA processing and was suggested to have a role in the regulation of hormone 
response elements in vitamin D resistant patients (Chen et al., 2006). Finally, the 
heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding 
protein 1, 37kDa) (HNRNPD) which is a part of a complex molecule that binds to 
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the AU-rich element on the mRNA to initiate RNA decay was found to be down-
regulated (FC=-1.3) (Grosset et al., 2000). 
 
 
 
 
 
Table 3.14: Genes involved in mRNA processing in nuclear missense mutation 
 
Gene 
symbol  
Gene name  P-value  Fold 
change  
CPEB1 Cytoplasmic polyadenylation element 
binding protein 1 
0.02 -1.46 
DHX9 DEAH (Asp-Glu-Ala-His) box 
polypeptide 9 
0.01 -1.32 
HNRNPC Heterogeneous nuclear 
ribonucleoprotein C (C1/C2) 
0.02 -1.31 
HNRNPD Heterogeneous nuclear 
ribonucleoprotein D  
0.03 -1.35 
HNRNPK Heterogeneous nuclear 
ribonucleoprotein K 
0.05 -1.30 
HNRNPM Heterogeneous nuclear 
ribonucleoprotein M 
0.01 -1.50 
KHDRBS1 KH domain containing, RNA binding, 
signal transduction associated 1 
0.03 -1.24 
NONO Non-POU domain containing, octamer-
binding 
0.03 -1.35 
POLR2B Polymerase (RNA) II (DNA directed) 
polypeptide B, 140kDa 
0.02 -1.30 
PRPF4 PRP4 pre-mRNA processing factor 4 
homolog (yeast) 
0.02 -1.23 
PRPF8 PRP8 pre-mRNA processing factor 8 
homolog (S. cerevisiae) 
0.04 -1.25 
RBM4B RNA binding motif protein 4B 0.01 -1.21 
SNRPB Small nuclear ribonucleoprotein 
polypeptides B and B1 
0.01 -1.39 
(*)SRSF1 
 
FUS interacting protein 
(serine/arginine-rich) 1 
0.02 -1.37 
(*)TARDBP TAR DNA binding protein 0.04 -1.55 
 
*Selected genes for qRT-PCR validation.  
 
 
126 
 
 
 
Figure 3.9: A representative diagram showing the dysregulated RNA processing genes in fALS-
TARDBP nuclear missense mutation   
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3.6.3 Comparative analysis of the differentially expressed gene from the 
cytoplasmic and nuclear missense mutation using the Human Exon 1.0 ST 
Array 
To further explore the effect of the TARDBP missense mutation on gene 
expression in fALS, it was interesting to find which genes were specific to each 
cellular component and which gene were in shared in both. Therefore, GeneVenn 
tool was used to identify those genes. 653 genes out of the 702 genes were 
cytoplasmic specific while 636 genes out of the 685 genes were nuclear specific 
and 49 genes were in both (Figure 3.10). The transcript IDs were uploaded into 
DAVID to identify the dysregulated biological process in each cellular 
compartment. The highest enriched in cytoplasmic missense mutation were 
mRNA splicing and transcription (ES= 3.5 and 1.6 respectively) and the nuclear 
missense mutation were enriched with mitotic nuclear division, DNA replication 
and mRNA splicing (ES= 7, 2.7 and 2.3 respectively). None of the 49 shared 
genes belonged to a biological process. The shared gene list was also 
investigated manually, 37 genes were annotated and 12 genes were 
unannotated. None of the annotated genes belonged to the mRNA splicing genes 
that were identified in each cellular component. 
 
 
 
Figure 3.10: Comparative analysis of the differentially expressed gene from the cytoplasmic 
and nuclear missense mutation using the Human Exon 1.0 ST Array. Venn diagram showing 
653 genes specific to the cytoplasmic missense mutation while 636 genes were specific to the 
nuclear missense mutation and 49 genes were shared in both cellular fractions. MT= missense 
mutation, TT= truncated mutation  
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3.7 qRT-PCR validation of fALS RNA processing genes 
 
Key exon array differentially expressed genes were identified in order to attempt 
validation by qRT-PCR. Two genes involved in RNA processing were selected 
from each comparison study. From the cytoplasmic MT vs. cytoplasmic CON the 
following genes were selected: small nuclear ribonucleoprotein 200kDa 
(SNRNP200) (FC=-1.34 and p-value=0.032) and splicing factor 3a, subunit 1, 
120kDa (SF3A1) (FC=-1.28 and p-value=0.05). From the nuclear MT vs. nuclear 
CON the following genes were selected: FUS interacting protein (serine/arginine-
rich) 1 (SRSF10) (FC=-1.37 and p-value= 0.02) and TAR DNA binding protein 
(TARDBP) (FC=-1.55 and p-value= 0.04). All genes were normalized against the 
β-actin housekeeping gene. The statistical analysis was performed using Graph 
Pad Prism and unpaired t-test was applied.  
 
The nuclear candidate genes confirmed the directional change of gene 
expression (down-regulation) compared to the Human Exon 1.0 ST Array data. 
However, the cytoplasmic candidate genes did not. Unfortunately, none of the 
four genes showed statistical significant results (p-values > 0.05) although trends 
were shown in the correct direction for TARDBP and SRSF10 (See figure 3.11 
A&B, 3.12A&B). 
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Figure 3.11: qRT-PCR validation of the RNA processing cytoplasmic genes in fALS fibroblasts. 
(A)The relative expression of the SNRNP200 gene. The statistical analysis showed insignificant 
p-value (p-value = 0.6915) with slight increase of SNRNP200 gene expression, (n=3). (B) The 
relative expression of the SF3A1 gene. The statistical analysis also showed insignificant (p-value= 
0.4380) with increased SF3A1 gene expression, (n=3). (n= the sample size, NS= not significant, 
the error bars represents the SEM). 
                     
 
Figure 3.12: qRT-PCR validation of the RNA processing nuclear genes in fALS fibroblasts. 
(A)The relative expression of the TARDBP gene. The directional change of the gene expression 
was confirmed (down-regulation), however the p-value was insignificant (p-value=0.2388), (n=3). 
(B)The relative expression of the SRSF10 gene. The directional change of the gene expression 
was confirmed (down-regulation), however the p-value was insignificant (p=0.3026), (n=3). (n= 
the sample size, NS= not significant, the error bars represents the SEM. 
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3.8 Discussion 
 
Several animal models have been generated to provide an understanding of the 
pathological mechanisms underlying the disease process of ALS. In particular, 
mammalian models of mutant TARDBP include transgenic mice and rats as well 
as genetically engineered non-mammalian models like drosophila, zebrafish and 
Caenorhabditis elegans (C. elegans) (Liu et al., 2013). In the current study, 
fibroblasts derived from fALS-TARDBP were chosen to study the pathological 
role of mutant TDP-43 in fALS-TARDBP. From a technical point of view 
fibroblasts are useful because they are accessible from the patient through a skin 
biopsy, they are easy to grow and suitable for RNA extraction. In addition, several 
studies on ALS and other neurodegenerative disorders such as AD and PD have 
shown the effectiveness of using fibroblasts to investigate the underling 
pathophysiological disease process (Nagasaka et al., 2005, Mortiboys et al., 
2008, Highley et al., 2014, Raman et al., 2015).  
 
In the present study, patients and controls were age and gender matched to 
minimize variations. The cell fractionation and RNA isolation methods were 
challenging. However, a good degree of separation with acceptable quality and 
quantity of RNA was achieved. The Nanodrop spectrophotometer measurements 
showed that a good quantity of RNA could be derived from all samples. Moreover, 
the Agilent Bioanalyser electropherograms showed two significant features; clear 
sharp peaks of rRNA 28s and rRNA 18s with higher RNA concentration in the 
cytoplasm than in nucleus and the level of rRNA 28s were approximately twice 
the level of rRNA 18s suggesting full length transcripts although the RIN values 
were of a moderate level.  A clear genomic DNA peak was observed in nuclear 
RNA samples which was eliminated successfully by DNase treatment.  The RNA 
quantity and quality were affected although to an acceptable degree. Peaks of 
genomic DNA in the cytoplasmic electropherograms were not present. This does 
not completely exclude the presence of DNA however it suggests a low possibility 
of cross contamination between cellular compartments. This was in agreement 
with an earlier study which demonstrated superb cell fractionation and RNA 
isolation results using a similar strategy (Trask et al., 2009). 
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The current study aimed to elucidate the possible dysregulated biological 
processes present in the cytoplasm and the nucleus of fALS-TARDBP patients. 
Thus, three biological replicates for each disease and controls were used. The 
fibroblasts were collected from three different TARDBP missense mutations: 
p.A321V, p.M337V and p.G2875. Pooling the samples as one mutation in the 
analysis was not the most effective method to study the effect of individual 
mutations, however, this strategy provided an overall view of the effect of 
TARDBP missense mutations on the disease process. Partek® Genomics Suite 
TM 6.6 software was used to identify the statistically significant differentially 
expressed genes and the DAVID online tool facilitated the assigning of these 
genes into biological processes. fALS-TARDBP cytoplasmic differentially 
expressed genes fell into the following biological processes: methylation, 
neuronal differentiation, RNA processing, and cytoskeleton organization. 
Moreover, the fALS-TARDBP nuclear differentially expressed genes belonged to 
the following biological processes: nuclear division, cellular response to stress 
and mRNA processing. Several of these defective biological processes have 
been shown to be aberrant in ALS. This strongly supports the effectiveness of 
fibroblasts as a model to study ALS and the relevance of the experimental model 
used to investigate possible aberrant processes in fALS.    
 
3.8.1 Cytoplasmic fALS-TARDBP fibroblasts 
 
3.8.1.1 Methylation 
 
It was surprising to find that DNA methylation showed the highest enriched 
cytoplasmic pathway in fALS-TARDBP related cases as this has not been 
observed before. The current literature focuses on understanding the effect of 
epigenetics on sALS cases rather than fALS. This is because familial cases are 
characterised as being caused by alterations in the genome, whereas, sALS is 
believed to be influenced by gene mutations, life style, environmental factors and 
epigenetic modifications.  
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As some gene mutations are a shared aetiology in cases of sALS and fALS, an 
attempt was to search the literature for studies that may have a similar pattern of 
dysregulated genes as in the present study. Unfortunately, only DNMT1 was 
shown to be increased in the motor neurons of the motor cortex in sALS and was 
decreased in fALS-TARDBP in the current study (Chestnut et al., 2011).      
 
All genes related to DNA methylation were down-regulated and have not been 
reported before, GATAD2A, RAB6C, CARM1, EHMT1, HELLS and SUZ12 with 
the exception of BTG2 which was up-regulated. This may suggest that 
hypomethylation is associated with fALS-TARDBP cases and might lead to 
increased level of transcription of some genes. 
 
3.8.1.2 Neuron differentiation  
 
It was shown in the analysis that the second highest enriched biological process 
in cytoplasmic fALS-TARDBP was neuron differentiation showing a significant 
number of genes. Investigating these genes revealed that the majority were 
increased and involved in cell cycle regulation (BTG2 and MYH10), differentiation 
(ID3 and ID4), mitosis (PRKG1) and cell growth (PTPRM). This was expected as 
the cell model in this study was primary fibroblasts which undergo continuous cell 
division and growth. An interesting observation was that these genes are also 
expressed in neurons.  PRKG1 is strongly expressed in hippocampal neurons 
(Hofmann, 2005). Furthermore, MYH10 is expressed in the hippocampal neurons 
and involved in maintaining spine morphology (Ryu et al., 2006). A mutation in 
MYH10 was suggested to be associated with brain malformations (Tuzovic et al., 
2013). ID3 and ID4 genes were involved in neural cell differentiation and therefore 
are essential for normal development of the central nervous system (Lyden et al., 
1999, Bedford et al., 2005).  
 
Several genes involved in cell differentiation into cortical cells during 
development such as LHX2, EMX2, PLXNA3 and into astroglia, NOTCH1, were 
down-regulated. These gene expression changes in ALS-derived fibroblasts 
strongly suggest that fibroblasts are good model to study neurodegenerative 
disorders, as there is an overlap in the genes that are expressed.  
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3.8.1.3 RNA processing 
 
RNA processing is an umbrella term describing a range of molecular functions 
which are involved in the production of a mature mRNA. These include: RNA 
splicing, editing, transport and degradation. Studies have shown that 
dysregulated RNA processing was identified as a pathogenic mechanism in both 
fALS and sALS (Vance et al., 2006, Lagier-Tourenne et al., 2010, Polymenidou 
et al., 2012). In the current study, the number of genes dysregulated in RNA 
processing in the cytoplasmic fALS-TARDBP cases were significantly high. The 
majority of these genes were related to RNA splicing.  
 
Dysregulated spliceosome complexes have been previously reported in sALS-
TARDBP (Highley et al., 2014). Genes associated with spliceosome complexes 
were shown to be dysregulated in the present work, SART-3, ZCRB1, RBM39 
were up-regulated and SNRNP200 and PRPF8 were down-regulated. In addition, 
splicing factors were also reduced SF3A1, SF3A3 and SFRS15. Furthermore, the 
splicing regulatory factor HNRNPM was shown to be expressed at low levels in 
sALS fibroblasts (Raman et al., 2015). In contrast, in the present work HNRNPM 
was shown to be increased in fALS, perhaps reflecting a mutant TARDBP specific 
effect. 
 
RNA editing is one of the most important post-transcriptional modification steps 
that is involved in normal gene expression. The editing enzyme encoded by the 
ADARB1 gene is vital for normal GluR2 function in maintaining Ca++ ion 
impermeability in neurons. Studies suggest that in sALS ADARB1 expression is 
altered leading to reduced GluR2 editing and possibly as a result, increased Ca++ 
permeability (Aizawa et al., 2010, Hideyama et al., 2012, Yamashita and Kwak, 
2014). In fALS-TARDBP the ADARB1 expression was increased suggesting 
normal or perhaps increased editing of GluR2 in fALS.  Two genes involved in 
pseudouridylation were slightly increased PUS3 & PUS10. They were suggested 
to promote tRNA stability and RNA recognition during the translation process 
(Chen and Patton, 2000, Hamma and Ferre-D'Amare, 2006, McCleverty et al., 
2007). 
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MicroRNAs are short sequences of RNA (22nt) that regulate gene expression by 
inhibiting translation or enhancing mRNA degradation (Nelson et al., 2003). A 
single gene involved in the biogenesis of microRNAs was down-regulated 
(EIF2C2 also known as AGO2), this was also found decreased in sALS 
fibroblasts (Raman et al., 2015). Briefly, during microRNA transcription by RNA 
polymerase ׀׀ a primary hairpin loop microRNA is formed. DGCR8 protein binds 
to the primary microRNA along with the enzyme DROSHA to cleave the primary 
microRNA and produce a shorter sequence known as precursor microRNA that 
is capable of export from the nucleus. In the cytoplasm the microRNA is bound 
to DICER1 which cleaves the stem loop leaving the ds-microRNA. AGO2 
interacts with DICER1 and bind to the ds-microRNA. This is followed by 
unwinding and releasing of one strand of the microRNA. The single strand 
microRNA associated with AGO forms an RNA induced silencing complex 
(RISC). RISC plays an important role in regulating gene expression by inhibiting 
mRNA transcription or translation (Bartels and Tsongalis, 2009). The down-
regulation of AGO2 might cause this process to be hindered and gene expression 
to be dysregulated.   
  
3.8.1.4 Cytoskeleton organization 
 
A proper cytoskeleton organization is required for normal cell function. The 
cytoskeleton is mainly categorized into shapers, movers and motors. The 
shapers and movers maintain cell rigidity and movement of the cell. They are 
composed of three main types: the intermediate filaments, actin filaments and 
microtubules. The motors are associated with anterograde and retrograde 
transport of molecules and cargoes in the cell and are dynactin, kinesins and 
dynein. Alteration of these cellular structures has been shown to be associated 
with several neurodegenerative disorders such as: AD, PD and ALS (McMurray, 
2000, Bamburg and Bloom, 2009, Parisiadou and Cai, 2010).  
 
Cytoskeletal defects are an important contributor to ALS pathology. Early studies 
showed that both mutant transgenic mice models SOD1G37R and SOD1G85R 
showed evidence of dysfunctional axonal transport caused by  defective 
neurofilament subunits and tubulin (Williamson and Cleveland, 1999). In a more 
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recent study, mutation in the actin binding protein Profilin1 (PFN1) gene was 
shown to inhibit axonal outgrowth of motor neurons in fALS (Wu et al., 2012). In 
addition, the CRMP4 missense mutation was identified in motor neurons of ALS 
patients (Blasco et al., 2013). Expression of this variant in mouse motor neuron 
cultures showed an increased cell death and decreased axonal outgrowth 
(Blasco et al., 2013).  Furthermore, mutations in dynactin and dynein have been 
shown to be associated with faulty retrograde transport in ALS (Munch et al., 
2004).  
 
In the current study, genes involved in cytoskeleton organization were also 
dysregulated. The actin binding proteins (Caldesmon1, TPM1 and MYH10), actin 
depolymerizing factor destrin (DSTN) the protein kinase cGMP-dependent type I 
(PRKG1) and the magnesium-dependent enzyme (ATP2C1) which is involved in 
transporting Ca++, were all up-regulated. In contrast, a group of genes were 
down-regulated. These genes were involved in actin polymerization (FGD1 and 
INF2), cell motility and migration (AMOT and Talin2) and cell cycle process 
(CKS2). These observations strongly support the involvement of cytoskeletal 
dysregulation in ALS. 
 
 
3.8.2 Nuclear fALS-TARDBP fibroblasts 
 
3.8.2.1 Nuclear division 
 
Nuclear division (also known as karyokinesis) is the process by which a single 
cell nucleus is divided into daughter cells. This typically consists of the following 
stages: prophase, prometaphase, metaphase, anaphase, and telophase. Nuclear 
missense fALS-TARDBP fibroblasts showed a significant down-regulation of 
genes involved in nuclear division. 
 
Genes involved in the kinetochore complex (DSN1 and ZWILCH), kinetochore 
stabilization, (HAUS6), centromere development (C13orf34), spindle assembly 
and check point (PBK and BUB1B), microtubule attachment to kinetochore 
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(SKA3) and chromosome segregation (NCAPD3 and NUSAP1) were decreased. 
Moreover, the (CIT) gene which is located in the central spindle and shown to be 
associated with CNS development was also reduced. Mutations in this gene have 
been shown to be associated with bipolar disorder (Di Cunto et al., 2000, Kato, 
2007).  
 
Dysregulation of kinesin was reported to be associated with ALS (Ferraiuolo et 
al., 2011). Here, the KIF20B gene was shown to be reduced which may suggest 
defective axonal transport (Bosco et al., 2010). Furthermore, TARDBP gene 
expression was reduced in the nuclear missense mutation (Neumann et al., 2006, 
Vance et al., 2006). This reduction in expression may reflect the process of 
degradation of mutant TARDBP transcripts in the nucleus. Also, the overall 
marked decrease in nuclear division related genes could explain the slow growth 
rate of missense mutated fALS-TARDBP fibroblasts.  
 
3.8.2.2 Cellular response to stress  
 
Normally, DNA lesions are continually repaired in most dividing cells. However, 
DNA lesions in post-mitotic neuronal cells have been shown to trigger a cell death 
response (Madabhushi et al., 2014). It was expected to find an increased 
expression of genes involved in cellular response to stress as TDP-43 
sequestration and production of stress granules stimulates a stress response 
which leads to an immediate motor neuron cell death. In the present study a 
significant down-regulation in genes involved in DNA damage response was 
observed in ALS-TARDBP fibroblasts. A general reduction of expression of 
genes involved in DNA repair was observed (ATAD5, RAD51C, BRCA2, 
C19orf62, MORF4L1, ERO1L, POLD3, POLE2, RFC2, RFC3, RFC5, TYMS, 
C9orf80 and MCM7). By searching the literature for a similar outcome, a single 
study by Yu et al., showed that TDP-43 is able to form a complex molecule with 
fragile X mental retardation protein (FMRP) and staufen (STAU1) to regulate 
several genes (Yu et al., 2012). One of these genes was the DNA damage repair 
gene Sirtuin 1 (SIRT1). The depletion of TDP-43 in the SH-SY5Y cell line showed 
a significant low expression of SIRT1 (Yu et al., 2012). In contrast, 
overexpression of SIRT1 was observed in both mutant SOD1G93A ALS transgenic 
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mouse and AD mouse model which suggest its protective mechanism for cell 
survival (Kim et al., 2007).  
 
The down-regulation effect of this alteration suggests a reduced DNA repair 
process in fALS-TARDBP. Both Yu et al., and the current study observations 
propose that the decrease in DNA repair genes could be a unique feature of ALS-
TARDBP (Yu et al., 2012). Also, this data supports that fibroblasts are good 
model that to an extent mimics gene changes in CNS.  
 
3.8.2.3 mRNA processing 
 
TDP-43 is an RNA processing protein that is predominantly located in the nucleus 
and has a major role in RNA metabolism. Mutations in TARDBP were strongly 
linked to dysregulated RNA processing, primarily splicing (Tollervey et al., 2011). 
A defective TDP-43 splicing mechanism was shown in FTLD-TDP post-mortem 
brain tissue (Tollervey et al., 2011). Down-regulation of expression of 
spliceosomal complex proteins SNRNP48 and SNRNP25 in motor neurons of 
post-mortem tissue has been previously observed (Highley et al., 2014). Also, 
dysregulated RNA processing genes were evident in sALS-TARDBP fibroblasts, 
in which altered splicing was observed (Raman et al., 2015). 
 
One of the aims of this project was to study the transcriptomic profile of the 
nuclear fALS-TARDBP separated from the cytoplasm to acquire a more precise 
view of the effect of the TARDBP mutation on RNA processing as this has not 
been examined previously. A significant reduction in genes involved in splicing 
was demonstrated (TARDBP, HNRNPK, HNRNPM, KHDRBS1, NONO, PRPF4, 
PRPF8 SRSF10 and SNRPB) of which two genes SRSF10 and HNRNPM had a 
similar pattern of regulation shown in sALS-TARDBP fibroblasts (Raman et al., 
2015). Furthermore, a group of genes involved in mRNA processing other than 
splicing were down-regulated, the transcription regulator DHX9, transcription 
initiator POLR2B, translation initiator factor CPEB1 and RNA decay HNRNPD. In 
addition, an interesting finding was the down-regulation of the RNA binding 
protein HNRNPC that regulates the vitamin D hormone response elements.  As 
ALS is a multisystem disorder, speculations of vitamin D deficiency in ALS 
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patients has been recently proposed and suggested as a therapeutic target 
(Gianforcaro and Hamadeh, 2014). This observation supports the risk of fALS-
TARDBP to vitamin D deficiency. As an overall view, it is clearly found that the 
presence of TARDBP missense mutation in fibroblasts causes alteration in the 
ability of these cells to process RNA.   
 
3.8.3 qRT-PCR validation  
 
At the time of this experimental study using Human Exon 1.0 ST Arrays to 
understand the possible dysregulated biological processes in 2012, the attention 
was narrowed to validate the predicted genes involved in RNA processing from 
both cellular compartments to confirm the effect of TARDBP missense mutation 
on RNA processing in fALS as there was a number of studies suggesting an 
impaired RNA processing associated with mutant TARDBP. Unfortunately, gene 
expression of the selected cytoplasmic fALS-TARDBP genes showed results in 
disagreement compared to the Human Exon 1.0 ST Array outcome. Both SF3A1 
and SNRNP200 showed an opposing trend of gene expression than that 
observed on the arrays. The nuclear fALS-TARDBP candidate genes TARDBP 
and SRSF10 confirmed the trend change although they demonstrated 
insignificant p-values. 
 
This could be due to the method of quantification of gene expression and the 
oligonucleotide probes design on the Human Exon 1.0 ST Array. Gene 
expression levels are based on averaging the signal intensities of the total set of 
exons on the arrays to provide an expression level of that transcript. In contrast, 
qRT-PCR is amplifying a comparatively small and specific region of the transcript. 
Thus, this may be the basis of the discrepant result. Also, due to low levels of 
RNA concentrations obtained from fibroblasts the amount of RNA used for the 
reverse transcription reaction was little which may affected the correct 
quantification of the transcripts. In addition, there was a slight variation in the Ct 
values of the normalizer (β-actin) used in the qRT-PCR which may led to in the 
insignificant results obtained. 
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Arriving at a strong conclusion based on the validation results was not possible 
as the number of genes selected to confirm the changes that occurred on the 
arrays were insufficient. In addition, a general observation was that the fold 
changes produced from the arrays were relatively low, making validation even 
more difficult. Also, the robustness of the Human Exon Arrays were questioned 
in some studies (see section 3.8.5 below)      
 
 
3.8.4 The overall effect of TARDBP missense mutation in fALS using the 
Human Exon 1.0 ST Arrays  
 
The Human Exon 1.0 ST Arrays were used to understand the effect of the 
TARDBP missense mutation on the disease process. An overall view of the effect 
of the mutation on gene expression was shown. Dysregulated RNA processing 
was markedly affected in both cellular compartments in fALS. It was also shown 
that mRNA splicing regulation was significantly affected in both cellular fractions 
indicting that the mislocalization of TDP-43 caused by the TARDBP missense 
mutation in fALS plays a key role in splicing alteration (see section 3.6.3). This 
observation was in agreement with earlier studies on ALS which showed 
dysregulated splicing in the presence of TARDBP mutations (Highley et al., 2014, 
Raman et al., 2015).   
 
3.8.5 The Human Exon 1.0 ST Arrays design  
 
At the time of analysing the Human Exon 1.0 ST Array data, an enormous number 
of unknown gene sequences appeared in the data. As the Human Exon 1.0 ST 
Array GeneChip® probes were designed based on the available data libraries 
which contained all the known and predicted exon sequences at the time of 
manufacture (July, 2003), this may explain the large number of unannotated 
genes. Furthermore, a study was performed by Gaidatzis et al., which tested the 
efficiency of the Human Exon 1.0 ST Array. This was done by running RNA 
sequencing in parallel to the arrays and comparing results. It was shown that the 
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arrays contained probes that were not detected in the RNA sequencing data 
which may suggests faulty designed probes and poor annotation (Gaidatzis et 
al., 2009).  
 
With the Gaidatzis et al., observation in mind another possible issue is raised 
which was the mathematical method of identifying differentially expressed genes 
on Human Exon 1.0 ST Arrays. It is based on averaging the signal intensities of 
all probes of a particular gene (http://www.affymetrix.com). This may give rise to 
false expression of some genes. The overall conclusion in the literature is that 
there are weaknesses in the design of the Human Exon 1.0 ST Arrays. To 
address this and specifically the detection of known splice variants, Affymetrix 
introduced the Affymetrix® Human Transcriptome Arrays (HTA) (Xu et al., 2011). 
 
In summary, this work did show that the fibroblasts are a good model for studying 
fALS and that the separation of the two cellular components might provide some 
insights into the effect of the TARDBP missense mutation in fALS.  However, at 
the time (April, 2013) no further analysis was performed on the arrays nor further 
validation experiments completed. Due to the difficulty with validation, this led to 
the design of a new experiment using the recently developed Affymetrix® Human 
Transcriptome Arrays (HTA) (Xu et al., 2011) which promised more robust 
results. 
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Chapter 4: Human Transcriptome Array 2.0 GeneChip®   
4.1 Human Transcriptome Array 2.0 GeneChip®  
  
 
In this current work, the Human Transcriptome Array 2.0 GeneChip® were used 
to study gene expression profiling in fALS-TARDBP. These arrays were designed 
with better features that the Human Exon 1.0 ST Arrays (see section 1.1.6.3).  
 
A further aim was added into the experiment designed which was to improve the 
cell component separation method by monitoring cell membrane lysis under a 
light microscope. This was to ensure the isolation of an intact nucleus prior to 
RNA extraction. The cell fractionation was performed by osmotic pressure and 
centrifugation and the RNA extraction was achieved by the Trizol method (Refer 
to 2.2.2.1 for the method). In addition to the missense TARDBP mutation 
fibroblasts used in the Human Exon 1.0 ST Arrays, three truncation TARDBP 
mutation cases carrying p.Y374X mutation were also included.  
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4.2 Nuclear isolation 
 
It has been previously demonstrated that studying gene expression profiling of 
total mRNA showed a significant contribution from nuclear polyadenylated mRNA 
that was characterized as cytoplasmic mRNA (Trask et al., 2009). This was based 
on the assumption that polyadenylated mRNA were only found in the cytoplasmic 
fraction. The literature shows that total mRNA does not accurately represent the 
steady state level of cytoplasmic mRNA. It was demonstrated that the levels of 
cytoplasmic mRNA were influenced by different factors, for example: the turnover 
time of a transcript (Trask et al., 2009).  
 
In the current work nuclei were separated from the cytoplasm from patient and 
control fibroblasts to study the effect of TARDBP mutation on the disease process 
and investigate the possible dysregulated biological processes in relation to the 
disease. Cell lysis was monitored throughout the cell fractionation step. Cells 
were stained with trypan blue and visualized under the light microscope (Figure 
4.1).   
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Figure 4.1: Representative images of isolated intact nucleus stained with trypan blue and 
visualised under light microscope from three condition. (A) Control 2303, (B) Patient 51 MT and 
(C) Patient TT 192 (D) Poorly isolated nucleus demonstrating cytoplasmic material. MT=missense 
mutation, TT=Truncated mutation.  
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4.3 Cytoplasmic and nuclear RNA concentrations and quality 
measurements using Agilent Bioanalyser 2100 
 
The Agilent Bioanalyser 2100 was used to measure the quantity and quality of 
RNA (Table 4.1 and Figure 4.2) (Refer to section 2.5 for Agilent Bioanalyser 2100 
method of RNA quantification).  
 
The RNA samples from both cellular compartments showed better quality of RNA 
than the Human Exon 1.0 ST Arrays RNA samples. Also, the electropherograms 
did not show detectable levels of DNA contamination. This was achieved by 
modifying both, the cell fractionation and RNA extraction methods. The 
fibroblasts were monitored throughout the cell lysis procedure to ensure proper 
separation. Also, the Trizol method was used for RNA extraction. Trizol separates 
the lysate into a three layers, clear upper aqueous layer which contain the RNA, 
a middle interphase which contain the DNA and a lower layer which contains 
proteins. Therefore, it was easier to aspirate the RNA sample avoiding any 
interfering genomic DNA and proteins during RNA extraction. 
       
The sample selection was based on RIN cut-off value> 8 and a minimum of 
~200ng yield. The cytoplasmic RNA samples yields ranged 2.5µg to 14.2µg and 
the nuclear samples ranged from 0.8µg to 10.8µg (Table 4.1). Thus, all samples 
were taken forwards.   
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Table 4.1: RNA yields from cytoplasmic and nuclear extractions by the Agilent 
Bioanalyser. µg=nanograms, RIN= RNA integrity number, ng/µl= nanograms/ 
microliter, Con= Control, Pat= Patient, ID= Identification 
 
Cellular 
fraction   
Mutation 
type 
Sample ID  RNA yields 
(ng/µl) 
RIN Total RNA 
yield (µg) 
Cytoplasmic  - Con155 284 9.3 14.2 
Con 2303 198 9.6 9.9 
Con170 148 9 7.4 
Con159 216 9.3 10.8 
Missense 
mutation 
Pat 48 81 9.7 4 
Pat 55 68 9.7 3.8 
Pat 51 147 9.5 7.3 
Truncated 
mutation 
Pat192 81 9.7 4 
Pat193 128 9 6.4 
Pat194 50 9 2.5 
Nuclear  - Con 155 128 8 6.4 
Con 2303 192 9.5 9.6 
Con 170 136 9.9 6.8 
Con 159 218 9.8 10.9 
Missense 
mutation 
Pat 48 27 8 1.35 
Pat 55 72 9.6 3.6 
Pat 51 100 8.7 5 
Truncated 
mutation 
Pat 192 36 9.1 1.8 
Pat 193 144 9.7 7.2 
Pat 194 16 8 0.8 
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Figure 4.2: Representative electropherograms generated by the Agilent Bioanalyser 2100 of 
cytoplasmic and nuclear RNA samples (A) Standard ladder graph that represents the RNA 
markers which act as a reference for the other RNA samples. (B) Cytoplasmic RNA sample 
(patient 193) and (C) Nuclear RNA sample (patient 193). The Y axis represents the UV light 
absorption (FU) and the X axis represents size (nt).  
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4.4 Human Transcriptome Arrays 2.0 GeneChip® 
 
Human Transcriptome Arrays 2.0 GeneChip® Affymetrix were used to determine 
differentially expressed genes. As a quality control of the sample preparation, 
sample concentrations were measured as specific stages by the Nanodrop 1000 
spectrophotometer and the Agilent Bioanalyser 2100. RNA samples were linearly 
amplified to reach (15µg) of cRNA for the preparation of ss cDNA. A successful 
cRNA amplification was achieved and the yields ranged from 38.8µg to 203µg 
(Table 4.2). The ss cDNA was prepared and the cut-off value was to achieve 
(5.5µg) in order to perform the fragmentation and labelling step. Samples show 
satisfactory amount of ss cDNA ranging from 12µg to 23.5µg (Table 4.3).  
 
 
 
Table 4.2: cRNA yields. µg= micrograms, RIN= RNA integrity number, ng/µl= 
nanograms/ microliter, Con= Control, Pat= Patient, ID= Identification  
 
Cellular 
fraction   
Mutation types Sample ID Yields (ng/µl) Total yields 
(µg) 
Cytoplasmic  - Con 2302 1222.55 73 
Con170 1105.70 66 
Con159  736.39 44 
Con155 2205.89 132 
Missense 
mutation 
Pat 48 1157.57 69 
Pat 51 888.90 53 
Pat 55 3388.94 203 
Truncated 
mutation 
Pat 192 1833.75 110 
Pat 193 1460.08 87.6 
Pat 194 1817.46 109 
Nuclear  - Con 2302 1204.57 72 
Con170 2049.17 122.9 
Con159  1498.74 89.9 
Con155 3389.85 203 
Missense 
mutation 
 
Pat 48 1721.47 103 
Pat 51 647.96 38.8 
Pat 55 1476.04 88.5 
Truncated 
mutation 
Pat 192 2312.14 138.7 
Pat 193 3122.39 187 
Pat 194 1859.12 111.5 
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Table 4.3: Single-Stranded cDNA yield. µg= micrograms, RIN= RNA integrity 
number, ng/µl= nanograms/ microliter, Con= Control, Pat= Patient, ID= 
Identification 
 
 
Cellular 
fraction    
Mutation type Sample ID Yields 
(ng/µl) 
Total yields 
(µg) 
Cytoplasmic  - Con 2302 507.98 15 
Con170 483.45 14.5 
Con159  436.75 13 
Con155 688.60 20.6 
Missense 
mutation 
Pat 48 433.21 12.9 
Pat 51 478.45 14 
Pat 55 751.11 22.5 
Truncated 
mutation 
Pat 192 612.10 18 
Pat 193 603.54 18 
Pat 194 543.29 16 
Nuclear  - Con 2302 486.03 14.5 
Con170 581.62 17 
Con159  530.30 15.9 
Con155 784.38 23.5 
Missense 
mutation 
Pat 48 552.50 16.5 
Pat 51 407.36 12 
Pat 55 645.25 19 
Truncated 
mutation 
Pat 192 649.63 19 
Pat 193 767.60 23 
Pat 194 484 14.5 
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4.4.1 Fragmentation 
The ss cDNA samples were fragmented to enable their binding to the probes on 
the arrays. The recommended fragment length is 40nt to 70nt. Controls and 
patients samples were fragmented properly with most of the fragmented ss cDNA 
being ~70nt long (Figure 4.3). 
 
 
 
Figure 4.3: Representative electropherogram of fragmented single stranded DNA sample (patient 
193). The peak point of fragments can be assessed to be approximately ~70nt in length.  
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4.4.2 Gel shift assay 
The gel shift assay is a procedure that assess the efficiency of the labelling step 
(See section 2.7.10 for the procedure). Figure 4.4 demonstrated that positive 
samples showed bands at the expected position (400bp) and the negative 
samples did not show bands. This indicates that the samples were properly 
labelled.  
 
 
 
 
Figure 4.4: 4-20% graded TBE gel electrophoresis. The gel is stained with ethidium bromide 
and visualized under UV light. Avidin treated (positive) samples showed bands which 
corresponds to the expected bands size (400bp). Untreated samples acted as negative 
controls. Hyperladder V and IV were used. 
 
Sample type Control Control  Control  Missense mutation  Truncated mutation  
Sample ID Nuclear 155 Nuclear 2303 Nuclear 170 Nuclear 48 Cytoplasmic 193 
 
 
 
 
 
 
 
 
 
151 
 
4.4.3 Human Transcriptome Arrays 2.0 quality control 
 
The Human Transcriptome Arrays raw data were converted to CEL files using the 
Affymetrix GeneChip Command Console (AGCC) software. The quality control 
check of the arrays was performed through Affymetrix Expression Console v1.0 
software. The samples were monitored throughout the preparation process by 
the exogenous poly-A RNA positive controls (see section 2.7.2). Figure 4.5 shows 
a linear graph of the spiked in poly-A controls for both the cytoplasmic and nuclear 
samples. Cytoplasmic samples demonstrated a good quality of amplified spiked 
in poly-A controls except control 2303 and patient 55 which showed a slight 
reduction of the expression of the four spiked in poly-A controls. However the 
level of expression of these genes were as expected (Figure 4.5A). The 
hybridization intensities of the poly-A spiked in controls of the nuclear samples 
showed a good quality of amplification (Figure 4.5B). 
 
The process of hybridization, washing and staining of the arrays were monitored 
by a set of prelabeled hybridization control which are BioB, BioC, BioD and Cre 
(see section 2.7.11). Cytoplasmic and nuclear samples illustrated an even 
distribution of the hybridization controls signal intensity (Figure 4.6A&B). In 
addition, the probe set intensities were measured and a box plot graph was 
produced to determine the overall deviation of probe set signals for each array. 
This was presented as a box plot diagram that shows the upper quartile, lower 
quartiles and median. The whiskers illustrates the highest and lowest average 
signal intensities of the probes. The red line across the boxes represent the 
median which expected to range from 0.1 to 0.2. The median value of the 
cytoplasmic and nuclear samples was detected at ~0.1 (Figure 4.7). 
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Figure 4.5: Poly-A spiked in controls linear graph of the HTA. (A)The cytoplasmic hybridization 
intensities of the poly-A spiked in controls. All cytoplasmic samples demonstrated good quality of 
amplification except control 2303 showed a reduction of gene expression of the spiked in controls. 
(B) The poly-A spiked in hybridization intensities of the nuclear samples. 
 
 
 
  
 
Figure 4.6: The Hybridization controls (BioB, BioC, BioD and Cre) linear graph of HTA. (A) The 
cytoplasmic hybridization controls linear graph. (B) The nuclear hybridization controls linear 
graph. Overall all samples show even hybridization intensity. 
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Figure 4.7: Box plot graph of the relative expression signals after normalization of the HTA. Each 
box plot represents the mean and standard deviation of an array. The red middle line across the 
box plots is the median gene expression of all samples after normalization. The whiskers 
represent the highest and the lowest average signal intensities of the probes. (A) The relative log 
expression signal of cytoplasmic samples. (B) The relative log expression signal of the nuclear 
samples. They demonstrate an overall acceptable range of averaged signal intensities. 
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4.5 Gene expression profiling using the Transcriptome Analysis Console 
(TAC) software  
CHP files from controls and patients were generated from GeneChip® Command 
Console® (AGCC) Software and were uploaded into the TAC software. CHP files 
ware normalized prior to analysis. A one-way ANOVA test was carried out and 
the significant differentially expressed transcripts with a p-value < 0.05 and fold 
change > + 2 were identified. The main approaches were first to identify 
statistically significant genes that are differentially expressed in fALS-TARDBP 
from both missense MT vs. control CON and truncated mutations TT vs. control 
CON in each cellular component then to assign these genes to biological 
processes through available online software.  
 
Cytoplasmic MT vs. cytoplasmic CON showed 80 differentially expressed genes; 
43 were up-regulated and 37 were down-regulated. In addition, the cytoplasmic 
TT vs. cytoplasmic CON demonstrated 221 differentially expressed genes; 182 
were up-regulated and 39 were down-regulated (Figure 4.8). Within the nuclear 
extract, nuclear MT vs. nuclear CON showed 73 differentially expressed genes; 
45 were up-regulated and 28 were down-regulated. In addition, the nuclear TT 
vs. nuclear CON demonstrated differentially expressed genes 321; 263 were up-
regulated and 58 were down-regulated (Figure 4.9). It was surprisingly that at FC 
> 2 and a p-value < 0.05 very few genes were identified in both mutation types 
and cellular compartments. The GeneVenn tool was used to determine 
differentially expressed genes that were specific to each type of mutation and in 
each cellular component. Common genes were also identified (Figure 4.10 and 
4.11).  
 
The gene lists were uploaded into DAVID v6.7 to study the biological processes 
involved in the disease process. The cut-off value of enrichment score was set to 
> 1.3 which is considered the lowest significant value equivalent to a p-value of 
0.05 (Huang da et al., 2009). Similarly, very few biological processes were 
identified. The differentially expressed genes from cytoplasmic MT vs. 
cytoplasmic CON showed that vesicle-mediated transport was the only significant 
biological process affected in fALS-TARDBP missense mutation. Furthermore, 
155 
 
cytoplasmic TT vs. cytoplasmic CON demonstrated that regulation of acute 
inflammatory response, response to nutrient and negative regulation of 
proteolysis were the most significant enriched biological processes. On the other 
hand, nuclear MT vs. nuclear CON illustrated that bone development and 
nucleosome assembly were both affected. Lastly, DAVID online software did not 
show any significant biological process for nuclear TT vs. nuclear CON with the 
highest enrichment score being 0.99 (Table 4.4). 6 genes were common in both 
the cytoplasmic MT and TT, 3 were annotated and 3 were unannotated.  On the 
other hand, 8 gene were common in both nuclear MT and TT, 2 were annotated 
and 6 were unannotated (Table 4.5 and Table 4.6). 
 
The results generated by TAC software were therefore not satisfactory. This was 
most probably due to two reasons, first, the normalization step prior to data 
analysis. CHP files from the cytoplasmic RNA and nuclear RNA were normalized 
together by the expression console software this may have deceased the number 
of genes significantly. Second was the inability to manipulate the fold change at 
the time of analysis at FC + 1.2 (April 2015) which made it difficult to reduce the 
stringency and get higher number of differentially expressed genes and it was 
obvious that the number of genes in each biological process were significantly 
low with undetected biological process in the nuclear truncated mutation although 
it showed the highest number of differentially expressed genes. With the 
limitations of the TAC software, Qlucore Omics Explorer software was the best 
alternative available option to analyse the data. This had adjustable fold change 
setting and was easy to use.     
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Figure 4.8: Differentially expressed genes in cytoplasmic MT and cytoplasmic TT compared to 
controls using the TAC software. 
 
 
 
 
 
Figure 4.9: Differentially expressed genes in nuclear MT and nuclear TT compared to controls 
using the TAC software. 
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Figure 4.10: Comparative study of differentially expressed genes in the cytoplasmic MT vs. TT. 
Venn diagram showing 74 genes specific to the cytoplasmic missense mutation, 215 genes 
specific to the cytoplasmic truncation mutation and 6 genes were found common in both types of 
mutations using the TAC software.  
 
 
 
Figure 4.11: Comparative study of differentially expressed genes in the nuclear MT vs. TT. Venn 
diagram showing 65 genes specific to the cytoplasmic missense mutation, 313 genes specific to 
the cytoplasmic truncation mutation and 8 genes were found common in both types of mutations 
using the TAC software.  
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Table 4.4: Functionally enriched biological processes generated by DAVID for 
cytoplasmic MT & TT and nuclear MT & TT (TAC software). GO= Gene ontology, 
no.=number, ES= Enrichment score, MT= missense mutation, TT= truncated 
mutation  
 
 
GO Biological process Gene no. P- value ES 
 
Cytoplasmic MT vs. CON 
 
BP_FAT Vesicle-mediated transport 6 2.0E-3 1.78 
 
Cytoplasmic TT vs. CON 
 
BP_FAT Regulation of acute inflammatory 
response 
3 3.4E-3 1.57 
BP_FAT Response to nutrient 5 2.7E-3 1.47 
BP_FAT Negative regulation of proteolysis 3 3.7E-3 1.31 
 
Nuclear MT vs.CON 
 
BP_FAT Bone development 3 2.1E-2 1.69 
BP_FAT Nucleosome assembly 3 1.0E-2 1.42 
 
Nuclear TT vs. CON 
 
BP_FAT Keratinocyte differentiation 3 3.1E-2 0.99 
 
Table 4.5: Common annotated genes in cytoplasmic MT and TT (TAC software). 
MT=missense mutation, TT=truncated mutation, FC=fold change   
 
Gene 
symbol  
Gene name  FC  
MT 
FC  
TT 
FSIP1 Fibrous sheath interacting protein 1 2.09 2.95 
MGAT5 Mannosyl (alpha-1,6-)-glycoprotein beta-
1,6-N-acetyl-glucosaminyltransferase 
2.17 
 
2.15 
 
NAV2 Neuron navigator 2 -2.11 -2.15 
 
Table 4.6: Common annotated genes in nuclear MT and TT (TAC software). 
MT=missense mutation, TT=truncated mutation, FC=fold change   
 
Gene 
symbol  
Gene name  FC  
 MT 
FC  
 TT 
ARL17A ADP-ribosylation factor-like 17A 2.67 2.14 
ARL17B  ADP-ribosylation factor-like 17B 2.99 2.93 
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4.6 Gene expression profiling using Qlucore Omics Explorer software 
 
Gene expression profiling from the cytoplasmic and nuclear RNA fractions were 
studied using Qlucore Omics Explorer software. CEL files were uploaded into the 
Qlucore Omics Explorer software and samples were normalized according to 
their cellular component and mutation type prior to the analysis. The p-value was 
set to < 0.05 and fold change to > + 1.2. Two comparison studies were carried 
out on each type of mutation, fALS-TARDBP missense mutation MT and fALS-
TARDBP truncated mutation TT. The analysis was set similarly to the Human 
Exon 1.0 ST Array with the aim to identify biological pathways dysregulated 
specifically and commonly in response to the TARDBP mutations in each RNA 
compartment. 
 
The cytoplasmic MT vs. cytoplasmic CON showed 224 differentially expressed 
genes; 162 genes were up-regulated and 62 genes were down regulated. 
Cytoplasmic TT vs. cytoplasmic CON revealed 421 differentially expressed 
genes; 290 genes were up-regulated and 131 genes were down regulated. 
However, nuclear MT vs nuclear CON presented 552 differentially expressed 
genes; 344 genes were up-regulated and 208 genes were down regulated (Figure 
4.12). The nuclear TT vs. nuclear CON illustrated 685 differentially expressed 
genes; 270 genes were up-regulated and 415 genes were down regulated (Figure 
4.13). GeneVenn tool was also used to determine differentially expressed genes 
to each type of mutation and each cellular component. Common genes were also 
identified (This is shown further in section 4.6.1.3 and 4.6.2.3).   
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Figure 4.12: Differentially expressed genes in cytoplasmic MT and cytoplasmic TT compared to 
controls using the Qlucore Omics Explorer software  
 
 
 
Figure 4.13: Differentially expressed genes in nuclear MT and nuclear TT compared to controls 
using the Qlucore Omics Explorer software 
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4.6.1 Cytoplasmic gene expression profiling using the Human 
Transcriptome Arrays   
 
4.6.1.1 Differential gene expression of cytoplasmic MT vs. CON 
 
Qlucore Omics Explorer software generated the principal component analysis 
(PCA) graph which is a statistical test that illustrates the variability of a set of 
values. The highest percentage of variability is blotted on the longest axis. The 
PCA graph of cytoplasmic MT vs. cytoplasmic CON showed a good separation 
between patients and controls (Figure 4.14). The gene list was uploaded into 
DAVID analysis tool to identify the biological processes to what these genes 
belong. Using a high stringency classification those with a significant enrichment 
score > 1.3 were selected. The most significantly enriched biological processes 
were the following: RNA processing, angiogenesis, cell adhesion and 
neurological system process (Table 4.7). A more detailed examination of the 
genes within these significant pathways is provided below.  
 
Figure 4.14: Principal component analysis plot of cytoplasmic MT vs. cytoplasmic CON. It shows 
a 77% variability between patients and controls clustering at the first principal component (PC1). 
It demonstrates good separated cluster (Blue = MT) & (Yellow = CON) 
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Table 4.7: Functionally enriched biological processes generated by DAVID of the 
cytoplasmic MT vs. CON differentially expressed genes (High stringency). GO= 
Gene ontology, no.=number, ES= enrichment score 
 
GO  Biological process  Gene no. P-value ES 
BP_FAT RNA processing 7 6.0E-2 1.58 
BP_FAT Angiogenesis 4 4.0E-2 1.47 
BP_FAT Cell adhesion 8 6.5E-2 1.39 
BP_FAT Neurological system process 10 1.6E-1 1.33 
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4.6.1.1.1 RNA processing  
 
As mentioned previously (section 3.6.1.1.3), RNA processing is an essential 
cellular metabolic process which involves a wide range of sequential events 
which control gene expression. These include: RNA splicing, editing, transport, 
translation and RNA decay. The majority of genes involved in RNA processing 
have been shown to be down-regulated in cytoplasmic fALS-TARDBP missense 
mutation samples (Table 4.8) and (Figure 4.15).  
 
The U2 small nuclear RNA auxiliary factor 1-like 4 (U2AF1L4) is a splicing factor 
which is involved in RNA splicing was decreased (FC=-1.2). Northern blotting 
showed that the expression of U2AF1L4 was high in the brain  (Shepard et al., 
2002). Furthermore, the small nuclear ribonucleoprotein polypeptide A (SNRPA) 
gene was down-regulated (FC=-1.3). It is a component of the spliceosome and 
binds to the U1 snRNP that is involved in pre-mRNA splicing (Sillekens et al., 
1987, Nelissen et al., 1991). The methyltransferase like 1 (METTL1) gene was 
also reduced (FC=-1.2). It encodes for a methyltransferase protein which was 
suggested to have an S-adenosylmethionine (SAM) binding site. It is thought to 
be involved in transferring methyl groups from one molecule to another in the cell, 
and is therefore, suggested to be involved in regulating gene expression through 
methylation (Bahr et al., 1999). The poly (A) binding protein, nuclear 1 (PABPN1) 
was also reduced (FC=-1.2). The gene encodes for a nuclear protein which is 
involved in the regulation of nascent RNA polyadenylation (Fan et al., 2001). 
Furthermore, two pseudogenes, the proliferation-associated 2G4 (PA2G4P4) 
and the ribosomal protein L36a pseudogene (RPL36A) were also reduced (FC=-
1.3 and -1.2 respectively). In contrast, a single gene showed a significant 
increase in gene expression. The adenosine deaminase, RNA specific B1 
(ADARB1) which is responsible for the editing of the GluR2 pre-mRNA at the Q/R 
site converting adenosine to inosine was increased (FC= 1.6). This was 
suggested to have an effect the Ca++ ion permeability through the GluR2 
receptor (Eckmann et al., 2001).  
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As the majority of RNA processing takes place in the nucleus, it is not surprising 
to find that genes related to RNA processing i.e. splicing, and polyadenylation 
and also gene related to methylation being reduced in the cytoplasmic missense 
mutation. However, to further investigate the expression of these gene in the 
nuclear missense mutation,   the nuclear MT vs. CON gene list was investigated. 
Surprisingly none of the genes were identified. Therefore, this may suggest that 
as a result of TDP-43 mutation, RNA splicing factors, spliceosome complexes 
and other RNA binding proteins are degraded in the nucleus. 
 
The overall observation suggests a decreased expression of genes involved in 
RNA processing in the fALS missense mutation. This observation indicates that 
less splicing regulation takes place in fALS-TARDBP missense mutation. Also 
dysregulated RNA processing genes was observed in the cytoplasmic fraction 
using the Human Exon 1.0 ST Arrays (see section 3.6.1.1.3).  
 
 
Table 4.8: Genes involved in RNA processing in the cytoplasmic missense 
mutation  
 
Gene symbol  Gene name  P-value  Fold 
change  
ADARB1 * Adenosine deaminase, RNA-
specific, B1 (RED1 homolog rat) 
0.009  1.66 
 
METTL1 * Methyltransferase like 1 0.04 -1.23 
PABPN1 Poly(A) binding protein, nuclear 1 0.02 -1.21 
PA2G4P4 Proliferation-associated 2G4, 38kDa; 
pseudogene 4 
0.009 
 
-1.34 
 
RPL36A Ribosomal protein L36a pseudogene  0.01 -1.25 
SNRPA Small nuclear ribonucleoprotein 
polypeptide A 
0.02 -1.30 
U2AF1L4 U2 small nuclear RNA auxiliary factor 
1-like 4 
0.02 -1.28 
(*) selected candidate genes for validation by qRT-PCR 
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Figure 4.15: A representative diagram showing the dysregulated RNA processing genes in fALS-
TARDBP cytoplasmic missense mutation   
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4.6.1.1.2 Angiogenesis 
 
The vascular endothelial growth factor (VEGF) gene which is involved in 
angiogenesis has been suggested to be associated with the pathology of ALS 
(Oosthuyse et al., 2001). Normally, VEGF is a mitogen which has a role in 
angiogenesis and neurogenesis. A study showed that the depletion of VEGF in a 
mouse model resulted in low expression of VEGF in the brain and spinal cord 
producing symptoms resembling ALS (Oosthuyse et al., 2001). Furthermore, 
mutations in the angiogenin (ANG) gene are associated with ALS. ANG has a 
role in vessel repair, endothelial cell proliferation, migration and rRNA 
transcription (Gao and Xu, 2008). 
 
 In the current study, four genes associated with angiogenesis were up-regulated 
in the cytoplasm of the fALS missense mutation cases (Table 4.9). VEGF gene 
expression is stimulated by external factors such as hypoxia and also by internal 
factors such as circulating cytokines, interleukin 6 and interleukin 1β. Here, the 
proinflammatory cytokine interleukin 18 (interferon-gamma-inducing factor) 
(IL18) was shown to be up-regulated (FC=1.2). It is involved in immune defence 
and has been associated with cancer metastasis (Vidal-Vanaclocha et al., 2000, 
Ferrara, 2004). Furthermore, the endothelin receptor type A (EDNRA) was 
increased (FC=1.2). The EDNRA is activated via the binding of endothelin-1, 
which is produced by endothelial cells, to the receptor. This action induces blood 
vessel vasoconstriction (Miyamoto et al., 1996).  The kruppel-like factor 5 
(intestinal) (KLF5) belongs to the zinc finger protein Kruppel-like factor subfamily 
and is considered a transcription factor which is essential for normal development 
of arterial walls and angiogenesis. KLF5 +/- knockout mice showed decreased 
levels of angiogenesis activity (Shindo et al., 2002). The KLF5 gene was up-
regulated (FC=1.2). Finally the transforming growth factor, alpha (TGFA) was 
also increase (FC=1.2). TGFA is involved in cell proliferation, differentiation and 
development. Overexpression of TGFA was shown to be associated with several 
types of cancer (Singh and Coffey, 2014). Overall there are few number of 
differentially expressed gene related to angiogenesis in fALS-TARDBP missense 
mutation. Possibly not a significant pathway however may be considered in future 
work (Figure 4.16). 
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Table 4.9: Genes involved in angiogenesis in the cytoplasmic missense mutation 
 
Gene 
symbol  
Gene name  P-value  Fold change  
EDNRA Endothelin receptor type A 0.01 1.24 
IL18 Interleukin 18 (interferon-gamma-
inducing factor) 
0.02 
 
1.26 
 
KLF5 Kruppel-like factor 5 (intestinal) 0.03 1.26 
TGFA Transforming growth factor, alpha 0.02 1.21 
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Figure 4.16: A representative diagram showing the dysregulated genes involved in angiogenesis 
in fALS-TARDBP cytoplasmic missense mutation. White circles= white blood cells, red circles= 
red blood cell, yellow ovals= platelet.     
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4.6.1.1.3 Cell adhesion 
 
Cell adhesion is the process by which cells are attached to each other via 
adhesion molecules to maintain normal cellular structure, cell integrity, protect 
against invading pathogens and can be involved in injury repair (Gumbiner, 
1996). In the cytoplasmic fALS-TARDBP cell adhesion molecules were found to 
be dysregulated as discussed below (Table 4.10). 
 
The CD9 molecule (CD9) belongs to the tetraspanin superfamily which is involved 
in cell adhesion and migration. It is expressed on mast cells, dendritic cells and 
megakaryocytes (Leung et al., 2011).  Defects in the CD9 genes results in loss 
of its expression and associated with cancer and metastasis (Zoller, 2009). This 
gene was shown to be up-regulated (FC=1.2). Furthermore, the 
platelet/endothelial cell adhesion molecule (PECAM1) which facilitates 
endothelial cell junctions was increased (FC=1.2). It is expressed on platelets, 
leukocytes and T-lymphocytes (Ma et al., 2010). The protocadherin beta 15 
(PCDHB15) belongs to a subfamily of the cadherin molecules which are Ca++ 
dependent adhesion molecules. PCDHB15 has suggested to have a role in 
neural cell adhesion and was shown to be up-regulated (FC=1.2) (Wu and 
Maniatis, 1999). In contrast, cadherin 2, type 1, N-cadherin (neuronal) (CDH2) is 
involved in the maintenance of cell integrity was down-regulated (FC=-2.2). It was 
shown that CDH2 is necessary to facilitate pre-synaptic and post-synaptic 
adhesion (Tanaka et al., 2000). The trophinin associated protein (tastin) (TROAP) 
that has a role in the attachment of the blastocyst to the endometrium during 
implantation was also deceased (FC=-1.2) (Fukuda et al., 1995). Finally, the 
tumour necrosis factor, alpha-induced protein 6 (TNFAIP6) was reduced (FC=-
1.2). It was demonstrated that genes involved in cell adhesion were dysregulated 
in fALS missense mutation with a number of genes were up-regulated and down-
regulated, acting across several systems (Figure 4.17).  
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Table 4.10: Genes involved in cell adhesion in the cytoplasmic missense 
mutation 
 
Gene 
symbol  
Gene name  P-value  Fold 
change  
CD9 CD9 molecule 0.01 1.29 
CDH2 Cadherin 2, type 1, N-cadherin (neuronal) 0.04 -2.24 
PCDHB15 Protocadherin beta 15 0.02 1.21 
PECAM1 Platelet/endothelial cell adhesion 
molecule 
0.02 1.22 
RPSA Ribosomal protein SA pseudogene 0.04 -1.27 
TMEM8A NULL///Transmembrane protein 8A 0.02 1.36 
TNFAIP6 Tumour necrosis factor, alpha-induced 
protein 6 
0.03 -1.28 
TROAP Trophinin associated protein (tastin) 0.03 -1.24 
*NULL=Not accurately characterized yet 
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Figure 4.17: A representative diagram showing the cell adhesion molecules in fALS-TARDBP 
cytoplasmic missense mutation and their previously described roles.    
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4.6.1.1.4 Neurological system process 
 
DAVID analysis tool grouped some genes under the term neurological process 
(Table 4.11). This was defined by the gene ontology terminology as genes 
carrying functions in relation to the CNS. A large group of chemoreceptors were 
shown to be increased in expression. They are G-protein-coupled receptors with 
a characteristic 7-transmembrane domain structure that are activated by 
exogenous stimuli (Buck and Axel, 1991). Several olfactory receptor gene were 
up-regulated, olfactory receptor, family 4, subfamily D, member 10 (OR4D10) 
(FC=1.2), olfactory receptor, family 5, subfamily H, member 1 (OR5H1) (FC=1.2), 
olfactory receptor, family 5, subfamily R, member 1 (OR5R1) (FC=1.3), olfactory 
receptor, family 51, subfamily B, member 4 (OR51B4) (FC=1.2), olfactory 
receptor, family 52, subfamily J, member 3 (OR52J3) (FC=1.3). On the other 
hand, the olfactory receptor, family 1, subfamily G, member 1 (OR1G1) was 
down-regulated (FC=-1.4).  
 
The CD9 molecule (CD9) was up-regulated (FC= 1.2). As previously described it 
is involved in both cell adhesion and signal transduction (see section 4.6.1.1.3). 
It also was shown to be expressed in the CNS (Tole and Patterson, 1993). The 
LIM homeobox 8 (LHX8) gene which is involved in neuronal differentiation was 
increased (FC=2.2). Mutations in the LHX8 gene have been suggested to be 
associated with defective cholinergic neuronal development (Zhao et al., 2003). 
Furthermore, the arrestin, beta 1 (ARRB1) gene was up-regulated (FC=1.4). It 
encodes for a cofactor that acts by inhibiting the beta-adrenergic receptor kinase 
(BARK) signalling pathway (Zhao et al., 2003). The regulating synaptic 
membrane exocytosis 1 (RIMS1) mediates synaptic vesicle release at the 
presynaptic nerve ending by creating a scaffold with other proteins that enables 
the transportation of synaptic vesicle to the presynaptic terminal (Schoch et al., 
2002). This gene was shown to be increased (FC=2.0). 
 
It is shown that genes involved in the neurological system process were up-
regulated in the fALS-TARDBP missense mutation even though the work was 
carried out using fibroblasts. This was mainly involved in olfactory receptors, cell 
adhesion, exocytosis, neuronal differentiation and BARK signalling pathway. 
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Table 4.11: Genes involved in neurological system process in the cytoplasmic 
missense mutation 
 
 
Gene 
symbol  
Gene name  P-value  Fold 
change  
ARRB1 Arrestin, beta 1 0.02 1.46 
CD9 CD9 molecule 0.01 1.29 
LHX8 LIM homeobox 8 0.02 2.25 
OR1G1 Olfactory receptor, family 1, subfamily G, 
member 1 
0.02 -1.40 
OR4D10 Olfactory receptor, family 4, subfamily D, 
member 10 
0.04 1.20 
OR5H1 Olfactory receptor, family 5, subfamily H, 
member 1 
0.01 1.20 
OR5R1 Olfactory receptor, family 5, subfamily R, 
member 1 
0.04 1.34 
OR51B4 Olfactory receptor, family 51, subfamily B, 
member 4 
0.008 1.22 
OR52J3 Olfactory receptor, family 52, subfamily J, 
member 3 
0.006 1.33 
RIMS1 Regulating synaptic membrane exocytosis 1 0.01 2.02 
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4.6.1.2 Differential gene expression of cytoplasmic TT vs. CON 
 
The PCA of cytoplasmic TT vs. cytoplasmic CON showed an acceptable 
separation cluster between patients and controls (Figure 4.18). The differentially 
expressed genes were explored using the DAVID analysis tool. Those genes with 
a significant enrichment score > 1.3 were selected. The significant enriched 
biological processes were found in two clusters: angiogenesis and adherens 
junction (Table 4.12). A further description is shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: Principal component analysis plot of cytoplasmic TT vs. cytoplasmic CON. Samples 
illustrate good separation with an 82 % variability between patients and controls clustering at the 
first principal component (PC1). (Red = TT) & (Yellow = CON).  
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Table 4.12: Functionally enriched biological processes generated by DAVID of 
the cytoplasmic TT vs. CON differentially expressed genes. GO=Gene ontology, 
no.=number, ES=Enrichment score 
 
GO  Biological process  Gene no. P-value ES 
BP_FAT Angiogenesis 8 1.8E-3 2.45 
CC_FAT Adherens junction 8 2.9E-3 1.89 
 
 
 
 
4.6.1.2.1 Angiogenesis 
 
Genes involved in angiogenesis were also shown to be up-regulated in fALS-
TARDBP truncated mutation similarly to that in missense mutation however none 
of the same genes were identified (Table 4.13).  
 
The epithelial mitogen homolog (mouse) (EPGN) was up-regulated (FC=1.2). 
The gene encodes for a ligand which belongs to the epidermal growth factor 
family. It binds to the epidermal growth factor receptor to activate cell proliferation 
and migration signalling pathways (Herbst and Bunn, 2003). Moreover, the 
fibroblast growth factor 1 (acidic) (FGF1) which is suggested to be an 
angiogenesis factor was also increased (FC=1.2) (Magnusson et al., 2007). The 
mesenchyme homeobox 2 (MEOX2) gene was up-regulated (FC=1.2) and was 
shown to be involved in vascular differentiation (Gorski et al., 1993, Wu et al., 
2005). In addition, the sema domain, seven thrombospondin repeats (type 1 and 
type 1-like), transmembrane domain (TM) and short cytoplasmic domain, 
(semaphorin) 5A (SEMA5A) was increased (FC=1.6). It is involved in axon 
guidance in both attracting and inhibiting axonal growth during neuronal 
development (Kantor et al., 2004). The T-box 1 (TBX1) gene encodes for the 
TBX1 transcription factor that involves in the development of normal arterial 
blood. A TBX1 mutation in mice showed phenotypic characteristics similar to 
DiGeorge syndrome (Jerome and Papaioannou, 2001). This gene was shown to 
be up-regulated (FC=1.2). The Thy-1 cell surface antigen (THY1) is a 
glycoprotein which is expressed on the cell surface. It is involved in cell 
proliferation, differentiation and apoptosis. It has been suggested to be a tumour 
suppressor for ovarian cancer (Lung et al., 2005). The tumour necrosis factor 
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(ligand) superfamily, member 12 (TNFSF12) is a member of the tumour necrosis 
factor (TNF) ligand family which is involved in cellular pathways such as: cell 
proliferation and apoptosis was increased (FC=1.2). It also was shown to be 
involved in angiogenesis by promoting endothelial cell proliferation and migration 
(Chicheportiche et al., 1997, Lynch et al., 1999). Finally the Rho GTPase 
activating protein 24 (ARHGAP24) was the only gene in the list to be down-
regulated (FC=-1.3). It is involved in regulating endothelial cell proliferation and 
migration through the Rho signalling pathway. Knock-down of the ARHGAP24 in 
mice showed an inhibition of endothelial cell migration and proliferation. This 
strongly suggests an ARHGAP24 association with angiogenesis (Su et al., 2004). 
Genes involved in angiogenesis were increased in the cytoplasmic truncated 
mutation (Figure 4.19). The present observation along with the dysregulated 
angiogenesis related genes observed in missense mutation may suggests the 
association of dysregulated angiogenesis in the disease process. 
 
Angiogenesis-related genes from both mutations were combined together and 
were uploaded into DAVID in order to detect any similarities or differences in 
angiogenesis pathway. The Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway did not show any significant pathway. This may indicate distinct affected 
targeted genes underlying each type of mutation. It may also reflects the 
response to the cellular environment within the fibroblasts. 
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Table 4.13: Genes involved in angiogenesis in the cytoplasmic truncation 
mutation 
 
Gene 
symbol  
Gene name  P-value  Fold 
change  
ARHGAP24 Rho GTPase activating protein 24 0.01 -1.38 
EPGN Epithelial mitogen homolog (mouse) 0.04 1.28 
FGF1 Fibroblast growth factor 1 (acidic) 0.01 1.22 
MEOX2 Mesenchyme homeobox 2 0.03 1.21 
SEMA5A* Sema domain, seven thrombospondin 
repeats (type 1 and type 1-like), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 5A 
0.01 
 
1.65 
 
TBX1 T-box 1 0.02 1.20 
THY1 Thy-1 cell surface antigen 0.009 1.42 
TNFSF12 Tumor necrosis factor (ligand) 
superfamily, member 12 
0.03 
 
1.21 
 
(*) selected candidate genes for validation by qRT-PCR  
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Figure 4.19: A representative diagram showing the dysregulated genes involved in angiogenesis 
in fALS-TARDBP cytoplasmic truncated mutation. White circles= white blood cells, red circles= 
red blood cell, yellow ovals= platelet.     
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4.6.1.2.2 Adherens junction 
 
Adhesion junction molecules are anchoring proteins that are able to extend from 
one cell to attach to adjacent cell facilitating the adhesion process. Several genes 
were dysregulated in the fALS-TARDBP truncated mutation (Table 4.14).     
 
The LIM domain 7 (LMO7) was up-regulated (FC=1.6). It has been suggested 
that LMO7 regulates emerin expression, a protein that facilitates the membrane 
anchoring of the cytoskeleton (Holaska et al., 2006). In addition, the membrane 
protein, palmitoylated 7 (MAGUK p55 subfamily member 7) (MPP7) was 
increased (FC=1.2). MPP7 stimulates polarity and facilitates tight junction 
formation of epithelial cells (Stucke et al., 2007). In contrast some genes involved 
in adhesion were down-regulated. Two genes belonging to the Rho family of 
GTPases were reduced, the Rho GTPase activating protein 24 (ARHGAP24) (as 
seen above) and Cdc42 GTPase-activating protein (ARHGAP31) (FC=-1.3 &-1.3 
respectively). Both genes are involved in regulating endothelial cells proliferation, 
migration and cytoskeletal arrangement through the Rho signalling pathway (Su 
et al., 2004, Tcherkezian et al., 2006). Furthermore, the enabled homolog (ENAH) 
which facilitates the movement of actin filament was down-regulated (FC=-1.5). 
Overexpression of ENAH was suggested to be associated with carcinoma cell 
invasion and metastasis (Philippar et al., 2008). The tensin like C1 domain 
containing phosphatase (tensin 2) (TENC1) was reduced (FC=-1.2). It belongs to 
the tensin family which are adhesion molecules that have been suggested to have 
a role in promoting cell migration (Chen et al., 2002). Both Talin 1 & Talin 2 were 
down-regulated (FC=-1.2 &-1.2 respectively). They are involved in cell adhesion 
process which facilitate the adhesion of cells through activating the connection of 
integrin molecules to the actin cytoskeleton (Monkley et al., 2001, Chen et al., 
2002).  
 
It was shown that genes involved in adhesion were mostly down-regulated in 
fALS truncated mutation. Although both fALS-TARDBP missense mutation and 
truncated mutation showed that cell adhesion/ adherens junction was 
dysregulated, it was interesting to find if any of the cell adhesion/ adherens 
junction genes from both mutations belonged to similar or distinct pathway. Thus, 
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genes from both mutations were combined then uploaded into DAVID and the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway was generated in 
order to identify significant pathways. It was shown that cell adhesion process 
was dysregulated similarly in both mutations, two genes; CDH2 and PECAM1; 
from the fALS-TARDBP missense mutation belonged to the cell adhesion 
molecule pathway and the fALS-TARDBP truncated mutation showed that TLN1 
and TLN2 belonged in the focal adhesion pathway (Figure 4.20 and 4.21). 
Therefore, dysregulated cell adhesion related pathways may be a common 
dysregulated biological process in fALS-TARDBP mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
181 
 
Table 4.14: Genes involved in the adherens junction in the cytoplasmic truncation 
mutation 
 
Gene 
symbol  
Gene name  P-value  Fold 
change 
ARHGAP24 Rho GTPase activating protein 24 0.01 -1.38 
ARHGAP31 Cdc42 GTPase-activating protein 0.04 -1.36 
ENAH * Enabled homolog (Drosophila) 0.002 -1.58 
LMO7 LIM domain 7 0.009 1.65 
MPP7 Membrane protein, palmitoylated 7 
(MAGUK p55 subfamily member 7) 
0.01 1.24 
 
TENC1 Tensin like C1 domain containing 
phosphatase (tensin 2) 
0.02 
 
-1.26 
 
TLN1 Talin 1 0.04 -1.24 
TLN2 Talin 2 0.003 -1.25 
(*) selected candidate genes for validation by qRT-PCR  
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Figure 4.20: Cell adhesion molecules pathway showing, CDH2 and PECAM1 dysregulated in 
fALS-TARDBP missense mutation. 
 
 
 
 
 
183 
 
 
Figure 4.21: Focal adhesion pathway showing, Talin (i.e. TLN1 and TLN2 blotted as one gene 
on the diagram by DAVID) dysregulated in fALS-TARDBP truncated mutation.  
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4.6.1.3 Comparative analysis of differentially expressed genes in the 
cytoplasmic fractions of missense and truncation TARDBP mutation 
 
It was interesting to distinguish genes related to each type of mutation and find 
genes that were common to fALS, this was performed using an online tool known 
as GeneVenn. The venn diagram showed 209 differentially expressed genes 
were specific to the cytoplasmic missense mutation, 406 differentially expressed 
genes were specific to the cytoplasmic truncated mutation and 15 genes were 
common in both (Figure 4.22).  
 
Using DAVID online software we explored each specific list separately. Both 
cytoplasmic MT and cytoplasmic TT specific genes showed the same biological 
process to be affected which was angiogenesis however with different set of 
genes (enrichment score of 1.32 and 2.53 respectively). The 15 common genes 
did not demonstrate any clustering within a biological pathway (Table 4.15). This 
may suggest distinct biological processes affected by the two different types of 
mutations, within the cytoplasmic RNA fraction. 
 
 
 
 
 
Figure 4.22: Comparative analysis of differentially expressed genes in the cytoplasmic fractions 
of missense MT and truncation TT TARDBP mutation. Venn diagram showing 209 genes specific 
to the cytoplasmic missense mutation, 406 genes specific to the cytoplasmic truncation mutation 
and 15 genes were found common in both types of mutations.  
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Table 4.15: Common genes in cytoplasmic missense and truncation mutation 
 
Gene Symbol Gene name  FC MT FC TT 
ARL17A ADP-ribosylation factor-like 17A 1.51 2.45 
DHRS4-AS1 DHRS4 Antisense RNA 1 1.45 1.54 
FSIP1 NULL/// Fibrous sheath interacting protein 1 1.85 2.11 
GABARAPL1 GABA(A) receptor-associated protein like 1 1.61 1.36 
HCG11 HLA complex group 11 (non-protein coding) 1.28 1.45 
HCG20 NULL 1.22 1.22 
MIR632 NULL /// MicroRNA 632 /// zinc finger protein 207 -1.30 -1.40 
OR9A1P Olfactory receptor, family 9, subfamily A, member 1 pseudogene -1.32 -1.22 
OTTHUMG00000007307  NULL 1.24 1.200 
OTTHUMG00000157236  NULL 1.61 1.42 
PABPN1  Poly(A) binding protein, nuclear 1 -1.21 -1.26 
RNA5SP376 RNA, 5S ribosomal pseudogene 376 1.20 1.22 
RNA5SP377 RNA, 5S ribosomal pseudogene 377 1.20 1.22 
SNRPA Small nuclear ribonucleoprotein polypeptide A -1.30 -1.47 
VSIG1  NULL/// V-set and immunoglobulin domain containing 1 1.20 1.20 
 
*NULL= gene not annotated, NULL/// gene name= not accurately characterized yet.   
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4.6.2 Nuclear gene expression profiling using the Human Transcriptome 
Arrays  
 
4.6.2.1 Differential gene expression of nuclear MT vs. CON 
 
The PCA of nuclear MT vs. nuclear CON showed a good separation of clusters 
between patients and controls (Figure 4.23). The differentially expressed genes 
were explored using DAVID. As previously mentioned, the cut-off value of 
enrichment score was set to > 1.3.  
 
The highest enrichment clustering was found in the following biological process 
and biological processes: nuclear mRNA splicing via spliceosome, regulation of 
translation, mRNA transport and nucleosome organization (Table 4.16). A further 
discussion of these biological processes is provided below. 
 
 
 
Figure 4.23: Principal Component Analysis plot of nuclear MT vs. nuclear CON. Samples 
elucidate a good separation with a 78% separation between patients and controls clustering at 
the first principal component (PC1). (Blue = MT) & (Yellow = CON).  
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Table 4.16: Functionally enriched biological processes generated by DAVID of 
the nuclear MT vs. nuclear CON differentially expressed genes. GO= Gene 
ontology, no.=number, ES= Enrichment score  
 
GO Biological process Gene no. P- value ES 
BP_FAT Nuclear mRNA splicing via spliceosome 11 1.6E-4 4.79 
BP_FAT Regulation of translation 9 1.5E-3 2.31 
BP_FAT mRNA transport 6 1.2E-2 1.71 
BP_FAT Nucleosome organization 6 1.6E-2 1.34 
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4.6.2.1.1 Nuclear mRNA splicing via spliceosome 
 
The majority of the RNA processing takes place in the nucleus and this involves 
RNA splicing, editing, 5’ capping and polyadenylation. The analysis of nuclear 
MT vs. nuclear CON revealed an overall down-regulation of genes involved in 
mRNA splicing via the spliceosome (Table 4.17).  
 
Three heterogeneous nuclear ribonucleoproteins were reduced. The 
heterogeneous nuclear ribonucleoprotein A0 (HNRNPA0) (FC=-1.2) which is 
involved in RNA splicing by its association with the HNRNP complexes (Myer and 
Steitz, 1995). Also, the heterogeneous nuclear ribonucleoprotein F (HNRNPF) 
was down-regulated (FC=-1.2). It is essential for proper splicing of pre-mRNA 
(Gamberi et al., 1997). Moreover, the heterogeneous nuclear ribonucleoprotein 
R (HNRNPR) was reduced (FC=-1.2). It is also involved in RNA processing and 
mainly hnRNA splicing. HNRNPR has been shown to interact with the SMN gene 
causing a disrupted splicing event in mouse model of spinal muscular atrophy 
(Rossoll et al., 2002).  
 
A group of small nuclear ribonucleoproteins were down-regulated. The small 
nuclear ribonucleoprotein 40kDa (U5) (SNRNP40) is part of the U5 small nuclear 
ribonucleoprotein which is a component of the spliceosome complex. It facilitates 
the removal of intron sequences of nascent RNA. SNRNP40 gene was reduced 
(FC=-1.2) (Achsel et al., 1998). In addition, three genes encoding for proteins 
belonging to the U2 ribonucleoprotein complex that were involved in pre-RNA 
splicing were down-regulated, the small nuclear ribonucleoprotein polypeptide B 
(SNRPB2) (FC=-1.2), the small nuclear ribonucleoprotein polypeptide E-like 1 
(SNRPE) (FC=-1.3), and  the PHD finger protein 5A (PHF5A) (FC=-1.2) (Habets 
et al., 1987, Hubert et al., 2013, Pasternack et al., 2013). The mago-nashi 
homolog, proliferation-associated (Drosophila) (MAGOH) was reduced (FC=-
1.2). This gene encodes for the MAGOH protein which is a component of the 
exon junction complex (EJC). The EJC has a major role in determining the fate 
of the mRNA molecule towards either translation or degradation (Silver et al., 
2010, Le Hir et al., 2016). Lastly, the tRNA splicing endonuclease 15 homolog (S. 
cerevisiae) (TSEN15) was also down-regulated (FC=-1.4). It encodes for the 
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enzyme tRNA splicing endonuclease which is involved in tRNA splicing 
(Paushkin et al., 2004). 
 
Significant down-regulation of genes involved in mRNA splicing were shown in 
the nuclear fALS missense mutation (Figure 4.24). This may suggest that 
TARDBP missense mutation has a marked effect upon splicing regulation and it 
is likely to be less splicing occurring. Also, it may indicate that due to increased 
number of splicing alteration, these heterogeneous nuclear ribonucleoprotein and 
the small nuclear ribonucleoprotein are subjected to degradation within the 
nucleus. This observation might play a significant role in the disease process. 
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Table 4.17: Genes involved in nuclear mRNA splicing via spliceosome in the 
nuclear missense mutation  
 
Gene 
symbol  
Gene name  p-value  Fold 
change  
HNRNPA0 Heterogeneous nuclear ribonucleoprotein 
A0 
0.036 -1.24 
HNRNPF Heterogeneous nuclear ribonucleoprotein 
F 
0.038 -1.24 
HNRNPR Heterogeneous nuclear ribonucleoprotein 
R 
0.01 -1.23 
MAGOH Mago-nashi homolog, proliferation-
associated (Drosophila) 
0.032 -1.25 
PHF5A PHD finger protein 5A 0.005 -1.31 
RPL36A Ribosomal protein L36a pseudogene  0.036 -1.22 
SNRNP40 Small nuclear ribonucleoprotein 40kDa 
(U5) 
0.002 -1.23 
SNRPB2 Small nuclear ribonucleoprotein 
polypeptide B     
0.040 -1.24 
*SNRPD1 Small nuclear ribonucleoprotein D1 
polypeptide 16kDa, LOC100129492 
0.049 
 
-1.32 
 
SNRPE Small nuclear ribonucleoprotein 
polypeptide E-like 1 
0.012 
 
-1.36 
 
*SNRPG Similar to small nuclear ribonucleoprotein 
polypeptide G, HCG23490 
0.038 -1.31 
 
TSEN15 tRNA splicing endonuclease 15 homolog 
(S. cerevisiae) 
0.048 
 
-1.43 
 
*Not accurately characterized yet 
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Figure 4.24: A representative diagram showing the dysregulated RNA processing (splicing/ 
spliceosome) genes in fALS-TARDBP nuclear missense mutation.  
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4.6.2.1.2 Regulation of translation 
 
The central dogma that DNA is transcribed into RNA then translated into protein 
was established when the process of transcription and translation were 
discovered. It was believed that transcription took place in the nucleus and the 
translation machinery was located in the cytosol. Here it was shown that genes 
involved in the regulation of translation were dysregulated in the nuclear fALS 
missense mutation with the majority being down-regulated (Table 4.18). 
  
The insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) was reduced 
(FC=-1.9). It has been suggested that the encoded RNA binding protein binds to 
the Insulin-like growth factor 2 at the promotor region to repress its translation in 
adulthood (Nielsen et al., 1999, Jiang et al., 2006). Furthermore, the poly (A) 
binding protein interacting protein 2 (PAIP2) was down-regulated (FC=-1.2). This 
protein inhibits the translation process by interfering with the poly (A) binding 
protein (PABP) which is one of the essential molecules for translation 
(Khaleghpour et al., 2001). The quaking homolog, KH domain RNA binding 
(mouse) (QKI) was also reduced (FC=-1.2). It is an RNA binding protein that is 
involved in RNA splicing, transport and translation. In addition, it has been 
suggested previously that the decrease in QKI expression was associated with 
decreased oligodendrocyte-myelin genes in Schizophrenia (Lauriat et al., 2008). 
Moreover, the SAP domain containing ribonucleoprotein (SARNP) was down-
regulated (FC=-1.3). SARNP is involved in transcription and RNA processing. It 
was shown that SARNP promotes cell proliferation (Fukuda et al., 2002). As 
previously mentioned, the mago-nashi homolog, proliferation-associated 
(Drosophila) (MAGOH) which is part of the EJC that controls mRNA fate in 
translation was also down-regulated (FC=-1.2) (Silver et al., 2010, Le Hir et al., 
2016). In contrast, three genes were up-regulated. The amyloid beta (A4) 
precursor-like protein 1 (APLP1) was increased (FC=1.2). This gene encodes for 
the membrane bound glycoprotein which belongs to the amyloid precursor 
protein family. The APLP1 was linked to Alzheimer's-like pathology (Guilarte, 
2010). Moreover, the insulin-like growth factor binding protein 5 (IGFBP5) which 
is involved in the tyrosine kinase receptor pathway was significantly up-regulated 
(FC=4.6). The insulin-like growth factor 1 (IGF1) normally binds to Insulin-like 
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growth factor 1 receptor and activates the tyrosine kinase receptor pathway which 
promotes cell growth and proliferation. IGFBP5 binds to the Insulin-like growth 
factor 1 (IGF1) to inhibit its function (Mitsiades et al., 2004, Salih et al., 2004). 
Finally, the nanos homolog 1 (Drosophila) (NANOS1) which is considered a 
translation repressor that controls the germ line cell division was increased 
(FC=1.4) (Asaoka-Taguchi et al., 1999, Wang and Lin, 2004). 
 
Genes involved in mRNA translation were dysregulated with the majority being 
down-regulated in fALS-TARDBP missense mutation (Figure 4.25). It is worth 
indicating that genes related to translation process are expected to be detected 
in the nucleus where their transcripts originally been synthesised. These 
transcripts are normally exported to the cytoplasm were translation takes place. 
However, low expression of group of genes related to translation machinery 
beyond normal levels may indicate a rapid turnover time of these transcripts. 
Also, perhaps these genes are expressed less in TARDBP mutation. Finally the 
possibility of the transcripts being degraded within the nucleus.   
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Table 4.18: Genes involved in the regulation of translation in the nuclear 
missense mutation 
 
Gene 
symbol  
Gene name  P-value  Fold 
change  
APLP1 Amyloid beta (A4) precursor-like protein 
1 
0.008 1.26 
GATC Glutamyl-tRNA(Gln) amidotransferase, 
subunit C homolog (bacterial) 
0.007 
 
-1.23 
 
IGF2BP3 Insulin-like growth factor 2 mRNA 
binding protein 3 
0.04 
 
-1.98 
 
IGFBP5 Insulin-like growth factor binding protein 
5 
0.04 4.65 
MAGOH Mago-nashi homolog, proliferation-
associated (Drosophila) 
0.03 
 
-1.25 
 
NANOS1 Nanos homolog 1 (Drosophila) 0.006 1.40 
PAIP2 Poly(A) binding protein interacting 
protein 2 
0.002 -1.21 
QKI Quaking homolog, KH domain RNA 
binding (mouse) 
0.008 
 
-1.22 
 
SARNP SAP domain containing 
ribonucleoprotein 
0.02 -1.34 
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Figure 4.25: A representative diagram showing the dysregulated genes involved in regulation of 
translation in fALS-TARDBP nuclear missense mutation.  
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4.6.2.1.3 mRNA transport 
 
After pre-mRNAs are transcribed and subjected to modification, mature mRNAs 
are generated. They are then bound to protein molecules which facilitate their 
transport from the nucleoplasm to the cytoplasm via the nuclear pores where they 
are subjected to either translation or degradation. Therefore, the main goal of 
mRNA synthesis is accomplished when a proper mRNA transport system is 
functioning within the cell (Vargas et al., 2005). TDP-43 is known to have a vital 
role in transporting mRNA molecules. Mutations in TARDPB may result in an 
impaired transport system. It has been shown that genes involved in mRNA 
transport were down-regulated (Table 4.19) and (Figure 4.26). 
 
The mago-nashi homolog, proliferation-associated (Drosophila) (MAGOH) was 
down-regulated (FC=-1.2). It was demonstrated that MAGOH is involved in non-
sense mediated decay and remains associated to mRNA after nuclear export 
(Gehring et al., 2009). Also, the mago-nashi homolog B (Drosophila) (MAGOHB) 
which has similar function to MAGOH was down-regulated (FC=-1.3). The DEAD 
(Asp-Glu-Ala-As) box polypeptide 19B (DDX19B) which belongs to the family of 
RNA helicases was reduced (FC=-1.2). The encoded protein is localized mainly 
at cytoplasmic side of nuclear pore (Linder and Jankowsky, 2011). The 
nucleoporin like 1 (NUPL1) gene was also reduced (FC=-1.3). It is part of the 
nuclear pore complex which is localized at the rim of the nucleus that facilitates 
molecule movement between the nucleus and the cytoplasm (Chug et al., 2015). 
As previously shown the quaking homolog, KH domain RNA binding (mouse) 
(QKI) which is involved in mRNA transport was also reduced (FC=-1.2) (Lauriat 
et al., 2008).  
 
It appears that mRNA transport in fALS-TARDBP is impaired as a result of the 
mutation. It also may indicate that mRNA transcripts associated with these RNA 
binding proteins and hnRNPs are held in the nucleus as a result of impaired 
binding and export which may subject these transcripts to decay. This 
observation may also follow the previous observed down-regulation in translation.     
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Table 4.19: Genes involved in mRNA transport in the nuclear missense mutation  
 
Gene symbol  Gene name  p-value  Fold 
change  
DDX19B DEAD (Asp-Glu-Ala-As) box 
polypeptide 19B 
0.002 
 
-1.25 
 
MAGOHB Mago-nashi homolog B 
(Drosophila) 
0.04 -1.31 
MAGOH Mago-nashi homolog, proliferation-
associated (Drosophila) 
0.03 
 
-1.25 
 
NUPL1 Nucleoporin like 1 0.03 -1.31 
QKI Quaking homolog, KH domain RNA 
binding (mouse) 
0.008 
 
-1.22 
 
*LOC728554 Similar to THO complex 3 0.03 
 
-1.46 
 
*Not accurately characterized yet 
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Figure 4.26: A representative diagram showing the dysregulated genes involved in mRNA 
transport in fALS-TARDBP nuclear missense mutation.  
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4.6.2.1.4 Nucleosome organization 
 
Nucleosomes are unique molecular structures that are composed of 
approximately 200bp of DNA wrapped around histone molecules. These 
nucleosome units are built up to form the chromatin. Nucleosomes are known to 
be subjected to epigenetic modifications such as acetylation, methylation and 
phosphorylation which influence gene expression by enhancing or silencing the 
targeted gene. A group of genes involved in nucleosome organization were 
dysregulated with the majority down-regulated in fALS-TARDBP missense 
mutation (Table 4.20) and (Figure 4.27). 
 
The ASF1 anti-silencing function 1 homolog A (S. cerevisiae) (ASF1A) was 
reduced (FC=-1.4). It participates in chromatin assembly during DNA replication 
and repair (Mello et al., 2002). Furthermore, the CCCTC-binding factor (zinc 
finger protein) (CTCF) was also down-regulated (FC=-1.3). The CTCF is a 
transcription insulator which regulates the DNA expression by creating a 
boundary between a silencer or an enhancer and the promotor region. Therefore, 
they are able to activate or repress gene expression (Jeong and Pfeifer, 2004). 
Three genes belonging to the core octamer histone structure that make up the 
nucleosome which are subjected to posttranscriptional modifications such as 
methylation were down-regulated, histone cluster 1, H4a (HIST1H4A), histone 
cluster 1, H4c (HIST1H4C) and histone cluster 2, H2ab (HIST2H2AB) (FC=-1.7, 
FC=-1.6 & FC=-1.8 respectively) (Marzluff et al., 2002). In addition, the H3 
histone, family 3B (H3.3B) (H3F3A) was reduced (FC=-1.3). This is considered a 
H3 variant histone and also known as replacement histone which is essential for 
nucleosome assembly. It has a unique characteristic of being synthesised during 
any cell cycle phase and not restricted to the S phase (Tagami et al., 2004). 
Finally, the transition protein 1 (during histone to protamine replacement) (TNP1) 
which an essential protein for normal histone replacement with protamine during 
spermatogenesis was reduced (FC=-1.2) (Meistrich et al., 2003).  
 
This suggests that nucleosome regulation is impaired in fALS-TARDBP missense 
mutation with the majority of genes being down-regulated. This may indicate a 
reduced DNA synthesis in fibroblasts which affects cell division and also DNA 
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repair. This also may explain the low growth rate of fALS-TARDBP fibroblasts in 
the laboratory.  
 
 
Table 4.20: Nucleosome organization in the nuclear missense mutation 
 
Gene 
symbol  
Gene name  p-value  Fold 
change  
ASF1A ASF1 anti-silencing function 1 
homolog A (S. cerevisiae) 
0.03 
 
-1.40 
 
CTCF CCCTC-binding factor (zinc finger 
protein) 
0.04 -1.32 
H3F3A H3 histone, family 3B (H3.3B)  0.01 -1.35 
HIST1H4A Histone cluster 1, H4a  0.03 -1.74 
HIST1H4C Histone cluster 1, H4c  0.03 -1.67 
HIST2H2AB Histone cluster 2, H2ab 0.006 -1.84 
TNP1 Transition protein 1 (during histone to 
protamine replacement) 
0.02 
 
1.24 
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Figure 4.27: A representative diagram showing the dysregulated genes involved in nucleosome 
organization in fALS-TARDBP nuclear missense mutation.  
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4.6.2.2 Differential gene expression of nuclear TT vs. CON 
 
PCA of nuclear TT vs. nuclear CON was carried out and showed a good 
separation of clusters between patients and controls (Figure 4.28). Differentially 
expressed genes were explored using DAVID. The significant enriched biological 
process was the G-protein coupled receptor protein signalling pathway (Table 
4.21). A full description of the genes involved were described below.  
 
 
 
 
Figure 4.28: Principal Component Analysis plot of nuclear TT vs. nuclear CON. Samples reveal 
a good separation with a 79% variability between patients and controls clustering at the first 
principal component (PC1). (Red = TT) & (Yellow = CON).  
 
 
 
Table 4.21: Functionally enriched biological process generated by DAVID of the 
nuclear TT vs. CON differentially expressed genes  
 
Gene 
ontology  
Biological process Number 
of genes 
P- 
value 
Enrichment 
Score 
BP_FAT G-protein coupled receptor 
protein signaling pathway 
30 3.7E-3 1.72 
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4.6.2.2.1 G-protein coupled receptor protein signalling pathway 
 
G-protein coupled receptors are a large group of protein receptors that are 
expressed on the most cells. They have a common seven-transmembrane 
domain structure that bind to ligands causing a conformational change in the 
receptor structure which triggers signal transductions via the activation of G-
proteins. Ligands for these receptors are a wide range of molecules such as: 
hormones, neurotransmitters and odours (Venkatakrishnan et al., 2013). A large 
number of G-protein coupled receptors were down-regulated in nuclear fALS-
TARDBP truncated mutation (Table 4.22). A further elucidation of these genes is 
shown below.  
 
The 5-hydroxytryptamine (serotonin) receptor 6 (HTR6) was reduced (FC=-1.2). 
The encoded protein is a receptor that binds the neurotransmitter serotonin which 
is able to activate the cAMP pathway by activating adenylate cyclase through the 
G-proteins (Wacker et al., 2013). Furthermore, the melanocortin 3 receptor 
(MC3R) was also reduced (FC=-1.3). The melanocortin hormone binds to the 
MC3R which activates the cAMP through the G-protein activation (Lee et al., 
2001). Also, the cholinergic receptor, muscarinic 4 (CHRM4) was reduced (FC=-
1.5). CHRM4 receptor was shown to bind to  acetylcholine which is known to be 
involved in potassium channel activation (Ockenga et al., 2013). The glycine 
receptor, beta (GLRB) was down-regulated (FC=-1.5). GLRB is activated by 
several molecules including amino acids and has a role in inhibiting postsynaptic 
neurons. Mutation in the GLRB is associated with hyperekplexia (Rees et al., 
2002). 
 
The G protein-coupled receptor 3 (GPR3) was also down-regulated (FC=-1.2). It 
was shown that GPR3 acts as a cell cycle inhibitor for oocytic meiosis, the 
inactivation of GPR3 gene allows the resumption of the cell cycle. Therefore it 
was suggested to play a role in cell cycle arrest in oocyte (Mehlmann et al., 2004). 
Moreover, the chemokine (C-C motif) receptor 9 (CCR9) was down-regulated 
(FC=-1.2). CCR9 has been suggested to activate chemokines shown to play vital 
role in thymocyte migration (Zabel et al., 1999).  
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The opiate receptor-like 1 (OPRL1) was reduced (FC=-1.2). It is the receptor of 
the nociception ligand. OPRL1 is expressed in several areas in the brain which 
are responsible for learning and motivation (Mollereau and Mouledous, 2000). It 
was shown that OPRL1 has a negative effect on adenylyl cyclase by etorphine 
and an inhibitory effect on Ca++ ion channels (Mollereau et al., 1994, Beedle et 
al., 2004). Furthermore, the sphingosine-1-phosphate receptor 4 (S1PR4) was 
down-regulated (FC=-1.3). S1PR4 is a member of the sphingosine-1-phosphate 
receptor family which activate a plethora of pathways. S1PR4 is the receptor for 
the lysosphingolipid sphingosine 1-phosphate (S1P). The activation of the S1PR4 
was suggested to activate Ca++ ion mobility (Villullas et al., 2003).  
 
Furthermore, the taste receptor, type 2, member 39 (TAS2R39) which was 
recently shown to be involved in the recognition of bitterness taste of some 
substances such as theaflavins and soy isoflavones was reduced (FC=-1.2) 
(Roland et al., 2011, Yamazaki et al., 2014). The purinergic receptor P2Y, G-
protein coupled, 8 (P2RY8) which may be involved in the purinergic signalling 
was also down-regulated (FC=-1.2) (Fields and Burnstock, 2006). The MAS-
related GPR, member G (MRGPRG) was reduced (FC=-1.2). It is characterized 
as an itch receptor which is stimulated by some drugs like chloroquine. 
Administrating chloroquine to MRGPRG deficient mice did not cause a skin 
itchiness reaction. Therefore, it was suggested to be an itch receptor (Liu et al., 
2009).  
 
A large group of olfactory receptor family that belong to the G-protein coupled 
receptor 1 family were down-regulated. Olfactory receptor family genes were also 
showed to be dysregulated in the cytoplasmic missense mutation MT (see section 
4.6.1.1.4). The olfactory receptor, family 10, subfamily G, member 7 (OR10G7) 
(FC=-1.2), olfactory receptor, family 10, subfamily G, member 9 (OR10G9) (FC=-
1.2), olfactory receptor, family 2, subfamily A, member 12 (OR2A12) (FC=-1.2), 
olfactory receptor, family 2, subfamily A, member 4; olfactory receptor, family 2, 
subfamily A, member 7 (OR2A4) (FC=-1.3), olfactory receptor, family 4, subfamily 
C, member 5 (OR4C5) (FC=-1.3), olfactory receptor, family 4, subfamily M, 
member 2 (OR4M2) (FC=-1.2), olfactory receptor, family 4, subfamily N, member 
2; seven transmembrane helix receptor (OR4N2) (FC=-1.2), olfactory receptor, 
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family 4, subfamily P, member 4 (OR4P4) (FC=-1.2), olfactory receptor, family 5, 
subfamily L, member 2 (OR5L2) (FC=-1.2), olfactory receptor, family 51, 
subfamily S, member 1 (OR51S1) (FC=-1.2), olfactory receptor, family 52, 
subfamily L, member 1(OR52L1) (FC=-1.2), olfactory receptor, family 6, 
subfamily C, member 4 (OR6C4) (FC=-1.2), olfactory receptor, family 6, 
subfamily C, member 70 (OR6C70) (FC=-1.2), olfactory receptor, family 8, 
subfamily J, member 1 (OR8J1) (FC=-1.2) and vomeronasal 1 receptor 2 
(VN1R2) (FC=-1.3) (Young and Trask, 2002, Shirokova et al., 2008).  
 
Moreover, the basic helix-loop-helix family, member a15 (BHLHA15) was down-
regulated (FC=-1.2). It is also known as Mist1 which is a transcription factor that 
binds to enhancer box (E-box) regions on DNA to regulate gene expression 
(Lemercier et al., 1997). The potassium channels, subfamily K, member 2 
(KCNK2) was down-regulated (FC=-1.2) (Meadows et al., 2000). Potassium 
channels are important structures that maintain the membrane action potential. 
The prolactin releasing hormone (PRLH) was reduced (FC=-1.2). Prolactin 
releasing hormone (PRLH) stimulates the anterior pituitary gland to release the 
prolactin hormone which has a direct effect in binding to receptors on the 
mammary glands and ovaries (Yoshimura et al., 1994, Hinuma et al., 1998). 
Finally, the opsin 3 (OPN3) is an encephalic photoreception which convert the 
photons into signals that activate vision cascades was increased (FC=1.2) 
(Tarttelin et al., 2012).  
 
The data showed that there is a significant overall down-regulation in G-protein 
coupled receptors in fALS-TARDBP truncated mutation and were mainly found in 
relation to the cAMP pathway and diverse chemoreceptors.   
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Table 4.22: Genes involved in the G-protein coupled receptor protein signalling 
pathway in nuclear truncation mutation  
 
Gene 
symbol  
Gene name  P-value  Fold 
change  
BHLHA15 Basic helix-loop-helix family, member a15 0.04 -1.21 
CCR9 Chemokine (C-C motif) receptor 9 0.03 -1.21 
CHRM4 Cholinergic receptor, muscarinic 4 0.01 -1.50 
GLRB Glycine receptor, beta 0.01 -1.50 
GPR3 G protein-coupled receptor 3 0.03 -1.27 
HTR6 5-hydroxytryptamine (serotonin) receptor 6 0.02 -1.25 
MC3R Melanocortin 3 receptor 0.01 -1.33 
MRGPRG MAS-related GPR, member G 0.002 -1.23 
KCNK2 Potassium channel, subfamily K, member 2 0.03 -1.27 
OR10G7 Olfactory receptor, family 10, subfamily G, 
member 7 
0.02 -1.21 
OR10G9 Olfactory receptor, family 10, subfamily G, 
member 9 
0.01 -1.24 
OR2A12 Olfactory receptor, family 2, subfamily A, 
member 12 
0.01 -1.21 
OR2A4 Olfactory receptor, family 2, subfamily A, 
member 4; olfactory receptor, family 2, subfamily 
A, member 7 
0.02 -1.30 
 
OR4C5 Olfactory receptor, family 4, subfamily C, 
member 5 
0.02 -1.35 
OR4M2 Olfactory receptor, family 4, subfamily M, 
member 2 
0.04 -1.23 
OR4N2 Olfactory receptor, family 4, subfamily N, 
member 2; seven transmembrane helix receptor 
0.0001 -1.20 
OR4P4 Olfactory receptor, family 4, subfamily P, 
member 4 
0.01 -1.23 
OR5L2 Olfactory receptor, family 5, subfamily L, member 
2 
0.04 -1.24 
OR51S1 Olfactory receptor, family 51, subfamily S, 
member 1 
0.009 -1.24 
OR52L1 Olfactory receptor, family 52, subfamily L, 
member 1 
0.02 -1.23 
OR6C4 Olfactory receptor, family 6, subfamily C, 
member 4 
0.02 -1.22 
OR6C70 Olfactory receptor, family 6, subfamily C, 
member 70 
0.04 -1.25 
OR8J1 Olfactory receptor, family 8, subfamily J, member 
1 
0.001 -1.22 
OPN3 Opsin 3 0.01 1.24 
OPRL1 Opiate receptor-like 1 0.004 -1.26 
PRLH Prolactin releasing hormone 0.03 -1.22 
P2RY8 Purinergic receptor P2Y, G-protein coupled, 8 0.006 -1.23 
S1PR4 Sphingosine-1-phosphate receptor 4 0.04 -1.31 
TAS2R39 Taste receptor, type 2, member 39 0.005 -1.27 
VN1R2 Vomeronasal 1 receptor 2 0.009 -1.39 
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4.6.2.3 Comparative analysis of differentially expressed genes in the 
nuclear fractions of missense and truncation TARDBP mutation 
 
The identification of differentially expressed genes associated with each type of 
mutation was also applied to the nuclear comparison study. As previously the 
GeneVenn software was used. The venn diagram showed 529 differentially 
expressed were specific to the nuclear MT, 658 differentially expressed genes 
were specific to the nuclear TT and 23 genes were found common in both. It 
important to clarify that after generating the venn diagram of four genes from the 
nuclear TT gene list were missing. After investigating the gene lists it was shown 
that ARL17A gene was present in the data as five repeats. Therefore, the 
software pooled the repeated copies as one gene (Figure 4.29). DAVID online 
software showed that the highest enriched pathway of the missense mutation MT 
in the nuclear fraction belonged to mRNA processing and the truncated mutation 
TT were mostly involved in G-protein coupled receptor signalling pathway 
(enrichment score of 4.98 and 1.95 respectively). The common genes were: 
ARL17A, GABPB1-AS1, KIRREL3, TEX2 and THY1 (Table 4.23). The other 
genes were pseudogenes and not annotated gene (NULL). The common nuclear 
genes did not belong to any significant biological process. 
 
 
 
 
 
Figure 4.29: Comparative analysis of differentially expressed genes in the nuclear fractions of 
missense and truncation TARDBP mutation. Venn diagram showing 529 genes specific to the 
nuclear missense mutation, 658 genes specific to the nuclear truncation mutation and 23 genes 
were found common in both types of mutations. 
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Table 4.23: Common genes in missense MT and truncation mutation TT. FC= fold change 
Gene Symbol Gene Title FC MT FC TT 
ARL17A ADP-ribosylation factor-like 17A 1.71 1.47 
CASP7 NULL /// caspase 7, apoptosis-related cysteine peptidase -1.21 -1.21 
ENOSF1 NULL /// enolase superfamily member 1 -1.29 -1.22 
FAM215A Family with sequence similarity 215, member A (non-protein coding) /// NULL 1.26 1.46 
GABPB1-AS1 GABPB1 antisense RNA 1 -1.20 -1.24 
GS1-5L10.1 NULL /// NULL 1.22 1.55 
KIRREL3 Kin of IRRE like 3 (Drosophila) 1.33 1.23 
MRPL24 NULL /// mitochondrial ribosomal protein L24 -1.30 -1.23 
NEK7 NIMA-related kinase 7 /// NULL 1.25 1.35 
NREP NULL /// neuronal regeneration related protein -1.32 -1.42 
OTTHUMG00000019246 NULL  1.32 1.33 
RNA5SP302 RNA, 5S ribosomal pseudogene 302 1.31 1.30 
RNU4-10P RNA, U4 small nuclear 10, pseudogene 1.20 1.25 
RNU4-5P RNA, U4 small nuclear 5, pseudogene 1.38 1.27 
RNY1P8 RNA, Ro-associated Y1 pseudogene 8 1.23 1.45 
RPL35A NULL /// ribosomal protein L35a -1.26 -1.23 
RPS3AP47 Ribosomal protein S3a pseudogene 47 -1.39 -1.20 
SEC23A NULL /// Sec23 homolog A (S. cerevisiae) -1.26 -1.25 
SNRPEP4 Small nuclear ribonucleoprotein polypeptide E pseudogene 4 -1.42 -1.31 
TEX2 Testis expressed 2 1.37 1.30 
THY1 Thy-1 cell surface antigen 1.59 1.36 
TMEM78 NULL /// transmembrane protein 78 1.29 1.28 
WDFY3-AS1 NULL /// WDFY3 antisense RNA 1 1.31 1.76 
NULL= not annotated gene, NULL/// gene name= not accurately annotated yet.  
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4.6.2.4 Comparative analysis of differentially expressed genes in the 
cytoplasmic vs. nuclear in missense mutation and truncation mutation  
 
The identification of differentially expressed genes associated with cellular 
component within each type of mutation was also applied. As previously, the 
GeneVenn software was used and the following observations were found: 190 
genes were specific to the  cytoplasmic MT while 518 genes were specific to the 
nuclear MT and 34 common (Figure 4.30) and 334 genes were specific to the 
cytoplasmic TT while 597 genes were specific to the nuclear and 81 genes were 
in common (Figure 4.31).  
 
 
 
 
 
Figure 4.30: Comparative analysis of differentially expressed genes in the cytoplasmic vs. 
nuclear in TARDBP missense mutation. Venn diagram showing 190 genes specific to the 
cytoplasmic missense mutation, 518 genes specific to the nuclear missense mutation and 34 
genes were found common in both. 
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Figure 4.31: Comparative analysis of differentially expressed genes in the cytoplasmic vs. 
nuclear in TARDBP truncation mutation. Venn diagram showing 334 genes specific to the 
cytoplasmic truncation mutation, 597 genes specific to the nuclear truncation mutation and 81 
genes were found common in both. 
 
 
 
 
4.7 qRT-PCR validation of the fALS-TARDBP cytoplasmic MT and 
cytoplasmic TT genes 
 
Candidate genes were chosen for validation using the same RNA material used 
in the HTA. In addition, the Q-RCR was performed using the prime time qRT-
PCR method which is different to that of the Human Exon 1.0 ST Array qRT-PCR 
validation method (See section 2.9.3).  
 
To validate the cytoplasmic MT and cytoplasmic TT gene changes by qRT-PCR, 
two candidate from the fALS cytoplasmic MT genes involved in RNA processing 
were selected which were the following: ADARB1 (FC=1.6 and p-value=0.009) 
and METTL1 (FC= -1.23 and a p-value=0.04). In addition, candidate from the 
fALS cytoplasmic TT genes were selected from both angiogenesis and adherens 
junction genes which were the following: SEMA5A (FC=1.6 and p-value=0.01) 
and ENAH (FC=-1.5 and p-value= 0.002). All genes were normalized against the 
housekeeping gene β-actin, as the expression of β-actin was consistent in all 
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samples. An unpaired t-test was applied using Graph Pad Prism. qRT-PCR of 
ADARB1 confirmed the directional change of gene expression (up-regulation). In 
addition, qRT-PCR of ENAH also confirmed the directional change of gene 
expression (down-regulation). However, neither showed statistical significance. 
METTL1 and SEMA5A did not show any noticeable changes between ALS 
samples. (Figure 4.32 A&B, Figure 4.33A&B). 
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Figure 4.32: qRT-PCR validation of the RNA processing cytoplasmic genes in fALS MT 
fibroblasts. (A)The relative expression of the ADARB1 gene. The statistical analysis showed 
insignificant p-value (p-value = 0.0869) with significant increase of ADARB1 gene expression 
(confirmed directional change) (B) The relative expression of the METTL1 gene. The statistical 
analysis also showed insignificant (p-value= 0.7572) with no significant difference METTL1 gene 
expression. (MT= missense mutation, NS= not significant, the error bars represents the SEM). 
  
 
 
 
 
Figure 4.33: qRT-PCR validation of the angiogenesis and adherens junction cytoplasmic genes 
in fALS TT fibroblasts. (A)The relative expression of the SEMA5A gene. The statistical analysis 
showed insignificant p-value (p-value = 0.8883) with no difference of SEMA5A gene expression, 
(B) The relative expression of the ENAH gene. The statistical analysis also showed insignificant 
(p-value= 0.6333) with significant decrease ENAH gene expression (confirmed directional 
change). (TT= truncated mutation, NS= not significant, the error bars represents the SEM). 
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4.8 Fluorescence in situ hybridization of fALS nuclear controls, missense 
mutation and truncated mutation  
Fluorescence in situ hybridization (FISH) is a powerful technique that reveals the 
location of nucleic acid inside the cell using a designed complementary labelled 
probe (see section 2.11 for the method).  
 
A preliminary experiment was performed aiming to validate nuclear genes 
expressed in the fALS-TARDBP missense mutation and truncated mutation. Due 
to the overall low fold changes observed in the HTA data, the nuclear gene lists 
were investigated manually in order to pick genes with a relatively high fold 
change, high signal intensity and a significant p-value. This was applied to enable 
their visual detection using the confocal microscope. From the nuclear missense 
mutation matrix metalloproteinase-1 (MMP1) was selected (FC= 4.0, p-value= 
0.03, signal intensity was high=8.4) and from the nuclear truncated mutation 
LUC7 like 3 pre-MRNA splicing factor (LUC7L3) was selected (FC= 2.0, p-value= 
0.01, signal intensity was high=7.4). RNA U6 small nuclear 1 (RNU6-1) was used 
as a positive control and was the recommended gene by the manufacturer and 
had been designed and optimized specifically for nuclear FISH experiments.  
 
The nuclear FISH experiment was performed twice. Unfortunately, both 
experiments failed to show any positive signals (Figure 4.34, 4.35 and 4.36). 
Although, probes were stated to be optimized by the manufacture against several 
tissue types including skin tissue, individual probes should have been optimized 
for fibroblasts which was not performed. This was due to limited reagent supply 
and limited time remaining for the current lab work. 
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Figure 4.34: FISH of fALS-TARDBP and control using RNU6-1 probe labelled Cy5 (filter=650nm) 
(A) Control (control155) showing negative detection of RNU6-1 in the nuclei. (B) fALS-TARDBP 
missense mutation (patient 48) showing negative detection of RNU6-1 in the nuclei. (C) fALS-
TARDBP truncated mutation (patient 192) showing negative detection of RNU6-1 in the nuclei. 
(D) Negative control (control 155) negative detection of RNU6-1 in the nuclei. The red arrows 
point to nuclei. 
 
 
Figure 4.35: FISH of fALS-TARDBP and control using MMP1 probe labelled FITC (filter=488nm) 
(A) Control (control155) showing negative detection of MMP1 1 in the nuclei. (B) fALS-TARDBP 
missense mutation (patient 48) showing negative detection of MMP1 in the nuclei. (C) fALS-
TARDBP truncated mutation (patient 192) showing negative detection of MMP1 in the nuclei. (D) 
Negative control (patient 48) negative detection of MMP1 in the nuclei. The red arrows point to 
nuclei.  
 
 
 
Figure 4.36: FISH of fALS-TARDBP and control using LUC7L3 probe labelled Cy3 (filter=550nm) 
(A) Control (control155) showing negative detection of LUC7L3 in the nuclei. (B) fALS-TARDBP 
missense mutation (patient 48) showing negative detection of LUC7L3 in the nuclei. (C) fALS-
TARDBP truncated mutation (patient 192) showing negative detection of LUC7L3 in the nuclei. 
(D) Negative control (patient 192) negative detection of LUC7L3 in the nuclei. The red arrows 
point to nuclei.  
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4.9 Discussion 
 
ALS is known to be a multisystem disorder and influenced by genetic and 
environmental factors. The current study aimed to identify the affected biological 
processes in two types of fALS-TARDBP mutations, the missense mutation and 
the truncation mutation. This approach has the potential to highlight possible 
common causes of ALS pathology which could then be targeted for therapy. In 
this experiment the nuclear and cytoplasmic separation method was modified in 
order to achieve a confident degree of separation of the two compartments. Cell 
membrane lysis was monitored throughout the separation step to ensure intact 
nuclear isolation prior to RNA extraction. In addition the RNA extraction was 
performed using the Trizol method. The nuclear isolation method was 
challenging, nevertheless it was performed successfully and clear images of 
intact nuclei ware obtained from control, missense mutation and truncated 
mutation fibroblasts. This was in agreement with an earlier study by Wang et., al  
who demonstrated isolated nuclei from mouse embryo fibroblasts with minimum 
cytoplasmic or perinuclear material (Wang et al., 2006). In addition, a high degree 
of RNA quality and quantity was reached. The electropherograms illustrated 
distinct peaks of rRNA 28s and rRNA 18s with the level of rRNA 28s were 
approximately twice the level of rRNA 18s suggesting full length transcripts. 
Furthermore, the RIN values from the extracted RNA were high (> 8).   
 
Although in the current work there was a minimum genomic DNA contamination 
in the cytoplasmic fraction, it would be helpful to perform western blots in future 
using cytoplasmic and nuclear markers as an additional evidence to support the 
cellular separation method. 
 
This study was designed to demonstrate the possibility that dysregulated 
biological processes exist in the cytoplasm and the nucleus of fALS-TARDBP 
missense mutations and truncated mutations. Thus, three biological repeats from 
patients and age and gender matched controls were used. The Qlucore Omics 
Explorer software was utilized to identify the most significant differentially 
expressed genes in both mutation types. Grouping these genes into biological 
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processes was achieved using the DAVID analysis tool.  Figure 4.37 shows 
diagram that illustrates the significantly identified biological processes in a single 
glance. Angiogenesis and cell adhesion/ adherens junction biological processes 
were present in both cytoplasmic fALS-TARDBP mutations and therefore will be 
discussed together. However, the rest of the biological processes will be 
discussed separately in respect to each type of mutation and cellular 
compartment.  
 
 
 
 
Figure 4.37: Schematic diagram demonstrate significantly identified biological processes. (A) 
cytoplasmic fALS MT, (B) cytoplasmic fALS TT, (C) nuclear fALS MT and (D) nuclear fALS TT. 
fALS= familial amyotrophic lateral sclerosis, MT= missense mutation, TT=truncated mutation.  
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4.9.1 Biological processes presented in both cytoplasmic fALS-TARDBP 
MT and TT mutations 
 
4.9.1.1 Angiogenesis  
 
VEGF was the first angiogenic factor that was shown to be associated with ALS. 
The depletion of VEGF in mouse model showed low levels of VEGF in brain and 
spinal cord associated with symptoms strongly linked to an ALS type disorder 
(Oosthuyse et al., 2001).  In addition, mutations in angiogenin (ANG) have been 
associated with ALS (Greenway et al., 2006).  ANG is known to be involved in 
endothelial cell proliferation, migration, synthesis of new blood vessels and 
enhancement of rRNA transcription. It was also shown to promote neuronal cell 
survival by neurovascular perfusion (Gao and Xu, 2008). In the current study, 
both mutations showed that angiogenesis was affected in the disease process 
although not all genes were shared by both. Most of these genes were involved 
in cell proliferation, differentiation and normal development of vessel walls. Four 
genes involved in angiogenesis were slightly elevated in fALS-TARDBP 
missense mutation than controls, EDNRA, IL18, KLF5 and TGFA. This may 
indicate the fALS-TARDBP missense mutation may generate a relatively higher 
activity of angiogenesis than normal. The fALS-TARDBP truncated mutation also 
included a number of up-regulated differentially expressed genes. MEOX2, which 
is involved in vascular differentiation, was up-regulated. This observation was in 
contrast to MEOX2 expression in Alzheimer’s disease which showed low levels 
of expression (Wu et al., 2005). Furthermore, TBX1 which is involved in arterial 
development was increased. It was shown previously that TBX1-/- mice model 
showed a phenotype similar to DiGeorge syndrome which showed neurological 
abnormalities therefore, was suggested to be associated with the syndrome. In 
addition, it was proposed that patients with DiGeorge syndrome were at a higher 
risk for developing schizophrenia and early onset PD (Zinkstok and van 
Amelsvoort, 2005, Butcher et al., 2013). These observations illustrate that a 
process involving genes associated with angiogenesis is associated with fALS-
TARDBP.   
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4.9.1.2 Cell adhesion/ adherens junction 
 
Cell adhesion is a vital process that maintains cell integrity, structure, and 
protection against pathogens (Gumbiner, 1996). Cell adhesion molecules are 
important for normal cell development and migration. Also, they have a vital role  
in stimulating immune cell interactions (Mackay and Imhof, 1993). Defects in cell 
adhesion molecules were linked to several neurological diseases such as, AD 
which is characterized by mutations in the amyloid precursor protein (APP) and 
ALS which demonstrated decreased expression of plasma fibronectin (Ono et al., 
2000, Liu et al., 2012). Also, mutant SOD1G93A transgenic mice showed a 
significant low expression of adhesion molecules such as, gap junction protein, 
delta 2, 36 kDa (GJD2) and protocadherin beta 9 (PCDHB9) (Boutahar et al., 
2011). Moreover, NSC34SOD1-G93A transfected cell lines showed low expression 
of the adhesion molecule, laminin, alpha 4 (LAMA4) (Kirby et al., 2005). In the 
current work fibroblasts from both the cytoplasmic missense mutation and 
truncated mutations showed several dysregulated adhesion molecule genes. In 
the fALS-TARDBP missense mutation four genes were up-regulated CD9, 
PCDHB15, PECAM1 and TMEM8A, and four genes were down-regulated: 
CDH2, TNFAIP6 and TROAP. On the other hand, the majority of fALS-TARDBP 
truncated mutation genes were reduced: ARHGAP24, ARHGAP31, ENAH, 
TENC1, TLN1 and TLN2 with only two increased; LMO7 and MPP7.  
 
Since adhesion molecules play an important role in immune responses, it was 
suggested that they may contribute to the occurrence of neuroinflammation in 
ALS patients. Neuroinflammation is the inflammation of the CNS that is triggered 
by factors including infections, toxins or brain injury. Studies have shown the 
involvement of neuroinflammation in the ALS disease process (Engelhardt and 
Appel, 1990, Hall et al., 1998, Alexianu et al., 2001). The development of an 
immune response was shown to occur at the early stage of the disease and is 
considered a protective immune response which then worsens to a progressive 
neurotoxic condition (Hooten et al., 2015). Microglial activation was shown in 
patients and also in the mutant SOD1 G93A transgenic mouse which demonstrated 
a progressive course of the disease due to rapid neuroinflammation rather than 
the progression of neuronal death (Hall et al., 1998, Corcia et al., 2012). An 
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elevated level of proinflammatory factors such as CD3 and the intercellular 
adhesion molecule-1 were reported in the mutant SOD1G93A transgenic mouse 
(Alexianu et al., 2001). It has been reported in ALS that activated astrocytes 
release soluble mediators such as IL-6, chemokine (C-C) motif ligand 2,  (CCL2) 
and C-X-C motif chemokine 10 (CXCL10) (Farina et al., 2007, Philips and 
Robberecht, 2011). Also, tumour necrosis factor activated pathways (TNF) were 
shown to be significantly involved in ALS (Brohawn et al., 2016). These 
observations in the current work, along with the published literature, therefore 
suggest that the adhesion molecules may participate in the pathogenesis of ALS 
which may offer a therapeutic target to slow the progression of the disease. 
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4.9.2 Cytoplasmic MT vs. CON  
 
4.9.2.1 RNA processing 
 
Evidence on the dysregulation of RNA processing in ALS is growing in the field. 
Current literature shows a number of defective RNA processing genes associated 
with ALS. Mutations in the RNA processing genes, TARDBP, FUS, C9ORF72, 
MATR3, hnRNPA1, ANG, SETX and ELP have all been linked to ALS 
pathogenesis with SMN2 being a risk factor for ALS (Sreedharan et al., 2008, 
Van Deerlin et al., 2008, Corcia et al., 2009, Kwiatkowski et al., 2009, Simpson 
et al., 2009b, Avemaria et al., 2011, Aparicio-Erriu and Prehn, 2012, Kim et al., 
2013, Johnson et al., 2014, Scotter et al., 2015). Therefore, dysregulation of RNA 
metabolism could be a promising target for therapy. A group of RNA processing 
genes were dysregulated in the fALS-TARDBP missense mutation. Dysregulated 
RNA splicing and the spliceosomal components have previously been suggested 
to be associated with ALS and FTLD (Tollervey et al., 2011, Highley et al., 2014). 
In the current study genes involved in RNA splicing were down-regulated, 
U2AF1L4 and SNRPA. The reduction in SNRPA expression was in agreement 
with an earlier study profiling sporadic ALS fibroblasts (Raman et al., 2015).  
 
Furthermore, the METTL1 gene that regulates DNA methylation as a 
posttranscriptional modification step was also reduced. The literature is scarce in 
studies relating methylation with fALS. Although, a single gene belonging to 
methylation was dysregulated, this observation along with the Human Exon 
Arrays result (section 3.6.1.1.1) suggest that the fALS-TARDBP missense 
mutation may be linked to hypomethylation that may lead to increased level of 
transcriptional activity in cells. Moreover, ADARB1 which encodes for the RNA 
editing enzyme responsible for GluR2 editing was increased. This observation 
was also shown in Human Exon Arrays result (3.6.1.1.3.3). It is clearly shown 
that RNA processing and methylation are dysregulated in fALS-TARDBP. 
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4.9.2.2 Neurological system process 
 
A group of genes involved in the neurological system which belonged to different 
biological processes were identified however, all were related to the CNS. Genes 
involved in cell adhesion (CD9), exocytosis (RIMS1), neuronal differentiation 
(LHX8), the BARK signalling pathway (ARRB1) and olfactory receptors 
(OR4D10, OR5H1, OR5R1, OR51B4 and OR52J3) were elevated with the 
exception of (OR1G1) which was reduced. It was interesting and surprising to 
find a group of olfactory receptors expressed in a fibroblast model. A recent study 
has shown that human keratinocytes express chemoreceptors of which the 
majority are olfactory receptors (Busse et al., 2014). This may explain the 
presence of olfactory receptors in the data.  
 
Neurotransmitters are chemical molecules that control signalling in the brain. 
Exocytosis is the process that facilitates the release of these chemical molecules 
from the presynaptic neuron into the synaptic cleft via vesicle-membrane fusion. 
As a result postsynaptic neuron activation occurs. Defects in glutamate receptors, 
glutamate uptake or release leads to disrupted signalling in the brain. This has 
been demonstrated in several neurological diseases such as ALS, AD and 
epilepsy (Hynd et al., 2004, Van den Bosch et al., 2006, Cho, 2013). One of the 
known causative agents in ALS is excitotoxicity which results from elevated 
glutamate in the synaptic cleft which leads to impaired Ca++ ions influx and 
neuronal death. This is proposed to be due to defects in the glutamate receptors 
(Ferraiuolo et al., 2011). 
 
Controlled exocytosis and neurotransmitters levels are essential functions for 
normal brain signalling. Thus, increased exocytosis could lead to imbalance of 
neurotransmitter release leading to ALS pathology. Although, a single gene 
involved in exocytosis was up-regulated in this current work (RIMS1) and there 
is no current evidence of its association with ALS. This may indicate that elevated 
levels of neurotransmitter such as glutamate could be due to increased 
exocytosis which may contribute to the disease pathogenesis. Lastly, The 
ARRB1 was shown to have a desensitization effect on the beta-adrenergic 
receptor kinase (BARK) signalling pathway and this gene was up-regulated. This 
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may indicate dysregulated BARK signalling pathway in fALS-TARDBP (Lohse et 
al., 1990). These observations strongly indicate that TARDBP missense mutation 
has a multiple biological effects which confirms the diversity of ALS aetiology. 
 
4.9.3 Nuclear MT vs. CON 
 
4.9.3.1 Nuclear mRNA splicing via spliceosome 
 
In the current work, evidences of the association of dysregulated RNA processing 
with fALS-TARDBP missense mutation is apparent. This was previously 
highlighted as a significantly dysregulated biological process in the missense 
mutation in both cellular comparisons (see chapter 3, sections 3.6.1.1.3 and 
3.6.2.1.3).  
 
Nuclear MT vs. nuclear CON showed that the most significantly enriched 
biological process was nuclear mRNA splicing. Aberrant hnRNA splicing 
mechanism has been previously implicated in ALS (Rabin et al., 2010, Highley et 
al., 2014, Raman et al., 2015). Here, several genes related to hnRNA splicing 
were down-regulated. Heterogeneous nuclear ribonucleoproteins were 
decreased, including HNRNPA0, HNRNPF and HNRNPR which indicate a 
decreased potential for splicing events. The HNRNPR gene has previously been 
shown to also disrupt the SMN splicing pattern in a spinal muscular atrophy 
mouse model (Rossoll et al., 2002). A mutated SMN2 gene was suggested to be 
a risk factor for ALS. Thus, from Rossoll et al., it is suggested that decreased 
levels of HNRNPR in the nuclear missense mutation may have an impact on 
lowering SMN2 gene expression in fALS-TARDBP and therefore increase the risk 
of the disease. Furthermore, small nuclear ribonucleoproteins which are involved 
in hnRNA splicing were also down-regulated SNRNP40, SNRPB2 and SNRPE. 
SNRPB2 gene expression was, as indicated above, in agreement with Highley et 
al., in which they suggested a dysfunctional spliceosomal component in ALS 
(Highley et al., 2014). Moreover, the U2 small nuclear ribonucleoproteins 
complex component PHF5A, the EJC protein MAGOH and the tRNA splicing 
enzyme TSEN15 were also down-regulated. These observations strongly support 
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the association of dysregulated mRNA processing in fALS-TARDBP missense 
mutation and could be a favourable area for further study and a possible 
therapeutic target.  
 
4.9.3.2 Regulation of translation 
 
Protein synthesis is a fundamental process to maintain cell viability. For the 
synthesis of a polypeptide the following cellular molecules are required: 
ribosomes, messenger RNA (mRNA) and aminoacylation of transfer RNA 
(tRNA). These molecules are found significantly and actively in the cytoplasm. 
However, several studies challenged that mRNA translation is a unique process 
in the cytoplasm and can also occur in the nucleus (Iborra et al., 2001, Brogna et 
al., 2002, Iborra et al., 2004). In the present work, three genes involved in 
translation inhibition were reduced, IGF2BP3, NANOS1 and PAIP2 suggesting 
elevated levels of translation. The QKI gene involved in RNA metabolism 
including translation was also reduced. Lauriat et al., suggested that reduced QKI 
might be associate with decreased oligodendrocyte-myelin in schizophrenia 
(Lauriat et al., 2008). Furthermore, as discussed earlier, genes involved in RNA 
processing were reduced (MAGOH and SARNP). Also, the IGFBP5 gene was 
increased which acts as tyrosine kinase receptor pathway inhibitor. Therefore, 
increased levels of IGFBP5 in fALS-TARDBP may suggest low cell growth and 
proliferation rate as a result of tyrosine kinase receptor pathway inhibition. 
IGFBP5 was also suggested to co-express with the Six5 gene which is known to 
be linked to myotonic dystrophy-1 (Sato et al., 2002). The significant increase of 
IGFBP5 gene may strongly suggest its association with fALS-TARDBP. 
Furthermore, APLP1 which was suggested to be associated with Alzheimer’s like 
pathology due to manganese exposure was also shown to be elevated in fALS-
TARDBP.  
 
 
4.9.3.3 mRNA transport 
 
TDP-43 is a shuttling protein which is involved in mRNA transport from the 
nucleus to the cytoplasm where translation or degradation takes place (Buratti 
224 
 
and Baralle, 2010). Therefore, it is suggested that defects in TDP-43 possibly 
lead to low expression of its associated mRNA molecules and also may result in 
lower expression of other genes involved in the transport system within the cell. 
This was observed in the current work, as a group of gene involved in mRNA 
transport were reduced, DDX19B, MAGOHB, MAGOH, NUPL1 and QKI. 
Although the number of genes involved in mRNA transport were low, this still may 
indicate a disrupted mRNA transport system in fALS-TARDBP. As this was not 
reported before, it is possibly a novel underlying aetiology in fALS-TARDBP.  
 
4.9.3.4 Nucleosome organization 
 
Nucleosomes are known molecular units that are subjected to epigenetic 
changes, such as: methylation, acetylation and phosphorylation which have an 
impact on gene expression. In the present work, it was shown that a group of 
histone family of genes expression were reduced in fALS-TARDBP missense 
mutation, H3F3A, HIST1H4A, HIST1H4C and HIST2H2AB. Affected DNA 
methylation was suggested to be associated with sALS and might impact upon 
histone expression (Martin and Wong, 2013). Furthermore, AD was also shown 
to be associated with reduced acetylation which led to reduced histone synthesis 
(Zhang et al., 2012). Also, hypomethylation was suggested in PD patients (Feng 
et al., 2015). Other genes that regulate chromatin assembly and gene expression 
were reduced, ASF1A and CTCF. Epigenetic modifications in fALS-TARDBP 
were also suggested in the Human Exon Array 1.0 ST chapter (section 3.8.1.1). 
Here it is shown that histone molecule synthesis was down-regulated. It suggests 
that epigenetic modifications on histones may contribute to the disease process.    
 
4.9.4 Nuclear TT vs. CON 
 
4.9.4.1 G-protein coupled receptor protein signalling pathway 
 
Signal transduction pathways are methods of cellular communications through 
cell membrane receptors. Stimulation of the receptors activates a series of 
molecular interactions know as cascades as a response to the bound ligand. 
225 
 
There are two types of ligands activators and inhibitors. Signal transduction 
pathways controls diverse cellular processes such as cell proliferation, growth, 
migration and apoptosis (Venkatakrishnan et al., 2013). G-protein coupled 
receptors are a type of receptors that share a common characteristic which is to 
activate G-proteins at the early stage of the signal transduction pathway. 
Defective G-protein coupled receptor protein signalling has been associated with 
several diseases such as cancer, neuromuscular disorders and autism (Rojas 
Walh, 2007, Heng et al., 2013, Kanazawa et al., 2015). In ALS dysfunctional G-
protein coupled receptor e.g. metabotropic glutamates receptor was associated 
with the disease pathogenesis (Aizawa et al., 2010).  
 
Glutamate is the main neurotransmitter in neuronal excitation. One-way of 
activating the glutamate receptors is the binding of glutamate to the postsynaptic 
neuron after presynaptic depolarization this activates intracellular G-proteins 
which activate series of molecule which ends by ion channel opening. Therefore, 
dysfunctional glutamate receptor activity can lead to neuronal excitotoxicity 
(Heath and Shaw, 2002). In addition, defective G-protein coupled receptors, 
dopamine and metabotropic glutamate receptors were associated with PD 
(Jenkins et al., 2016). Furthermore, using gene expression profiling  several G-
protein coupled receptors have been associated with AD (Zhao et al., 2016).  
 
In this current work a large number of G-protein coupled receptors were down-
regulated in the nuclear fALS-TARDBP truncated mutation samples. The cAMP 
activators (HTR6 and MC3R) and cAMP inhibitor OPRL1 were reduced. A large 
number of receptors related to sensation were also decreased, the itch receptor 
MRGPRG, purinergic receptor P2RY8 and taste receptor, TAS2R39. Studies 
showed that ALS patients score low in olfactory test which may suggested low 
expression of olfactory receptors (Elian, 1991, Doty, 2012). In the present work, 
a significant number of olfactory receptors were reduced OR10G7, OR10G9, 
OR2A12, OR2A4, OR4C5, OR4M2, OR4N2, OR4P4, OR5L2, OR51S1, OR52L1, 
OR6C4, OR6C70, OR8J1 and VN1R2 in fALS-TARDBP truncation mutation. 
 
Moreover, genes involved in cell cycle arrest, GPR3, cell migration, CCR9 and 
potassium ion channel, KCNK2 were reduced. Furthermore, the neurotransmitter 
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inhibitor, GLRB was down-regulated. Mutation in this gene was associated with 
hyperekplexia which is characterized by stiffness of voluntary muscles and 
excessive startle reaction (Rees et al., 2002). The transcription factor BHLHA15 
was down-regulated. Also, the PRLH was reduced. The data shows a marked 
reduction of the G-protein coupled receptor proteins affected by the fALS-
TARDPB truncated mutation. It would be interesting to investigate the 
downstream effect of these G-protein coupled receptor proteins which might be 
a scope for therapeutic targets.  
 
 
4.10 Gene expression validation 
 
Gene expression studies require validation steps to confirm the results of the 
arrays. Two methods were used to validate the HTA data. The cytoplasmic genes 
were validated using qPCR while the nuclear genes were attempted to validate 
by a new approach which was FISH.  
 
4.10.1 qRT-PCR fALS cytoplasmic MT and cytoplasmic TT genes 
validation 
 
From the fALS-TARDBP missense mutation only ADARB1 confirmed the 
directional change of expression compared to the HTA outcome. However, the 
METTL1 gene expression did not show any difference. Similarly, in fALS-
TARDBP the truncated mutation samples, the directional change of ENAH was 
confirmed while the SEMA5A gene did not show any difference. However, the 
two genes showing a directional change in correlation with that of the HTA data 
did not show a statistical significant result. This observation might be due to the 
low fold changes that were generally seen in the data (Fold changes: ADARB1= 
1.6, METTL1= -1.2, ENAH =-1.5 and SEMA5A = 1.6). Therefore, it was difficult 
to demonstrate the change in gene expression. However, by comparing the 
results generated from the Human exon arrays 1.0 ST with the HTA it was 
obvious that the fALS-TARDBP showed some similar biological process. The 
reproducibility of similar outcomes by different microarray GeneChips® may be 
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suggested as a method of validation of the current results to an extent. This was 
shown in the ADARB1 gene, it was up-regulated in both Human exon arrays 1.0 
ST and HTA cytoplasmic fALS-TARDBP missense mutation (FC=1.9, p-
value=0.03 and FC=1.6, p-value=0.009 respectively). None of the other 
differentially expressed cytoplasmic fALS-TARDBP genes within the RNA 
processing were shared with the Human exon arrays. However, in the nuclear 
fALS-TARDBP missense mutation, SNRPB/B2 gene, was shared with the 
Human exon 1.0 ST arrays nuclear fraction.  
 
 
4.10.2 Fluorescence in situ hybridization of fALS nuclear controls, 
missense mutation and truncated mutation  
 
As mentioned previously, FISH is a powerful technique that can aid in the 
localization of RNA molecules within the cell using designed complementary 
labelled probes (see section 2.11 for the method). In the present work, a 
preliminary experiment was performed aiming to validate nuclear genes 
expressed in both types of fALS-TARDBP mutation. Although the experiment was 
attempted twice, both failed to show positive results. The reasons behind that 
could be improper optimization of individual probes which was necessary prior to 
the actual testing. Optimization would set the threshold concentrations required 
of each probes, set the actual time needed for fibroblast permeabilization and 
also can suggest any faulty manufacture design of probes or reagents. The 
experiments were carried out towards the end of the available time in the 
laboratory and hence were not carried out with the usual levels of integrity. There 
was not enough time, or finances, to carry out further experiments. 
4.11 The overall effect of the TARDBP mutation on the biological 
processes in fALS using the HTA 
 
ALS is a complex neurodegenerative disorder caused by several underlying 
aetiologies and therefore is considered a multifactorial disorder though patients 
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present with progressive muscle wasting with symptoms varying according to the 
muscle groups affected. However, it is proposed that patients go through a similar 
disease process. The literature shows that in ALS-TARDBP studies that aimed 
to investigate the possible affected pathways, researchers do not always 
differentiate between the mutation types, assuming that the effects of mutations 
are the same. However, the current work showed that cytoplasmic fALS-TARDBP 
missense mutation were presented with defective RNA processing in the form of 
RNA editing, mRNA polyadenylation and splicing via spliceosome complex. 
However, the truncated mutation showed angiogenesis to be the most affected 
biological process. 
 
The nuclear fALS-TARDBP missense mutation also demonstrated that RNA 
processing was the most affected pathway, while the nuclear truncated mutation 
showed the G-protein coupled receptor signalling pathway to be affected. This 
current work strongly suggests that different types of fALS-TARDBP mutations 
may affect different underlying biological processes and this should be in 
consideration when developing targeted treatments for fALS-TARDBP patients.  
 
Furthermore, gene expression profiling using microarray GeneChips® has shown 
to be effective in identifying gene signature biomarkers that might help in 
stratifying disease types. Also, in identifying prognostic biomarkers, this may help 
monitoring disease progression and predict survival. The present work shows 
that distinct dysregulated genes were shown in different fALS-TARDBP mutation 
types.  
 
4.12 Comparative analysis of differently expressed genes in the cytoplasm 
vs. nucleus in both missense mutation and truncated  
  
A comparative analysis of differently expressed genes in the cytoplasm and the 
nucleus was performed as shown previously in section 4.6.2.4. It was shown that 
there is a significant number of differentially expressed nuclear genes in both 
mutation types. ~71% of the total identified transcripts in the missense mutation 
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were found in the nuclear component and ~62% of the total transcripts identified 
in the truncation mutation were from the nucleus. Only ~4% from the total 
transcripts identified in the missense mutation were common in both cellular 
components and ~7% from the total transcripts identified in the truncated 
mutation were common in both cellular components. This indicates that the 
number of shared genes is low.  
 
It is worth noting that this initial comparative study demonstrate the possible effect 
of the TARDBP mutation on the disease process. The large number of genes in 
the nuclear fraction in both mutation types may suggest that there are significant 
number of transcripts being synthesised in the nucleus however, they do not 
reach their final destination i.e. the cytoplasm. These might be faulty transcripts 
or spliced transcripts as a result of TARDBP mutation and therefore were held in 
the nucleus and subjected to degradation. Another possible reason is the loss of 
TDP-43 functional role in mRNA transport due to the TARDBP mutation and 
therefore these transcripts are being also held in the nucleus.  
 
This observation strongly supports that mutant TARDBP disrupts the RNA 
processing mechanism in the fALS. However, further analysis of this comparative 
study remain to be established. Also, due to time constraint alternative splicing 
analysis was not performed in the current work. 
 
However, due to the low levels of gene expression changes using both the 
Human Exon 1.0 ST arrays and the newly designed HTA it was proposed to study 
the gene expression of fALS-TARDBP using RNA sequencing since this has 
been purported to provide a  more robust analysis. An experimental design was 
established for RNA sequencing which was applied on the cytoplasmic fALS-
TARDBP missense mutation and the truncation mutation (see chapter 5).    
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Chapter 5: Next generation sequencing (RNA sequencing) 
5.1 Next generation sequencing (RNA sequencing)  
In this work, RNA sequencing technology was chosen to study the effect of 
TARDBP mutation on the disease process in only the cytoplasmic fractions of 
both TARDBP mutations (refer to section 1.1.6.4 for RNA sequencing 
technology). This allows the identification of an underlying biological process and 
pathways affected in fALS-TARDBP. Also comparing the data outcome of the 
sequencing with the microarrays results from the previous experiments i.e. 
chapter 3: Human Exon Arrays 1.0 ST and chapter 4: Human Transcriptome 
Arrays may highlight the identification of specific dysregulated biological 
processes in each type of mutation.  
 
5.2 Sample preparation and quality control  
In this experiment cDNA libraries from the cytoplasmic fALS-TARDBP missense 
mutation (n=3) MT, fALS-TARDBP truncated mutation TT (n=3) and controls 
(n=4) were prepared for RNA sequencing as described in (section 2.10). The 
peak distribution of the fragmented DNA libraries was expected to be ~ 300bp. 
This was achieved efficiently as shown in (Figure 5.1). Two samples of the fALS-
TARDBP truncated mutation had the lowest concentration; patient 192 and 194. 
However, the required total cDNA concentration in each library was 10nM. cDNA 
libraries were kept in a final volume of 25µl of water thus the total cDNA library 
concentration of patient 192 and 194 were 60nM and 62.5nM receptively which 
was sufficient and were taken forward to be sequenced (Table 5.1). 
 
The Sequence Analysis Viewer Software from Illumina assessed the quality 
control of the run. The quality control output graphs generated by the software 
offered essential quality control checks of the data accuracy and reliability. These 
include an overall accuracy of the library preparation, base calling, variant calling 
and read alignment. The most well-known metric that is measured is the Phred 
quality score (Q score). The Q-score can be defined as the predicted probability 
value of a base sequence call being incorrect. The higher the Q-score the most 
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likely base calling error is low. Table 5.2 summaries the Q-scores and the 
corresponding predicted base calling error. The results showed a Q30=90.6% of 
all libraries (Figure 5.2)  
 
The cluster density and passing filter box plot was generated to assess how 
optimal the reads were. The cluster density and the passing filter showed a good 
overlapping which indicate a low base call error (Figure 5.3 lane 6 & 7).  The 
signal intensity of the bases are shown in (Figure 5.4). The bases were visualised 
at high intensity levels at the beginning of the sequencing procedure where the 
first strand DNA is sequenced however at cycle 50 a loss of the signals occurred 
due to laser energy drop. At the 100 cycle the second strand DNA is sequenced 
where more chemical material is added to boost the synthesis cycle. 
  
The bioinformatics analysis was performed in collaboration with Dr Wenbin Wei/ 
Professor Winston Hide group. The RNA sequencing was paired end reads.  The 
Illumina sequencer generated the bcl files which then were converted to fastq 
files by bcl2fastq program. The fastq files were then aligned to the GRCh37 
human genome using bcbio’s star aligner. The reads were counted using the 
feature Counts. The total number of reads, mapped reads and the percentage of 
mapped reads of the cytoplasmic samples are shown in table 
(http://bcbionextgen.readthedocs.io/en/latest/contents/introduction.html) 
 
  
Figure 5.1. : Representative electropherogram of a DNA library preparation. The peak point can 
be assessed to be approximately 300 bp in length as expected for the libraries.   
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Table 5.1: DNA library concentration. FU= fluorescence unite, nmol/µl= 
nanomole/microliter, nM=nanomoles.   
 
Sample type  Mutation 
type 
Sample  Qubit (FU)  nM 
 
Cytoplasmic  None  Con 2303 3.72 16.35164835 
Con 155 8.43 37.05495 
Con 170 1.95 8.571429 
Con 159 2.67 11.73626 
Missense  Pat 48 7.44 32.7033 
Pat 51 2.91 12.79121 
Pat 55 1.03 4.527473 
Truncated  Pat 192 0.546 2.4 
Pat 193 1.4 6.153846 
Pat 194 0.586 2.575824 
Nuclear  None  Con 2303 4.28 18.81319 
Con 155 2.13 9.362637 
Con 170 3.83 16.83516 
Con 159 1.11 4.879121 
Missense  Pat 48 5.08 22.32967 
Pat 51 4.52 19.86813 
Pat 55 4.66 20.48352 
Truncated  Pat 192 3.09 13.58242 
Pat 193 1.8 7.912088 
Pat 194 3.65 16.04396 
 
 
 
 
 
Table 5.2: Phred Quality scoring 
 
Phred Quality Score (Q-score) Predicted base calling error Base calling accuracy % 
Q 10 1 in 10 90  
Q 20  1 in 100 99 
Q 30 1 in 1000 99.9 
Q 40 1 in 10,000 99.99 
Q 50 1 in 100,000 99.999 
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Figure 5.2: Illumina Hi scan SQ system generated the Q-score of the overall libraries (the Q30= 
90.6%). 
 
 
 
Figure 5.3: Cluster density and passing filter box plot quality control. The (X) axis represents the 
lanes 1-8. The Y axis represents the cluster density. The image shows the cluster density and 
passing filter for the 8 lanes. The samples were loaded on lane 6 and 7 (10 samples in each lane). 
The blue box is the density cluster box, the green box is the passing filter box and the red line is 
the median. The density and the passing filter boxes are overlapping which indicate that they are 
optimal.   
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 Figure 5.4: The signal intensity of the bases of the 8 lanes. The (X) axis is the number of 
synthesis cycles and the (Y) axis is the signal intensity. Bases are coloured differently for easy 
identification. The bases was maintained at a high levels at the beginning of the sequencing 
procedure where the first strand DNA is sequenced however at cycle 50 a drop of the signals 
occurred due to laser energy loss. At the 100 cycle the second strand DNA is sequenced where 
more chemical material is added to boost the synthesis cycle.   
 
Table 5.3: The total number of reads, mapped reads and the percentage of 
mapped read of the cytoplasmic fractions 
Condition  Cytoplasmic 
samples 
Total reads Mapped reads % Mapped 
reads 
Controls  155 17189777 16487970 95.92% 
159 26466289 25667408 96.98% 
170 22047680 20905844 94.82% 
2303 47879824 47083438 98.34% 
Missense 
mutation  
48 33927329 32963378 97.16% 
51 19798829 18581774 93.85% 
55 14730221 14296927 97.06% 
Truncated 
mutation  
192 18093922 17612955 97.34% 
193 23911777 23222052 97.12% 
194 23436050 21898231 93.44% 
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5.3 Gene expression profiling 
The differentially expressed genes were identified using the edgeR 
program with the criteria of a fold change > +1.5 and p-value <0.05 of only 
the cytoplasmic fraction of each type of mutation. Two comparisons were 
performed, cytoplasmic MT vs. cytoplasmic CON which revealed 868 
differentially expressed genes; 377 were up-regulated and 491 were down-
regulated; and cytoplasmic MT vs. cytoplasmic CON which showed 1437 
differentially expressed genes; 747 were up-regulated and 690 were down-
regulated (Figure 5.5). 
 
 
Figure 5.5: Differentially expressed genes in cytoplasmic MT and cytoplasmic TT compared to 
controls using the edgeR software.  
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5.3.1 Cytoplasmic MT vs. CON 
 
DAVID analysis tool was used to identify significantly enriched biological 
processes (enrichment score > 1.3) that were dysregulated in the cytoplasmic 
fALS-TARDBP missense mutation. The most significantly enriched biological 
processes were the following: response to steroid hormone stimulus, cell 
adhesion, anterior/posterior pattern formation and angiogenesis (Table 5.4). A 
further detailed examination of the genes within these biological processes is 
demonstrated below.   
 
 
Table 5.4: Functionally enriched biological processes generated by DAVID of 
cytoplasmic MT vs. CON. GO=Gene ontology, no.=number, ES= Enrichment 
score 
 
GO  Biological process Gene 
no. 
P-value ES 
BP_FAT Response to steroid hormone 
stimulus 
18 3.2E-8 4.4 
BP_FAT Cell adhesion 43 4.7E-4 3.19 
BP_FAT Anterior/posterior pattern 
formation 
14 1.3E-3 3.17 
BP_FAT Angiogenesis 14 2.1E-3 2.29 
BP_FAT Reproductive developmental 
process 
20 2.3E-3 2.17 
BP_FAT In utero embryonic development 23 3.5E-3 2 
BP_FAT Response to organic nitrogen 8 6.3E-3 1.97 
BP_FAT Regulation of apoptosis 42 2.2E-3 1.68
  
BP_FAT Response to insulin stimulus 11 2.6E-3 1.5 
BP_FAT Regulation of growth 20 3.2E-2 1.48 
BP_FAT Positive regulation of 
macromolecule metabolic 
process 
43 1.7E-2 1.47 
BP_FAT Urogenital system development 12 1.6E-3 1.43 
BP_FAT Response to extracellular 
stimulus 
16 1.1E-2 1.41 
BP_FAT Regulation of neurological system 
process 
10 4.3E-2 1.38 
BP_FAT Tube development 20 2.8E-4 1.35 
BP_FAT Embryonic limb morphogenesis 9 1.1E-2 1.34 
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5.3.1.1 Response to steroid hormone stimulus 
 
The highest enriched biological process observed in the fALS-TARDBP missense 
mutation was the response to steroid hormone stimulus. Genes that belonged to 
this biological process were believed to be influenced by steroid hormones. 
Steroid hormones are lipid soluble molecules that are able to diffuse through the 
plasma membrane lipid bilayer and bind directly to the targeted receptor forming 
a hormone-receptor complex which is capable of inducing a change in gene 
expression (Schwartz et al., 2016). Dysregulated genes associated with their 
susceptibility to steroid hormones were shown in the fALS-TARDBP cytoplasmic 
missense mutation and will be discussed below (Table 5.5). 
 
 Alkaline phosphatase, liver/bone/kidney (ALPL) was up-regulated (FC=6.2). It is 
also known as tissue-nonspecific alkaline phosphatase (TNSAP). The gene 
encodes an enzyme which is expressed on mineralizing cells such as 
osteoblasts. Mutations in ALPL are associated with hypophosphatasia. ALPL-/- 
mice showed a similar phenotype, severe skeletal abnormalities due to 
hypomineralization and developed seizures (Liu et al., 2014). Furthermore, the 
butyrylcholinesterase (BCHE) was increased (FC= 51.8). It is also known as 
pseudocholinesterase and acts on the hydrolysis of the neurotransmitter 
acetylcholine. It has been shown that an elevated levels of  BCHE was associated 
with AD (Greig et al., 2002b). The angiopoietin 1 (ANGPT1) was up-regulated 
(FC=2). ANGPT1 was shown to activate the MAPK pathway via the tyrosine-
protein kinase receptor TIE-2. This promotes differentiation and migration of 
endothelial cells (Uebelhoer et al., 2012). Moreover, ANGPT1 is highly expressed 
in cancers such as, neuroblastoma, multiple myeloma and prostate cancer 
(Hayes et al., 2000, Metheny-Barlow and Li, 2003).  
 
In addition, cyclin D2 (CCND2) was increased (FC=4.2). It belongs to the cyclin 
family which is involved in regulating the cell cycle. CCND2 forms complexes with 
the cyclin-dependent kinases CDK4/CDK6 which regulate G1/S transition phase 
specifically. Uncontrolled activation of CCND2 was shown to be associated with 
tumours such as glioblastoma, breast cancer and lymphoma (Koyama-Nasu et 
al., 2013). The GATA binding protein 3 (GATA3) was up-regulated (FC= 17.9). 
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GATA3 is a transcription factor which is involved in the regulation of T-cell 
development. It is also involved in the normal growth of the mammary glands 
however, overexpression GATA3 was shown to be associated with poor 
prognosis of breast cancer (Chou et al., 2010). 
 
Also, the glutathione S-transferase mu 3 (GSTM3) which is an enzyme that is  
involved in the detoxification of toxicants was shown to be increased (FC= 3.8) 
(Shin et al., 2016). The insulin-like growth factor binding protein 2, 36kDa 
(IGFBP2) was up-regulated (FC= 20). IGFBP2 is an essential protein that binds 
to the GF-׀ with a high affinity. It promotes cell proliferation, adhesion and survival 
(Shen et al., 2012). The oxytocin receptor (OXTR) was also increased (FC=5.3). 
This receptor binds the oxytocin peptide which can activate the cAMP signalling 
pathway through G-protein activation. OXTRs are expressed on mammary gland 
and myometrium. It is also found in the CNS where it regulates social behaviours 
(Bale et al., 2001). In addition, the platelet-derived growth factor beta polypeptide 
(simian sarcoma viral (v-sis) oncogene homolog) (PDGFB) was increased 
(FC=10). PDGFB is a tyrosine kinase receptor which can activate downstream 
signalling pathways that involve cell differentiation, migration and survival 
(Nicolas et al., 2013). In addition, regulator of G-protein signalling 9 (RGS9) was 
upregulated (FC=11.6). RGS9 belongs to the RGS family of proteins that are 
involved in inhibiting the G-protein by increasing the GTP hydrolysis thereby 
deactivating the adenylate cyclase enzyme (He et al., 1998). Moreover, the 
suppressor of cytokine signalling 2 (SOCS2) was increased (FC=2.7). SOCS2 
was shown to inhibit the cytokine receptor activity through the JAK/STAT pathway 
(Minamoto et al., 1997). Furthermore, somatostatin (SST) was increased 
(FC=22). Somatostatin is a hormone which has an inhibitory effect on other 
secondary hormones like insulin, glycogen, thyroid stimulating hormone and 
growth hormone. It is also a neurotransmitter which promotes neuronal 
excitability by activating G protein-coupled receptors. It was shown that 
somatostatin decreases with age and was shown to be associated with AD (Saito 
et al., 2005, Liguz-Lecznar et al., 2016) . The tumour necrosis factor receptor 
superfamily, member 11b (TNFRSF11B) was up-regulated (FC=2). It is also 
known as osteoprotegerin (OPG) and, as stated, belongs to the TNF-receptor 
superfamily. It is considered a decoy receptor which inhibits osteoclastogenesis 
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by binding to the RANK ligand and thereby inhibits the RANK / RANKL pathway. 
Mutation in TNFRSF11B were suggested to associate with idiopathic 
hyperphosphatasia (Cundy et al., 2002, Janssens et al., 2005). The WAP four-
disulfide core domain 1 (WFDC1) was significantly increased (FC=118.6). 
WFDC1 is a protease inhibitor which was reported to be expressed at a low levels 
in prostate cancer but no mutation in the gene was detected (Watson et al., 2004).  
 
In contrast a group of genes were down-regulated. The carbonic anhydrase IX 
(CA9) was reduced (FC=-5.3). CA9 belongs to the carbonic anhydrase family 
which has a major role in normal cell proliferation and is also considered a tumour 
suppresser. Low levels of CA9 were associated with poor prognosis of renal cell 
carcinoma (Bui et al., 2003). Furthermore, the v-fos FBJ murine osteosarcoma 
viral oncogene homolog (FOS) was decreased (FC=-4.7). FOS It is a proto-
oncogene which encodes the for FOS protein. The FOS protein is capable of 
binding to the JUN protein to form the activator protein 1 (AP-1) complex. The 
AP-1 complex promotes cell proliferation via the activation MAPK pathway (Milde-
Langosch, 2005).  In addition, the serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1 (SERPINA1) was reduced (FC=-14.6). 
SERPINA1 is a protease inhibitor which acts in protecting the cells from harmful 
enzymes especially those produced in inflammation such as neutrophil elastase 
(Churg et al., 2001). Finally the solute carrier family 6 (neurotransmitter 
transporter, GABA), member 1 (SLC6A1) was down-regulated (FC=-13.9). 
SLC6A1 is involved in the reuptake of the neurotransmitter gamma-aminobutyric 
acid (GABA) from the synaptic cleft into the presynaptic neuron. It was suggested 
that the dysregulation of the SLC6A1 was may disturb the GABA status in the 
brain which may result in seizures (Carvill et al., 2015).  
 
It was shown that the steroid hormones have a significant effect on gene 
expression. This was clearly observed in fALS-TARDBP missense mutation with 
the majority of the genes being up-regulated with the top highest up-regulated 
genes were BCHE, GATA3, IGFBP2, PDGFB, RGS9, SST and WFDC1. 
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Table 5.5: Genes involved in response to steroid hormone stimulus in the 
cytoplasmic missense mutation  
 
Gene 
symbol 
Gene name  P-value Fold 
change  
ALPL Alkaline phosphatase, 
liver/bone/kidney 
0.02 6.24 
ANGPT1 Angiopoietin 1 0.03 2.08 
BCHE Butyrylcholinesterase 0.01 51.81 
CA9 Carbonic anhydrase IX 0.04 -5.31 
CCND2 Cyclin D2 0.01 4.26 
FOS  V-fos FBJ murine osteosarcoma viral 
oncogene homolog 
0.03 -4.76 
GATA3 GATA binding protein 3 0.01 17.92 
GSTM3 Glutathione S-transferase mu 3 (brain) 0.0003 3.88 
IGFBP2 Insulin-like growth factor binding 
protein 2, 36kDa 
0.007 20.08 
OXTR  Oxytocin receptor 0.003 5.32 
PDGFB
  
Platelet-derived growth factor beta 
polypeptide (simian sarcoma viral (v-
sis) oncogene homolog) 
0.0008 
 
10.20 
 
RGS9 Regulator of G-protein signalling 9 0.03 11.60 
SERPINA1 Serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 1 
0.02 
 
-14.68 
SLC6A1 Solute carrier family 6 
(neurotransmitter transporter, GABA), 
member 1 
0.04 -13.91 
 
SOCS2 Suppressor of cytokine signalling 2 0.007 2.74 
SST Somatostatin 0.03 22.04 
TNFRSF1
1B 
Tumour necrosis factor receptor 
superfamily, member 11b 
0.04 2.08 
WFDC1 WAP four-disulfide core domain 1 4.86E-05 118.62 
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5.3.1.2 Cell adhesion 
 
Cell adhesion was previously shown to be associated with fALS (refer to section 
4.6.1.1.3 and 4.6.1.2.2). Here, by studying gene expression profiling using RNA 
sequencing the data revealed that the largest number of dysregulated genes in 
fALS-TARDBP missense mutation belonged to cell adhesion biological process 
with the majority being significantly down-regulated though some were up-
regulated (Table 5.6).  A further elaboration is shown below. 
 
Laminin, alpha 3 (LAMA3) was up-regulated (FC=6). LAMA3 belongs to the 
laminin family and was shown to be involved in epithelial basement membranes 
adhesion (Ryan et al., 1994). Furthermore, endomucin (EMCN) was increased 
(FC=16). EMCN is a mucin-like sialoglycoprotein which has been suggested to 
negatively control cell adhesion by preventing the formation of focal adhesion 
complexes (Kinoshita et al., 2001). In addition the CD9 molecule (CD9) was also 
up-regulated (FC=6.6). It is expressed on dendritic cells and megakaryocytes. It 
is involved in cell adhesion and migration (Leung et al., 2011).  Mutation in the 
CD9 gene was shown be associated with cancer and metastasis (Zoller, 2009). 
The ALX homeobox 1 gene (ALX1) was increased (FC=12). ALX1 is a 
transcription factor that is involved in cartilage synthesis. Mutations in ALX1 were 
suggested to be associated with frontonasal dysplasia (FND) (Dee et al., 2013). 
Moreover, three genes belonging to the cadherin superfamily were up-regulated, 
tumour suppressor homolog 3 (Drosophila) (FAT3) (FC=5), cadherin 10, type 2 
(T2-cadherin) (CDH10) (FC=5.7) and protocadherin 17 (PCDH17) (FC=11). 
Cadherins are transmembrane glycoproteins that are expressed on several types 
of cells and have a major role in cell-cell adhesion. (Brasch et al., 2012).  
 
The L1 cell adhesion molecule (L1CAM) was up-regulated (FC=14). L1CAM is 
an adhesion molecule that has a major role in the CNS development including 
neuronal cell differentiation and migration (Schafer and Frotscher, 2012). 
Plakophilin 3 (PKP3) expression was also increased (FC=3.4). It is involved in 
cell adhesion by promoting the adhesion of cadherins to the cytoskeleton 
(Schmidt et al., 1999). The sorbin and SH3 domain containing 1 (SORBS1) which 
is involved in focal cell adhesion complexes was increased (FC=10) (Aakula et 
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al., 2016). Furthermore, the protein tyrosine phosphatase, receptor type, C 
(PTPRC) which belongs to the protein tyrosine phosphatase family was up-
regulated (FC=4). PTPRC is able to activate signalling pathways such as the JAK 
pathway which promote cell cycle, cell differentiation and growth (Porcu et al., 
2012).  Thy-1 cell surface antigen (THY1) was increased (FC=1.9). THY1 is 
involved in cell proliferation, differentiation and apoptosis. It is also mediates cell 
adhesion and was considered a tumour suppressor for ovarian cancer (Lung et 
al., 2005, Rege and Hagood, 2006). The calsyntenin 2 (CLSTN2) gene was up-
regulated (FC=35.7). CLSTN2 has been shown to be involved in cell adhesion 
and also was demonstrated to be highly expressed in GABAergic neurons 
(Hintsch et al., 2002). Furthermore, the roundabout, axon guidance receptor, 
homolog 2 (Drosophila) (ROBO2) was elevated (FC=7.7). ROBO2 is involved in 
axonal guidance (Fricke et al., 2001). Mutations in this gene have been 
associated with familial vesicoureteral reflux (Bertoli-Avella et al., 2008). Also the 
signal-regulatory protein alpha (SIRPA) was increased (FC=1.5). It is expressed 
mainly on myeloid cells which maintain cell migration and phagocytosis by 
interacting with the CD47 ligand (Matozaki et al., 2009).  
 
As indicated above the majority of genes in this category were down-regulated. 
The polycystic kidney disease 1 (autosomal dominant) was reduced (PKD1) 
(FC=-1.9). PKD1 is considered an integral protein involved in cell to cell adhesion. 
Mutations in PKD1 are known to be associated with autosomal dominant 
polycystic kidney disease (ADPKD) (Song et al., 2009). Also the WNT1 inducible 
signalling pathway protein 1 (WISP1) was down-regulated (FC=-4). It is a 
member of the connective tissue growth factor family which is involved in cell 
adhesion and cell proliferation via the WNT signalling pathway (Xu et al., 2000). 
Furthermore, the AE binding protein 1 (AEBP1) was decreased (FC=-3). AEBP1 
is a transcriptional repressor which was suggested to be associated with 
adipogenesis through the MAP-kinase pathway (Bost et al., 2005). The SCO-
spondin homolog (Bos taurus) (SSPO) was down-regulated (FC=-19). It was 
shown that SSPO is involved in the normal development of the CNS and 
especially in axon guidance (Goncalves-Mendes et al., 2003). The Adhesion 
molecule with Ig-like domain 2 (AMIGO2) was reduced (FC=-6). It encodes for a 
transmembrane protein that is involved in cell-cell adhesion (Kuja-Panula et al., 
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2003). The amine oxidase, copper containing 3 (vascular adhesion protein 1) 
(AOC3) was down-regulated (FC=-22.8). AOC3 is expressed on the endothelial 
cell surface and is also involved in white blood cell migration and adhesion 
(Koskinen et al., 2007).  
 
Four genes from the collagen family were down regulated. The collagen, type V, 
alpha 1 (COL5A1) (FC=-2.4). COL5A1 It is involved in the assembly of fibres 
synthesised by type V and type I collagens. Mutation in COL5A1 gene have been 
associated with Ehlers-Danlos syndromes (DePaepe et al., 1997). The three 
other genes have previously been described as mainly expressed in the 
epidermal keratinocytes and to be involved in the adhesion of the epithelial cells 
to the basement membrane, they are collagen, type XV, alpha 1 (COL15A) (FC=-
2.5), collagen, type XVI, alpha 1 (COL16A1) (FC=-4) and collagen type VII, alpha 
1(COL7A1) (FC=-5.9). Mutations in the COL7A1 gene have been associated with 
Bart syndrome and epidermolysis bullosa (Pan et al., 1992, Christiano et al., 
1996, Ee et al., 2007).  
 
 
A group of genes belonging to the cadherin superfamily were also down-
regulated. The cadherin 2, type 1, N-cadherin (neuronal) (CDH2) was down-
regulated (FC=-2.8). CDH2 is involved in neuronal cell adhesion. Mutations in 
this gene have been associated with obsessive-compulsive disorder (Moya et al., 
2013). Also the calsyntenin 3 (CLSTN3) was reduced (FC=-5.4). It is involved in 
cell adhesion and was shown to be expressed in GABAergic neurons (Hintsch et 
al., 2002, Ortiz-Medina et al., 2015). In addition the dachsous 1 (Drosophila) 
(DCHS1) was reduced (FC=-7). Along with other adhesion molecules, DCHS1 
forms adhesion complexes during neurogenesis which are essential for CNS 
development (Cappello et al., 2013). Furthermore, three more genes also 
belonging to the cadherin superfamily were down-regulated, the mucin-like 
protocadherin (CDHR5) (FC=-9), protocadherin 9 (PCDH9) (FC=-3) and 
protocadherin gamma subfamily C, 5 (PCDHGC5) (FC=-6.7) (Paris and Williams, 
2000, Wu et al., 2001, Wang et al., 2012). 
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Chondroadherin (CHAD) gene expression was also decreased (FC=-18.7). 
CHAD has been shown to have an inhibitory effect on cartilage synthesis by 
reducing chondrocyte differentiation (Tillgren et al., 2015). Moreover, the 
fibronectin leucine rich transmembrane protein 1 (FLRT1) was decreased (FC=-
3.5). FLRT1 is a member of the leucine rich repeat superfamily which is involved 
in cell adhesion through the activation of the Ras/Raf/ERK pathway (Wheldon et 
al., 2010). The NME/NM23 nucleoside diphosphate kinase 2 (NME2) was also 
reduced (FC=-5). The encoded protein was shown to be associated with tumour 
suppression in several cancers such as ovarian, breast and lung cancer  (Thakur 
et al., 2011). The periostin, osteoblast specific factor (POSTN) was down-
regulated (FC=-14). It has been shown that POSTN acts as a ligand for α-V/beta-
5 and α-V/beta-3 integrin therefore it was suggested to have a role in cell 
adhesion of the ovarian epithelium (Gillan et al., 2002). The expression of the 
sushi, nidogen and EGF-like domains 1(SNED1) gene was decreased (FC=-2). 
It is known to be highly expressed in the kidney stroma (Leimeister et al., 2004). 
Furthermore, tenascin C (TNC) gene expression was reduced (FC=-3.6). It was 
previously shown that TNC inhibits integrin dependent adhesion (Probstmeier 
and Pesheva, 1999). In addition, tophinin associated protein (tastin) (TROAP) 
was down-regulated (FC=-2.5). It has been suggested to have a role in facilitating 
the blastocyst attachment to the endometrium (Fukuda et al., 1995). The trophinin 
(TRO) was decreased (FC=-1.9). The encoded protein is vital for the adhesion of 
the trophoblast to maternal epithelium (Harada et al., 2007). The lectin, 
galactoside-binding, soluble, 4 (LGALS4) was reduced (FC=-28.5). LGALS4 
promotes cell adhesion by binding to the extracellular matrix (Huflejt et al., 1997). 
Finally, the tuberous sclerosis 1 (TSC1) gene was down-regulated (FC=-1.7). It 
is a tumour suppressor which has previously been shown to inhibit the mTORC1 
signalling pathway (Inoki et al., 2002). 
 
It is clearly shown that cell adhesion process is disrupted in fALS-TARDBP 
missense mutation and there is a marked reduction in gene expression. This 
strongly suggests less cell adhesion is undergoing which may leads to serious 
consequences. Less cell adhesion in fibroblasts possibly infer to the blood brain 
barrier breakdown observed in ALS patients especially that the skin biopsies in 
this study were collected at the active stage of the disease.   
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Table 5.6: Genes involved in cell adhesion in the cytoplasmic missense 
mutation  
 
Gene 
symbol 
Gene name  P-value Fold 
change  
AEBP1 AE binding protein 1 0.04 -3.09 
ALX1 ALX homeobox 1 0.04 12.23 
AMIGO2 Adhesion molecule with Ig-like domain 2 0.008 -6.06 
AOC3 Amine oxidase, copper containing 3 
(vascular adhesion protein 1) 
0.008 -22.89 
 
CD9 CD9 molecule 0.04 6.68 
CDH2 Cadherin 2, type 1, N-cadherin 
(neuronal) 
0.002 -2.82 
CDH10 Cadherin 10, type 2 (T2-cadherin) 0.01 5.78 
CDHR5 Mucin-like protocadherin 0.02 -9.05 
CHAD Chondroadherin 0.03 -18.70 
CLSTN2 Calsyntenin 2 0.001 35.79 
CLSTN3 Calsyntenin 3 0.01 -5.41 
COL5A1 Collagen, type V, alpha 1 0.04 -2.47 
COL7A1 Collagen, type VII, alpha 1 0.01 -5.94 
COL15A1 Collagen, type XV, alpha 1 0.04 -2.52 
COL16A1 Collagen, type XVI, alpha 1 0.01 -4.09 
DCHS1 Dachsous 1 (Drosophila) 0.001 -7.16 
EFS Embryonal Fyn-associated substrate 0.02 -1.99 
EMCN Endomucin 0.001 16.26 
FAT3 FAT tumor suppressor homolog 3 
(Drosophila) 
0.02 5.02 
 
FLRT1 Fibronectin leucine rich transmembrane 
protein 1 
0.01 
 
-3.58 
 
LAMA3 Laminin, alpha 3 0.009 6.27 
LGALS4 Lectin, galactoside-binding, soluble, 4 0.01 -28.53 
L1CAM L1 cell adhesion molecule 0.01 14.35 
NME2 NME/NM23 nucleoside diphosphate 
kinase 2 
0.003 
 
-5.29 
 
PCDH9 Protocadherin 9 0.04 -3.07 
PCDH17 Protocadherin 17 0.04 11.12 
PCDHGC5 Protocadherin gamma subfamily C, 5 0.009 
 
-6.79 
 
PKD1 Polycystic kidney disease 1 (autosomal 
dominant) 
0.02 
 
-1.98 
 
PKP3 Plakophilin 3 0.02 3.41 
POSTN Periostin, osteoblast specific factor 0.01 -14.45 
PTPRC Protein tyrosine phosphatase, receptor 
type, C 
0.03 
 
4.20 
 
ROBO2 Roundabout, axon guidance receptor, 
homolog 2 (Drosophila) 
0.03 
 
7.74 
SIRPA Signal-regulatory protein alpha 0.04 1.59 
SNED1 Sushi, nidogen and EGF-like domains 1 0.04 -2.10 
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SORBS1 Sorbin and SH3 domain containing 1 0.001 10.42 
SSPO SCO-spondin homolog (Bos taurus) 0.006 -19.03 
THY1 Thy-1 cell surface antigen 0.009 1.95 
TMEM8A Transmembrane protein 8A 0.007 1.87 
TNC Tenascin C 0.005 -3.60 
TRO Trophinin 0.03 -1.95 
TROAP Trophinin associated protein (tastin) 0.01 
 
-2.57 
 
TSC1 Tuberous sclerosis 1 0.04 -1.76 
WISP1 WNT1 inducible signaling pathway 
protein 1 
0.01 -4.11 
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5.3.1.3 Anterior/posterior pattern formation 
 
A group of genes were grouped under the banner of anterior/posterior pattern 
formation by DAVID. These are defined as genes that have a role in cellular 
development and differentiation that were located anatomically at the anterior-
posterior axis of the body.  No specific pattern of dysregulation was observed as 
there was an equal number of genes up-regulated and down-regulated in fALS-
TARDBP missense mutation (Table 5.7). 
 
The ALX homeobox 1(ALX1) gene was up-regulated (FC=12). It belongs to the 
homeobox protein family which are group of transcription factors that control the 
expression of genes responsible for organ structure.  Mutations in ALX1 were 
previously shown to cause frontonasal dysplasia which is uncontrolled cell 
proliferation and migration during embryonic development (Dee et al., 2013). 
Furthermore, the homeobox B9 (HOXB9) gene was increased (FC=53.7). It is a 
transcription factor that promotes cell proliferation, growth and differentiation. 
Elevated levels of HOXB9 have been shown to be associated with breast cancer 
and lung metastasis (Hayashida et al., 2010). The homeobox D13 (HOXD13) was 
also increased (FC=3.5) which is a transcription factor that promotes cell 
proliferation and growth of the limbs. Mutations in HOXD13 gene were previously 
shown to be associated with hand-foot-genital syndrome (HFGS) (Goodman et 
al., 2000). The BTG family, member 2 (BTG2) was up-regulated (FC=2.5). It has 
been shown to be involved in the cell cycle regulation of at the G1 and S phase 
(Duriez et al., 2002) and is induced by the p53 tumour suppresser protein and 
DNA damage (Rouault et al., 1996). The presenilin 2 (Alzheimer disease 4) 
(PSEN2) was up-regulated (FC= 2.2). Mutations in PSEN2 are linked to AD and 
have been suggested to be involved in the production of increased levels of APP 
in AD pathology (Levy-Lahad et al., 1996). The secreted frizzled-related protein 
1 (SFRP1) was also increased (FC=4.3). It is involved in cell growth and also can 
activate the Wnt-dependent signalling pathway which is essential for cell 
development (Taketo, 2004). Furthermore, the zinc finger and BTB domain 
containing 16 (ZBTB16) was increased (FC= 28.5). It is a zinc finger transcription 
factor shown to be involved in osteoblastic differentiation (Ikeda et al., 2005). On 
the other hand, the secreted frizzled-related protein 2 (SFRP2) was down-
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regulated (FC= -20.6). Similar to SFRP1, SFRP2  is involved in the activation of 
the Wnt-dependent signalling pathway which is essential for cell development 
(Taketo, 2004). The homeobox B3 (HOXB3) (FC= -2) was also reduced. HOXB3 
is a transcription factor that promotes cell development and was shown to be 
associated with acute myeloid leukemia (AML) (Lindblad et al., 2015). The 
homeobox C6 (HOXC6) was decreased (FC=-2.2). HOXC6 was shown to be 
expressed in prostate cancer and was suggested to have a lower expression in 
breast cancer (Chariot et al., 1996, Hamid et al., 2015) Furthermore, the 
homeobox C8 (HOXC8) was down-regulated (FC=-2). HOXC8 is a prognostic 
factor for epithelial ovarian cancer (EOC). Elevated levels of HOXC8 were 
suggested to associate with poor prognosis of the disease (Lu et al., 2016). The 
activity-regulated cytoskeleton-associated protein (ARC) was also reduced (FC= 
-8.4). It is involved in brain plasticity by promoting long term potentiation and 
memory by increasing the AMPAR population on the postsynaptic neuron 
(Pevzner et al., 2012). The hematopoietically expressed homeobox (HHEX) was 
decreased (FC=-5).  HHEX is a transcription factor that controls endothelial cell 
development (Donaldson et al., 2005). Finally, the homeobox D9 (HOXD9) was 
down-regulated (FC=-2.4). HOXD9 is a transcription factor that is involved in 
proliferation, migration and apoptosis. It was recently been associated with 
hepatocellular carcinoma (Lv et al., 2015). 
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Table 5.7: genes involved in anterior/posterior pattern formation in the 
cytoplasmic missense mutation  
 
Gene 
ontology  
Biological process P-value  Fold 
change 
ALX1 ALX homeobox 1 0.04 12.23 
ARC Activity-regulated cytoskeleton-associated 
protein 
0.01 -8.49 
BTG2 BTG family, member 2 0.03 2.56 
HHEX Hematopoietically expressed homeobox 0.02 -5.13 
HOXB3 Homeobox B3 0.03 -2.08 
HOXB9 Homeobox B9 0.002 53.75 
HOXC6 Homeobox C6 0.01 -2.29 
HOXC8 Homeobox C8 0.03 -2.08 
HOXD9 Homeobox D9 0.04 -2.42 
HOXD13 Homeobox D13 0.008 3.52 
PSEN2 Presenilin 2 (Alzheimer disease 4) 0.03 2.26 
SFRP1 Secreted frizzled-related protein 1 0.006 4.38 
SFRP2 Secreted frizzled-related protein 2 0.001 -20.65 
ZBTB16 Zinc finger and BTB domain containing 16 0.006 28.55 
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5.3.1.4 Angiogenesis 
 
As mentioned previously, dysregulated angiogenesis related genes were shown 
to associate with ALS (see section 4.6.1.1.2 and 4.6.1.2.1).  A large group of 
genes related to angiogenesis were up-regulated in the fALS-TARDBP missense 
mutation (Table 5.8) similar to the observation in the HTA data. 
  
The endomucin (EMCN) was increased (FC=16.2). It is a mucin-like 
sialoglycoprotein which was suggested to negatively control cell adhesion by the 
inhibition of the focal adhesion complexes. This was demonstrated by interfering 
with the binding of the cells to the extracellular matrix (ECM) (Kinoshita et al., 
2001). In addition, EMCN was shown to be highly expressed in endothelial cells 
and significantly up-regulated during cell proliferation, therefore it was suggested 
to be an angiogenic tumour marker (Liu et al., 2001). Furthermore, the HIV-1 Tat 
interactive protein 2, 30kDa (HTATIP2) was up-regulated (FC=1.7). It was first 
identified in small cell lung carcinoma cell lines (SCLC) and was suggested to 
have a suppressive effect on cancer metastasis (Shtivelman, 1997, Whitman et 
al., 2000). The T-box 4 (TBX4) was also increased (FC=11.4). TBX4 encodes a 
transcription factor which is important for the development of the lower limbs. 
Mutations in TBX4 have been shown to be associated small patella syndrome 
(SPS) (Agulnik et al., 1996, Bongers et al., 2004). Moreover, the tumour necrosis 
factor (ligand) superfamily, member 12 (TNFSF12) was up-regulated (FC=1.8). 
The TNFSF12 is a cytokine that belongs to the tumour necrosis factor ligand 
family. It is involved in angiogenesis by mediating endothelial cell proliferation 
and migration. Also it can prompt cell death by activating apoptotic pathways 
(Chicheportiche et al., 1997, Lynch et al., 1999). The Thy-1 cell surface antigen 
(THY1) was increased (FC=1.9). Thy-1 is a cell surface glycoprotein which may 
induce cell proliferation, differentiation and apoptosis. In addition it was 
suggested to act as a tumour suppressor for ovarian cancer (Lung et al., 2005). 
As mentioned previously, angiopoietin 1 (ANGPT1) was also increased (FC=2). 
ANGPT1 binds to the tyrosine-protein kinase receptor TIE-2 which activates the 
MAPK pathway. This promotes differentiation and migration of the endothelial 
cells (Uebelhoer et al., 2012). In addition, ANGPT1 was shown to be highly 
expressed in cancers such as prostate cancer, multiple myeloma and 
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neuroblastoma (Hayes et al., 2000, Metheny-Barlow and Li, 2003). The heart and 
neural crest derivatives expressed 2 (HAND2) was up-regulated (FC=2.7). It is a 
transcription factor that is essential for cardiogenesis (McFadden et al., 2005). In 
addition, the placental growth factor (PGF) was increased (FC=4.3). PGF is a 
cytokine that binds to VEGFR1 which results in the activation of endothelial cell 
migration, growth and survival (Fischer et al., 2007). It is considered a prognostic 
marker for several tumours therefore, it has an important role in determining 
tumour progression (Kim et al., 2012). The interleukin 18 (interferon-gamma-
inducing factor) (IL18) was increased (FC= 8). It is a proinflammatory cytokine 
that binds to its IL18 receptor which activates an immune response. It is also an 
angiogenic factor that is involved in endothelial cell proliferation. Elevated levels 
of IL18 have been shown to be associated with cancers such melanoma and 
renal cancer (Park et al., 2001, Palma et al., 2013). The transforming growth 
factor, alpha (TGFA) was also up-regulated (FC=4.5). It induces cell signalling 
transduction and activates pathways that mediate cell proliferation, differentiation 
and angiogenesis (Singh and Coffey, 2014). In contrast a group of genes were 
down-regulated. Angiopoietin 2 (ANGPT2) was reduced (FC=-22.7).  It acts as 
an antagonist for the ANGPT1. It competes for the binding to the TIE-2 receptor. 
Similar to ANGPT1, ANGPT2 can activate the MAPK pathway which results in 
endothelial cell differentiation and migration.  ANGPT2 was shown to be highly 
expressed in cancers such as lung cancer, breast cancer and hepatocellular 
carcinoma (Metheny-Barlow and Li, 2003, Sfiligoi et al., 2003, Hu and Cheng, 
2009). Furthermore, angiopoietin-like 6 (ANGPTL6) was down-regulated (FC=-
5.6). It belongs to the angiopoietin family proteins and is involved in vascular 
endothelial cell chemotaxis (Oike et al., 2003, Oike et al., 2004). The collagen, 
type XV, alpha 1 (COL15A1) was also reduced (FC=-2.5). COL15A1 was 
suggested to have an anti-angiogenic function and to be a tumour suppresser 
(Sasaki et al., 2000). Finally, the vascular endothelial growth factor A (VEGFA) 
was reduced (FC=-3.2). VEGFA is involved in vascular formation this includes 
angiogenesis and vasculogenesis. It also promotes endothelial cell migration. It 
has a major role in the CNS as it stimulates the development of blood vessels. 
Furthermore, transgenic mice-/- for hypoxia response element of the VEGFA gene 
showed a phenotype similar to ALS (Oosthuyse et al., 2001, Mackenzie and 
Ruhrberg, 2012).  
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This data shows, again, that genes previously associated with angiogenesis are 
dysregulated in fALS-TARDBP missense mutation with the majority being up-
regulated. However, it is possible that these changes are as a result of increased 
oxygen demand in fibroblast.   
 
 
Table 5.8: Genes involved in angiogenesis in the cytoplasmic missense 
mutation  
 
Gene 
symbol 
Gene name  P-value Fold 
change  
ANGPT1 Angiopoietin 1 0.03 2.08 
ANGPT2 Angiopoietin 2 0.005 -22.77 
ANGPTL6 Angiopoietin-like 6 0.01 -5.60 
COL15A1 Collagen, type XV, alpha 1 0.04 -2.52 
EMCN Endomucin 0.001 16.26 
HAND2 Heart and neural crest derivatives 
expressed 2 
0.01 2.71 
HTATIP2 HIV-1 Tat interactive protein 2, 30kDa 0.03 1.71 
IL18 Interleukin 18 (interferon-gamma-
inducing factor) 
0.003 8.09 
PGF Placental growth factor 0.001 4.36 
TBX4 T-box 4 0.04 11.40 
THY1 Thy-1 cell surface antigen 0.009 1.95 
TGFA Transforming growth factor, alpha 0.01 4.58 
TNFSF12  Tumor necrosis factor (ligand) 
superfamily, member 12 
0.04 
 
1.82 
 
VEGFA Vascular endothelial growth factor A 0.02 -3.25 
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5.3.2 Cytoplasmic TT vs. CON 
 
As in the missense mutation study, the DAVID analysis tool was used to identify 
significantly enriched biological processes (enrichment score > 1.3) that were 
dysregulated in cytoplasmic fALS-TARDBP truncated mutation. The most 
significantly enriched biological processes were the following: response to 
vitamins, regulation of mitotic cell cycle, response to steroid hormone stimulus, 
blood vessel development and vesicle-mediated transport (Table 5.9). A more 
detailed examination of the genes within these biological processes is 
demonstrated below.   
 
 
Table 5.9: Functionally enriched biological processes generated by DAVID of 
cytoplasmic TT vs. CON. GO=Gene ontology, no.=number, ES= Enrichment sore 
GO  Biological process Gene no. P- 
value 
ES 
BP_FAT Response to vitamins 12 2.1E-3 4.04 
BP_FAT Regulation of mitotic cell cycle 16 8.1E-2 3.12  
BP_FAT Response to steroid hormone 
stimulus 
23 3.6E-3 2.74 
BP_FAT Blood vessel development 25 1.6E-2 2.42 
BP_FAT Vesicle-mediated transport 52 5.4E-3 2.26 
BP_FAT Stem cell development 7 4.2E-3 2.02 
BP_FAT Tissue morphogenesis 24 6.8E-4 1.63 
BP_FAT Tube development 22 3.0E-2 1.6 
BP_FAT Positive regulation of vascular 
endothelial growth factor 
receptor signalling pathway 
4 6.7E-3 1.53 
BP_FAT Positive regulation of protein 
kinase cascade R 
17 5.2E-2 1.47 
BP_FAT Response to amine stimulus 8 8.9E-3 1.46 
BP_FAT Morphogenesis of a polarized 
epithelium 
4 1.5E-2 1.43 
BP_FAT Reproductive process in a 
multicellular organism  
49 4.0E-3 1.4 
BP_FAT Regulation of hormone levels 16 4.5E-2 1.35 
BP_FAT Circulatory system process 20 2.0E-2 1.31 
BP_FAT Regulation of synaptic 
transmission 
15 4.0E-2 1.25 
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5.3.2.1 Response to vitamins 
 
 
The highest enriched biological process was the response to vitamins. Vitamins 
are organic compounds that are essential for normal development. Studies have 
shown that vitamins capable of altering gene expression such are vitamin K, 
vitamin A and vitamin E (Wang et al., 1995, Landes et al., 2003, McGrane, 2007). 
A group of genes that were up-regulated in fALS-TARDBP truncated mutation 
and are involved in vitamin metabolism are indicated in Table 5.10.  
 
The aldehyde dehydrogenase 1 family, member A2 was up-regulated (ALDH1A2) 
(FC=3.8). ALDH1A2 is a member of the aldehyde dehydrogenase family. It is 
involved in the synthesis of retinoic acid (vitamin A) from retinaldehyde which is 
vital for the development of the spinal cord (Deak et al., 2005).The retinol binding 
protein 4, plasma (RBP4) was increased (FC=4.4). RBP4 binds to retinoic acid in 
the blood to properly deliver the retinoic acid from the liver to other sites in the 
body and preventing it being filtered by the renal system (Folli et al., 2005). Two 
genes involved in embryonic development and bone and cartilage synthesis were 
up-regulated, the bone morphogenetic protein 4 (BMP4) (FC=43.5) and bone 
morphogenetic protein 7 (BMP7) (FC=16.6) (Bakrania et al., 2008). Furthermore, 
the butyrylcholinesterase (BCHE) was up-regulated (FC=23.4). It was previously 
shown that it has a role in the hydrolysis of the neurotransmitter acetylcholine. In 
addition, elevated levels of BCHE were shown to be associated with AD (Greig 
et al., 2002b). Two proinflammatory cytokines that are involve in inflammation 
were up-regulated, chemokine (C-C motif) ligand 2 (CCL2) (FC=2.7) and 
interleukin 1, beta (IL1B) (FC=4.2) (Corrigall et al., 2001). Also, the imprinting 
gene mesoderm specific transcript homolog (mouse) (MEST) which is expressed 
mainly in the mesodermal tissues during embryonic development  was increased 
(FC=7) (Kobayashi et al., 1997). The hydroxysteroid (17-beta) dehydrogenase 2 
(HSD17B2) was up-regulated (FC=11.6). The encoded protein is an enzyme 
which negatively regulates estradiol hormone activity (Plourde et al., 2008). The 
oxytocin, prepropeptide (OXT) was elevated (FC=49). OXT is a hormone and a 
neurotransmitter that is produced by the hypothalamus and has an effect on the 
uterus and mammary gland.  It is also found in the CNS wherein it regulates social 
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behaviours (Bale et al., 2001). The kruppel-like factor 4 (gut) (KLF4) was 
increased (FC=1.8). KLF4 is a member of the krüppel like factor family, is a 
transcription factor and a tumour suppresser. It has roles in proliferation, 
development, inflammation and apoptosis (Rowland and Peeper, 2006).  Finally, 
only a single gene was reduced, the prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase) (PTGS2) (FC=-4.6). PTGS2 
is known to have a major role during injury and inflammation (Yamauchi et al., 
2013). 
 
As an overall, a high number of genes influenced by vitamins was observed in 
fALS-TARDBP truncated mutation and also the highest enriched biological 
process. This observation may reflects ALS patients’ diet. As the disease 
progress, a high nutritional supplements are given to ALS patients to compensate 
the body mass loss. This may alter expression of some genes as seen above.  
Also, this observation could be as a result of the vitamin supplement added to the 
fibroblast culture media to maintain their growth.     
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Table 5.10: Genes involved in response to vitamin in the cytoplasmic truncation 
mutation  
 
Gene 
symbol 
Gene name  P-value Fold 
change  
ALDH1A2 Aldehyde dehydrogenase 1 
family, member A2 
0.01 
 
3.88 
 
BCHE Butyrylcholinesterase 0.01 23.48 
BMP4 Bone morphogenetic protein 4 0.002 43.56 
BMP7 Bone morphogenetic protein 7 0.01 16.66 
CCL2 Chemokine (C-C motif) ligand 2 0.04 2.78 
HSD17B2 Hydroxysteroid (17-beta) 
dehydrogenase 2 
0.01 
 
11.60 
 
IL1B Interleukin 1, beta 0.003 4.27 
KLF4 Kruppel-like factor 4 (gut) 0.01 1.83 
MEST Mesoderm specific transcript 
homolog (mouse) 
3.51513E-05 
 
7.36 
 
OXT Oxytocin, prepropeptide 0.002 49.14 
PTGS2 Prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
0.01 
 
-4.68 
 
RBP4 Retinol binding protein 4, 
plasma 
0.04 4.43 
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5.3.2.2 Regulation of the mitotic cell cycle 
 
 
In the fALS-TARDBP truncated mutation comparison a number of dysregulated 
genes related to the mitotic cell cycle were identified with equal numbers of up-
regulated and down-regulated gene expression (Table 5.11).  
 
The CD28 molecule (CD28) was up-regulated (FC=10.5). It is a surface protein 
that can co-stimulate T-cells and is important for their proliferation and survival 
(Mikolajczak et al., 2004). Furthermore, the epithelial mitogen homolog (mouse) 
(EPGN) was increased (FC=12). EPGN belongs to the epidermal growth factor 
family which encodes for a legend that binds to the epidermal growth factor 
receptor and can activate cell migration and proliferation signalling pathways 
(Herbst and Bunn, 2003). In addition, the transforming growth factor, alpha 
(TGFA) was up-regulated (FC=8). The TGFA is involved in cell proliferation, 
differentiation and development. Overexpression of TGFA was shown to be 
associated with several types of cancer (Singh and Coffey, 2014). The insulin-
like growth factor 2 (somatomedin A) (IGF2) was also increased (FC=40). IGF2 
binds to the IGF1 receptor which stimulates cell proliferation therefore is 
considered a mitogenic signalling molecule (Morrione et al., 1997). The nuclear 
factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 
1(NFKBIL1) was up-regulated (FC=1.7). It is involved in the regulation of the 
innate immune response and is considered a tumour suppressor (Pajerowski et 
al., 2009). In addition, two proinflammatory cytokines were up-regulated, 
interleukin 1, alpha (IL1A) (FC=7) and interleukin 1, beta (IL1B) (FC=4.2).  
 
On the other hand, a group of genes were down-regulated. The Mdm2, 
transformed 3T3 cell double minute 2, p53 binding protein (mouse) binding 
protein, 104kDa (MTBP) was reduced (FC=-2.6). MTBP may regulate cell growth 
and was suggested to be a tumour suppressor gene (Boyd et al., 2000). Also the 
sphingosine kinase 1(SPHK1) was down-regulated (FC=-2). SPHK1 is involved 
in the phosphorylation of sphingosine to form sphingosine-1-phosphate that has 
a role in cell growth and proliferation (Wang et al., 2013). The hect domain and 
RLD 2 (HERC2) was also reduced (FC=-7.4). HERC2 is a shuttling protein that 
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is involved in the ubiquitination of several proteins and therefore, mediates protein 
degradation (Wang et al., 2009a). 
 
The nucleolar and spindle associated protein 1 (NUSAP1) was reduced (FC=-
2.7). NUSAP1 interact with cellular microtubule proteins which are involved in cell 
mitosis (Raemaekers et al., 2003a). Also the extra spindle pole bodies homolog 
1 (S. cerevisiae) (ESPL1) was down-regulated (FC=-2.7). ESPL1 is involved in 
the control of proper cell division by promoting the cleavage of the sister 
chromatin during anaphase (Sun et al., 2009). The NIMA (never in mitosis gene 
a)-related kinase 2 (NEK2) was reduced (FC=-4.9) NEK2 was shown to be 
involved in centromere separation during cell division and was detectable at the 
S phase and reached its highest expression at the G2 phase (Cappello et al., 
2014). The centromere protein F, 350/400ka (mitosin) (CENPF) was also down-
regulated (FC=-3). It is part of the centromere kinetochore complex. Therefore, it 
was suggested to play a role in cell division and especially during chromosome 
segregation (Eisch et al., 2016). Finally, the discs, large (Drosophila) homolog-
associated protein 5 (DLGAP5) was decreased (FC=-3.5). DLGAP5 is a 
kinetochore protein which is involved in cell division by promoting microtubule 
stabilization and chromosome alignment (Wong and Fang, 2006).   
 
It can be observed that the majority of the down-regulated genes were related to 
mitotic cell division while the up-regulate genes were related to cell proliferation 
pathways. This may indicated that some of the fibroblasts are subjected to death 
as a result of the TARDBP mutation and also a compensatory process is 
established by activating the proliferation pathways.   
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Table 5.11: Genes involved in regulation of mitotic cell cycle in the cytoplasmic 
truncation mutation  
 
Gene 
symbol 
Gene name  P-value Fold 
change  
CD28 CD28 molecule 0.04 10.54 
CENPF Centromere protein F, 
350/400ka (mitosin) 
0.007 
 
-3.10 
 
DLGAP5 Discs, large (Drosophila) 
homolog-associated protein 5 
0.03 
 
-3.54 
 
EPGN Epithelial mitogen homolog 
(mouse) 
0.002 12.21 
ESPL1 Extra spindle pole bodies 
homolog 1 (S. cerevisiae) 
0.007 
 
-2.71 
 
HERC2 Hect domain and RLD 2 0.01 -7.40 
IGF2 Insulin-like growth factor 2 
(somatomedin A); insulin  
6.3434E-08 
 
40.15 
 
IL1A Interleukin 1, alpha 0.01 7.22 
IL1B Interleukin 1, beta 0.003 4.27 
MTBP Mdm2, transformed 3T3 cell 
double minute 2, p53 binding 
protein (mouse) binding protein, 
104kDa 
0.02 
 
-2.69 
 
NEK2 NIMA (never in mitosis gene a)-
related kinase 2 
0.01 
 
-4.98 
 
NFKBIL1 Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor-like 1 
0.02 
 
1.79 
 
NUSAP1 Nucleolar and spindle 
associated protein 1 
0.03 
 
-2.78 
 
SBDSP1 Shwachman-Bodian-Diamond 
syndrome pseudogene 
0.01 
 
1.78 
 
SPHK1 Sphingosine kinase 1 0.04 -2.07 
TGFA Transforming growth factor, 
alpha 
0.007 8.20 
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5.3.2.3 Response to steroid hormone stimulus 
 
 
The third highest enriched biological process demonstrated in the fALS-TARDBP 
truncated mutation comparison was the response to steroid hormone stimulus. 
This was a similar observation to the ALS-TARDBP missense mutation. Genes 
that belonged to this biological process were also supposed to be stimulated by 
steroid hormones. As mentioned previously, steroid hormones are lipid soluble 
molecules which are capable to diffuse though plasma membrane lipid bilayer to 
bind to targeted receptor forming complexes which are then able to induce gene 
expression changes (Schwartz et al., 2016). Dysregulated genes associated with 
steroid hormone susceptibility were demonstrated in fALS-TARDBP cytoplasmic 
truncated mutation and are discussed below (Table 5.12). 
 
The WAP four-disulfide core domain 1 (WFDC1) was up-regulated (FC= 26). 
WFDC1 is a protease inhibitor and is considered a tumour marker. It is expressed 
at low levels in prostate cancer and breast cancer however no mutation has been 
detected (Watson et al., 2004, Madar et al., 2009). Furthermore, the aldehyde 
dehydrogenase 1 family, member A2 (ALDH1A2) was increased (FC=3.8). 
ALDH1A2 is involved in the formation of retinoic acid from retinaldehyde that is 
vital for the development and maturation of the spinal cord (Deak et al., 2005). 
Moreover, three genes belong to the transforming growth factor-β superfamily 
were up-regulated, bone morphogenetic protein 4 (BMP4) (FC=43.5), bone 
morphogenetic protein 7 (BMP7) (FC=16.6) and myostatin (MSTN) (FC=3.8). 
Both BMP4 and BMP7 are involved in bone and cartilage formation and 
embryonic development while MSTN was shown to inhibit skeletal muscle 
development (Bakrania et al., 2008, Gu et al., 2016). The tumour necrosis factor 
receptor superfamily, member 11b (TNFRSF11B) was increased (FC=2.7). It is 
also known as osteoprotegerin (OPG) which is considered a decoy receptor 
which inhibits osteoclast synthesis by binding to the RANK ligand therefore 
inhibits the RANK / RANKL pathway. Mutation in this gene was suggested to 
associate with idiopathic hyperphosphatasia (Cundy et al., 2002, Janssens et al., 
2005). The cyclin D2 (CCND2) was also increased (FC=3.4). CCND2 regulates 
the cell division process by forming complexes with the cyclin-dependent kinases 
261 
 
CDK4/CDK6. CCND2-CDK4/CDK6 complexes regulate the G1/S transition 
phase. Uncontrolled regulation of CCND2 has been shown to be associated with 
tumours such as lymphoma, glioblastoma and breast cancer (Koyama-Nasu et 
al., 2013). Also the cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) 
was increased (FC=2). CDKN1A is a cell cycle regulator that functions mainly at 
the G1 phase. It was shown that it promote cell arrest by inhibiting the 
CDK2/CDK4 complex formation (Bendjennat et al., 2003).  
 
In addition, two peptide hormones were up-regulated. Adrenomedullin (ADM) 
was increased (FC=2.4). This peptide hormone has a variety of functions, these 
include growth, angiogenesis and smooth muscle dilatation (Fernandez et al., 
2008). Also the oxytocin, prepropeptide (OXT) was also elevated (FC=49). 
Oxytocin is a hormone and a neurotransmitter which is synthesised in the 
hypothalamus and has an effect on the mammary gland and uterus.  It is also 
expressed in the CNS and was shown to regulate social behaviours (Bale et al., 
2001). Furthermore, three genes involved in inflammation were up-regulated. The 
chemokine (C-C motif) ligand 2 (CCL2) was increased (FC=2.7). CCL2 binds to 
its receptor chemokine C-C motif receptor to initiate the recruitment of monocytes 
and macrophages to the site of inflammation. Elevated levels of CCL2 were 
associated with a poor prognosis of late stage metastatic breast cancer (Qian et 
al., 2011). In addition, the prostaglandin-endoperoxide synthase 2 (prostaglandin 
G/H synthase and cyclooxygenase) was also increased (PTGS2) (FC=-4.6). 
PTGS2 is shown to have a major role in tissue injury and inflammation (Yamauchi 
et al., 2013). Also the interleukin 1, beta (IL1B) was up-regulated (FC=4). The 
butyrylcholinesterase (BCHE) was up-regulated (FC=23.4). BCHE acts on the 
hydrolysis of the acetylcholine and was shown to be highly expressed in AD 
(Greig et al., 2002b). 
 
A group of enzymatic genes were up-regulated. The cytochrome P450, family 11, 
subfamily A, polypeptide 1(CYP11A1) was up-regulated (FC=2.4). This gene 
encodes for a monooxygenase enzyme that is involved in the synthesis of lipids 
and steroids (Sahakitrungruang et al., 2011). The glutathione peroxidase 4 
(phospholipid hydroperoxidase) (GPX4) was increased (FC=2). GPX4 belongs to 
the glutathione peroxidases family which are antioxidant enzymes. It reduces 
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hydroperoxide radicals generated from cholesterol and phospholipid metabolism 
(Liang et al., 2007).  Furthermore, the alpha-2-macroglobulin (A2M) was up-
regulated (FC=6). A2M is a protease inhibitor which is able to inactivate several 
proteins and is able to prevent fibrinolysis by inhibiting plasmin, it also binds to 
thrombin which results in the inhibition of coagulation (de Boer et al., 1993). On 
the other hand, two enzymatic genes were down-regulated. The nitric oxide 
synthase 3 (endothelial cell) (NOS3) was decreased (FC=-7.8). NOS3 is an 
enzyme that promotes the synthesis of nitric oxide which has a major role in 
vasodilatation. Polymorphisms in the NOS3 have been suggested to be 
associated with AD (Dasar et al., 2012). Moreover, carbamoyl-phosphate 
synthetase 1, mitochondrial (CPS1) was also decreased (FC=-2.7). CPS1 is an 
essential enzyme that is involved in the elimination of the toxic effect of ammonia 
by converting ammonia to carbamoyl phosphate. This is the initial step of the urea 
cycle which takes place in the mitochondria (Haberle et al., 2003).  
 
The aryl-hydrocarbon receptor nuclear translocator 2 (ARNT2) was down-
regulated (FC=-1.5). ARNT2 was shown to be expressed in the CNS and 
mutations in this gene were associated with Webb-Dattani syndrome (Haberle et 
al., 2003). The cortactin binding protein 2 (CTTNBP2) was down-regulated (FC=-
12.175). The encoded protein was suggested to play a role in dendritic 
spinogenesis (Chen et al., 2012). Finally the oestrogen receptor 1 (ESR1) was 
reduced (FC=-3.7). ESR1 is a steroid receptor and is a member of a nuclear 
receptor family which is activated by oestrogen hormone. The activation of ESR1 
by oestrogen involves in the development female sexual system (Kos et al., 
2001). 
 
The majority of genes that were influenced by steroid hormones were increased 
in the fALS-TARDBP truncated mutation with only five genes being shared with 
the fALS-TARDBP missense mutation, BCHE, WFDC, CCND2, GSTM3 and 
TNFRSF11B (Figure 5.6). Although both mutations were harbouring the same 
biological processes in name, a large number of distinct genes were observed.  
 
It was shown that genes involved in response to steroid hormone stimulus were 
dysregulated and the majority were up-regulated in both the fALS-TARDBP 
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missense mutation and truncated mutation. It was interesting to find if any of the 
cell genes from both mutations belonged to a similar or distinct pathway. Thus, 
response to steroid hormone gene list from both mutations were combined then 
uploaded into DAVID and the KEGG pathway was generated in order to identify 
the significant pathways. A number of pathways were highlighted, the MAP 
kinase pathway showing, Fos and PDGF dysregulated genes specifically to fALS-
TARDBP missense mutation while IL1 was specifically to the fALS-TARDBP 
truncated mutation (Figure 5.7). Furthermore, the cytokine-cytokine receptor 
interaction pathway was demonstrated, PDGFB was a dysregulated gene 
specific to the fALS-TARDBP missense mutation and CCL2, BMP7 and IL1B 
genes were specific to the fALS-TARDBP truncated mutation, TNFRSF11B was 
found a common gene in both mutations (Figure 5.8). 
 
Two pathways specfic to the fALS-TARDBP truncated mutation were 
dysregulated, the TGF beta signalling pathway showing, BMP4 and  BMP7 
dysregulated gene specifically and the VEGF signalling pathway showing, NOS3 
and PTGS2 dysregulated gene (Figure 5.9 and 5.10). 
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Table 5.12: Genes involved in response to steroid hormone stimulus in the 
cytoplasmic truncation mutation 
 
Gene 
symbol 
Gene name  P-value Fold 
change  
ADM Adrenomedullin 0.01 2.43 
ALDH1A2 Aldehyde dehydrogenase 1 family, 
member A2 
0.01 
 
3.88 
ARNT2 Aryl-hydrocarbon receptor nuclear 
translocator 2 
0.05 -1.53 
A2M Alpha-2-macroglobulin 0.002 6.06 
BCHE Butyrylcholinesterase 0.01 23.48 
BMP4 Bone morphogenetic protein 4 0.002 43.56 
BMP7 Bone morphogenetic protein 7 0.01 16.66 
CCL2 Chemokine (C-C motif) ligand 2 0.04 2.78 
CCND2 Cyclin D2 0.006 3.48 
CDKN1A Cyclin-dependent kinase inhibitor 
1A (p21, Cip1) 
0.01 
 
2.14 
CPS1 Carbamoyl-phosphate synthetase 
1, mitochondrial 
0.001 
 
-2.76 
CTTNBP2 Cortactin binding protein 2 0.03 -12.17 
CYP11A1 Cytochrome P450, family 11, 
subfamily A, polypeptide 1 
0.03 2.42 
 
ESR1 Estrogen receptor 1 0.04 -3.79 
GPX4 Glutathione peroxidase 4 
(phospholipid hydroperoxidase) 
0.02 2.02 
 
GSTM3 Glutathione S-transferase mu 3 
(brain) 
1.70603E-05 
 
3.83 
 
IL1B Interleukin 1, beta 0.003 4.27 
MSTN Myostatin 0.01 3.83 
NOS3 Nitric oxide synthase 3 (endothelial 
cell) 
0.009 
 
-7.83 
OXT Oxytocin, prepropeptide 0.002 49.14 
PTGS2 Prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
0.016 
 
-4.68 
TNFRSF11
B 
tumor necrosis factor receptor 
superfamily, member 11b 
7.46286E-05 
 
2.70 
 
WFDC1 WAP four-disulfide core domain 1 0.0001 26.02 
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Figure 5.6: Comparative analysis of the steroid hormone differentially expressed genes in MT 
and TT mutations. Venn diagram showing 13 genes specific to response to steroid hormone 
stimulus in fALS-TARDBP missense mutation while 18 genes were specific to fALS-TARDBP 
truncated mutation and 5 genes were in common. 
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Figure 5.7: MAP kinase pathway showing, Fos and PDGF dysregulated gene specifically to fALS-TARDBP missense mutation and IL1 specifically to the 
fALS-TARDBP truncated mutation. Thus, the MAP kinase pathway is possibly a common dysregulated pathway in both mutation types. 
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Figure 5.8: Cytokine- cytokine receptor interaction pathway showing, PDGFB dysregulated gene specifically to fALS-TARDBP missense mutation and CCL2, 
BMP7, IL1B genes specifically to the fALS-TARDBP truncated mutation. TNFRSF11B is a common gene in both mutations. Thus, the cytokine- cytokine receptor 
interaction pathway is possibly a common dysregulated pathway in both mutation types.   
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Figure 5.9: TGF beta signalling pathway showing, BMP4, BMP7 dysregulated gene in TARDBP truncated mutation. This may suggest that the TGF beta 
signalling pathway is dysregulated in fALS-TARDBP truncated mutation.
269 
 
 
 
 
Figure 5.10: VEGF signalling pathway showing, NOS3 and PTGS2 dysregulated gene specifically to TARDBP truncated mutation. This may suggest that the 
VEGF signalling pathway is dysregulated in fALS-TARDBP truncated mutation.
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5.3.2.4 Blood vessel development 
 
 
The biological process blood vessel development was also shown to be 
dysregulated in the fALS-TARDBP truncated mutation with the majority of genes 
being up-regulated (Table 5.13). A further discussion of the dysregulated genes 
is shown below. 
 
Rho GTPase activating protein 24 (ARHGAP24) was down-regulated (FC=-1.9). 
ARHGAP24 regulates endothelial cell migration and proliferation. Mice knocked-
down for the ARHGAP24 gene showed a suppression of endothelial cell 
migration and proliferation. This strongly supports the association of ARHGAP24 
with angiogenesis (Su et al., 2004). The tumour necrosis factor (ligand) 
superfamily, member 12 (TNFSF12) was increased (FC=1.9). The encoded 
cytokine is involved in angiogenesis by mediating endothelial cell migration and 
proliferation. Also it may initiate cell death by activating apoptotic pathways 
(Chicheportiche et al., 1997, Lynch et al., 1999). In addition the EGF-like-domain, 
multiple 7 (EGFL7) was elevated (FC=2.5). EGFL7 is also known as vascular 
endothelial statin has a role in promoting vasculogenesis (Parker et al., 2004). 
The mesenchyme homeobox 2 (MEOX2) was up-regulated (FC=5). MEOX2 has 
been shown to be involved in vascular differentiation. It was also previously 
suggested to be linked with Alzheimer’s disease (Gorski et al., 1993, Wu et al., 
2005). The transforming growth factor, alpha (TGFA) was up-regulated (FC=8). 
TGFA is a signalling molecule that activates pathways involved in proliferation, 
differentiation and angiogenesis (Singh and Coffey, 2014). Also the anti-
angiogenic factor, collagen, type XV (COL15A1), alpha 1, (COL15A1) was 
increased (FC=2) (Sasaki et al., 2000). In addition, the plasminogen activator, 
tissue (PLAT) was up-regulated (FC=2). PLAT is produced by the vascular 
endothelial cells which is considered a fibrinolytic enzyme that converts 
plasminogen to plasmin maintaining blood viscosity (Ny et al., 1984).  
 
Three fibroblast growth factors were up-regulated. These proteins have diverse 
cellular functions which are best characterized as mitogenic and especially during 
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embryonic development. Each of these genes were found to predominate in 
function in particular tissues, the fibroblast growth factor 10 (FGF10) was shown 
to have a role in keratinocyte development (FC=8.6) and was up-regulated (Sun 
et al., 2015). Also the fibroblast growth factor 18 (FGF18) was shown to 
participate in  bone and cartilage synthesis (FC=5) (Moore et al., 2005). Whilst 
the fibroblast growth factor 9 (glia-activating factor) (FGF9) was shown to function 
as male sex determining factor (FC=2.8) (Colvin et al., 2001). Two transcription 
factors that belong to the T-box family were up-regulated, the T-box 1(TBX1) 
(FC=4.5) which is involved in the maturation of normal arterial blood. Mutant 
TBX1 in mice showed phenotypic features of DiGeorge syndrome (Jerome and 
Papaioannou, 2001). Also, the T-box 4 (TBX4) was increased (FC=10.5). T-box 
4 is essential for the development of the lower limbs. A TBX4 mutation was 
associated small patella syndrome (SPS) (Agulnik et al., 1996, Bongers et al., 
2004). Furthermore, genes involved in cell proliferation and migration were up-
regulated. The Thy-1 cell surface antigen (THY1) was increased (FC=2). THY1 
was shown to mediate cell differentiation, proliferation and apoptosis. It is also 
involved in adhesion and was considered a tumour suppressor for ovarian cancer 
(Lung et al., 2005, Rege and Hagood, 2006). Also, the bone morphogenetic 
protein 4 (BMP4) which is important for the development of bone and cartilage 
synthesis was up-regulated (FC=43.5) (Bakrania et al., 2008). Also, the epithelial 
mitogen homolog (mouse) (EPGN) was increased (FC=12). EPGN binds to the 
epidermal growth factor receptor which activates cell migration and proliferation 
signalling pathways (Herbst and Bunn, 2003).  
 
The adrenergic, alpha-1B-, receptor (ADRA1B) was up-regulated (FC=3). 
ADRA1B is a G protein-coupled receptor which is capable of binding to the 
phospholipase C enzyme to facilitate the hydrolysis of the compound 
phosphatidylinositol 4, 5-bisphosphate into diacylglycerol and inositol 1,4,5-
trisphosphate. Both diacylglycerol and inositol 1, 4, 5-trisphosphate act as second 
messengers that activate other proteins in the cell. One of the outcomes of the 
activation of these molecules is the elevation of Ca++ ion concentration in the 
cytoplasm along with protein kinases. The phospholipase C, delta 3 (PLCD3) was 
also shown to be increased (FC=1.7) (Haenisch et al., 2010, Jungmichel et al., 
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2014). Finally, the proinflammatory cytokine interleukin 1, beta (IL1B) was also 
up-regulated (FC=4). 
In contrast, a lower number of genes involved in blood vessel development were 
down-regulated. The vasodilator enzyme nitric oxide synthase 3 (endothelial cell) 
(NOS3) was shown to be down-regulated (FC=-7.8) (Dasar et al., 2012). 
Furthermore, the hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor) (HIF1A) was reduced (FC=-1.8). HIF1A is a transcription 
factor that is induced in response to oxygen levels. It is involved in transcribing 
several gene associated with angiogenesis such as erythropoietin and VEGF 
(Lee et al., 2004). In addition, endothelial cell-specific chemotaxis regulator 
(ECSCR) was down-regulated (FC=-6.6). The encoded gene is capable of 
initiating endothelial cell signalling transduction which promotes cell migration 
(Verma et al., 2010). The Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of 
VLA-4 receptor) (ITGA4) was decreased (FC=-3.5). It was suggested that ITGA4 
is involved in endothelial cell adhesion and proliferation (Garmy-Susini et al., 
2005). The inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 
(ID1) was reduced (FC=-3). The ID1 is a member of the Inhibitor of DNA binding 
family which they inhibit DNA transcription by binding to the transcription factors 
(Lyden et al., 1999). Moreover, neuropilin 2 (NRP2) was down-regulated (FC=-
3.7). It has been reported that the NRP2 receptors were involved in neuronal 
migration during brain development by determining their destinations. Neurons 
that express NRP2 were shown to be directed to the cortex region (Marin et al., 
2001).  
 
Comparing the genes related to angiogenesis in the cytopasmic missense 
mutation to the genes related to blood vessel development in truncated mutation 
revealed that the majority of genes were distinct to each muation with only five 
gene being shared, COL15A1, TBX4, TGFA, THY1 and TNFSF12 (Figure 5.11).  
It was shown that genes involved in angiogenesis and blood vessel development 
were dysregulated and mostly up-regulated in the fALS-TARDBP missense 
mutation and truncated mutation respectively. It was interesting to find if any of 
the genes form both mutations belonged to similar or distinct pathway. Thus, 
genes from both mutations were combined then uploaded into DAVID and KEGG 
pathway was generated in order to identify the significant pathways. It was shown 
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that FGF9, FGF10, FGF18 and IL1B from the fALS-TARDBP truncated mutation 
were dysregulated in the MAP signalling pathway (Figure 5.12). None of the 
genes from the missense mutation list belonged to a particular pathway.  
 
 
 
Table 5.13: Genes involved in blood vessel development in the cytoplasmic 
truncation mutation  
 
Gene 
symbol 
Gene name  P-value Fold 
change  
ADRA1B Adrenergic, alpha-1B-, receptor 0.04 3.42 
ARHGAP24 Rho GTPase activating protein 24 0.02 -1.90 
BMP4 Bone morphogenetic protein 4 0.002 43.56 
COL15A1 Collagen, type XV, alpha 1 0.04 2.30 
ECSCR Endothelial cell-specific chemotaxis 
regulator 
0.01 -6.62 
EGFL7 EGF-like-domain, multiple 7 0.01 2.56 
EPGN Epithelial mitogen homolog (mouse) 0.002 12.21 
FGF9 Fibroblast growth factor 9 (glia-
activating factor) 
0.01 2.84 
 
FGF10 Fibroblast growth factor 10 0.01 8.64 
FGF18 Fibroblast growth factor 18 0.01 5.45 
HIF1A Hypoxia inducible factor 1, alpha 
subunit (basic helix-loop-helix 
transcription factor) 
0.01 
 
-1.84 
 
ID1  Inhibitor of DNA binding 1, dominant 
negative helix-loop-helix protein 
0.02 
 
-3.36 
 
IL1B Interleukin 1, beta 0.003 4.27 
ITGA4 Integrin, alpha 4 (antigen CD49D, 
alpha 4 subunit of VLA-4 receptor) 
0.001 
 
-3.53 
 
MEOX2 Mesenchyme homeobox 2 0.04 5.04 
NOS3 Nitric oxide synthase 3 (endothelial 
cell) 
0.009 -7.83 
NRP2 Neuropilin 2 0.008 -3.79 
PLAT Plasminogen activator, tissue 0.03 2.06 
PLCD3 Phospholipase C, delta 3 0.03 1.79 
TBX1 T-box 1 0.002 4.55 
TBX4 T-box 4 0.04 10.59 
THY1 Thy-1 cell surface antigen 0.002 2.23 
TGFA Transforming growth factor, alpha 0.007 8.20 
TGFBR3 Transforming growth factor, beta 
receptor III 
0.002 2.45 
TNFSF12 Tumor necrosis factor (ligand) 
superfamily, member 12 
0.01 
 
1.98 
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Figure 5.11: Comparative analysis of the angiogenesis/blood vessel development differentially 
expressed genes in both MT and TT mutations. Venn diagram showing 9 genes specific to 
angiogenesis in fALS-TARDBP missense mutation while 20 genes were specific to blood vessel 
development in fALS-TARDBP truncated mutation and 5 genes were in common. 
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Figure 5.12: MAP kinase pathway showing, FGF9, FGF10, FGF18 and IL1B dysregulated gene specifically to TARDBP truncated mutation. MAP kinase 
pathway perhaps a dysregulated pathway in fALS-TARDBP truncated mutation.
276 
 
5.3.2.5 Vesicle-mediated transport 
 
The axonal transport system in neuronal cells is mediated by the motor proteins, 
kinesins and dyneins, which are essential molecules for cargo, organelle and 
vesicle movement along the axon in both directions i.e. anterograde and 
retrograde. Studies showed that defective axonal transport is strongly linked to 
ALS. Here, it is shown that the largest number of dysregulated genes were related 
to vesicle-mediated transport in the fALS-TARDBP truncated mutation (Table 
5.14). A further elucidation of the genes involved is described below. 
 
Clathrins are a family of protein receptors that mediate endocytosis via receptor 
mediated endocytosis. Two genes belonging to the clathrins were up-regulated.  
The adaptor-related protein complex 1, mu 2 subunit (AP1M2) (FC=10). AP1M2 
is expressed mainly in the epithelium and is involved in cargo endocytosis from 
the plasma membrane to the Golgi apparatus where molecules are modified 
(Robinson and Pimpl, 2014). Also the clathrin light chain subunit, clathrin, light 
chain (Lcb) (CLTB) was increased (FC=2) (Wu et al., 2016). Furthermore, three 
members of the vesicle associated membrane proteins that are involved in the 
docking and fusion process of the synaptic vesicles were increased, vesicle-
associated membrane protein 2 (synaptobrevin 2) (VAMP2) (FC=1.6), vesicle-
associated membrane protein 5 (myobrevin) (VAMP5) (FC=2) and syntaxin 8 
(STX8) (FC=1.7) (McNew et al., 2000). Protein kinase C and casein kinase 
substrate in neurons 3 (PACSIN3) was increased (FC=2.5). PACSIN3 is involved 
in vesicle trafficking by associating  the actin filaments with the vesicles (Roach 
and Plomann, 2007).  
 
Membrane associated ring-CH proteins are enzymes that are involved in protein 
degradation by adding ubiquitin to the lysine residues of protein molecules. As a 
result, signalling pathways which end by protein elimination are activated. 
Recently, these proteins were shown to be involved in other functions such as 
endocytosis and protein transport (Samji et al., 2014). Two members of the 
membrane associated ring-CH proteins were up-regulated, membrane-
associated ring finger (C3HC4) 2 (MARCH2) (FC=1.8) and membrane-
associated ring finger (C3HC4) 3 (MARCH3) (FC=2.6). The coatomer protein 
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complex, subunit zeta 2 (COPZ2) was also up-regulated (FC=1.7). COPZ2 is part 
of the coatomer protein complex which is involved in the synthesis of the coat 
protein I (COPI). COPI is essential for Golgi-to-ER retrograde transport 
(Moelleken et al., 2007). Also the regulating synaptic membrane exocytosis 
1(RIMS1) gene which creates a scaffold with other exocytotic proteins that 
mediate vesicles release at the synaptic cleft was increased (FC=3) (Schoch et 
al., 2002). The chemokine (C-X-C motif) ligand 16 (CXCL16) was increased 
(FC=2.6). CXCL16 is a cytokine that is a member of the CXC chemokine family. 
CXCL16 is involved in leukocyte trafficking. Also it is activated in angiogenesis 
and is activated in immune response (Zlotnik and Yoshie, 2000). 
 
 
The B-cell receptor-associated protein 31 (BCAP31) was up-regulated (FC=1.5) 
BCAP31 is expressed on the surface of the endoplasmic reticulum and highly 
expressed in neurons. It is involved in vesicle export and also directs defective 
proteins to the degradation pathway (Cacciagli et al., 2013). Also, the low density 
lipoprotein receptor-related protein associated protein 1 (LRPAP1) was increased 
(FC=2). This protein is the ligand for the low density lipoprotein (LDL) receptor. 
LRPAP1 binds to members of the low density lipoprotein receptor family and 
interferes with the other ligand molecules to bind to the low density lipoprotein 
receptor (Korenberg et al., 1994). The naked cuticle homolog 2 (Drosophila) 
(NKD2) was up-regulated (FC=9).  
 
The encoded protein negatively regulated Wnt receptor signalling (Wharton et al., 
2001). Moreover, the v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
(HRAS) was increased (FC=10.6). HRAS is a GTPase enzyme that is activated 
under the influence of growth factors. Therefore, it is involved in cell proliferation 
and growth though the activation of the MAPK signalling pathway (Zhang et al., 
2006). The glutamate receptor, ionotropic, AMPA 1 (GRIA1) was up-regulated 
(FC=2.8). GRIA1 encodes for the ionotropic AMPA 1 receptor that is activated 
upon the binding to glutamate which stimulate the opening of the ion channels in 
the neuronal cells (Anggono and Huganir, 2012). Also the amyloid beta (A4) 
precursor-like protein 1 (APLP1) was increased (FC=3). APLP1 encodes for the 
membrane bound glycoprotein which is similar in structure to the  amyloid beta 
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precursor the hallmark for AD (Guilarte, 2010). The ferritin light polypeptide (FTL) 
was increased (FC=1.8). The gene encodes for the light peptide chain of the iron 
storage protein ferritin (Carmona et al., 2014). 
 
In contrast, a group of genes were down-regulated. Four genes associated with 
the COPII-coated vesicles that are involved in the protein transport were down-
regulated, SEC24 family, member A (S. cerevisiae) (SEC24A) (FC=-1.7), SEC24 
family, member D (S. cerevisiae) (SEC24D) (FC=-2), SEC23 homolog A (S. 
cerevisiae) (SEC23) (FC=-1.7) and the ADP-ribosylation factor GTPase 
activating protein (ARFGAP1) (FC=-1.9) (Bigay et al., 2003, Mancias and 
Goldberg, 2008). Also, the USO1 homolog, vesicle docking protein (yeast) 
(USO1) was reduced (FC= -1.5). This protein was shown to bind to the COP2 
which mediates vesicle exiting from the endoplasmic reticulum and targeting to 
the Golgi apparatus (Allan et al., 2000). 
 
Furthermore, the component of oligomeric Golgi complex 3 (COG3) was 
decreased (FC=-1.7). COG3 is a member of the conserved oligomeric Golgi 
complex which is essential for glycoprotein modifications and transport (Ungar et 
al., 2002). Also the dedicator of cytokinesis 1 (DOCK1) was decreased (FC=-2.8). 
DOCK1 is a protein that controls the Rac-GTPase enzyme during the G-protein 
activation through signalling transduction. Therefore, it is involved in several 
processes including phagocytosis (Bagci et al., 2014). The dopey family member 
1(DOPEY1) was reduced (FC=-2). DOPEY1 was suggested to be involved in 
vesicle transport within the cell (Tanaka et al., 2014). Moreover, the kinesin family 
member 20A (KIF20A) was down-regulated (FC=-4.7). As has been stated 
previously kinesins are proteins that mediate the movement of cellular organelles 
including vesicles within the cell (Bosco et al., 2010). 
 
Four genes related to clathrins were down-regulated. The phosphatidylinositol 
binding clathrin assembly protein (PICALM) was decreased (FC=-1.5). It is 
involved in the clathrin-vesicle assembly which mediates endocytosis. Reduced 
levels of PICALM have been associated with AD (Thomas et al., 2016). Also, the 
clathrin interactor 1 (CLINT1) was reduced (FC=-2). CLINT1 is part of the clathrin-
coated vesicles which are involved in retrograde transport from the endosomes 
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to the trans-Golgi (Saint-Pol et al., 2004). The two other genes were component 
of the clathrin-coated vesicles which facilitate the transport of proteins from the 
plasma membrane to the Golgi apparatus and hence to the lysosomes were 
down-regulated, adaptor-related protein complex 1, gamma 1 subunit (AP1G1) 
(FC=-1.7) and adaptor-related protein complex 3, beta 2 subunit (AP3B2) (FC=-
6) (Robinson and Bonifacino, 2001). Furthermore, the dynamin 1 (DNM1) gene 
was down regulated (FC=-1.7). It was suggested that dynamin 1 is an essential 
protein for the dissociation of the newly formed endocytosed vesicle from the 
plasma membrane (Razzaq et al., 2001). Also, the protein amphiphysin (AMPH) 
was decreased (FC=-3) which has been suggested to play a role in directing the 
DNM1 protein to the site of vesical cleavage (Razzaq et al., 2001). In addition, 
the Ca++-dependent secretion activator 2 (CADPS2) was reduced (FC=-4). 
CADPS2 mediates exocytosis of vesicles and has been suggested to be 
associated with autism. CADPS2-/- mice showed phenotypic characteristics 
similar to autism (Sadakata et al., 2007). 
 
Huntingtin (HTT) was reduced (FC=-1.7). HTT is a nuclear protein that is involved 
in regulating gene expression by binding to transcription factors. Mutations in this 
gene cause Huntington’s disease (Futter et al., 2009). Two cellular receptors 
were down-regulated. The adenosine A2a receptor (ADORA2A) was one (FC=-
11). ADORA2A is a G protein coupled receptor which was shown to increase 
cAMP levels. Therefore, it has a role in cardiac rhythm, inflammation and blood 
flow (Raskovalova et al., 2005). Also, the low density lipoprotein receptor-related 
protein 4 (LRP4) (FC=-2). Also known as multiple epidermal growth factor-like 
domains 7, it was shown to be strongly associated with the activation of the Wnt 
signalling pathway (Barik et al., 2014).  
 
Other genes that were involved in protein trafficking were down-regulated. ADP-
ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited) 
(ARFGEF2) (FC=-2), phosphoinositide kinase, FYVE finger containing 
(PIKFYVE) (FC=-1.7), Golgi associated PDZ and coiled-coil motif containing 
(GOPC) (FC=-1.7), zinc finger, FYVE domain containing 16 (ZFYVE16) (FC=-
1.6), the N-ethylmaleimide-sensitive factor attachment protein, gamma (NAPG) 
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(FC=-1.6), secretory carrier membrane protein 5 (SCAMP5) (FC=-3.9) and 
synuclein, alpha (non A4 component of amyloid precursor) (SNCA) (FC=-5).  
 
Three genes were grouped by DAVID under vesicle-mediated transport which 
were more related to the immune response. The elastase, neutrophil expressed 
(ELANE) was increased (FC=8). ELANE is an enzyme that is secreted by the 
neutrophils and monocytes as a response to inflammation (Chua and Laurent, 
2006). Also, the pentraxin-related gene, rapidly induced by IL-1 beta (PTX3) was 
elevated (FC=2). PTX3 is an acute phase protein which is has a major role in 
immune defense against pathogens (Bozza et al., 2006). Furthermore, the CD36 
molecule (thrombospondin receptor) (CD36) was increased (FC=14). CD36 is an 
integral membrane protein that is expressed on different types of cells and 
capable to bind to several ligands, therefore can activate diverse cellular 
pathways such as: atherogenesis, lipid metabolism and inflammation (Park, 
2014). 
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Table 5.14: Genes involved in vesicle-mediated transport in the cytoplasmic 
truncation mutation  
 
Gene 
symbol 
Gene name  P-value Fold 
change  
ADORA2A Adenosine A2a receptor 0.04 -11.40 
AMPH Amphiphysin 0.009 -3.12 
AP1G1 Adaptor-related protein complex 1, 
gamma 1 subunit 
0.02 
 
-1.77 
 
AP1M2 Adaptor-related protein complex 1, mu 2 
subunit 
0.04 
 
10.40 
 
AP3B2 Adaptor-related protein complex 3, beta 
2 subunit 
0.04 
 
-6.18 
 
APLP1 Amyloid beta (A4) precursor-like protein 
1 
0.01 3.12 
ARFGAP1 ADP-ribosylation factor GTPase 
activating protein 1 
0.04 
 
-1.96 
 
ARFGEF2 ADP-ribosylation factor guanine 
nucleotide-exchange factor 2 (brefeldin 
A-inhibited) 
0.006 
 
-2.06 
 
BCAP31 B-cell receptor-associated protein 31 0.04 1.56 
BLOC1S1 Biogenesis of lysosomal organelles 
complex-1, subunit 1 
0.02 
 
1.81 
 
CADPS2 Ca++-dependent secretion activator 2 0.01 -4.22 
CD36 CD36 molecule (thrombospondin 
receptor) 
0.001 14.46 
CLINT1 Clathrin interactor 1 0.006 -2.04 
CLTB Clathrin, light chain (Lcb) 0.006 2.05 
COG3 Component of oligomeric golgi complex 
3 
0.04 -1.71 
COPZ2 Coatomer protein complex, subunit zeta 
2 
0.01 1.74 
CXCL16 Chemokine (C-X-C motif) ligand 16 0.04 2.62 
DOCK1 Dedicator of cytokinesis 1 0.01 -2.82 
DOPEY1 Dopey family member 1 0.02 -2.44 
DNM1 Dynamin 1 0.03 -1.79 
ELANE Elastase, neutrophil expressed 0.002 8.22 
FTL Ferritin, light polypeptide 0.03 1.89 
GOPC Golgi associated PDZ and coiled-coil 
motif containing 
0.02 -1.77 
GRIA1 Glutamate receptor, ionotropic, AMPA 1 0.006 2.80 
HRAS v-Ha-ras Harvey rat sarcoma viral 
oncogene homolog 
0.04 
 
10.61 
 
HTT Huntingtin 0.03 -1.71 
KIF20A Kinesin family member 20A 0.004 -4.74 
LRP4 Low density lipoprotein receptor-related 
protein 4 
0.04 -2.08 
LRPAP1 Low density lipoprotein receptor-related 
protein associated protein 1 
0.02 2.04 
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LRRN3 Leucine rich repeat neuronal 3 0.01 5.92 
MARCH2 Membrane-associated ring finger 
(C3HC4) 2 
0.03 1.81 
MARCH3 Membrane-associated ring finger 
(C3HC4) 3 
0.01 2.64 
MON2 MON2 homolog (S. cerevisiae) 0.04 -2.15 
NAPG N-ethylmaleimide-sensitive factor 
attachment protein, gamma 
0.04 
 
-1.60 
 
NKD2 Naked cuticle homolog 2 (Drosophila) 0.04 9.29 
NME2 Non-metastatic cells 1, protein (NM23A) 
expressed in; NME1-NME2 readthrough 
transcript; non-metastatic cells 2, protein 
(NM23B) expressed in 
0.02 
 
-3.41 
 
PACSIN3 Protein kinase C and casein kinase 
substrate in neurons 3 
0.0006 
 
2.52 
 
PICALM Phosphatidylinositol binding clathrin 
assembly protein 
0.04 
 
-1.57 
 
PIKFYVE Phosphoinositide kinase, FYVE finger 
containing 
0.04 
 
-1.72 
 
PTX3 Pentraxin-related gene, rapidly induced 
by IL-1 beta 
0.02 2.02 
RIMS1 Regulating synaptic membrane 
exocytosis 1 
0.01 3.02 
SCAMP5 Secretory carrier membrane protein 5 0.005 -3.97 
SEC23A SEC23 homolog A (S. cerevisiae) 0.04 -1.75 
SEC24A SEC24 family, member A (S. cerevisiae) 0.02 -1.75 
SEC24D SEC24 family, member D (S. cerevisiae) 0.004 -2.09 
SNCA Synuclein, alpha (non A4 component of 
amyloid precursor) 
0.01 
 
-5.08 
 
STON1-
GTF2A1L 
Stonin 1; STON1-GTF2A1L readthrough 
transcript; general transcription factor 
IIA, 1-like 
0.04 
 
10.40 
 
STX8 Syntaxin 8 0.03 1.74 
USO1 USO1 homolog, vesicle docking protein 
(yeast) 
0.03 -1.58 
 
VAMP2 Vesicle-associated membrane protein 2 
(synaptobrevin 2) 
0.01 
 
1.68 
 
VAMP5 Vesicle-associated membrane protein 5 
(myobrevin) 
0.01 
 
2.11 
 
ZFYVE16 Zinc finger, FYVE domain containing 16 0.03 -1.69 
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5.3.3 Comparative analysis of differentially expressed genes in the 
cytoplasmic fractions of missense and truncation TARDBP mutation 
 
It was interesting to identify which genes belonged to each mutation type and 
which were common in all of the fALS-TARDBP cases examined. Therefore, a 
venn diagram was generated using the online GeneVenn programme (Figure 
5.13). The venn diagram showed 609 differentially expressed genes were 
specific to the missense mutation, 1178 differentially expressed genes were 
specific to the truncated mutation and 259 genes were common. The genes were 
explored using the DAVID analysis tool. The fALS-TARDBP missense mutation 
showed that the largest number of genes were belonged to cell adhesion while 
the fALS-TARDBP truncated mutation showed the highest enriched and largest 
number of genes were found in vesicle-mediated transport. A small group of the 
common genes were related to response to organic substance (Tables 5.15, 5.16 
& 5.17). Therefore, it is clearly shown that distinct biological processes affected 
by the two types of mutation in fALS-TARDBP within the cytoplasmic fraction. 
 
 
 
 
Figure 5.13: Comparative analysis of differentially expressed genes in the cytoplasmic fractions 
of missense and truncation TARDBP mutation. Venn diagram showing 609 genes specific to the 
cytoplasmic missense mutation, 1178 genes specific to the cytoplasmic truncation mutation and 
259 genes were found common in both types of mutations.  
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Table 5.15: Functionally enriched biological processes generated by DAVID of 
cytoplasmic specific missense mutation genes. GO= gene ontology, 
no.=number, ES=Enrichment score 
 
GO  Biological process Gene 
no. 
P-value ES 
BP_FAT In utero embryonic development 11 1.3E-2 3.04 
BP_FAT Cell adhesion 30 4.9E-3 2.86 
BP_FAT Response to endogenous 
stimulus 
27 9.6E-6 2.84 
BP_FAT Regulation of RNA metabolic 
process 
61 1.2E-2 2.32 
BP_FAT Pattern specification process 18 3.7E-4 1.81 
BP_FAT Tube development 18 1.2E-4 1.55 
BP_FAT Cytoskeleton organization 20 1.3E-2 1.52 
BP_FAT Kidney development 7 3.2E-2 1.35 
BP_FAT Angiogenesis 9 3.1E-2 1.32 
 
 
Table 5.16: Functionally enriched biological processes generated by DAVID of 
cytoplasmic specific truncated mutation genes. GO= gene ontology, 
no.=number, ES=Enrichment score  
 
GO  Biological process Gene 
no. 
P- value ES 
BP_FAT Vesicle-mediated transport 46 3.2E-3 2.43 
BP_FAT Stem cell differentiation 7 5.1E-3 2.39 
BP_FAT Positive regulation of cell 
cycle 
12 3.2E-2 2.12 
BP_FAT Response to organic 
substance 
28 3.8E-2 2.05 
BP_FAT Regulation of cytokine 
production 
7 1.4E-3 1.81 
 
Table 5.17: Functionally enriched biological processes generated by DAVID of 
the cytoplasmic common genes. GO= gene ontology, no.=number, 
ES=Enrichment score 
 
GO  Biological process Gene no. P-value ES 
BP_FAT Response to organic 
substance 
15 1.4E-2 1.65 
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5.4 Discussion 
 
RNA sequencing has been shown to provide more accurate and precise detection 
and measurements of the transcriptome as it can identify mutations, alternative 
splicing and posttranscriptional modifications (Morozova and Marra, 2008). RNA 
sequencing was performed on the cytoplasmic fALS-TARDBP missense 
mutation and truncated mutation in order to generate an in depth understanding 
of the effect of mutant TDP-43 from both types of mutation and to confirm 
previous genes identified as deregulated by the other experimental paradigms; 
the Human Exon 1.0 ST Array and the HTA.  
 
In the present study, three biological repeats from patients and controls age and 
gender matched were studied. The differentially expressed genes in the 
cytoplasm of fALS-TARDBP missense mutation and truncated mutation were 
grouped into biological processes using the online DAVID analysis tool. Figure 
5.14 shows a diagram that demonstrates the significantly identified biological 
processes in both mutations.  The response to steroid hormone stimulus and 
angiogenesis / blood vessel development were the biological processes that are 
present in both cytoplasmic fALS-TARDBP mutations therefore they are 
discussed together below. However, the rest of the biological processes are 
discussed further individually in respect to each type of mutation.  
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Figure 5.14: A diagram illustrating significantly identified biological processes. (A) Cytoplasmic 
fALS-TARDBP MT and (B) Cytoplasmic fALS-TARDBP TT. MT=missense mutation, TT 
truncation mutation. 
 
 
 
 
 
5.4.1 Biological processes presented in both cytoplasmic fALS-TARDBP 
MT and TT mutations 
 
5.4.1.1 Response to steroid hormone stimulus 
 
As the incidence of patients diagnosed with ALS is higher in males than in 
females, several studies suggested the role of steroid sex hormones in the 
pathogenesis of ALS (Jones, 1988). A qualitative analysis was performed on 
female ALS patients which showed that the longer exposure to oestrogen 
throughout life was associated with a higher survival rate compared to females 
with lower exposure to oestrogen (de Jong et al., 2013). Furthermore, the serum 
levels of free testosterone hormone was reported to be significantly lower in ALS 
male patients than in controls (Militello et al., 2002). Patacchioli et al., assessed 
the adrenal activity of ALS patients by measuring the salivary cortisol levels which 
were reported to be higher in ALS patients that controls (Patacchioli et al., 2003). 
Also, morning cortisol plasma levels were shown to be higher in ALS patients 
(Spataro et al., 2015). In addition, ALS mouse models showed dysregulated 
hormonal changes. An elevated level of serum corticosterone was observed in 
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SOD1G93A transgenic mice (Fidler et al., 2011). Reduced plasma levels of 
testosterone and elevated levels of corticosterone were observed in Wobbler 
mouse (Deniselle et al., 2016). Therefore, a disrupted endocrine system is 
suggested to be associated with ALS and may account of the higher incidence of 
ALS in males compared to females.  
 
Steroid hormones are lipid soluble molecules that are able to diffuse through the 
plasma membrane and bind to the targeted receptor forming hormone-receptor 
complexes that are able to induce gene expression change (Schwartz et al., 
2016). In the current study, dysregulated genes related to steroid hormones were 
demonstrated. The highest significantly up-regulated genes in fALS-TARDBP 
missense mutation were BCHE, WFDC1, GATA3, GFBP2, PDGFB and SST 
while the highest increased genes in the fALS-TARDBP truncated mutation were 
BCHE, WFDC1, BMP4, BMP7 and OXT. In contrast, the significantly down-
regulated genes in fALS-TARDBP missense mutation were SERPINA1 and 
SLC6A1. However, in fALS-TARDBP truncated mutation these were CTTNBP2 
and NOS3. It would be interesting to further investigate the hormonal status of 
fALS patients in the present study (if available) at the time of skin biopsy collection 
and/or clinical history of hormonal measurements during their lifetime. This may 
help to obtain an indication of how these genes were influenced by hormones.  
 
However, the literature shows that some of the dysregulated genes in the present 
study have been investigated previously and were related to steroid hormone 
changes. The BCHE enzyme levels were studied in chick enterocytes in both 
gender types. Interestingly, BCHE enzyme level was significantly higher in 
females than males. This may suggest the involvement of sex hormones in BCHE 
expression (Sine et al., 1991). Also, the same observation was demonstrated in 
female rats which showed higher BCHE plasma levels than males (Alves-Amaral 
et al., 2010). Furthermore, the marked elevation of BCHE in the current study 
may indicate that more cleavage of the neurotransmitter acetylcholine is 
occurring in the motor neurons (Greig et al., 2002a). 
 
 
288 
 
Moreover, the GFBP2 was shown also to be markedly increased. A study has 
shown that under the influence of high oestrogen levels the GFBP2 expression 
in rat hippocampus was significantly increased compared to controls (Takeo et 
al., 2009). 
 
Also an elevated levels of GFBP2 in spinal motor neurons was shown in sALS 
(Wilczak et al., 2003). Moreover, Zhang et al., reported that TARDBPA315T mice 
model demonstrated a hyperactive SST in the cortical region of the mice model 
brain which may have a role in motor neurons excitotoxicity observed in the 
disease (Zhang et al., 2016). The SST gene was also shown to be elevated in 
fALS-TARDBP missense mutation. The OXT was shown to be markedly 
increased in the fALS-TARDBP truncated mutation.  OXT  expression was shown 
to be influenced by oestrogen (Ivell and Walther, 1999).  
 
In the current study, the majority of genes that were influenced by steroid 
hormones were markedly increased with only five genes being shared, BCHE, 
WFDC1, CCND2, GSTM3 and TNFRSF11B. Although both mutations were 
harbouring the same biological processes, distinct genes were observed. Thus, 
it may be suggested that fALS-TARDBP patients should not be treated similarly 
as the underlying affected pathways may be different. 
 
5.4.1.2 Angiogenesis / Blood vessel development 
  
The current literature illustrates that defective genes related to angiogenesis have 
been strongly associated with ALS (Oosthuyse et al., 2001, Gao and Xu, 2008). 
Also, the chapter 4: HTA experiment showed genes associated to angiogenesis 
in both fALS-TARDBP mutation types being dysregulated (Refer to section 
4.9.1.1). Here, using RNA sequencing technology to study gene expression in 
both mutations revealed angiogenesis / blood vessel development biological 
processes to be affected with a higher number of dysregulated gene and 
significantly higher fold changes compared to HTA. 
 
Oosthuyse et al., reported that the deletion of the hypoxia-response element of 
the  VEGF gene in a mouse model resulted in low expression of the VEGF in 
289 
 
brain and spinal cord with symptoms resembling an ALS type disorder. Therefore, 
dyregulated VEGF was strongly associated with ALS. In the current study, a 
member of the VEGF family, VEGFA, was shown to be decreased in the fALS-
TARDBP missense mutation. This strongly supports Oosthuyse et al., 
observation that VEGFA could be a significant candidate gene associated with 
the fALS-TARDBP missense mutation. Furthermore, the majority of the fALS-
TARDBP missense genes were increased, ANGPT1, EMCN, HAND, HTATIP2, 
IL18, PGF, TBX4, THY1, TGFA and TNFSF12. Only four genes were decreased, 
ANGPT2, ANGPTL6, COL15A1 and VEGFA. Also it was interesting to find that 
IL18 was shared with the HTA experiment which may indicate its association with 
fALS-TARDBP missense mutation.  
 
The fALS-TARDBP truncated mutation revealed a higher number of genes 
compared to the missense mutation, this was also observed in the HTAs. The 
majority of the genes in the fALS-TARDBP truncated mutation were also 
increased, ADRA1B, BMP4, COL15A1, EGFL7, EPGN, FGF9, FGF10, FGF18, 
IL1B, MEOX2, PLAT, PLCD3, TBX1, TBX4, THY1, TGFA, TGFBR3 and 
TNFSF12. The decreased genes were ARHGAP24, ECSCR, HIF1A, ID1, ITGA4, 
NOS3 and NRP2. Also, a several  genes were shared with the HTA experiment, 
EPGN, MEOX2, TBX1,THY1 and TNFSF12 with a similar increased trend.  
 
Furthermore, comparing the genes related to angiogenesis in the cytoplasmic 
missense mutation to the blood vessel development in the truncated mutation 
showed that the majority of gene were distinct to each mutation with only five 
genes being shared. Therefore, approaching each type of fALS-TARDBP 
mutation separately may be required when designing treatments for patients. 
     
 
 
 
 
 
290 
 
5.4.2 Cytoplasmic MT vs. CON   
 
5.4.2.1 Cell adhesion  
 
Current literature illustrates a limited number of observations linking ALS to 
dysregulated adhesion molecules. Ono et al., reported decreased levels of 
collagen IV in both skin and serum of ALS patients and the levels of collagen IV 
were shown to progressively decrease with the progress of ALS. Therefore, it 
was strongly suggested to be correlated with ALS pathogenesis (Ono et al., 
1998).  Ono et al., also reported a significant reduction in plasma  fibronectin in 
ALS patients (Ono et al., 2000). Using a whole human genome oligo microarray, 
Aronica et al, demonstrated dysregulated collagens and integrins in sALS 
(Aronica et al., 2015). In the present work, studying gene expression using RNA 
sequencing revealed a large number of genes that belonged to a cell adhesion 
group were significantly affected in the fALS-TARDBP missense mutation with 
the majority being significantly down-regulated. 
  
Cadherins are important cell surface molecules that have a role in signal 
transduction and promote normal cell development and morphogenesis (Maitre 
and Heisenberg, 2013). A large group of members of the cadherin superfamily 
were significantly reduced, CDH2, CLSTN3, DCHS1, CDHR5, PCDH9 and 
PCDHGC5. Furthermore, members of the collagen family were also reduced, 
COL5A1, COL15A, COL16A1 and COL7A1. Also integrins that facilitate focal 
adhesion, PKD1, TNC, DCHS1 and AMIGO2 were down-regulated. Decreased 
expression of integrins such as: ITGA1, ITGB4, ITGA3, ITGB1 ITGA5, ITGAV 
and ITGA11 and the extracellular matrix molecules such as collagens including 
collagen IV and fibronectin have been previously demonstrated in sALS (Aronica 
et al., 2015).  
 
Furthermore, a couple of genes that belonged to cellular pathways that mediate 
cell adhesion were also down-regulated. WISP1 which activates the WNT 
pathway was reduced, the AEBP1 which negatively regulated the MAP kinase 
pathway was also decreased, the FLRT1 which is involved in the RAS/RAF/ERK 
pathway was down-regulated and TSC1 which promotes the mTORC1 signalling 
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pathway was decreased. Moreover, SSPO which is involved in axonal guidance 
was decreased. Two genes that facilitate uterine cell adhesion were also 
reduced, POSTN and TROAP.  
 
Several members of the cadherin superfamily were shown to be up-regulated in 
fALS-TARDBP missense mutation, FAT3, CDH10 and PCDH17. Also PKP3 that 
facilitates the binding of cadherins to intracellular actin filaments was increased. 
Other cell adhesion molecules that mediate cell adhesion, migration and 
proliferation were also up-regulated, CD9, L1CAM, THY1, ALX1 and SIRPA. 
Furthermore, focal adhesion molecules which are cell surface proteins that 
mediate adhesion though binding to the extracellular matrix were up-regulated, 
EMCN and SORBS1.  
 
The laminin family of proteins are involved in the adhesion to the extracellular 
matrix. Laminin 1 was previously shown to be expressed in astrocytes of sALS-
SOD1 spinal cord. In the current work, LAMA3 a member of the laminin family 
was highly expressed (Wiksten et al., 2007). Interestingly, genes that are 
normally expressed in the CNS were also shown to be expressed in fibroblasts, 
CLSTN2 which is expressed on GABAergic neurons and ROBO2 that mediates 
axonal guidance were up-regulated. This observation along with the previously 
shown results (section 3.6.1.1.2) demonstrates that fibroblasts are good models 
that may mimic some of the changes on the CNS and therefore would be a 
favourable model to study ALS.  
 
The majority of the effect of TARDBP mutation is fALS was shown to involve 
down-regulation cell adhesion molecules. Dysregulated cadherins, integrins and 
collagens were strongly suggested to be linked with the fALS-TARDBP missense 
mutation. 
 
 
5.4.2.1 Anterior/posterior pattern formation 
 
A group of genes related to the anterior/posterior pattern formation were 
dysregulated in the fALS-TARDBP missense mutation.   
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The transcription factors ALX1, HOXB9, HOXD13 were increased. Mutations in 
ALX1 have been linked to frontonasal dysplasia (Dee et al., 2013). In addition, 
HOXB9 was  shown to be expressed at a high level in  breast cancer and lung 
metastasis (Hayashida et al., 2010). Mutations in HOXD13 have been shown to 
be linked with hand-foot-genital syndrome (HFGS) (Goodman et al., 2000). 
PSEN2 was increased, mutations in PSEN2 are associated with AD and have 
been thought to cause the increased levels of APP in AD (Levy-Lahad et al., 
1996). On the other hand, several transcription factors that promote cell 
proliferation were decreased HOXB3, HOXC6, HOXC8, HOXD9 and HHEX. Also 
the ARC gene has shown to be reduced. It was suggested that ARC plays a role 
in promoting long term potentiation and memory by increasing the AMPAR on the 
postsynaptic neuron (Pevzner et al., 2012). 
 
5.4.3 Cytoplasmic TT vs. CON 
 
5.4.3.1 Response to vitamins 
  
Vitamins are vital organic compounds that mediate normal cell development 
though their effect on gene expression (Wang et al., 1995, Landes et al., 2003, 
McGrane, 2007). Surprisingly, a group of up-regulated genes were categorised 
under response to vitamin and were the highest enriched biological process in 
fALS-TARDBP truncated mutation. 
 
Two genes involved in bone and cartilage synthesis BMP4 and BMP7 were up-
regulated. BMP7 was shown to be positively influenced by vitamin D (Nobili and 
Reif, 2015). Furthermore, vitamin A was shown to induce an increased 
expression of HSD17B2 which also was increased in the fALS-TARDBP 
truncated mutation (Su et al., 2007). In addition, two genes involved in vitamin A 
synthesis were up-regulated, ALDH1A2 and RBP4. Vitamin C was suggested to 
be involved in cellular reprogramming by activating four genes one of which was 
the KLF4 which showed increased expression in fALS-TARDBP truncated 
mutation (Shi et al., 2010).  
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The overall elevated levels of genes influenced by vitamins could be due to the 
effect of the vitamin supplement added to the fibroblasts culture media to maintain 
their growth, and although these supplements are added to all fibroblast cultures, 
the ALS fibroblasts may be responding differently due to their genetic 
background. It also could reflect ALS patients’ diet which is high in supplements 
which leaves epigenetic changes on patient derived cells (Rosenfeld and Ellis, 
2008).   
 
 
5.4.3.2 Regulation of mitotic cell division 
 
Genes involved in cell division were shown to be dysregulated in the fALS-
TARDBP truncated mutation. The most apparent reason for detecting these 
genes was that fibroblasts used in this project as a model to study fALS-TARDBP. 
Fibroblasts are known to undergo continuous cell division therefore it is possible 
to identify genes related to mitotic cell division. However, it was shown that 
neuronal cell cycle genes continue to be active during neurogenesis until full 
maturation is reached. Afterwards, cell cycle arrest occurs and neurons become 
post-mitotic however some cell division proteins are detectable and the reason 
for that is still not fully understood. Also, DNA repair enzymes continue to be 
active (Herrup and Yang, 2007).  
 
A couple of studies have reported an increased expression of genes related to 
cell cycle in ALS. Mutant SOD1G93A transgenic mouse showed an increased 
expression of cell cycle genes in motor neurons, protein phosphatase 3 catalytic 
subunit (PPP3CA), cyclin L1 (CCNL1), cyclin E2 (CCNE2) and cyclin D2 
(CCND2) (Ferraiuolo et al., 2007). Furthermore, the cell cycle checkpoint kinases 
(CHK1/CHK2) was also shown to be increased in sALS (Aronica et al., 2015). In 
the current study a group of genes related to cell division were up-regulated. 
Genes that were involved in cell proliferation were increased EPGN, CD28, TGFA 
and IGF2. Interestingly, EPGN was also shown to be up-regulated in the fALS-
TARDBP truncated mutation using the HTA (section 4.6.1.2.1). A study have 
shown that DNA damage in post-mitotic neurons activates cell cycle re-entry 
which may be responsible for the neuronal death (Kruman et al., 2004). 
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Therefore, the increased expression of genes related to mitotic cell division may 
contribute to the neuron loss in the disease.   
 
Moreover, genes involved in cell proliferation MTBP, SPHK1 were down-
regulated. Also, genes involved in cellular microtubule NUSAP1, centromere and 
kinetochore separation ESPL1, NEK2, CENPF and DLGAP5 were reduced. 
NUSAP1 was shown to be decreased in fALS-TARDBP missense mutation using 
the Human Exon Array 1.0 ST (section 3.8.2.1).  
 
 
 
5.4.3.3 Vesicle-mediated transport  
 
Axonal transport consists of three main structures which are: the cytoskeleton, 
the motor proteins and the carried cargo/vesical/organelle. Defects in any of 
these structures may result in failure to complete the transportation process 
effectively and be deleterious to the health of the neuron. Defective axonal 
transport has been reported by many studies and was strongly suggested to be 
associated with ALS, especially in the ALS-SOD1 mutation (De Vos et al., 2008). 
In 1999, Williamson and Cleveland studied the possible effect of SOD1 mutation 
on axonal transport. Interestingly, both mutant SOD1G85R and SOD1G37R mouse 
models revealed slow axonal transport at an early stage of the disease 
(Williamson and Cleveland, 1999). Furthermore, deficient retrograde axonal 
transport was reported in SOD1G93A mice (Bilsland et al., 2010). Also, the 
inhibition of kinesin-1 was reported in a mutant SOD1G93A mouse model (Morfini 
et al., 2013). In the current work, the largest number of dysregulated genes were 
related to vesicle-mediated transport in the fALS-TARDBP truncated mutation 
and the majority were down-regulated.  
 
Mutations in kinesin have been linked to ALS-SOD1, and here a member of the 
kinesin family, KIF20A was reduced (Bosco et al., 2010). Also, a mutation in 
DNM1 was suggested to be associated with ALS. DNM1 levels were reduced in 
the fALS-TARDBP truncated mutation (Munch et al., 2004). Furthermore, clathrin 
related genes were also down-regulated; AP1G1, AP3B2, CLINT1 and PICALM. 
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It has been shown that reduced levels of PICALM might be associated with AD 
(Thomas et al., 2016). The membrane trafficking gene SNCA was reduced. 
Mutations in SNCA have been reported in PD (Siddiqui et al., 2016). Also, the 
neuronal vesicle trafficking genes were decreased. Genes involved in Golgi to 
ER retrograde transport and in the oligomeric Golgi complex were also 
decreased. There is a significant reduction in the membrane trafficking genes in 
fALS-TARDBP truncated mutation which may have a serious consequences on 
motor neurons. Deficit in axonal transport is one of the major underlying aetiology 
in ALS which contribute to cell death and this was also observed in the current 
work.  
 
5.4.4 The overall effect of the TARDBP mutations on the biological 
processes in fALS and the possibility of identifying biomarkers  
 
ALS is a multifactorial complex disease and is nowadays categorized into several 
subgroups depending on the underlining genetic risk factor. Therefore, 
developing a generalized treatment for ALS patients is not the best approach and 
personalized medicine is highly recommended for proper treatment, prognostic 
and diagnostic biomarkers development (Picher-Martel et al., 2016). As this will 
provide a better prediction to patient survival. 
 
Gene expression profiling using RNA sequencing highlighted significant 
dysregulated biological processes in respect to each mutation type. In the 
cytoplasmic fALS-TARDBP missense mutation, marked dysregulation in cell 
adhesions was observed showing the largest number of differentially expressed 
genes. Moreover, the cytoplasmic fALS-TARDBP truncated mutation showed 
significant changes in gene involved in vesical-mediated transport and were also 
harbouring the highest number of genes. Furthermore, gene influenced by steroid 
hormones and genes related to angiogenesis/ blood vessel development were 
shared by both mutations however the majority of the genes were distinct to 
mutation type. The outcome of the present work strongly supports the possibility 
of identifying biomarkers as a diagnostic test to differentiate between fALS-
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TARDBP subtypes as well prognostic biomarkers to help in monitoring and 
predicting fALS-TARDBP patient survival. Also, the current work could shed light 
on possible targeted therapies for fALS-TARDBP patients which may significantly 
reduce the tragic motor neuron loss observed in the d fALS-TARDBP. However, 
further validation steps remain to be established.  
 
 
5.4.5. Microarray GeneChip® vs. RNA sequencing  
 
In the current work gene expression profiling was approached by both microarray 
GeneChip® and RNA sequencing technologies. The current work showed that 
these tools varies in their robustness to detect gene expression. Advantages and 
disadvantages of each technology is shown in Table 5.17 (Wang et al., 2009b).   
297 
 
Table 5.17: The advantages and disadvantages of microarray GeneChip® and RNA sequencing    
 
 Microarray GeneChip®  RNA sequencing  
 
 
Advantages  
 
1-Identify alternative spliced transcripts and novel 
transcripts to an extent.  
 
 
1-Robust in identifying alternative spliced transcripts and novel 
transcripts although this was not performed in this work due to 
time constraint. 
 
2-Accurate measurement of the RNA transcript expression, as 
reads are counted precisely.  
 
3-Identify all known and unknown genes.  
 
4-Identify abnormal transcript structure such as insertion, 
deletion and inversion. 
 
5-Do not require normalization as the reads are mapped to the 
human genome reference sequence. 
 
6-Higher reproducibility. 
  
7-RNA concentration required for sequencing is low.  
   
 
 
Disadvantages  
1-Probes were designed according to previously identified 
genes in databases.   
 
2-Inaccurately measurement of gene expression due to 
averaging signal intensity of all probes.   
 
3-Require normalization.  
 
4-In some instances fail reproducibility by other gene 
expression method such as qRT-PCR 
 
4-RNA concentration required is high.   
1-Large data to handle. 
 
2-Required sophisticated bioinformatics skills in order to 
handle with data.  
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Chapter 6: Discussion 
 
ALS is a devastating chronic progressive disorder with an average survival rate 
2-5 years. To date, there is no definitive underlying cellular pathway identified in 
ALS that can be targeted for therapy (Cooper-Knock et al., 2012a). The present 
work aimed to investigate the possible effects of TARDBP mutations on gene 
expression in fALS using fibroblasts as a surrogate model. The hypothesis was 
that cytoplasmic and nuclear transcriptomic profile from mutant TARDBP 
fibroblasts will generate different transcriptomic profiles than control fibroblasts 
and will establish the transcripts and pathways dysregulated in the presence of 
mutations in TARDBP. To test the hypothesis, the specific aims were set. The 
first aim was to obtain a good separation of the cytoplasm and nuclear 
compartments before extracting RNA. A good degree of RNA separation from 
each cellular component was achieved. It was shown that the cell fractionation 
method using osmotic pressure and centrifugation and RNA extraction by Trizol 
method was significantly better than the commercially available kit (Cell 
fractionation for Cytoplasmic and Nuclear RNA Purification by Norgen). 
Monitoring the cell fractionation under the light microscope allowed proper timing 
for the cellular component separation. Although fibroblasts in this project were 
cultured up to passage 12, it is worth noting that the higher the passage the more 
time was required for optimal fractionation. Therefore, using a standardized kit 
protocol may underestimate the actual separation process and could produce low 
RNA yields or poor separation.    
 
The current work also aimed to compare the expression profiles of the 
cytoplasmic and nuclear compartments from control and TARDBP mutations 
fibroblasts and to determine the possible effect of the mutations on the disease 
process. Transcriptome profiling was approached by GeneChip® microarrays and 
RNA sequencing. An interesting observation was that although there were a 
limited number of common significant differentially expressed genes across the 
GeneChip® microarrays and RNA sequencing, dysregulated RNA processing 
was repeatedly shown to be affected in the missense mutation in both cellular 
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compartments. Dysregulated spliceosome complexes have been previously 
reported in sALS-TARDBP (Highley et al., 2014). Genes associated with 
spliceosome complexes were shown to be dysregulated in the present work, 
SART-3, ZCRB1, RBM39, SNRNP200 and PRPF8. In addition, splicing factors 
were also dysregulated such as: SF3A1, SF3A3 and SFRS15. Furthermore, the 
splicing regulatory factor HNRNPM was shown to be expressed at low levels in 
sALS fibroblasts (Raman et al., 2015). In contrast, in the present work HNRNPM 
was shown to be increased in fALS, perhaps reflecting a mutant TARDBP specific 
effect. This strongly suggests the association of dysregulated RNA processing 
with fALS-TARDBP missense mutations.  
 
Whilst literature has shown that the Human Exon Arrays 1.0 ST low robustness 
due to manufacture design (Gaidatzis et al., 2009), they were still able to detect 
differentially expressed genes related to RNA processing in both cellular 
compartment of fALS-TARDBP missense mutation. Although, a limited number 
of differentially expressed genes were identified by the newly designed HTA, RNA 
processing was shown to be affected in both cellular compartments of fALS-
TARDBP missense mutation and dysregulated RNA splicing regulation was 
therefore common in both array types. Furthermore, the HTA recognized novel 
dysregulated RNA processing related biological processes in the missense 
mutations such as: mRNA transport, nucleosome organization and regulation of 
translation. In contrast, the fALS-TARDBP truncation mutation did not show RNA 
processing related pathways in both cellular compartments which may indicate 
that dysregulated RNA processing is more specific to the missense mutations. 
Moreover, in the current work there was a reduction in TARDBP gene expression 
in the fALS-TARDBP missense mutation. Therefore, it can be predicted that the 
reason there was marked down-regulation in genes related to RNA splicing, 
polyadenylation, transport, translation, olfactory receptors, cell adhesion and 
vesicle-mediated transport could be that their transcripts are associated with 
TDP-43 in normal conditions. However when TARDBP is mutated TDP-43 loses 
its functional role in RNA processing this result in a disruption of the binding of 
TDP-43 to transcripts. 
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Initially, the olfactory receptors were previously categorized as smell sensory 
receptors and thought to be expressed exclusively in the nose. Recently, olfactory 
receptors were shown to be expressed all over the human body which may 
indicate that they have vital roles other than smell (Nguyen et al., 2016). Olfactory 
receptors were shown to be expressed in the skin, lungs, heart, muscles, kidneys 
and sperm (Ferrer et al., 2016). Furthermore, it was shown that the activation of 
olfactory receptors in of the skin allowed cell viability, proliferation and migration. 
Down-regulation of olfactory receptors were observed in PD frontal cortex 
(Garcia-Esparcia et al., 2013). In addition, AD, PD and ALS patients achieved 
low scores in an olfaction test (scratch and sniff test) (Devanand et al., 2000, 
Doty, 2012, Nguyen et al., 2016). In the current study, the fALS-TARDBP 
truncation mutation showed an enormous number of down-regulated olfactory 
receptors genes in the nuclear compartment using the HTA. This marked 
reduction in olfactory receptors in fibroblasts could indicate also their loss in motor 
neurons in fALS-TARDBP truncation mutation which may lead to early cell loss 
in the disease. As the olfactory receptors were shown specifically in the truncated 
mutation, an olfactory test could be offered to fALS-TARDBP to differentiate 
between subtypes and aid in the diagnosis.  
 
RNA sequencing is believed to generate the most accurate and precise 
identification of the transcripts by mapping them to the human genome. In the 
present work RNA sequencing technology uncovered novel pathways in both the 
fALS missense mutation and the truncated mutation, such as: dysregulated 
genes influenced by steroid hormones. This observation may justify to an extent 
male predominance in the disease. Another interesting observation was the 
identification of a large number of dysregulated cell adhesion genes in fALS-
TARDBP missense mutation fibroblasts which may translate to possible defective 
blood and CNS barrier breakdown proposed in the disease process (Garbuzova-
Davis and Sanberg, 2014). Furthermore, both mutations shared commonality in 
angiogenesis which has been proposed to be associated with ALS (Oosthuyse 
et al., 2001, Greenway et al., 2006).  
 
Moreover, some dysregulated biological processes identified in the present work 
have been previously identified in ALS as a defective mechanism such as: the 
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defective cytoskeleton organization in the cytoplasmic fALS-TARDBP missense 
mutation (McMurray, 2000) and the dysregulated vesicle mediated transport 
system in the cytoplasmic fALS-TARDBP truncated mutation which have also 
been observed in the SOD1 mutation (De Vos et al., 2008). It is clearly shown 
that the new approach of cellular separation in gene expression profiling allowed 
the identification of interesting possible dysregulated biological processes in the 
fALS-TARDBP mutations that could have been masked as a result of studying 
global gene expression from whole cell RNA extractions.  
The comparative analysis of the cytoplasmic vs. nuclear gene expression of the 
fALS missense mutation revealed that mRNA splicing genes were dysregulated 
in both cellular fractions using the Human Exon Array 1.0 ST. Also a comparative 
analysis of the cytoplasmic vs. nuclear gene expression was performed on both 
mutation types using the HTA. This showed that a substantial number of nuclear 
genes were differentially expressed and a low number of genes were shared with 
the cytoplasmic fraction in both mutation types. As TDP-43 is predominantly a 
nuclear protein that gets mislocated to the cytoplasm when mutated this 
significant number of differentially expressed genes in the nucleus may indicate 
the loss of TDP-43 functional role in mRNA splicing which may result in faulty 
transcripts that are subjected to degradation. It was shown previously in this work 
that a group of genes related to mRNA transport were down-regulated which 
supports the increased levels of transcripts in the nucleus as a result of disruptive 
transport system caused by the mutation.      
 
Moreover, the current project showed a lack of statistically significant validation 
results of the selected candidate gene in the Human Exon Arrays 1.0 ST and the 
HTA, although some did confirm the directional change. Since the HTA and the 
RNA sequencing material used were the same samples it was interesting to 
cross-compare the expression levels of the genes by both technologies as this 
may indicate the reasons for lack of validation for some genes. Gene expression 
of ADARB1 and ENAH which showed a correct directional change by qRT-PCR 
from the HTA results also showed similar fold changes and significant p-values 
compared in the RNA sequencing data. In contrast, the METTL1 and SEMA5A 
showed no difference in qRT-PCR compared to the HTA results. Analysis of the 
RNA sequencing data showed METTL1 did not show any difference in gene 
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expression compared to controls and insignificant p-value (FC=1, p-value= 0.9). 
In addition the SEMA5A showed a lower gene expression than the HTA and 
insignificant p-value (FC=1.5, p-value=0.07). This observation may explain the 
reason of not achieving validation of the HTA results. However, more genes 
should have been selected for validation. Also validating the arrays from 
additional RNA material would have been favourable.   
 
Most studies aiming for identifying therapeutic targets for disease apply their 
studies on large cohorts which contain a wide range of variability leading to poor 
applications of treatments on individualized cases. In the case of ALS, a single 
drug to a multifactorial disease is perhaps not the best approach for patients. 
Genetic risk factors and environmental factors both play a vital role in patient 
response to treatment. Precise understanding of the disease subtypes provides 
a better understanding of the defective mechanisms to which treatments can be 
designed. Therefore, personalized medicine would appear to be a promising 
approach in modern medicine for better therapeutic outcome. It might reduce the 
serious consequences of generalized treatment to patients such as: toxicity, 
organ damage and subsequently treatment failure (Mini and Nobili, 2009, Ashley, 
2016). The present work showed dysregulated pathways in fALS-TARDBP 
mutations which might possibly be targeted for therapy such as: the dysregulated 
RNA processing in fALS-TARDBP missense mutation and the dysregulated 
olfactory receptors in the fALS-TARDBP truncation mutation. Also the current 
work sheds light on the possibility of identifying biomarkers for fALS-TARDBP 
subtypes which may help in predicting patient survival. However, further 
investigation and analysis to confirm these observations is required. 
 
Furthermore, fibroblasts have been shown to be a good model to study fALS-
TARDBP mutations, as several dysregulated biological processes that were 
identified mimic changes that occur in motor neurons and therefore make them a 
favourable model to represent the disease. The truncated TDP-43 has been 
shown to be expressed in the fibroblasts used in this project (Mead et al., in 
preparation). Recently, there has been  a significant development in the feasibility 
of using induced pluripotent stem cells (iPSC) and subsequent differentiation to 
motor neurons as a model for neurodegenerative disease (Hedges et al., 2016). 
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There are advantages and limitations of using iPSC as a model to study ALS. 
The major advantage of these over fibroblasts is the unlimited self-renewal. 
However reprograming fibroblasts to iPSC and then motor neurons does have 
some limitations. Whether or not gene expression profiling of genetically 
engineered cells will reflect the actual active form of the disease or it will reflect a 
pre-symptomatic stage of the disease is still unknown. Another concern is 
whether there will be a loss of epigenetic changes in the iPSC and motor neurons 
as a result of reprograming. Also, cell reprograming is labour intensive and 
requires a long period of time to generate the cell type of interest.  Lastly, the 
possibility of altering other genes in iPSC as a result of the genetic manipulation 
my lead to false gene expression levels but this currently remains unclear 
(Dolmetsch and Geschwind, 2011, Hedges et al., 2016). In this project fibroblasts 
were shown to be a good surrogate model for fALS-TARDBP. They are easy to 
collect from patients via skin biopsies, also were easy to grow in the laboratory 
and showed similarity to motor neurons changes in ALS. 
 
 
Future work  
 
Future work that could be completed is additional qRT-PCR validation of the 
differential expressed RNA processing genes in fALS-TARDBP missense 
mutation from the Human Exon Array 1.0 ST results. Genes such as HNRNPM, 
HNRNPC, HNRNPD, HNRNPK, SSF3A3, SFRS15, CPSF1 and LSM10 could be 
validated as this will support the dysregulation of RNA processing in fALS-
TARDBP in missense mutation and will evaluate the robustness of the arrays in 
detecting gene expression.  Also, further validation of RNA processing genes 
shown in fALS-TARDBP missense mutation from the HTA could be validated by 
qRT-PCR. This includes genes related to RNA splicing such as: SNRPA, 
U2AF1L4, PABPN1, HNRNPA0, HNRNPF, HNRNPR, SNRNP40, SNRPB2, 
SNRPE and PHF5A. Also it would be interesting to attempt the validation by qRT-
PCR of the dysregulated mRNA transport genes such as: MAGOH, MAGOHB, 
DDX19B, NUPL1 and QKI. 
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It would be interesting to investigate the differentially expressed genes at the 
alternative splicing level from both the HTA Genechips® and RNA sequencing. 
This may allow for the identification novel defective transcripts that are associated 
with the disease pathogenesis. It is also important to validate these alternatively 
spliced transcripts by PCR and their defective role at the protein level to be 
investigated by western blot. Moreover, confocal microscopy is a remarkable tool 
that helps in identifying the localization of transcripts and proteins expressed in 
the cells. The application of FISH and using the confocal microscope will help in 
identifying the precise location of the defective transcripts and their proteins in 
the cell. It may also help in showing the specificity of some genes to each type of 
mutation such as visualizing the loss of olfactory receptors in fALS-TARDBP 
truncated mutation.  
 
Furthermore, it would be interesting to also analyse the nuclear missense 
mutations vs. controls and the nuclear truncation mutation vs. controls data that 
were generated by RNA sequencing. This could also uncover possible 
dysregulated pathways related to the disease. Moreover, in depth analysis of the 
cytoplasmic vs. nuclear comparison in both HTA and RNA sequencing. This may 
highlight the possibility of identifying dysregulated transcripts as a result of the 
mutation specific to a cellular component. Subsequently, functional analysis of 
the defective transcripts in other cell models such as NSC34 could be applied. 
 
In summary, although there was some commonality in the fALS-TARDBP 
missense mutation and truncation mutation, the current work strongly supports 
the dysregulation of RNA processing is more related to the fALS-TARDBP 
missense mutation which was not observed in the truncation mutation. Also, the 
fALS-TARDBP truncation mutation showed other interesting pathways such as 
dysregulated olfactory receptors. This strongly highlights the importance of 
personalized medicine for better patient care. 
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